The amyloid hypothesis of Alzheimer's disease at 25Â ye

EMBO Molecular Medicine
8, 595-608
DOI: 10.15252/emmm.201606210

Citation Report

#	Article	IF	Citations
1	Amyloid-beta immunotherapy: the hope for Alzheimer disease?. Colombia Medica, 2016, , 203-212.	0.7	55
2	Yi-Zhi-Fang-Dai Formula Protects against AÎ²1â€“42Oligomer Induced Cell Damage via Increasing Hsp70 and Grp78 Expression in SH-SY5Y Cells. Evidence-based Complementary and Alternative Medicine, 2016, 2016, 1-11.	0.5	3
3	Human Neural Stem Cell Transplantation Rescues Cognitive Defects in APP/PS1 Model of Alzheimerâ€™s Disease by Enhancing Neuronal Connectivity and Metabolic Activity. Frontiers in Aging Neuroscience, 2016, 8, 282.	1.7	43
4	Amyloidosis in Retinal Neurodegenerative Diseases. Frontiers in Neurology, 2016, 7, 127.	1.1	34
5	Proteomic Substrate Identification for Membrane Proteases in the Brain. Frontiers in Molecular Neuroscience, 2016, 9, 96.	1.4	26
6	Region-Specific Differences in Amyloid Precursor Protein Expression in the Mouse Hippocampus. Frontiers in Molecular Neuroscience, 2016, 9, 134.	1.4	25
7	Fluoxetine Prevents AÎ²1-42-Induced Toxicity via a Paracrine Signaling Mediated by Transforming-Growth-Factor-Î²1. Frontiers in Pharmacology, 2016, 7, 389.	1.6	42
8	Ten Challenges of the Amyloid Hypothesis of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 55, 447-457.	1.2	71
9	Seizure protein 6 and its homolog seizure 6-like protein are physiological substrates of BACE1 in neurons. Molecular Neurodegeneration, 2016, 11, 67.	4.4	90
10	3D culture models of Alzheimerâ€™s disease: a road map to a â€œcure-in-a-dishâ€• Molecular Neurodegeneration, 2016, 11, 75.	4.4	109
11	Targets and Strategies Toward the Development of Alzheimer Therapeutics. Topics in Medicinal Chemistry, 2016, , 1-25.	0.4	0
12	Early changes in CSF sTREM2 in dominantly inherited Alzheimerâ€™s disease occur after amyloid deposition and neuronal injury. Science Translational Medicine, 2016, 8, 369ra178.	5.8	211
13	Recent advances in cerebrospinal fluid biomarkers for the detection of preclinical Alzheimer's disease. Current Opinion in Neurology, 2016, 29, 749-755.	1.8	10
14	Molecular and cellular pathophysiology of preclinical Alzheimerâ€™s disease. Behavioural Brain Research, 2016, 311, 54-69.	1.2	99
15	DISC1 a key molecular lead in psychiatry and neurodevelopment: No-More Disrupted-in-Schizophrenia 1. Molecular Psychiatry, 2016, 21, 1488-1489.	4.1	61
16	Emerging drugs to reduce abnormal Î²-amyloid protein in Alzheimerâ€™s disease patients. Expert Opinion on Emerging Drugs, 2016, 21, 377-391.	1.0	54
17	Opposite in vivo effects of agents that stimulate or inhibit the glutamate/cysteine exchanger system on the inhibition of hippocampal LTP by AÃŸ. Hippocampus, 2016, 26, 1655-1665.	0.9	6
18	Cited references and Medical Subject Headings (MeSH) as two different knowledge representations: clustering and mappings at the paper level. Scientometrics, 2016, 109, 2077-2091.	1.6	31

#	Article	IF	Citations
19	Editorial overview: Neuroscience: Back to the future in the developing insect nervous system. Current Opinion in Insect Science, 2016, 18, iv-vi.	2.2	0
20	Effects of bile acids on neurological function and disease. FASEB Journal, 2016, 30, 3658-3668.	0.2	118
21	Functions of the Alzheimerâ€™s Disease Protease BACE1 at the Synapse in the Central Nervous System. Journal of Molecular Neuroscience, 2016, 60, 305-315.	1.1	48
22	Atomic-resolution structure of a disease-relevant AÎ²(1â€“42) amyloid fibril. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E4976-84.	3.3	712
23	Alzheimerâ€related protein <scp>APL</scp> â€1 modulates lifespan through heterochronic gene regulation in Caenorhabditis elegans. Aging Cell, 2016, 15, 1051-1062.	3.0	24
24	Major amyloid-Î²â€“degrading enzymes, endothelin-converting enzyme-2 and neprilysin, are expressed by distinct populations of GABAergic interneurons in hippocampus and neocortex. Neurobiology of Aging, 2016, 48, 83-92.	1.5	34
25	Attack on amyloid-Î² protein. Nature, 2016, 537, 36-37.	13.7	42
26	The amyloid hypothesis of Alzheimer's disease at 25Âyears. EMBO Molecular Medicine, 2016, 8, 595-608.	3.3	4,226
27	How neuroinflammation contributes to neurodegeneration. Science, 2016, 353, 777-783.	6.0	1,408
28	The Head and the Heart. Journal of the American College of Cardiology, 2016, 68, 2408-2411.	1.2	6
29	Neurovascular Protective Function of Endothelial Nitric Oxideã€€â€“ Recent Advances â€“. Circulation Journal, 2016, 80, 1499-1503.	0.7	47
30	Transmembrane Substrate Determinants for Î³-Secretase Processing of APP CTFÎ². Biochemistry, 2016, 55, 5675-5688.	1.2	40
31	12-Crown-4 Ether Disrupts the Patient Brain-Derived Amyloid-Î²-Fibril Trimer: Insight from All-Atom Molecular Dynamics Simulations. ACS Chemical Neuroscience, 2016, 7, 1433-1441.	1.7	37
32	Exposure to the Functional Bacterial Amyloid Protein Curli Enhances Alpha-Synuclein Aggregation in Aged Fischer 344 Rats and Caenorhabditis elegans. Scientific Reports, 2016, 6, 34477.	1.6	319
33	Targeting tau protein in Alzheimer's disease. Lancet, The, 2016, 388, 2842-2844.	6.3	13
34	Exosomes in the Pathology of Neurodegenerative Diseases. Journal of Biological Chemistry, 2016, 291, 26589-26597.	1.6	190
35	Neuroglobin: From structure to function in health and disease. Molecular Aspects of Medicine, 2016, 52, 1-48.	2.7	91
36	RNA-Seeded Functional Amyloids Balance Growth and Survival. Developmental Cell, 2016, 39, 131-132.	3.1	8

#	Article	IF	Citations
37	The Aggregation Paths and Products of AÎ²42 Dimers Are Distinct from Those of the AÎ²42 Monomer. Biochemistry, 2016, 55, 6150-6161.	1.2	22
38	Tautomeric Effect of Histidine on the Monomeric Structure of Amyloid Î²-Peptide(1â€“40). Journal of Physical Chemistry B, 2016, 120, 11405-11411.	1.2	36
39	Clinical Impact of Amyloid Positron Emission Tomographyâ€”Is It Worth the Cost?. JAMA Neurology, 2016, 73, 1396.	4.5	11
40	The BACE1 inhibitor verubecestat (MK-8931) reduces CNS Î²-amyloid in animal models and in Alzheimerâ€™s disease patients. Science Translational Medicine, 2016, 8, 363ra150.	5.8	352
41	Apolipoprotein E metabolism and functions in brain and its role in Alzheimer's disease. Current Opinion in Lipidology, 2017, 28, 60-67.	1.2	123
42	Amyloid Plaques Show Binding Capacity of Exogenous Injected Amyloid-Î². Journal of Alzheimer's Disease, 2016, 55, 147-157.	1.2	5
43	Hyperbaric Oxygen Prevents Cognitive Impairments in Mice Induced by d-Galactose by Improving Cholinergic and Anti-apoptotic Functions. Neurochemical Research, 2017, 42, 1240-1253.	1.6	29
44	Two decades of new drug discovery and development for Alzheimer's disease. RSC Advances, 2017, 7, 6046-6058.	1.7	60
45	Selective inhibition of phosphodiesterases 4, 5 and 9 induces HSP20 phosphorylation and attenuates amyloid beta 1â€“42â€mediated cytotoxicity. FEBS Open Bio, 2017, 7, 64-73.	1.0	13
46	The discovery of Alzheimerâ€causing mutations in the <scp>APP</scp> gene and the formulation of the â€œamyloid cascade hypothesisâ€. FEBS Journal, 2017, 284, 1040-1044.	2.2	120
47	Alzheimer's disease: Innate immunity gone awry?. Metabolism: Clinical and Experimental, 2017, 69, S41-S49.	1.5	56
48	T cell responses in the central nervous system. Nature Reviews Immunology, 2017, 17, 179-194.	10.6	219
49	Vitamin D 3 protects against AÎ² peptide cytotoxicity in differentiated human neuroblastoma SH- SY5Y cells: A role for S1P1/p38MAPK/ATF4 axis. Neuropharmacology, 2017, 116, 328-342.	2.0	16
50	Weighted Protein Interaction Network Analysis of Frontotemporal Dementia. Journal of Proteome Research, 2017, 16, 999-1013.	1.8	39
51	Putting AD treatments and biomarkers to the test. Nature Reviews Neurology, 2017, 13, 74-76.	4.9	14
52	Presenilin-1 mutations and Alzheimerâ€™s disease. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 629-631.	3.3	164
53	Aberrant proteolytic processing and therapeutic strategies in Alzheimer disease. Advances in Biological Regulation, 2017, 64, 33-38.	1.4	30
54	Selecting AÎ² isoforms for an Alzheimer's disease cerebrospinal fluid biomarker panel. Biomarkers in Medicine, 2017, 11, 169-178.	0.6	11

#	Article	IF	Citations
55	Coconut oil protects cortical neurons from amyloid beta toxicity by enhancing signaling of cell survival pathways. Neurochemistry International, 2017, 105, 64-79.	1.9	44
56	Predicting Cognitive Decline across Four Decades in Mutation Carriers and Non-carriers in Autosomal-Dominant Alzheimerâ€™s Disease. Journal of the International Neuropsychological Society, 2017, 23, 195-203.	1.2	18
57	Crosstalk between sphingolipids and vitamin D3: potential role in the nervous system. British Journal of Pharmacology, 2017, 174, 605-627.	2.7	11
58	Dynamic presenilin 1 and synaptotagmin 1 interaction modulates exocytosis and amyloid Î² production. Molecular Neurodegeneration, 2017, 12, 15.	4.4	26
59	Nucleobindin 1 binds to multiple types of pre-fibrillar amyloid and inhibits fibrillization. Scientific Reports, 2017, 7, 42880.	1.6	29
60	Neural stem cell therapy for neurodegenerative disorders: The role of neurotrophic support. Neurochemistry International, 2017, 106, 94-100.	1.9	132
61	Clearance of cerebral AÎ² in Alzheimerâ€™s disease: reassessing the role of microglia and monocytes. Cellular and Molecular Life Sciences, 2017, 74, 2167-2201.	2.4	199
62	New horizons for focused ultrasound (FUS) â€“ therapeutic applications in neurodegenerative diseases. Metabolism: Clinical and Experimental, 2017, 69, S3-S7.	1.5	31
63	Therapeutic potential of nuclear receptor agonists in Alzheimer's disease. Journal of Lipid Research, 2017, 58, 1937-1949.	2.0	61
64	The Link between Type 2 Diabetes and Neurodegeneration: Roles for Amyloid-Î², Amylin, and Tau Proteins. Journal of Alzheimer's Disease, 2017, 59, 421-432.	1.2	154
65	An on-flow assay for screening of Î²-secretase ligands by immobilised capillary reactor-mass spectrometry. Analytical Methods, 2017, 9, 2189-2196.	1.3	10
66	Depletion of coagulation factor XII ameliorates brain pathology and cognitive impairment in Alzheimer disease mice. Blood, 2017, 129, 2547-2556.	0.6	69
67	Genome-wide association study identifies four novel loci associated with Alzheimerâ€™s endophenotypes and disease modifiers. Acta Neuropathologica, 2017, 133, 839-856.	3.9	199
68	Conformational Ensembles of the Wild-Type and S8C AÎ²1â€“42 Dimers. Journal of Physical Chemistry B, 2017, 121, 2434-2442.	1.2	31
69	secHsp70 as a tool to approach amyloid-Î²42 and other extracellular amyloids. Fly, 2017, 11, 179-184.	0.9	17
70	Differential contribution of APP metabolites to early cognitive deficits in a TgCRND8 mouse model of Alzheimerâ€™s disease. Science Advances, 2017, 3, e1601068.	4.7	45
71	PET Imaging Agents for Alzheimerâ€™s Disease. Topics in Medicinal Chemistry, 2017, , 181-197.	0.4	0
72	Translating protein phosphatase research into treatments for neurodegenerative diseases. Biochemical Society Transactions, 2017, 45, 101-112.	1.6	5

#	Article	IF	Citations
73	The role of drebrin in neurons. Journal of Neurochemistry, 2017, 141, 819-834.	2.1	55
74	Upregulated Expression of Heparanase and Heparanase 2 in the Brains of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2017, 58, 185-192.	1.2	32
75	Prevention of Amyloid-Î² and Tau Pathologies, Associated Neurodegeneration, and Cognitive Deficit by Early Treatment with a Neurotrophic Compound. Journal of Alzheimer's Disease, 2017, 58, 215-230.	1.2	18
76	Impact of GM1 on Membrane-Mediated Aggregation/Oligomerization of Î²-Amyloid: Unifying View. Biophysical Journal, 2017, 113, 1194-1199.	0.2	40
77	Understanding Alzheimer's disease by global quantification of protein phosphorylation and sialylated N-linked glycosylation profiles: A chance for new biomarkers in neuroproteomics?. Journal of Proteomics, 2017, 161, 11-25.	1.2	23
78	Amyloid Î² peptide promotes lysosomal degradation of clusterin via sortilin in hippocampal primary neurons. Neurobiology of Disease, 2017, 103, 78-88.	2.1	10
79	Tau Spread, Apolipoprotein E, Inflammation, and More. Neurologic Clinics, 2017, 35, 175-190.	0.8	18
80	Posttranslational modification impact on the mechanism by which amyloidâ€Î² induces synaptic dysfunction. EMBO Reports, 2017, 18, 962-981.	2.0	50
81	Downregulation of RBO-PI4KIIIÎ± Facilitates AÎ²₄₂Secretion and Ameliorates Neural Deficits in AÎ²₄₂-ExpressingDrosophila. Journal of Neuroscience, 2017, 37, 4928-4941.	1.7	15
82	A Critical Assessment of Research on Neurotransmitters in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2017, 57, 969-974.	1.2	34
83	Structural and biochemical differences between the Notch and the amyloid precursor protein transmembrane domains. Science Advances, 2017, 3, e1602794.	4.7	38
84	Small static electric field strength promotes aggregation-prone structures in amyloid-Î²(29-42). Journal of Chemical Physics, 2017, 146, 145101.	1.2	17
85	Influence of N -acetyl cysteine on beta-amyloid-induced Alzheimerâ€™s disease in a rat model: A behavioral and electrophysiological study. Brain Research Bulletin, 2017, 131, 142-149.	1.4	39
86	Chronic sleep restriction promotes brain inflammation and synapse loss, and potentiates memory impairment induced by amyloid-Î² oligomers in mice. Brain, Behavior, and Immunity, 2017, 64, 140-151.	2.0	89
87	Membrane damage is at the core of Alzheimer's disease. Lancet Neurology, The, 2017, 16, 342.	4.9	15
88	The contribution of transgenic and nontransgenic animal models in Alzheimerâ€™s disease drug research and development. Behavioural Pharmacology, 2017, 28, 95-111.	0.8	8
89	Amyloid Î² production is regulated by Î²2-adrenergic signaling-mediated post-translational modifications of the ryanodine receptor. Journal of Biological Chemistry, 2017, 292, 10153-10168.	1.6	50
90	Resistance to Alzheimer Disease Neuropathologic Changes and Apparent Cognitive Resilience in the Nun and Honolulu-Asia Aging Studies. Journal of Neuropathology and Experimental Neurology, 2017, 76, 458-466.	0.9	61

#	Article	IF	Citations
91	Alzheimerâ€™s Disease II. Topics in Medicinal Chemistry, 2017, , .	0.4	2
92	The Anti-Amyloid-Î² and Neuroprotective Properties of a Novel Tricyclic Pyrone Molecule. Journal of Alzheimer's Disease, 2017, 58, 559-574.	1.2	10
93	Hypericum perforatum extract attenuates behavioral, biochemical, and neurochemical abnormalities in Aluminum chloride-induced Alzheimerâ€™s disease rats. Biomedicine and Pharmacotherapy, 2017, 91, 931-937.	2.5	57
94	Peritoneal dialysis reduces amyloid-beta plasma levels in humans and attenuates Alzheimer-associated phenotypes in an APP/PS1 mouse model. Acta Neuropathologica, 2017, 134, 207-220.	3.9	90
95	Synaptic Impairment in Alzheimerâ€™s Disease: A Dysregulated Symphony. Trends in Neurosciences, 2017, 40, 347-357.	4.2	327
96	Dysregulated Metabolism of the Amyloidâ€Î² Protein and Therapeutic Approaches in Alzheimer Disease. Journal of Cellular Biochemistry, 2017, 118, 4183-4190.	1.2	34
97	Silent hippocampal seizures and spikes identified by foramen ovale electrodes in Alzheimer's disease. Nature Medicine, 2017, 23, 678-680.	15.2	283
98	Time course of Tau toxicity and pharmacologic prevention in a cellÂmodel of Tauopathy. Neurobiology of Aging, 2017, 57, 47-63.	1.5	19
99	Elucidating the AÎ²42 Anti-Aggregation Mechanism of Action of Tramiprosate in Alzheimerâ€™s Disease: Integrating Molecular Analytical Methods, Pharmacokinetic and Clinical Data. CNS Drugs, 2017, 31, 495-509.	2.7	60
100	Alterations of Golgi organization in Alzheimerâ€™s disease: A cause or a consequence?. Tissue and Cell, 2017, 49, 133-140.	1.0	27
101	Understanding mechanisms and seeking cures for Alzheimer's disease: why we must be â€œextraordinarily diverseâ€• American Journal of Physiology - Cell Physiology, 2017, 313, C353-C361.	2.1	7
102	Bar-coding neurodegeneration: Identifying sub-cellular effects of human neurodegenerative disease proteins using Drosophila leg neurons. DMM Disease Models and Mechanisms, 2017, 10, 1027-1038.	1.2	6
103	Synaptic dysfunction in Alzheimer's disease: From the role of amyloid Î²-peptide to the Î±-secretase ADAM10. European Journal of Pharmacology, 2017, 817, 30-37.	1.7	29
104	Spreading of Pathology in Alzheimerâ€™s Disease. Neurotoxicity Research, 2017, 32, 707-722.	1.3	13
105	Structural and functional analyses of pyroglutamate-amyloid-Î²-specific antibodies as a basis for Alzheimer immunotherapy. Journal of Biological Chemistry, 2017, 292, 12713-12724.	1.6	24
106	Dexibuprofen prevents neurodegeneration and cognitive decline in APPswe/PS1dE9 through multiple signaling pathways. Redox Biology, 2017, 13, 345-352.	3.9	36
108	Alzheimerâ€™s disease: How metal ions define Î²-amyloid function. Coordination Chemistry Reviews, 2017, 351, 127-159.	9.5	120
109	Alzheimerâ€™s Disease and ncRNAs. Advances in Experimental Medicine and Biology, 2017, 978, 337-361.	0.8	64

#	Article	IF	Citations
110	Alzheimerâ€™s Disease in the Latino Community: Intersection of Genetics and Social Determinants of Health. Journal of Alzheimer's Disease, 2017, 58, 979-992.	1.2	70
111	Myeloid Cells in the Central Nervous System. Immunity, 2017, 46, 943-956.	6.6	259
112	Alzheimer's disease: time to focus on the brain, not just molecules. Brain, 2017, 140, 251-253.	3.7	18
113	The double-edged role of copper in the fate of amyloid beta in the presence of anti-oxidants. Chemical Science, 2017, 8, 6155-6164.	3.7	20
114	Selective targeting of primary and secondary nucleation pathways in AÎ²42 aggregation using a rational antibody scanning method. Science Advances, 2017, 3, e1700488.	4.7	116
115	Propagation of Tau aggregates. Molecular Brain, 2017, 10, 18.	1.3	154
116	Î³-Secretase Modulators as AÎ²42-Lowering Pharmacological Agents to Treat Alzheimerâ€™s Disease. Topics in Medicinal Chemistry, 2017, , 87-118.	0.4	6
117	Different Molecular Mechanisms Mediate Direct or Glia-Dependent Prion Protein Fragment 90â€“231 Neurotoxic Effects in Cerebellar Granule Neurons. Neurotoxicity Research, 2017, 32, 381-397.	1.3	5
118	Insights on the Interaction between Transthyretin and AÎ² in Solution. A Saturation Transfer Difference (STD) NMR Analysis of the Role of Iododiflunisal. Journal of Medicinal Chemistry, 2017, 60, 5749-5758.	2.9	24
119	Why Is Research on Amyloid-Î² Failing to Give New Drugs for Alzheimerâ€™s Disease?. ACS Chemical Neuroscience, 2017, 8, 1435-1437.	1.7	201
120	Calmodulin-like skin protein is downregulated in human cerebrospinal fluids of Alzheimerâ€™s disease patients with apolipoprotein E4; a pilot study using postmortem samples. Neurological Research, 2017, 39, 767-772.	0.6	13
121	Alzheimerâ€™s disease: where next for anti-amyloid therapies?. Brain, 2017, 140, 853-855.	3.7	57
122	High-Resolution Structures of the Amyloid-Î² 1â€“42 Dimers from the Comparison of Four Atomistic Force Fields. Journal of Physical Chemistry B, 2017, 121, 5977-5987.	1.2	120
123	Trehalose induced conformational changes in the amyloid-Î² peptide. Pathology Research and Practice, 2017, 213, 643-648.	1.0	9
124	Alzheimer Disease. Mayo Clinic Proceedings, 2017, 92, 978-994.	1.4	57
125	Fermented Citrus reticulata (ponkan) fruit squeezed draff that contains a large amount of 4â€²-demethylnobiletin prevents MK801-induced memory impairment. Journal of Natural Medicines, 2017, 71, 617-631.	1.1	8
126	Semisynthesis and biological evaluation of prenylated resveratrol derivatives as multi-targeted agents for Alzheimerâ€™s disease. Journal of Natural Medicines, 2017, 71, 665-682.	1.1	28
127	The double faced role of copper in AÎ² homeostasis: A survey on the interrelationship between metal dyshomeostasis, UPS functioning and autophagy in neurodegeneration. Coordination Chemistry Reviews, 2017, 347, 1-22.	9.5	39

#	Article	IF	Citations
128	Glutaminyl cyclase activity correlates with levels of AÎ² peptides and mediators of angiogenesis in cerebrospinal fluid of Alzheimerâ€™s disease patients. Alzheimer's Research and Therapy, 2017, 9, 38.	3.0	24
129	Association Between Periodontitis and Amyloid Î² Peptide in Elderly People With and Without Cognitive Impairment. Journal of Periodontology, 2017, 88, 1051-1058.	1.7	32
130	C5a Increases the Injury to Primary Neurons Elicited by Fibrillar Amyloid Beta. ASN Neuro, 2017, 9, 175909141668787.	1.5	33
131	Bloodstream Amyloid-beta (1-40) Peptide, Cognition, and Outcomes in Heart Failure. Revista Espanola De Cardiologia (English Ed), 2017, 70, 924-932.	0.4	12
132	Novel 2-Arylbenzimidazole derivatives as multi-targeting agents to treat Alzheimerâ€™s disease. Medicinal Chemistry Research, 2017, 26, 1506-1515.	1.1	9
133	Nanotechnological strategies for nerve growth factor delivery: Therapeutic implications in Alzheimerâ€™s disease. Pharmacological Research, 2017, 120, 68-87.	3.1	67
134	Role of amyloid Î² protein receptors in mediating synaptic plasticity. Biomedical Reports, 2017, 6, 379-386.	0.9	7
135	Choroidal thinning: Alzheimer's disease and aging. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 8, 11-17.	1.2	37
136	Ion mobility-mass spectrometry and orthogonal gas-phase techniques to study amyloid formation and inhibition. Current Opinion in Structural Biology, 2017, 46, 7-15.	2.6	31
137	ErbB2 regulates autophagic flux to modulate the proteostasis of APP-CTFs in Alzheimerâ€™s disease. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E3129-E3138.	3.3	57
138	Co-injection of AÎ²1-40 and ApoE4 impaired spatial memory and hippocampal long-term potentiation in rats. Neuroscience Letters, 2017, 648, 47-52.	1.0	5
139	Cortical cells reveal APP as a new player in the regulation of GABAergic neurotransmission. Scientific Reports, 2017, 7, 370.	1.6	31
140	An intranasally delivered peptide drug ameliorates cognitive decline in Alzheimer transgenic mice. EMBO Molecular Medicine, 2017, 9, 703-715.	3.3	54
141	Effect of metal chelators on the aggregation of beta-amyloid peptides in the presence of copper and iron. BioMetals, 2017, 30, 285-293.	1.8	55
142	Chronic Traumatic Encephalopathy. Physical Medicine and Rehabilitation Clinics of North America, 2017, 28, 301-321.	0.7	14
143	Animal models in idiopathic inflammatory myopathies: How to overcome a translational roadblock?. Autoimmunity Reviews, 2017, 16, 478-494.	2.5	21
144	Electrochemical detection of Zn(II)- and Cu(II)-induced amyloid-Î² aggregation: Quantitative aspects and application to amyloid-Î² isoforms. Journal of Electroanalytical Chemistry, 2017, 791, 152-158.	1.9	12
145	The value of PET ligand discovery to CNS drug development. Future Medicinal Chemistry, 2017, 9, 351-356.	1.1	3

#	Article	IF	Citations
146	Unmodified and pyroglutamylated amyloid Î² peptides form hypertoxic heteroâ€•oligomers of unique secondary structure. FEBS Journal, 2017, 284, 1355-1369.	2.2	15
147	Hydroxytyrosol restores proper insulin signaling in an astrocytic model of Alzheimer's disease. BioFactors, 2017, 43, 540-548.	2.6	43
148	A disease with a sweet tooth: exploring the Warburg effect in Alzheimerâ€™s disease. Biogerontology, 2017, 18, 301-319.	2.0	56
149	Selenoprotein S is required for clearance of C99 through endoplasmic reticulum-associated degradation. Biochemical and Biophysical Research Communications, 2017, 486, 444-450.	1.0	23
150	Analysis of 138 pathogenic mutations in presenilin-1 on the in vitro production of AÎ²42 and AÎ²40 peptides by Î³-secretase. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E476-E485.	3.3	277
151	Systematic development of small molecules to inhibit specific microscopic steps of AÎ²42 aggregation in Alzheimerâ€™s disease. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E200-E208.	3.3	180
152	Alzheimerâ€™s disease: experimental models and reality. Acta Neuropathologica, 2017, 133, 155-175.	3.9	513
153	Redox-sensitive GFP to monitor oxidative stress in neurodegenerative diseases. Reviews in the Neurosciences, 2017, 28, 133-144.	1.4	7
154	The Amyloidâ€Î² Peptide in Amyloid Formation Processes: Interactions with Blood Proteins and Naturally Occurring Metal Ions. Israel Journal of Chemistry, 2017, 57, 674-685.	1.0	21
155	Toward Allosterically Increased Catalytic Activity of Insulin-Degrading Enzyme against Amyloid Peptides. Biochemistry, 2017, 56, 228-239.	1.2	47
156	Development of [11C]/[3H]THK-5351 â€“ A potential novel carbon-11 tau imaging PET radioligand. Nuclear Medicine and Biology, 2017, 46, 50-53.	0.3	16
157	Î±â€Synuclein Oligomers: A Study in Diversity. Israel Journal of Chemistry, 2017, 57, 699-723.	1.0	16
158	Alzheimer's Disease: It's More Than AÎ². FASEB Journal, 2017, 31, 2-4.	0.2	15
159	Conceptualizing cognitive health to optimize dementia prevention and care. Journal of the Neurological Sciences, 2017, 372, 126-127.	0.3	0
160	A Multi-network Approach Identifies Protein-Specific Co-expression in Asymptomatic and Symptomatic Alzheimerâ€™s Disease. Cell Systems, 2017, 4, 60-72.e4.	2.9	381
161	Search for Alzheimer's disease biomarkers in blood cells: hypotheses-driven approach. Biomarkers in Medicine, 2017, 11, 917-931.	0.6	47
162	Colivelin Ameliorates Impairments in Cognitive Behaviors and Synaptic Plasticity in APP/PS1 Transgenic Mice. Journal of Alzheimer's Disease, 2017, 59, 1067-1078.	1.2	15
163	Prion-like Protein Seeding and the Pathobiology of Alzheimerâ€™s Disease. , 2017, , 57-82.		0

#	Article	IF	Citations
164	A systemic view of Alzheimer disease â€" insights from amyloid-Î² metabolism beyond the brain. Nature Reviews Neurology, 2017, 13, 612-623.	4.9	581
165	Endosomal Traffic Jams Represent a Pathogenic Hub and Therapeutic Target in Alzheimerâ€™s Disease. Trends in Neurosciences, 2017, 40, 592-602.	4.2	114
166	Biophysical Aspects of Alzheimerâ€™s Disease: Implications for Pharmaceutical Sciences. Pharmaceutical Research, 2017, 34, 2628-2636.	1.7	1
167	The cytoplasmic nuclear shuttling of Beclin 1 in neurons with Alzheimerâ€™s disease-like injury. Neuroscience Letters, 2017, 661, 63-70.	1.0	10
168	Application of an Electrochemical Method to Evaluation of Amyloidâ€Î² Aggregation Inhibitors: Testing the RGKLVFFGRâ€NH₂ Peptide Antiaggregant. Electroanalysis, 2017, 29, 2906-2912.	1.5	6
169	Alzheimerâ€™s disease and cigarette smoke components: effects of nicotine, PAHs, and Cd(II), Cr(III), Pb(II), Pb(IV) ions on amyloid-Î² peptide aggregation. Scientific Reports, 2017, 7, 14423.	1.6	81
170	Tau-based therapies in neurodegeneration: opportunities and challenges. Nature Reviews Drug Discovery, 2017, 16, 863-883.	21.5	193
171	Î³â€Secretase in microglia â€" implications for neurodegeneration and neuroinflammation. Journal of Neurochemistry, 2017, 143, 445-454.	2.1	15
172	Genetic rodent models of brain disorders: Perspectives on experimental approaches and therapeutic strategies. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2017, 175, 368-379.	0.7	17
173	Multifunctional iminochromene-2H-carboxamide derivatives containing different aminomethylene triazole with BACE1 inhibitory, neuroprotective and metal chelating properties targeting Alzheimer's disease. European Journal of Medicinal Chemistry, 2017, 141, 690-702.	2.6	69
174	Mitochondria in Excitatory and Inhibitory Synapses have Similar Susceptibility to Amyloid-Î² Peptides Modeling Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2017, 60, 525-536.	1.2	14
175	Searching for new pharmacological targets for the treatment of Alzheimer's disease in Down syndrome. European Journal of Pharmacology, 2017, 817, 7-19.	1.7	15
176	Disruption of amyloid precursor protein ubiquitination selectively increases amyloid Î² (AÎ²) 40 levels via presenilin 2-mediated cleavage. Journal of Biological Chemistry, 2017, 292, 19873-19889.	1.6	20
177	Membrane Binding and Pore Formation by a Cytotoxic Fragment of Amyloid Î² Peptide. Journal of Physical Chemistry B, 2017, 121, 10293-10305.	1.2	55
178	Gut microbiome alterations in Alzheimerâ€™s disease. Scientific Reports, 2017, 7, 13537.	1.6	1,256
179	Dementia Pugilistica Revisited. Journal of Alzheimer's Disease, 2017, 60, 1209-1221.	1.2	30
180	A mechanistic model to predict effects of cathepsin B and cystatin C on Î²-amyloid aggregation and degradation. Journal of Biological Chemistry, 2017, 292, 21071-21082.	1.6	12
181	Beyond Amyloid â€" Widening the View on Alzheimer's Disease. Journal of Neurochemistry, 2017, 143, 394-395.	2.1	19

#	Article	IF	Citations
182	Dominant negative effect of the loss-of-function Î³-secretase mutants on the wild-type enzyme through heterooligomerization. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 12731-12736.	3.3	41
183	Chronic Cerebral Hypoperfusion Promotes Amyloid-Beta Pathogenesis via Activating Î²/Î³-Secretases. Neurochemical Research, 2017, 42, 3446-3455.	1.6	31
184	Gold Nanoparticles as a Probe for Amyloid-Î² Oligomer and Amyloid Formation. Journal of Physical Chemistry C, 2017, 121, 20007-20015.	1.5	51
185	The Effects of A21G Mutation on Transmembrane Amyloid Beta (11â€“40) Trimer: An In Silico Study. Journal of Physical Chemistry B, 2017, 121, 8467-8474.	1.2	24
186	Lessons from Anti-Amyloid-Î² Immunotherapies in Alzheimer Disease: Aiming at a Moving Target. Neurodegenerative Diseases, 2017, 17, 242-250.	0.8	34
187	Remote Control: Impacts of Peripheral Tumor Necrosis Factor-Alpha on Alzheimer Disease-Related Pathology. Journal of Neuroscience, 2017, 37, 8045-8047.	1.7	7
188	Chronic treatments with a 5-HT 4 receptor agonist decrease amyloid pathology in the entorhinal cortex and learning and memory deficits in the 5xFAD mouse model of Alzheimer's disease. Neuropharmacology, 2017, 126, 128-141.	2.0	41
189	Emerging role of amyloid beta in stress response: Implication for depression and diabetes. European Journal of Pharmacology, 2017, 817, 22-29.	1.7	44
190	Binding of Thioflavin T and Related Probes to Polymorphic Models of Amyloid-Î² Fibrils. Journal of Physical Chemistry B, 2017, 121, 8926-8934.	1.2	34
191	Anti-inflammatory (M2) macrophage media reduce transmission of oligomeric amyloid beta in differentiated SH-SY5Y cells. Neurobiology of Aging, 2017, 60, 173-182.	1.5	34
192	Tuning the stereo-hindrance of a curcumin scaffold for the selective imaging of the soluble forms of amyloid beta species. Chemical Science, 2017, 8, 7710-7717.	3.7	69
193	Memantine inhibits Î²-amyloid aggregation and disassembles preformed Î²-amyloid aggregates. Biochemical and Biophysical Research Communications, 2017, 493, 158-163.	1.0	22
194	New pyridine derivatives as inhibitors of acetylcholinesterase and amyloid aggregation. European Journal of Medicinal Chemistry, 2017, 141, 197-210.	2.6	32
195	Targeting Apolipoprotein E/Amyloid Î² Binding by Peptoid CPO_AÎ²17-21â€‰P Ameliorates Alzheimerâ€™s Disease Related Pathology and Cognitive Decline. Scientific Reports, 2017, 7, 8009.	1.6	47
196	Anti-AÎ² single-chain variable fragment antibodies restore memory acquisition in a Drosophila model of Alzheimerâ€™s disease. Scientific Reports, 2017, 7, 11268.	1.6	13
197	A mix-and-click method to measure amyloid-Î² concentration with sub-micromolar sensitivity. Royal Society Open Science, 2017, 4, 170325.	1.1	11
198	In silico studies of solvated F19W amyloid Î² (11â€“40) trimer. RSC Advances, 2017, 7, 42379-42386.	1.7	15
199	Effect of Alzheimer Familial Chromosomal Mutations on the Amyloid Fibril Interaction with Different PET Tracers: Insight from Molecular Modeling Studies. ACS Chemical Neuroscience, 2017, 8, 2655-2666.	1.7	8

#	Article	IF	Citations
200	E46K Î±-synuclein pathological mutation causes cell-autonomous toxicity without altering protein turnover or aggregation. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E8274-E8283.	3.3	35
201	Advances toward multifunctional cholinesterase and Î²-amyloid aggregation inhibitors. Future Medicinal Chemistry, 2017, 9, 1835-1854.	1.1	29
202	ASK1 in neurodegeneration. Advances in Biological Regulation, 2017, 66, 63-71.	1.4	40
203	Production of Monoclonal Antibodies to Pathologic Î²-sheet Oligomeric Conformers in Neurodegenerative Diseases. Scientific Reports, 2017, 7, 9881.	1.6	13
204	Diversity of Amyloid-beta Proteoforms in the Alzheimerâ€™s Disease Brain. Scientific Reports, 2017, 7, 9520.	1.6	125
205	Fibril structure of amyloid-Î²(1â€“42) by cryoâ€“electron microscopy. Science, 2017, 358, 116-119.	6.0	801
206	Amyloid beta: structure, biology and structure-based therapeutic development. Acta Pharmacologica Sinica, 2017, 38, 1205-1235.	2.8	1,094
207	Suppression of Oligomer Formation and Formation of Nonâ€Toxic Fibrils upon Addition of Mirrorâ€Image Aî²42 to the Natural <scp>l</scp>â€Enantiomer. Angewandte Chemie - International Edition, 2017, 56, 11506-11510.	7.2	76
208	Induced-Pluripotent-Stem-Cell-Derived Primitive Macrophages Provide a Platform for Modeling Tissue-Resident Macrophage Differentiation and Function. Immunity, 2017, 47, 183-198.e6.	6.6	245
209	Amyloid Î² concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimer's and Dementia, 2017, 13, 841-849.	0.4	423
210	Suppression of Oligomer Formation and Formation of Nonâ€Toxic Fibrils upon Addition of Mirrorâ€Image Aî²42 to the Natural <scp>l</scp>â€Enantiomer. Angewandte Chemie, 2017, 129, 11664-11668.	1.6	15
211	Downregulation of protein phosphatase 2A by apolipoprotein E: Implications for Alzheimer's disease. Molecular and Cellular Neurosciences, 2017, 83, 83-91.	1.0	43
213	Transcriptional regulation of APP by apoE: To boldly go where no isoform has gone before. BioEssays, 2017, 39, 1700062.	1.2	9
214	Interaction of misfolded proteins and mitochondria in neurodegenerative disorders. Biochemical Society Transactions, 2017, 45, 1025-1033.	1.6	66
215	Cognitive behavioral therapy (CBT) for preventing Alzheimerâ€™s disease. Behavioural Brain Research, 2017, 334, 163-177.	1.2	10
216	Structural studies of amyloid-Î² peptides: Unlocking the mechanism of aggregation and the associated toxicity. Biochimie, 2017, 140, 176-192.	1.3	59
217	Butyrylcholinesterase-knockout reduces fibrillar Î²-amyloid and conserves 18FDG retention in 5XFAD mouse model of Alzheimerâ€™s disease. Brain Research, 2017, 1671, 102-110.	1.1	27
218	Hydroxy-substituted trans -cinnamoyl derivatives as multifunctional tools in the context of Alzheimer's disease. European Journal of Medicinal Chemistry, 2017, 139, 378-389.	2.6	21

#	Article	IF	Citations
219	BACE inhibition-dependent repair of Alzheimerâ€™s pathophysiology. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 8631-8636.	3.3	93
220	Epigenetic regulation by G9a/<scp>GLP</scp> complex ameliorates amyloidâ€beta 1â€42 induced deficits in longâ€term plasticity and synaptic tagging/capture in hippocampal pyramidal neurons. Aging Cell, 2017, 16, 1062-1072.	3.0	34
221	The A2V mutation as a new tool for hindering AÎ² aggregation: A neutron and x-ray diffraction study. Scientific Reports, 2017, 7, 5510.	1.6	9
222	Clinical Applications of Small-molecule PET Radiotracers: Current Progress and Future Outlook. Seminars in Nuclear Medicine, 2017, 47, 429-453.	2.5	25
223	A human scFv antibody that targets and neutralizes high molecular weight pathogenic amyloidâ€Î² oligomers. Journal of Neurochemistry, 2017, 142, 934-947.	2.1	27
224	Surprisingly high stability of the AÎ² oligomer eliminating all-d-enantiomeric peptide D3 in media simulating the route of orally administered drugs. European Journal of Pharmaceutical Sciences, 2017, 107, 203-207.	1.9	21
226	BACE1 Deficiency Causes Abnormal Neuronal Clustering in the Dentate Gyrus. Stem Cell Reports, 2017, 9, 217-230.	2.3	4
227	Ponezumab in mildâ€toâ€moderate Alzheimer's disease: Randomized phase II PETâ€PIB study. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 393-401.	1.8	47
228	Ube3a deficiency inhibits amyloid plaque formation in APPswe/PS1Î´E9 mouse model of Alzheimerâ€™s disease. Human Molecular Genetics, 2017, 26, 4042-4054.	1.4	28
229	Frontal Cortex and Hippocampal γ-Secretase Activating Protein Levels in Prodromal Alzheimer Disease. Neurodegenerative Diseases, 2017, 17, 235-241.	0.8	11
230	Inactivation of Nitric Oxide Synthesis Exacerbates the Development of Alzheimer Disease Pathology in APPPS1 Mice (Amyloid Precursor Protein/Presenilin-1). Hypertension, 2017, 70, 613-623.	1.3	27
231	<scp>HDAC</scp>3 negatively regulates spatial memory in a mouse model of Alzheimer's disease. Aging Cell, 2017, 16, 1073-1082.	3.0	71
232	Impact of aging immune system on neurodegeneration and potential immunotherapies. Progress in Neurobiology, 2017, 157, 2-28.	2.8	39
233	Inhibition of glycogen synthase kinase-3 by BTA-EG4 reduces tau abnormalities in an organotypic brain slice culture model of Alzheimerâ€™s disease. Scientific Reports, 2017, 7, 7434.	1.6	20
234	APP/AÎ² structural diversity and Alzheimer's disease pathogenesis. Neurochemistry International, 2017, 110, 1-13.	1.9	78
235	Amyloidâ€Î² and islet amyloid pathologies link Alzheimerâ€™s disease and type 2 diabetes in a transgenic model. FASEB Journal, 2017, 31, 5409-5418.	0.2	87
236	Amyloid in Alzheimerâ€™s Disease: Guilty Beyond Reasonable Doubt?. Trends in Pharmacological Sciences, 2017, 38, 849-851.	4.0	22
237	<scp>APP</scp> mouse models for Alzheimer's disease preclinical studies. EMBO Journal, 2017, 36, 2473-2487.	3.5	530

#	Article	IF	Citations
238	Neuroprotective astrocyte-derived insulin/insulin-like growth factor 1 stimulates endocytic processing and extracellular release of neuron-bound AÎ² oligomers. Molecular Biology of the Cell, 2017, 28, 2623-2636.	0.9	88
239	Impaired JIP3-dependent axonal lysosome transport promotes amyloid plaque pathology. Journal of Cell Biology, 2017, 216, 3291-3305.	2.3	107
240	The role of astrocytes in amyloid production and Alzheimer's disease. Open Biology, 2017, 7, 170228.	1.5	269
241	Breaking the Cycle, Cholesterol Cycling, and Synapse Damage in Response to Amyloid-Î². Journal of Experimental Neuroscience, 2017, 11, 117906951773309.	2.3	3
242	Prophylactic Active Tau Immunization Leads to Sustained Reduction in Both Tau and Amyloid-Î² Pathologies in 3xTg Mice. Scientific Reports, 2017, 7, 17034.	1.6	39
243	18F PET with florbetapir for the early diagnosis of Alzheimerâ€™s disease dementia and other dementias in people with mild cognitive impairment (MCI). The Cochrane Library, 2017, 2017, CD012216.	1.5	32
244	18F PET with flutemetamol for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). The Cochrane Library, 2017, 2017, CD012884.	1.5	29
245	25 Years of the Amyloid Hypothesis of the Origin of Alzheimerâ€™s Disease: Advances, Failures, and New Perspectives. Neuroscience and Behavioral Physiology, 2017, 47, 1065-1070.	0.2	3
246	The AÎ² oligomer eliminating D-enantiomeric peptide RD2 improves cognition without changing plaque pathology. Scientific Reports, 2017, 7, 16275.	1.6	42
247	Amyloid Accumulation Drives Proteome-wide Alterations in Mouse Models of Alzheimerâ€™s Disease-like Pathology. Cell Reports, 2017, 21, 2614-2627.	2.9	56
248	Activation of Î³-Secretase Trimming Activity by Topological Changes of Transmembrane Domain 1 of Presenilin 1. Journal of Neuroscience, 2017, 37, 12272-12280.	1.7	27
249	CRISPR Transcriptional Activation Analysis Unmasks an Occult Î³-Secretase Processivity Defect in Familial Alzheimerâ€™s Disease Skin Fibroblasts. Cell Reports, 2017, 21, 1727-1736.	2.9	24
250	Complexity and Selectivity of Î³-Secretase Cleavage on Multiple Substrates: Consequences in Alzheimerâ€™s Disease and Cancer. Journal of Alzheimer's Disease, 2017, 61, 1-15.	1.2	17
251	Activation of G-protein-gated inwardly rectifying potassium (Kir3/GirK) channels rescues hippocampal functions in a mouse model of early amyloid-Î² pathology. Scientific Reports, 2017, 7, 14658.	1.6	41
252	EGCG inhibits the oligomerization of amyloid beta (16-22) hexamer: Theoretical studies. Journal of Molecular Graphics and Modelling, 2017, 76, 1-10.	1.3	38
253	Sembragiline: A Novel, Selective Monoamine Oxidase Type B Inhibitor for the Treatment of Alzheimerâ€™s Disease. Journal of Pharmacology and Experimental Therapeutics, 2017, 362, 413-423.	1.3	72
254	Amyloid plaques beyond AÎ²: a survey of the diverse modulators of amyloid aggregation. Biophysical Reviews, 2017, 9, 405-419.	1.5	74
255	Protein homeostasis of a metastable subproteome associated with Alzheimerâ€™s disease. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E5703-E5711.	3.3	77

#	Article	IF	Citations
256	Amylin Receptor: A Potential Therapeutic Target for Alzheimerâ€™s Disease. Trends in Molecular Medicine, 2017, 23, 709-720.	3.5	21
257	Towards the improvement in stability of an anti-AÎ² single-chain variable fragment, scFv-h3D6, as a way to enhance its therapeutic potential. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 167-175.	1.4	8
258	Excess APPO-glycosylation by GalNAc-T6 decreases AÎ² production. Journal of Biochemistry, 2017, 161, 99-111.	0.9	31
259	Role of Vitamin D in Amyloid clearance via LRP-1 upregulation in Alzheimerâ€™s disease: A potential therapeutic target?. Journal of Chemical Neuroanatomy, 2017, 85, 36-42.	1.0	32
260	Extracellular vesicles: Novel promising delivery systems for therapy of brain diseases. Journal of Controlled Release, 2017, 262, 247-258.	4.8	298
261	Silent Allosteric Modulation of mGluR5 Maintains Glutamate Signaling while Rescuing Alzheimerâ€™s Mouse Phenotypes. Cell Reports, 2017, 20, 76-88.	2.9	84
262	Ablating ErbB4 in PV neurons attenuates synaptic and cognitive deficits in an animal model of Alzheimer's disease. Neurobiology of Disease, 2017, 106, 171-180.	2.1	42
263	The fate of the brain cholinergic neurons in neurodegenerative diseases. Brain Research, 2017, 1670, 173-184.	1.1	102
264	Inhibition of Alzheimer's amyloid-beta aggregation in-vitro by carbenoxolone: Insight into mechanism of action. Neurochemistry International, 2017, 108, 481-493.	1.9	34
266	Adeno-Associated Virus (AAV) as a Vector for Gene Therapy. BioDrugs, 2017, 31, 317-334.	2.2	773
267	Quantification of Butyrylcholinesterase Activity as a Sensitive and Specific Biomarker of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2017, 58, 491-505.	1.2	57
268	Cell signalling pathway regulation by RanBPM: molecular insights and disease implications. Open Biology, 2017, 7, 170081.	1.5	34
269	Elucidating Important Sites and the Mechanism for Amyloid Fibril Formation by Coarse-Grained Molecular Dynamics. ACS Chemical Neuroscience, 2017, 8, 201-209.	1.7	32
270	Rejecting the Alzheimer's disease vaccine development for the wrong reasons. Drug Discovery Today, 2017, 22, 609-614.	3.2	8
271	Cannabinoids prevent the amyloid Î²â€induced activation of astroglial hemichannels: A neuroprotective mechanism. Glia, 2017, 65, 122-137.	2.5	50
272	Chitosan oligosaccharide: Biological activities and potential therapeutic applications. , 2017, 170, 80-97.		385
273	Alpha-synuclein and beta-amyloid â€“ different targets, same players: calcium, free radicals and mitochondria in the mechanism of neurodegeneration. Biochemical and Biophysical Research Communications, 2017, 483, 1110-1115.	1.0	67
274	Coarseâ€grained and Allâ€atom Simulations towards the Early and Late Steps of Amyloid Fibril Formation. Israel Journal of Chemistry, 2017, 57, 564-573.	1.0	23

#	Article	IF	Citations
275	Neuroinflammatory challenges compromise neuronal function in the aging brain: Postoperative cognitive delirium and Alzheimerâ€™s disease. Behavioural Brain Research, 2017, 322, 269-279.	1.2	55
276	The role of cell adhesion molecules in brain wiring and neuropsychiatric disorders. Molecular and Cellular Neurosciences, 2017, 81, 4-11.	1.0	28
277	RNAâ€binding proteins implicated in neurodegenerative diseases. Wiley Interdisciplinary Reviews RNA, 2017, 8, e1397.	3.2	45
278	Emerging pathways driving early synaptic pathology in Alzheimer's disease. Biochemical and Biophysical Research Communications, 2017, 483, 988-997.	1.0	69
279	Proteins behaving badly. Substoichiometric molecular control and amplification of the initiation and nature of amyloid fibril formation: lessons from and for blood clotting. Progress in Biophysics and Molecular Biology, 2017, 123, 16-41.	1.4	64
280	The Threshold Theory for Parkinson's Disease. Trends in Neurosciences, 2017, 40, 4-14.	4.2	153
281	Factor XII as a Therapeutic Target in Thromboembolic and Inflammatory Diseases. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 13-20.	1.1	108
282	Pumping the Brakes: Neurotrophic Factors for the Prevention of Cognitive Impairment and Dementia after Traumatic Brain Injury. Journal of Neurotrauma, 2017, 34, 971-986.	1.7	15
283	Increased Foxo3a Nuclear Translocation and Activity is an Early Neuronal Response to Î²Î³-Secretase-Mediated Processing of the Amyloid-Î² Protein Precursor: Utility of an AÎ²PP-GAL4 Reporter Assay. Journal of Alzheimer's Disease, 2017, 61, 673-688.	1.2	11
284	Intracellular trafficking of TREM2 is regulated by presenilin 1. Experimental and Molecular Medicine, 2017, 49, e405-e405.	3.2	17
285	A Novel Probe with a Chlorinated Î±-Cyanoacetophenone Acceptor Moiety Shows Near-Infrared Fluorescence Specific for Tau Fibrils. Chemical and Pharmaceutical Bulletin, 2017, 65, 1113-1116.	0.6	5
286	18F PET with florbetaben for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). The Cochrane Library, 2017, 2017, CD012883.	1.5	23
287	Multi-Feature Kernel Discriminant Dictionary Learning for Classification in Alzheimer's Disease. , 2017, , .		0
288	Polygalae Radix Extract Prevents Axonal Degeneration and Memory Deficits in a Transgenic Mouse Model of Alzheimerâ€™s Disease. Frontiers in Pharmacology, 2017, 8, 805.	1.6	34
289	Rodent Models for Alzheimerâ€™s Disease in Drug Discovery. , 2017, , 235-247.		5
290	Genetic, Transcriptome, Proteomic, and Epidemiological Evidence for Blood-Brain Barrier Disruption and Polymicrobial Brain Invasion as Determinant Factors in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease Reports, 2017, 1, 125-157.	1.2	47
291	Of Energy and Entropy: The Ineluctable Impact of Aging in Old Age Dementia. International Journal of Molecular Sciences, 2017, 18, 2672.	1.8	28
292	An Extract from Shrimp Processing By-Products Protects SH-SY5Y Cells from Neurotoxicity Induced by AÎ²25â€“35. Marine Drugs, 2017, 15, 83.	2.2	18

#	Article	IF	Citations
293	An Overview of the Protective Effects of Chitosan and Acetylated Chitosan Oligosaccharides against Neuronal Disorders. Marine Drugs, 2017, 15, 89.	2.2	54
294	Phytochemical Quantification and the In Vitro Acetylcholinesterase Inhibitory Activity of Phellodendron chinense and Its Components. Molecules, 2017, 22, 925.	1.7	14
295	Development of 2-Methoxyhuprine as Novel Lead for Alzheimerâ€™s Disease Therapy. Molecules, 2017, 22, 1265.	1.7	26
296	5-Hydroxycyclopenicillone Inhibits Î²-Amyloid Oligomerization and Produces Anti-Î²-Amyloid Neuroprotective Effects In Vitro. Molecules, 2017, 22, 1651.	1.7	10
297	BACE1 Function and Inhibition: Implications of Intervention in the Amyloid Pathway of Alzheimerâ€™s Disease Pathology. Molecules, 2017, 22, 1723.	1.7	89
298	Resveratrol and Amyloid-Beta: Mechanistic Insights. Nutrients, 2017, 9, 1122.	1.7	67
299	Some News on Old Concepts and the Epigenetics of Alzheimerâ€™s Disease. Journal of Clinical Epigenetics, 2017, 03, .	0.3	1
300	Involvement of Astrocytes in Alzheimerâ€™s Disease from a Neuroinflammatory and Oxidative Stress Perspective. Frontiers in Molecular Neuroscience, 2017, 10, 427.	1.4	377
301	Why are Functional Amyloids Non-Toxic in Humans?. Biomolecules, 2017, 7, 71.	1.8	68
302	Driver or Passenger: Epigenomes in Alzheimerâ€™s Disease. Epigenomes, 2017, 1, 5.	0.8	2
303	Amyloid Î² Modification: A Key to the Sporadic Alzheimer's Disease?. Frontiers in Genetics, 2017, 8, 58.	1.1	52
304	Protein Tyrosine Phosphatase 1B (PTP1B): A Potential Target for Alzheimerâ€™s Therapy?. Frontiers in Aging Neuroscience, 2017, 9, 7.	1.7	80
305	Cerebrospinal Fluid Levels of Amyloid Beta 1-43 Mirror 1-42 in Relation to Imaging Biomarkers of Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2017, 9, 9.	1.7	22
306	Transthyretin and BRICHOS: The Paradox of Amyloidogenic Proteins with Anti-Amyloidogenic Activity for AÎ² in the Central Nervous System. Frontiers in Neuroscience, 2017, 11, 119.	1.4	31
307	The Anti-Inflammatory Effects of Lipoxygenase and Cyclo-Oxygenase Inhibitors in Inflammation-Induced Human Fetal Glia Cells and the AÎ² Degradation Capacity of Human Fetal Astrocytes in an Ex vivo Assay. Frontiers in Neuroscience, 2017, 11, 299.	1.4	9
308	Axonal Degeneration during Aging and Its Functional Role in Neurodegenerative Disorders. Frontiers in Neuroscience, 2017, 11, 451.	1.4	139
309	MT5-MMP Promotes Alzheimerâ€™s Pathogenesis in the Frontal Cortex of 5xFAD Mice and APP Trafficking in vitro. Frontiers in Molecular Neuroscience, 2016, 9, 163.	1.4	34
310	Structure and Synaptic Function of Metal Binding to the Amyloid Precursor Protein and its Proteolytic Fragments. Frontiers in Molecular Neuroscience, 2017, 10, 21.	1.4	30

#	Article	IF	Citations
311	Therapeutic Potential of Secreted Amyloid Precursor Protein APPsÎ±. Frontiers in Molecular Neuroscience, 2017, 10, 30.	1.4	91
312	Fe65-PTB2 Dimerization Mimics Fe65-APP Interaction. Frontiers in Molecular Neuroscience, 2017, 10, 140.	1.4	10
313	Amyloid-precursor Like Proteins APLP1 and APLP2 Are Dispensable for Normal Development of the Neonatal Respiratory Network. Frontiers in Molecular Neuroscience, 2017, 10, 189.	1.4	5
314	Amyloid-Î² Impairs Vesicular Secretion in Neuronal and Astrocyte Peptidergic Transmission. Frontiers in Molecular Neuroscience, 2017, 10, 202.	1.4	9
315	Editorial: The Physiological Functions of the APP Gene Family. Frontiers in Molecular Neuroscience, 2017, 10, 334.	1.4	5
316	Indirubin Derivative 7-Bromoindirubin-3-Oxime (7Bio) Attenuates AÎ² Oligomer-Induced Cognitive Impairments in Mice. Frontiers in Molecular Neuroscience, 2017, 10, 393.	1.4	16
317	The Delicate Balance of Autophagy in Neurodegeneration. , 2017, , 387-399.		2
318	AÎ²Peptide Originated from Platelets Promises New Strategy in Anti-Alzheimerâ€™s Drug Development. BioMed Research International, 2017, 2017, 1-10.	0.9	25
319	Neuroprotective Effects and Mechanism of Î²-Asarone against AÎ²1â€“42-Induced Injury in Astrocytes. Evidence-based Complementary and Alternative Medicine, 2017, 2017, 1-14.	0.5	17
320	Nutrition and AGE-ing: Focusing on Alzheimerâ€™s Disease. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-10.	1.9	71
321	New drugs in psychiatry: focus on new pharmacological targets. F1000Research, 2017, 6, 397.	0.8	23
322	Analyzing Amyloid-Î² Peptide Modulation Profiles and Binding Sites of Î³-Secretase Modulators. Methods in Enzymology, 2017, 584, 157-183.	0.4	5
323	Amyloid-Related Imaging Abnormalities inÂan Aged Squirrel Monkey with Cerebral Amyloid Angiopathy. Journal of Alzheimer's Disease, 2017, 57, 519-530.	1.2	22
324	Numerical Simulations Reveal Randomness of Cu(II) Induced AÎ² Peptide Dimerization under Conditions Present in Glutamatergic Synapses. PLoS ONE, 2017, 12, e0170749.	1.1	19
325	Alzheimerâ€™s amyloid-Î² A2T variant and its N-terminal peptides inhibit amyloid-Î² fibrillization and rescue the induced cytotoxicity. PLoS ONE, 2017, 12, e0174561.	1.1	24
326	Progranulin gene delivery reduces plaque burden and synaptic atrophy in a mouse model of Alzheimer's disease. PLoS ONE, 2017, 12, e0182896.	1.1	35
327	Traffic-Related Air Pollution and Neurodegenerative Diseases: Epidemiological and Experimental Evidence, and Potential Underlying Mechanisms. Advances in Neurotoxicology, 2017, 1, 1-46.	0.7	6
328	Cognitive function in very old men does not correlate to biomarkers of Alzheimerâ€™s disease. BMC Geriatrics, 2017, 17, 208.	1.1	9

#	Article	IF	Citations
329	Drug candidates in clinical trials for Alzheimerâ€™s disease. Journal of Biomedical Science, 2017, 24, 47.	2.6	330
330	Non-canonical soluble amyloid-beta aggregates and plaque buffering: controversies and future directions for target discovery in Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2017, 9, 62.	3.0	62
331	PKR involvement in Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2017, 9, 83.	3.0	52
332	Neurons derived from sporadic Alzheimerâ€™s disease iPSCs reveal elevated TAU hyperphosphorylation, increased amyloid levels, and GSK3B activation. Alzheimer's Research and Therapy, 2017, 9, 90.	3.0	161
333	Posterior atrophy predicts time to dementia in patients with amyloid-positive mild cognitive impairment. Alzheimer's Research and Therapy, 2017, 9, 99.	3.0	11
334	Role of BACE1 in Alzheimerâ€™s synaptic function. Translational Neurodegeneration, 2017, 6, 23.	3.6	80
335	Distinct deposition of amyloid-Î² species in brains with Alzheimerâ€™s disease pathology visualized with MALDI imaging mass spectrometry. Acta Neuropathologica Communications, 2017, 5, 73.	2.4	85
336	Caffeine Neuroprotective Mechanism Against Î²-Amyloid Neurotoxicity in SHSY5Y Cell Line: Involvement of Adenosine, Ryanodine, and N-Methyl-D-Aspartate Receptors. Advanced Pharmaceutical Bulletin, 2017, 7, 579-584.	0.6	8
337	AL amyloidosis: from molecular mechanisms to targeted therapies. Hematology American Society of Hematology Education Program, 2017, 2017, 1-12.	0.9	137
338	Chronic Verubecestat Treatment Suppresses Amyloid Accumulation in Advanced Aged Tg2576-AÎ²PPswe Mice Without Inducing Microhemorrhage. Journal of Alzheimer's Disease, 2017, 59, 1393-1413.	1.2	24
339	PLGA nanoparticles modified with a BBB-penetrating peptide co-delivering AÎ² generation inhibitor and curcumin attenuate memory deficits and neuropathology in Alzheimer's disease mice. Oncotarget, 2017, 8, 81001-81013.	0.8	111
340	Developmental Exposure to Metals and its Contribution to Age-Related Neurodegeneration. , 2017, , 217-229.		1
341	Metabolism-Centric Overview of the Pathogenesis of Alzheimer's Disease. Yonsei Medical Journal, 2017, 58, 479.	0.9	94
342	Proteinopathy, oxidative stress and mitochondrial dysfunction: cross talk in Alzheimer's disease and Parkinson's disease. Drug Design, Development and Therapy, 2017, Volume11, 797-810.	2.0	217
343	Comprehensive Overview of Alzheimerâ€™s Disease Neurodegeneration, from Amyloid-Î² to Neuroinflammatory Modulation. , 0, , .		0
344	The emerging role of PET imaging in dementia. F1000Research, 2017, 6, 1830.	0.8	43
345	Large-Scale Oral Treatment Study with the Four Most Promising D3-Derivatives for the Treatment of Alzheimerâ€™s Disease. Molecules, 2017, 22, 1693.	1.7	26
346	A Case Report of a 37-Year-Old Alzheimer's Disease Patient with Prominent Striatum Amyloid Retention. Psychiatry Investigation, 2017, 14, 521.	0.7	6

#	Article	IF	Citations
347	Sostenibilidad y turismo en los paisajes culturales de la industrializaciÃ³n. Arbor, 2017, 193, 400.	0.1	8
348	MicroRNA-107 prevents amyloid-Î²-induced neurotoxicity and memory impairment in mice. International Journal of Molecular Medicine, 2018, 41, 1665-1672.	1.8	34
349	Current concepts and controversies in the pathogenesis of Parkinsonâ€™s disease dementia and Dementia with Lewy Bodies. F1000Research, 2017, 6, 1604.	0.8	35
350	Probing the Structure and Function Relationships of Presenilin by Substituted-Cysteine Accessibility Method. Methods in Enzymology, 2017, 584, 185-205.	0.4	10
351	Evolvability of Amyloidogenic Proteins in Human Brain. Journal of Alzheimer's Disease, 2018, 62, 73-83.	1.2	23
352	Autophagy activated by SIRT6 regulates AÎ² induced inflammatory response in RPEs. Biochemical and Biophysical Research Communications, 2018, 496, 1148-1154.	1.0	16
353	Elevated phospholipase D isoform 1 in Alzheimer's disease patients' hippocampus: Relevance to synaptic dysfunction and memory deficits. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 89-102.	1.8	27
354	Protective effects of 7,8-dihydroxyflavone on neuropathological and neurochemical changes in a mouse model of Alzheimer's disease. European Journal of Pharmacology, 2018, 828, 9-17.	1.7	36
355	TREM2 Is a Receptor for Î²-Amyloid that Mediates Microglial Function. Neuron, 2018, 97, 1023-1031.e7.	3.8	462
356	sAPPÎ² and sAPPÎ± increase structural complexity and E/I input ratio in primary hippocampal neurons and alter Ca2+ homeostasis and CREB1-signaling. Experimental Neurology, 2018, 304, 1-13.	2.0	9
357	Amyloid-Î² with isomerized Asp7 cytotoxicity is coupled to protein phosphorylation. Scientific Reports, 2018, 8, 3518.	1.6	24
358	Genetic variation in Aquaporin-4 moderates the relationship between sleep and brain AÎ²-amyloid burden. Translational Psychiatry, 2018, 8, 47.	2.4	92
359	Longitudinal Modeling of Functional Decline Associated with Pathologic Alzheimerâ€™s Disease in Older Persons without Cognitive Impairment. Journal of Alzheimer's Disease, 2018, 62, 855-865.	1.2	5
360	Chemical Kinetics for Bridging Molecular Mechanisms and Macroscopic Measurements of Amyloid Fibril Formation. Annual Review of Physical Chemistry, 2018, 69, 273-298.	4.8	161
361	Inhibition of amyloid AÎ² aggregation by high pressures or specific<scp>d</scp>-enantiomeric peptides. Chemical Communications, 2018, 54, 3294-3297.	2.2	13
362	Neuroimmune Axes of the Bloodâ€“Brain Barriers and Bloodâ€“Brain Interfaces: Bases for Physiological Regulation, Disease States, and Pharmacological Interventions. Pharmacological Reviews, 2018, 70, 278-314.	7.1	242
363	Weaker N-Terminal Interactions for the Protective over the Causative AÎ² Peptide Dimer Mutants. ACS Chemical Neuroscience, 2018, 9, 1247-1253.	1.7	18
364	Past to Future: What Animal Models Have Taught Us About Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2018, 64, S365-S378.	1.2	22

#	Article	IF	Citations
365	Amyloid growth and membrane damage: Current themes and emerging perspectives from theory and experiments on AÎ² and hIAPP. Biochimica Et Biophysica Acta - Biomembranes, 2018, 1860, 1625-1638.	1.4	103
366	An Artificial Neural Network Integrated Pipeline for Biomarker Discovery Using Alzheimer's Disease as a Case Study. Computational and Structural Biotechnology Journal, 2018, 16, 77-87.	1.9	56
367	Etiology of type 2 diabetes and Alzheimer's disease: Exploring the mitochondria. Mitochondrion, 2018, 43, 16-24.	1.6	40
368	Low Cerebrospinal Fluid AÎ²42 and AÎ²40 are Related to White Matter Lesions in Cognitively Normal Elderly. Journal of Alzheimer's Disease, 2018, 62, 1877-1886.	1.2	13
369	Critical review: involvement of endoplasmic reticulum stress in the aetiology of Alzheimer's disease. Open Biology, 2018, 8, 180024.	1.5	106
370	Diffusible, highly bioactive oligomers represent a critical minority of soluble AÎ² in Alzheimerâ€™s disease brain. Acta Neuropathologica, 2018, 136, 19-40.	3.9	100
371	Amyloid-Î² Peptide Interactions with Amphiphilic Surfactants: Electrostatic and Hydrophobic Effects. ACS Chemical Neuroscience, 2018, 9, 1680-1692.	1.7	51
372	Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-Î². Scientific Reports, 2018, 8, 6412.	1.6	182
373	Influence of various force fields in estimating the binding affinity of acetylcholinesterase inhibitors using fast pulling of ligand scheme. Chemical Physics Letters, 2018, 701, 65-71.	1.2	12
374	Amyloid assembly and disassembly. Journal of Cell Science, 2018, 131, .	1.2	138
375	Computational Analysis for the Rational Design of Anti-Amyloid Beta (AÎ²) Antibodies. Journal of Physical Chemistry B, 2018, 122, 4521-4536.	1.2	8
376	A solution NMR toolset to probe the molecular mechanisms of amyloid inhibitors. Chemical Communications, 2018, 54, 4644-4652.	2.2	33
377	Distinct inÂvivo roles of secreted <scp>APP</scp> ectodomain variants <scp>APP</scp> sÎ± and <scp>APP</scp> sÎ² in regulation of spine density, synaptic plasticity, and cognition. EMBO Journal, 2018, 37, .	3.5	62
378	Next generation antibody drugs: pursuit of the 'high-hanging fruit'. Nature Reviews Drug Discovery, 2018, 17, 197-223.	21.5	595
379	Evidence of demyelination in mild cognitive impairment and dementia using a direct and specific magnetic resonance imaging measure of myelin content. Alzheimer's and Dementia, 2018, 14, 998-1004.	0.4	105
380	Adenosine Augmentation Evoked by an ENT1 Inhibitor Improves Memory Impairment and Neuronal Plasticity in the APP/PS1 Mouse Model of Alzheimerâ€™s Disease. Molecular Neurobiology, 2018, 55, 8936-8952.	1.9	46
381	Adrenomedullin, a Novel Target for Neurodegenerative Diseases. Molecular Neurobiology, 2018, 55, 8799-8814.	1.9	17
382	Determining the Potential of Mean Force for Amyloid-Î² Dimerization: Combining Self-Consistent Field Theory with Molecular Dynamics Simulation. Journal of Chemical Theory and Computation, 2018, 14, 2696-2704.	2.3	16

#	Article	IF	Citations
383	The Vascular Hypothesis of Alzheimerâ€™s Disease: A Key to Preclinical Prediction of Dementia Using Neuroimaging. Journal of Alzheimer's Disease, 2018, 63, 35-52.	1.2	90
384	Therapeutic potential of vitamin E and its derivatives in traumatic brain injury-associated dementia. Neurological Sciences, 2018, 39, 989-998.	0.9	11
385	3D structure determination of amyloid fibrils using solid-state NMR spectroscopy. Methods, 2018, 138-139, 26-38.	1.9	60
386	Waterâ€Dispersible Polydopamineâ€Coated Nanofibers for Stimulation of Neuronal Growth and Adhesion. Advanced Healthcare Materials, 2018, 7, e1701485.	3.9	29
387	Can Curcumin Counteract Cognitive Decline? Clinical Trial Evidence and Rationale for Combining Ï‰-3 Fatty Acids with Curcumin. Advances in Nutrition, 2018, 9, 105-113.	2.9	20
388	Chitooligosaccharide: An evaluation of physicochemical and biological properties with the proposition for determination of thermal degradation products. Biomedicine and Pharmacotherapy, 2018, 102, 438-451.	2.5	65
389	Propafenone effects on the stable structures of AÎ²16-22 system. Chemical Physics Letters, 2018, 696, 55-60.	1.2	6
390	Precision pharmacology for Alzheimerâ€™s disease. Pharmacological Research, 2018, 130, 331-365.	3.1	79
391	Lentivirus-Mediated HDAC3 Inhibition Attenuates Oxidative Stress in APPswe/PS1dE9 Mice. Journal of Alzheimer's Disease, 2018, 61, 1411-1424.	1.2	30
392	Design, synthesis and pharmacological evaluation of N -benzyl-piperidinyl-aryl-acylhydrazone derivatives as donepezil hybrids: Discovery of novel multi-target anti-alzheimer prototype drug candidates. European Journal of Medicinal Chemistry, 2018, 147, 48-65.	2.6	52
393	Imbalance between firing homeostasis and synaptic plasticity drives early-phase Alzheimerâ€™s disease. Nature Neuroscience, 2018, 21, 463-473.	7.1	225
394	Peripheral and Central Effects of Memantine in a Mixed Preclinical Mice Model of Obesity and Familial Alzheimerâ€™s Disease. Molecular Neurobiology, 2018, 55, 7327-7339.	1.9	24
395	Neurobiological links between depression and AD: The role of TGF-Î²1 signaling as a new pharmacological target. Pharmacological Research, 2018, 130, 374-384.	3.1	126
396	BACE1 deletion in the adult mouse reverses preformed amyloid deposition and improves cognitive functions. Journal of Experimental Medicine, 2018, 215, 927-940.	4.2	92
397	Quantitative Measurement of γ-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms. Journal of Visualized Experiments, 2018, , .	0.2	1
398	Novel Multitarget-Directed Ligands Aiming at Symptoms and Causes of Alzheimerâ€™s Disease. ACS Chemical Neuroscience, 2018, 9, 1195-1214.	1.7	44
399	Role of Amyloid Precursor Protein (APP) and Its Derivatives in the Biology and Cell Fate Specification of Neural Stem Cells. Molecular Neurobiology, 2018, 55, 7107-7117.	1.9	56
400	Overexpression of SNX3 Decreases Amyloid-Î² Peptide Production by Reducing Internalization of Amyloid Precursor Protein. Neurodegenerative Diseases, 2018, 18, 26-37.	0.8	11

#	Article	IF	Citations
401	Depletion of amyloidâ€Î²2 peptides from solution by sequestration within fibrilâ€seeded hydrogels. Protein Science, 2018, 27, 1218-1230.	3.1	6
402	The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a nonâ€human primate model of Alzheimer's disease. Journal of Pathology, 2018, 245, 85-100.	2.1	180
403	Design, Synthesis, and Biological Evaluation of 1-Benzylamino-2-hydroxyalkyl Derivatives as New Potential Disease-Modifying Multifunctional Anti-Alzheimerâ€™s Agents. ACS Chemical Neuroscience, 2018, 9, 1074-1094.	1.7	47
404	Trial of Solanezumab for Mild Dementia Due to Alzheimerâ€™s Disease. New England Journal of Medicine, 2018, 378, 321-330.	13.9	795
405	Identification of rare RTN3 variants in Alzheimerâ€™s disease in Han Chinese. Human Genetics, 2018, 137, 141-150.	1.8	22
406	Factors influencing accuracy of cortical thickness in the diagnosis of Alzheimer's disease. Human Brain Mapping, 2018, 39, 1500-1515.	1.9	21
407	APP/Go protein GÎ²Î³-complex signaling mediates AÎ² degeneration and cognitive impairment in Alzheimer's disease models. Neurobiology of Aging, 2018, 64, 44-57.	1.5	15
408	Metabotropic glutamate receptors: the potential for therapeutic applications in Alzheimer's disease. Current Opinion in Pharmacology, 2018, 38, 1-7.	1.7	29
409	Celecoxib Prevents Cognitive Impairment and Neuroinflammation in Soluble Amyloid Î²-treated Rats. Neuroscience, 2018, 372, 58-73.	1.1	47
410	Development and validation of an UHPLC-ESI-QTOF-MS method for quantification of the highly hydrophilic amyloid-Î² oligomer eliminating all- D -enantiomeric peptide RD2 in mouse plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2018, 1073, 123-129.	1.2	0
411	Memantine for the Treatment of Dementia: A Review on its Current and Future Applications. Journal of Alzheimer's Disease, 2018, 62, 1223-1240.	1.2	150
412	Molecular characterization of the <scp>Î²</scp>â€amyloid(4â€10) epitope of plaque specific <scp>AÎ²</scp> antibodies by affinityâ€mass spectrometry using alanine site mutation. Journal of Peptide Science, 2018, 24, e3047.	0.8	9
413	Emerging Mechanisms in Alzheimerâ€™s Disease and Their Therapeutic Implications. Biological Psychiatry, 2018, 83, 298-299.	0.7	3
414	Immunotherapy for neurodegenerative diseases: the Alzheimer's disease paradigm. Current Opinion in Chemical Engineering, 2018, 19, 59-67.	3.8	8
415	Kv1.3 inhibition as a potential microglia-targeted therapy for Alzheimerâ€™s disease: preclinical proof of concept. Brain, 2018, 141, 596-612.	3.7	79
416	Organophosphorus Compounds at 80: Some Old and New Issues. Toxicological Sciences, 2018, 162, 24-35.	1.4	156
417	Alzheimerâ€™s Disease: From Firing Instability to Homeostasis Network Collapse. Neuron, 2018, 97, 32-58.	3.8	188
418	Dysregulation of Rab5â€mediated endocytic pathways in Alzheimer's disease. Traffic, 2018, 19, 253-262.	1.3	52

#	Article	IF	Citations
419	Oligoethyleneoxy-Modified ^{99m}Tc-Labeled Î²-Amyloid Imaging Probes with Improved Brain Pharmacokinetics for Single-Photon Emission Computed Tomography. Journal of Medicinal Chemistry, 2018, 61, 1330-1339.	2.9	14
420	Up-regulated Pro-inflammatory MicroRNAs (miRNAs) in Alzheimerâ€™s disease (AD) and Age-Related Macular Degeneration (AMD). Cellular and Molecular Neurobiology, 2018, 38, 1021-1031.	1.7	80
421	Bexarotene Binds to the Amyloid Precursor Protein Transmembrane Domain, Alters Its Î±-Helical Conformation, and Inhibits Î³-Secretase Nonselectively in Liposomes. ACS Chemical Neuroscience, 2018, 9, 1702-1713.	1.7	11
422	Imaging AÎ² and tau in early stage Alzheimerâ€™s disease with [18F]AV45 and [18F]AV1451. EJNMMI Research, 2018, 8, 19.	1.1	14
423	Prion-like propagation of Î²-amyloid aggregates in the absence of APP overexpression. Acta Neuropathologica Communications, 2018, 6, 26.	2.4	41
424	Well-Posedness of a Mathematical Model for Alzheimer's Disease. SIAM Journal on Mathematical Analysis, 2018, 50, 2362-2388.	0.9	9
425	Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimerâ€™s Disease. New England Journal of Medicine, 2018, 378, 1691-1703.	13.9	512
426	Generation of App knock-in mice reveals deletion mutations protective against Alzheimerâ€™s disease-like pathology. Nature Communications, 2018, 9, 1800.	5.8	33
427	Evidence for altered dendritic spine compartmentalization in Alzheimerâ€™s disease and functional effects in a mouse model. Acta Neuropathologica, 2018, 135, 839-854.	3.9	60
428	Supratherapeutic concentrations of cilostazol inhibits Î²-amyloid oligomerization in vitro. Neuroscience Letters, 2018, 677, 19-25.	1.0	12
429	The Neuronal Tau Protein Blocks in Vitro Fibrillation of the Amyloid-Î² (AÎ²) Peptide at the Oligomeric Stage. Journal of the American Chemical Society, 2018, 140, 8138-8146.	6.6	49
430	Brain Inflammation Connects Cognitive and Non-Cognitive Symptoms in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2018, 64, S313-S327.	1.2	31
431	Cysteine-Rich Repeat Domains 2 and 4 are Amyloid-Î² Binding Domains of Neurotrophin Receptor p75NTR and Potential Targets to Block Amyloid-Î² Neurotoxicity. Journal of Alzheimer's Disease, 2018, 63, 139-147.	1.2	9
432	New Insights Into Autophagy Dysfunction Related to Amyloid Beta Toxicity and Neuropathology in Alzheimer's Disease. International Review of Cell and Molecular Biology, 2018, 336, 321-361.	1.6	29
433	Targeting Amyloid-Î² Precursor Protein, APP, Splicing with Antisense Oligonucleotides Reduces Toxic Amyloid-Î² Production. Molecular Therapy, 2018, 26, 1539-1551.	3.7	27
434	AÎ²42 Protofibrils Interact with and Are Trafficked through Microglial-Derived Microvesicles. ACS Chemical Neuroscience, 2018, 9, 1416-1425.	1.7	32
435	Toward a New Concept of Alzheimerâ€™s Disease Models: A Perspective from Neuroinflammation. Journal of Alzheimer's Disease, 2018, 64, S329-S338.	1.2	22
436	Tongluo Xingnao effervescent tablet reverses memory deficit and reduces plaque load in APPswe/PS1dE9 mice. Experimental and Therapeutic Medicine, 2018, 15, 4005-4013.	0.8	5

#	Article	IF	Citations
437	Angiotensin-converting enzyme in innate and adaptive immunity. Nature Reviews Nephrology, 2018, 14, 325-336.	4.1	166
438	The Coming of Age of the Angiotensin Hypothesis in Alzheimerâ€™s Disease: Progress Toward Disease Prevention and Treatment?. Journal of Alzheimer's Disease, 2018, 62, 1443-1466.	1.2	105
439	Cystatin C promotes tau protein phosphorylation and causes microtubule instability by inhibiting intracellular turnover of GSK3Î² in neurons. Molecular and Cellular Neurosciences, 2018, 89, 1-8.	1.0	4
440	Volume and Connectivity of the Ventral Tegmental Area are Linked to Neurocognitive Signatures of Alzheimerâ€™s Disease in Humans. Journal of Alzheimer's Disease, 2018, 63, 167-180.	1.2	75
441	Bajijiasu Ameliorates Î²-Amyloid-Triggered Endoplasmic Reticulum Stress and Related Pathologies in an Alzheimerâ€™s Disease Model. Cellular Physiology and Biochemistry, 2018, 46, 107-117.	1.1	21
442	Potential Novel Approaches to Understand the Pathogenesis and Treat Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2018, 64, S299-S312.	1.2	22
443	VDAC1, mitochondrial dysfunction, and Alzheimer's disease. Pharmacological Research, 2018, 131, 87-101.	3.1	153
444	Zinc ion rapidly induces toxic, off-pathway amyloid-Î² oligomers distinct from amyloid-Î² derived diffusible ligands in Alzheimerâ€™s disease. Scientific Reports, 2018, 8, 4772.	1.6	104
445	Alzheimerâ€™s Disease, Oligomers, and Inflammation. Journal of Alzheimer's Disease, 2018, 62, 1261-1276.	1.2	141
446	Amyloid-Î² and Tau in Alzheimerâ€™s Disease: Novel Pathomechanisms and Non-Pharmacological Treatment Strategies. Journal of Alzheimer's Disease, 2018, 64, S517-S527.	1.2	42
447	Multifactorial Hypothesis and Multi-Targets for Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2018, 64, S107-S117.	1.2	112
448	An acute functional screen identifies an effective antibody targeting amyloid-Î² oligomers based on calcium imaging. Scientific Reports, 2018, 8, 4634.	1.6	15
449	The Alzheimer's Prevention Initiative Autosomalâ€Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomalâ€dominant Alzheimer's disease, including a placeboâ€treated noncarrier cohort. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 150-160.	1.8	107
450	Generation and Partial Characterization of Rabbit Monoclonal Antibody to Pyroglutamate Amyloid-Î²3-42 (pE3-AÎ²). Journal of Alzheimer's Disease, 2018, 62, 1635-1649.	1.2	8
451	Neuroinflammation, Gut Microbiome, and Alzheimerâ€™s Disease. Molecular Neurobiology, 2018, 55, 8243-8250.	1.9	90
452	Neuroprotective effects of Coptis chinensis Franch polysaccharide on amyloid-beta (AÎ²)-induced toxicity in a transgenic Caenorhabditis elegans model of Alzheimer's disease (AD). International Journal of Biological Macromolecules, 2018, 113, 991-995.	3.6	41
453	Trace amounts of pyroglutaminated AÎ²-(3â€“42) enhance aggregation of AÎ²-(1â€“42) on neuronal membranes at physiological concentrations: FCS analysis of cell surface. Biochimica Et Biophysica Acta - Biomembranes, 2018, 1860, 1603-1608.	1.4	5
454	Aggregation kinetics in the presence of brain lipids of AÎ²(1â€“40) cleaved from a soluble fusion protein. Biochimica Et Biophysica Acta - Biomembranes, 2018, 1860, 1681-1686.	1.4	7

#	Article	IF	Citations
455	Beta-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibition Impairs Synaptic Plasticity via Seizure Protein 6. Biological Psychiatry, 2018, 83, 428-437.	0.7	80
456	NLRP3 Inflammasome Inhibitor Ameliorates Amyloid Pathology in a Mouse Model of Alzheimerâ€™s Disease. Molecular Neurobiology, 2018, 55, 1977-1987.	1.9	153
457	Dynamic Nature of presenilin1/Î³-Secretase: Implication for Alzheimerâ€™s Disease Pathogenesis. Molecular Neurobiology, 2018, 55, 2275-2284.	1.9	24
458	AÎ² propagation and strains: Implications for the phenotypic diversity in Alzheimer's disease. Neurobiology of Disease, 2018, 109, 191-200.	2.1	57
459	Untangling Genetic Risk for Alzheimerâ€™s Disease. Biological Psychiatry, 2018, 83, 300-310.	0.7	160
460	Dynamic membrane interactions of antibacterial and antifungal biomolecules, and amyloid peptides, revealed by solid-state NMR spectroscopy. Biochimica Et Biophysica Acta - General Subjects, 2018, 1862, 307-323.	1.1	37
462	Early Preclinical Changes in Hippocampal CREB-Binding Protein Expression in a Mouse Model of Familial Alzheimerâ€™s Disease. Molecular Neurobiology, 2018, 55, 4885-4895.	1.9	21
463	Mechanisms of Mendelian dominance. Clinical Genetics, 2018, 93, 419-428.	1.0	70
464	Dementia risk and prevention by targeting modifiable vascular risk factors. Journal of Neurochemistry, 2018, 144, 565-581.	2.1	82
465	DHA, EPA and their combination at various ratios differently modulated AÎ²25-35-induced neurotoxicity in SH-SY5Y cells. Prostaglandins Leukotrienes and Essential Fatty Acids, 2018, 136, 85-94.	1.0	27
466	Î²APP Processing Drives Gradual Tau Pathology in an Age-Dependent Amyloid Rat Model of Alzheimerâ€™s Disease. Cerebral Cortex, 2018, 28, 3976-3993.	1.6	13
467	Plant-based chimeric HPV-virus-like particles bearing amyloid-Î² epitopes elicit antibodies able to recognize amyloid plaques in APP-tg mouse and Alzheimerâ€™s disease brains. Inflammopharmacology, 2018, 26, 817-827.	1.9	8
468	Microglia-Mediated Neuroprotection, TREM2 , and Alzheimerâ€™s Disease: Evidence From OpticalÂImaging. Biological Psychiatry, 2018, 83, 377-387.	0.7	84
469	The hypothalamus as the primary brain region of metabolic abnormalities in APP/PS1 transgenic mouse model of Alzheimer's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 263-273.	1.8	46
470	Direct pharmacological Akt activation rescues Alzheimer's disease like memory impairments and aberrant synaptic plasticity. Neuropharmacology, 2018, 128, 282-292.	2.0	66
471	Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimerâ€™s Disease. Clinical Pharmacokinetics, 2018, 57, 315-333.	1.6	66
472	How efficient are rodent models for Alzheimerâ€™s disease drug discovery?. Expert Opinion on Drug Discovery, 2018, 13, 113-115.	2.5	2
473	Modulation of Alzheimer's amyloid Î² peptide oligomerization and toxicity by extracellular Hsp70. Cell Stress and Chaperones, 2018, 23, 269-279.	1.2	33

#	Article	IF	Citations
474	Dysregulation of neurotrophin signaling in the pathogenesis of Alzheimer disease and of Alzheimer disease in Down syndrome. Free Radical Biology and Medicine, 2018, 114, 52-61.	1.3	56
475	Oxidative stress and the amyloid beta peptide in Alzheimerâ€™s disease. Redox Biology, 2018, 14, 450-464.	3.9	1,411
476	Dysfunction of autophagy and endosomal-lysosomal pathways: Roles in pathogenesis of Down syndrome and Alzheimer's Disease. Free Radical Biology and Medicine, 2018, 114, 40-51.	1.3	128
477	Food for thought: Leptin regulation of hippocampal function and its role in Alzheimer's disease. Neuropharmacology, 2018, 136, 298-306.	2.0	26
478	In Silico Strategies to Design Small Molecules to Study Beta-Amyloid Aggregation. Neuromethods, 2018, , 249-261.	0.2	1
479	Clinical aspects and biomarkers of Alzheimer's disease in Down syndrome. Free Radical Biology and Medicine, 2018, 114, 3-9.	1.3	61
480	Alzheimer's disease. European Journal of Neurology, 2018, 25, 59-70.	1.7	1,624
481	Myelin content changes in probable Alzheimer's disease and mild cognitive impairment: Associations with age and severity of neuropsychiatric impairment. Journal of Magnetic Resonance Imaging, 2018, 47, 1359-1372.	1.9	30
482	Absence of association of the Ala58Val (rs17571) CTSD gene variant with Parkinsonâ€™s disease or amyotrophic lateral sclerosis in a Han Chinese population. Neuroscience Letters, 2018, 662, 181-184.	1.0	2
483	Lymphatic drainage system of the brain: A novel target for intervention of neurological diseases. Progress in Neurobiology, 2018, 163-164, 118-143.	2.8	158
484	Anti-Amyloid-Î² Monoclonal Antibodies for Alzheimerâ€™s Disease: Pitfalls and Promise. Biological Psychiatry, 2018, 83, 311-319.	0.7	408
485	Expression, purification, and preliminary characterization of human presenilin-2. Process Biochemistry, 2018, 64, 63-73.	1.8	2
486	Calmodulinâ€like skin protein protects against spatial learning impairment in a mouse model of Alzheimer disease. Journal of Neurochemistry, 2018, 144, 218-233.	2.1	12
487	Alpha7 nicotinic acetylcholine receptor-specific agonist DMXBA (GTS-21) attenuates AÎ² accumulation through suppression of neuronal Î³-secretase activity and promotion of microglial amyloid-Î² phagocytosis and ameliorates cognitive impairment in a mouse model of Alzheimer's disease. Neurobiology of Aging, 2018, 62, 197-209.	1.5	44
488	Inhibition of poly(ADP-ribose) polymerase-1 alters expression of mitochondria-related genes in PC12 cells: relevance to mitochondrial homeostasis in neurodegenerative disorders. Biochimica Et Biophysica Acta - Molecular Cell Research, 2018, 1865, 281-288.	1.9	19
489	Peptides isolated from animal venom as a platform for new therapeutics for the treatment of Alzheimer's disease. Neuropeptides, 2018, 67, 79-86.	0.9	12
490	A Decade of Blood Biomarkers for Alzheimerâ€™s Disease Research: An Evolving Field, Improving Study Designs, and the Challenge of Replication. Journal of Alzheimer's Disease, 2018, 62, 1181-1198.	1.2	80
491	Brain amyloid burden and cerebrovascular disease are synergistically associated with neurometabolism in cognitively unimpaired older adults. Neurobiology of Aging, 2018, 63, 152-161.	1.5	16

#	Article	IF	Citations
492	Alzheimerâ€™s disease and gut microbiota modifications: The long way between preclinical studies and clinical evidence. Pharmacological Research, 2018, 129, 329-336.	3.1	152
493	Exploiting the therapeutic potential of ready-to-use drugs: Repurposing antibiotics against amyloid aggregation in neurodegenerative diseases. Progress in Neurobiology, 2018, 162, 17-36.	2.8	34
494	Amyloid Î² oligomers (AÎ²Os) in Alzheimerâ€™s disease. Journal of Neural Transmission, 2018, 125, 177-191.	1.4	114
495	Prion Protein as a Toxic Acceptor of Amyloid-Î² Oligomers. Biological Psychiatry, 2018, 83, 358-368.	0.7	66
496	Microglia in Alzheimerâ€™s disease. Journal of Cell Biology, 2018, 217, 459-472.	2.3	1,188
497	Short AÎ² peptides attenuate AÎ²42 toxicity in vivo. Journal of Experimental Medicine, 2018, 215, 283-301.	4.2	56
498	Could blocking the formation of amyloid channels rescue Alzheimer's phenotype?. EMBO Molecular Medicine, 2018, 10, 7-9.	3.3	3
499	N-3 PUFA diet enrichment prevents amyloid beta-induced depressive-like phenotype. Pharmacological Research, 2018, 129, 526-534.	3.1	21
500	The â€œglymphaticâ€•mechanism for solute clearance in Alzheimer's disease: game changer or unproven speculation?. FASEB Journal, 2018, 32, 543-551.	0.2	121
501	Overexpression of SNX7 reduces AÎ² production by enhancing lysosomal degradation of APP. Biochemical and Biophysical Research Communications, 2018, 495, 12-19.	1.0	18
502	Pericyte implantation in the brain enhances cerebral blood flow and reduces amyloid-Î² pathology in amyloid model mice. Experimental Neurology, 2018, 300, 13-21.	2.0	53
503	Total flavonoid extract from Dracoephalum moldavica L. attenuates Î²-amyloid-induced toxicity through anti-amyloidogenesic and neurotrophic pathways. Life Sciences, 2018, 193, 214-225.	2.0	25
504	NABi, a novel Î²-sheet breaker, inhibits AÎ² aggregation and neuronal toxicity: Therapeutic implications for Alzheimer's disease. Biochimica Et Biophysica Acta - General Subjects, 2018, 1862, 71-80.	1.1	3
505	Conserved brain myelination networks are altered in Alzheimer's and other neurodegenerative diseases. Alzheimer's and Dementia, 2018, 14, 352-366.	0.4	116
506	Innate Immunity and Neurodegeneration. Annual Review of Medicine, 2018, 69, 437-449.	5.0	221
507	Interactive versus additive relationships between regional cortical thinning and amyloid burden in predicting clinical decline in mild AD and MCI individuals. NeuroImage: Clinical, 2018, 17, 388-396.	1.4	8
508	A critical role of TRPM2 channel in AÎ²₄₂â€induced microglial activation and generation of tumor necrosis factorâ€Î±. Glia, 2018, 66, 562-575.	2.5	71
509	The function of the cellular prion protein in health and disease. Acta Neuropathologica, 2018, 135, 159-178.	3.9	72

#	Article	IF	Citations
510	Insulin-Degrading Enzyme in the Fight against Alzheimerâ€™s Disease. Trends in Pharmacological Sciences, 2018, 39, 49-58.	4.0	133
511	Magnesium boosts the memory restorative effect of environmental enrichment in Alzheimer's disease mice. CNS Neuroscience and Therapeutics, 2018, 24, 70-79.	1.9	32
512	Crosstalk between endoplasmic reticulum stress and brain inflammation in Alzheimer's disease. Neuropharmacology, 2018, 136, 350-360.	2.0	61
513	Alzheimer's disease as oligomeropathy. Neurochemistry International, 2018, 119, 57-70.	1.9	90
514	Modulation of Î³- and Î²-Secretases as Early Prevention Against Alzheimerâ€™s Disease. Biological Psychiatry, 2018, 83, 320-327.	0.7	54
515	Phagocytic Roles of Glial Cells in Healthy and Diseased Brains. Biomolecules and Therapeutics, 2018, 26, 350-357.	1.1	89
516	Making the final cut: pathogenic amyloid-Î² peptide generation by Î³-secretase. Cell Stress, 2018, 2, 292-310.	1.4	100
517	Overcoming the Bloodâ€“Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases. Advanced Materials, 2018, 30, e1801362.	11.1	415
518	Molecular Probes for Magnetic Resonance Imaging of Amyloid Î² Peptides. , 2018, , .		0
519	When pitch adds to volume: coregulation of transcript diversity predicts gene function. BMC Genomics, 2018, 19, 926.	1.2	1
520	Removal of blood amyloid-β with hemodialysis reduced brain amyloid-β, confirmed by brain imaging: a case report. Neuropsychiatric Disease and Treatment, 2018, Volume 14, 2931-2937.	1.0	10
521	Mechanisms of AMPA Receptor Endosomal Sorting. Frontiers in Molecular Neuroscience, 2018, 11, 440.	1.4	45
522	GRK5 â€“ A Functional Bridge Between Cardiovascular and Neurodegenerative Disorders. Frontiers in Pharmacology, 2018, 9, 1484.	1.6	19
523	Copper reduction and dioxygen activation in Cuâ€“amyloid beta peptide complexes: insight from molecular modelling. Metallomics, 2018, 10, 1618-1630.	1.0	31
524	Atomistic investigation of an Iowa Amyloid-Î² trimer in aqueous solution. RSC Advances, 2018, 8, 41705-41712.	1.7	9
525	Advances and Pitfalls in the Capillary Electrophoresis Analysis of Aggregates of Beta Amyloid Peptides. Separations, 2018, 5, 2.	1.1	2
526	Amyloid Beta Hypothesis: Attention to Î²- and Î³-Secretase Modulators. , 2018, , .		0
527	Centiloid scaling for quantification of brain amyloid with [18F]flutemetamol using multiple processing methods. EJNMMI Research, 2018, 8, 107.	1.1	55

#	Article	IF	Citations
528	Improved separation of Alzheimerâ€™s disease and related disorders using dual-point amyloid-PET. , 2018, , .		0
529	WHAT HAVE WE LEARNED FROM EXPEDITION III AND EPOCH TRIALS? PERSPECTIVE OF THE CTAD TASK FORCE. journal of prevention of Alzheimer's disease, The, 2018, 5, 1-4.	1.5	7
530	3 .Neuropathologie und molekulare Mechanismen. , 2018, , 35-122.		1
531	Resveratrol Sustains Insulin-Degrading Enzyme Activity toward AÎ²42. ACS Omega, 2018, 3, 13275-13282.	1.6	15
532	Decreased plasma Câ€reactive protein levels in <scp>APOE</scp> Îµ4 allele carriers. Annals of Clinical and Translational Neurology, 2018, 5, 1229-1240.	1.7	18
533	Amyloid precursor protein-fragments-containing inclusions in cardiomyocytes with basophilic degeneration and its association with cerebral amyloid angiopathy and myocardial fibrosis. Scientific Reports, 2018, 8, 16594.	1.6	11
534	Blood-Based Kinase Assessments in Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2018, 10, 338.	1.7	11
535	The Glymphatic System in Diabetes-Induced Dementia. Frontiers in Neurology, 2018, 9, 867.	1.1	28
536	Royal jelly coordinately enhances hippocampal neuronal expression of somatostatin and neprilysin genes conferring neuronal protection against toxic soluble amyloid-Î² oligomers implicated in Alzheimerâ€™s disease pathogenesis. Journal of Functional Foods, 2018, 51, 28-38.	1.6	5
537	Mitochondrial Metabolism in Major Neurological Diseases. Cells, 2018, 7, 229.	1.8	41
538	Possible Clues for Brain Energy Translation via Endolysosomal Trafficking of APP-CTFs in Alzheimerâ€™s Disease. Oxidative Medicine and Cellular Longevity, 2018, 2018, 1-11.	1.9	8
539	Dementia. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 159, 303-321.	1.0	14
540	Imaging and Molecular Mechanisms of Alzheimerâ€™s Disease: A Review. International Journal of Molecular Sciences, 2018, 19, 3702.	1.8	45
541	Chromones: privileged scaffolds for the production of multi-target-directed-ligand agents for the treatment of Alzheimerâ€™s disease. Expert Opinion on Drug Discovery, 2018, 13, 1141-1151.	2.5	14
542	Somatic APP gene recombination in Alzheimerâ€™s disease and normal neurons. Nature, 2018, 563, 639-645.	13.7	179
543	Toxic Protein Spread in Neurodegeneration: Reality versus Fantasy. Trends in Molecular Medicine, 2018, 24, 1007-1020.	3.5	26
544	Decoding the synaptic dysfunction of bioactive human AD brain soluble AÎ² to inspire novel therapeutic avenues for Alzheimerâ€™s disease. Acta Neuropathologica Communications, 2018, 6, 121.	2.4	46
545	The Ethyl Acetate Extract of Leaves of Ugni molinae Turcz. Improves Neuropathological Hallmarks of Alzheimerâ€™s Disease in Female APPswe/PS1dE9 Mice Fed with a High Fat Diet. Journal of Alzheimer's Disease, 2018, 66, 1175-1191.	1.2	10

#	Article	IF	Citations
546	Structural Optimization of Foldamer-Dendrimer Conjugates as Multivalent Agents against the Toxic Effects of Amyloid Beta Oligomers. Molecules, 2018, 23, 2523.	1.7	11
547	Effects of Androgens on the Amyloid-Î² Protein in Alzheimer's Disease. Endocrinology, 2018, 159, 3885-3894.	1.4	22
548	Inhibition of HDAC3 reverses Alzheimerâ€™s disease-related pathologies in vitro and in the 3xTg-AD mouse model. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E11148-E11157.	3.3	140
549	Visualization of Alzheimerâ€™s Disease Related Î±-/Î²-/Î³-Secretase Ternary Complex by Bimolecular Fluorescence Complementation Based Fluorescence Resonance Energy Transfer. Frontiers in Molecular Neuroscience, 2018, 11, 431.	1.4	7
550	The Multi-Scale Impact of the Alzheimerâ€™s Disease on the Topology Diversity of Astrocytes Molecular Communications Nanonetworks. IEEE Access, 2018, 6, 78904-78917.	2.6	18
551	N-Acetylcysteine Prevents the Spatial Memory Deficits and the Redox-Dependent RyR2 Decrease Displayed by an Alzheimerâ€™s Disease Rat Model. Frontiers in Aging Neuroscience, 2018, 10, 399.	1.7	42
552	Amyloid, tau, pathogen infection and antimicrobial protection in Alzheimerâ€™s disease â€“conformist, nonconformist, and realistic prospects for AD pathogenesis. Translational Neurodegeneration, 2018, 7, 34.	3.6	77
553	Molecular Recipe for Î³-Secretase Modulation from Computational Analysis of 60 Active Compounds. ACS Omega, 2018, 3, 18078-18088.	1.6	19
554	Speech Analysis by Natural Language Processing Techniques: A Possible Tool for Very Early Detection of Cognitive Decline?. Frontiers in Aging Neuroscience, 2018, 10, 369.	1.7	91
555	Transmission of amyloid-Î² protein pathology from cadaveric pituitary growth hormone. Nature, 2018, 564, 415-419.	13.7	122
556	A near atomic-scale view at the composition of amyloid-beta fibrils by atom probe tomography. Scientific Reports, 2018, 8, 17615.	1.6	20
557	Improving the Gene Ontology Resource to Facilitate More Informative Analysis and Interpretation of Alzheimerâ€™s Disease Data. Genes, 2018, 9, 593.	1.0	15
558	Advances in Multi-Functional Ligands and the Need for Metal-Related Pharmacology for the Management of Alzheimer Disease. Frontiers in Pharmacology, 2018, 9, 1247.	1.6	45
559	Current state of Alzheimerâ€™s fluid biomarkers. Acta Neuropathologica, 2018, 136, 821-853.	3.9	370
560	Iron Dysregulation and Dormant Microbes as Causative Agents for Impaired Blood Rheology and Pathological Clotting in Alzheimerâ€™s Type Dementia. Frontiers in Neuroscience, 2018, 12, 851.	1.4	17
561	Preparation of 4-Flexible Amino-2-Arylethenyl-Quinoline Derivatives as Multi-target Agents for the Treatment of Alzheimerâ€™s Disease. Molecules, 2018, 23, 3100.	1.7	12
562	Different tau species lead to heterogeneous tau pathology propagation and misfolding. Acta Neuropathologica Communications, 2018, 6, 132.	2.4	72
563	Early Changes in Hyppocampal Neurogenesis Induced by Soluble AÎ²1-42 Oligomers. Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry, 2018, 12, 330-338.	0.2	0

#	Article	IF	Citations
564	Nutrient-Dependent Changes of Protein Palmitoylation: Impact on Nuclear Enzymes and Regulation of Gene Expression. International Journal of Molecular Sciences, 2018, 19, 3820.	1.8	23
565	Commentary: Multiscale Analysis of Independent Alzheimer's Cohorts Finds Disruption of Molecular, Genetic, and Clinical Networks by Human Herpesvirus. Frontiers in Molecular Neuroscience, 2018, 11, 340.	1.4	3
566	Fucosterol from an Edible Brown Alga Ecklonia stolonifera Prevents Soluble Amyloid Beta-Induced Cognitive Dysfunction in Aging Rats. Marine Drugs, 2018, 16, 368.	2.2	36
567	Probing the Occurrence of Soluble Oligomers through Amyloid Aggregation Scaling Laws. Biomolecules, 2018, 8, 108.	1.8	10
568	Recent progress of drug nanoformulations targeting to brain. Journal of Controlled Release, 2018, 291, 37-64.	4.8	134
569	Synaptosomes. Neuromethods, 2018, , .	0.2	3
570	Passive Immunotherapies for Central Nervous System Disorders: Current Delivery Challenges and New Approaches. Bioconjugate Chemistry, 2018, 29, 3937-3966.	1.8	23
571	What have we learned recently from transgenic mouse models about neurodegeneration? The most promising discoveries of this millennium. Pharmacological Reports, 2018, 70, 1105-1115.	1.5	7
572	Microglia prevent peripheral immune cell invasion and promote an anti-inflammatory environment in the brain of APP-PS1 transgenic mice. Journal of Neuroinflammation, 2018, 15, 274.	3.1	89
573	Neuroinflammation in mouse models of Alzheimer's disease. Clinical and Experimental Neuroimmunology, 2018, 9, 211-218.	0.5	77
574	Ageing, Cellular Senescence and Neurodegenerative Disease. International Journal of Molecular Sciences, 2018, 19, 2937.	1.8	248
575	Amyloid-beta Degradation and Neuroprotection of Dauricine Mediated by Unfolded Protein Response in a Caenorhabditis elegans Model of Alzheimerâ€™s disease. Neuroscience, 2018, 392, 25-37.	1.1	17
576	Alzheimerâ€™s disease (AD) therapeutics â€“ 1: Repeated clinical failures continue to question the amyloid hypothesis of AD and the current understanding of AD causality. Biochemical Pharmacology, 2018, 158, 359-375.	2.0	59
577	BACE inhibitors in clinical development for the treatment of Alzheimerâ€™s disease. Expert Review of Neurotherapeutics, 2018, 18, 847-857.	1.4	66
578	Peripheral immune system in aging and Alzheimerâ€™s disease. Molecular Neurodegeneration, 2018, 13, 51.	4.4	143
579	Enantiomeric AÎ² peptides inhibit the fluid shear stress response of PIEZO1. Scientific Reports, 2018, 8, 14267.	1.6	52
580	Converging pathways in neurodegeneration, from genetics to mechanisms. Nature Neuroscience, 2018, 21, 1300-1309.	7.1	325
581	Microglia in neurodegeneration. Nature Neuroscience, 2018, 21, 1359-1369.	7.1	1,034

#	Article	IF	Citations
582	SAR by kinetics for drug discovery in protein misfolding diseases. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 10245-10250.	3.3	54
583	Increased Insoluble Amyloid-Î² Induces Negligible Cognitive Deficits in Old AppNL/NL Knock-In Mice. Journal of Alzheimer's Disease, 2018, 66, 801-809.	1.2	8
584	Incident cognitive impairment: longitudinal changes in molecular, structural and cognitive biomarkers. Brain, 2018, 141, 3233-3248.	3.7	24
585	Modelling Sporadic Alzheimerâ€™s Disease Using Induced Pluripotent Stem Cells. Neurochemical Research, 2018, 43, 2179-2198.	1.6	27
586	Questions concerning the role of amyloid-Î² in the definition, aetiology and diagnosis of Alzheimerâ€™s disease. Acta Neuropathologica, 2018, 136, 663-689.	3.9	151
587	Evidence of intraneuronal AÎ² accumulation preceding tau pathology in the entorhinal cortex. Acta Neuropathologica, 2018, 136, 901-917.	3.9	65
588	Liquid and Hydrogel Phases of PrPC Linked to Conformation Shifts and Triggered by Alzheimerâ€™s Amyloid-Î² Oligomers. Molecular Cell, 2018, 72, 426-443.e12.	4.5	87
589	An Apoptotic and Endosymbiotic Explanation of the Warburg and the Inverse Warburg Hypotheses. International Journal of Molecular Sciences, 2018, 19, 3100.	1.8	7
590	Endogenous DAMPs, Category I: Constitutively Expressed, Native Molecules (Cat. I DAMPs). , 2018, , 219-268.		0
591	ER stress is not elevated in the 5XFAD mouse model of Alzheimer's disease. Journal of Biological Chemistry, 2018, 293, 18434-18443.	1.6	37
592	Enriched Environment Significantly Reduced Senile Plaques in a Transgenic Mice Model of Alzheimerâ€™s Disease, Improving Memory. Frontiers in Aging Neuroscience, 2018, 10, 288.	1.7	22
593	Effects of Quercetin Intervention on Cognition Function in APP/PS1 Mice was Affected by Vitamin D Status. Molecular Nutrition and Food Research, 2018, 62, e1800621.	1.5	41
594	A promising, novel, and unique <scp>BACE</scp> 1 inhibitor emerges in the quest to prevent Alzheimer's disease. EMBO Molecular Medicine, 2018, 10, .	3.3	28
595	Natural Therapeutics for Alzheimerâ€™s Disease. , 2018, , 227-245.		0
596	Inhibition of miR-128 Abates AÎ²-Mediated Cytotoxicity by Targeting PPAR-Î³ via NF-ÎºB Inactivation in Primary Mouse Cortical Neurons and Neuro2a Cells. Yonsei Medical Journal, 2018, 59, 1096.	0.9	51
597	Orientation of a Diagnostic Ligand Bound to Macroscopically Aligned Amyloid-Î² Fibrils Determined by Solid-State NMR. Journal of Physical Chemistry Letters, 2018, 9, 6611-6615.	2.1	0
598	Visualizing Axonal Growth Cone Collapse and Early Amyloid β Effects in Cultured Mouse Neurons. Journal of Visualized Experiments, 2018, , .	0.2	4
599	Circulating Plasma microRNAs are Altered with Amyloidosis in a Mouse Model of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2018, 66, 835-852.	1.2	13

#	Article	IF	Citations
600	Blood-brain barrier-associated pericytes internalize and clear aggregated amyloid-Î²42 by LRP1-dependent apolipoprotein E isoform-specific mechanism. Molecular Neurodegeneration, 2018, 13, 57.	4.4	164
601	Modulating Conformation of AÎ²-Peptide: An Effective Way to Prevent Protein-Misfolding Disease. Inorganic Chemistry, 2018, 57, 13533-13543.	1.9	32
602	A histone acetylome-wide association study of Alzheimerâ€™s disease identifies disease-associated H3K27ac differences in the entorhinal cortex. Nature Neuroscience, 2018, 21, 1618-1627.	7.1	138
603	Glycoprotein NMB: a novel Alzheimerâ€™s disease associated marker expressed in a subset of activated microglia. Acta Neuropathologica Communications, 2018, 6, 108.	2.4	107
604	Surveying the Energy Landscapes of AÎ² Fibril Polymorphism. Journal of Physical Chemistry B, 2018, 122, 11414-11430.	1.2	18
605	Levels of Thyroid Hormones and Indices of Energy Metabolism in the Cerebral Cortex of Rats with Experimental Alzheimerâ€™s Disease. Neurophysiology, 2018, 50, 159-165.	0.2	5
606	The <scp>BACE</scp> â€1 inhibitor <scp>CNP</scp> 520 for prevention trials in Alzheimer's disease. EMBO Molecular Medicine, 2018, 10, .	3.3	112
607	Anti-neuroinflammatory effects of ethanolic extract of black chokeberry (Aronia melanocapaL.) in lipopolysaccharide-stimulated BV2 cells and ICR mice. Nutrition Research and Practice, 2018, 12, 13.	0.7	15
608	A standard model of Alzheimerâ€™s disease?. Prion, 2018, 12, 261-265.	0.9	20
609	Axonal organization defects in the hippocampus of adult conditional BACE1 knockout mice. Science Translational Medicine, 2018, 10, .	5.8	66
610	Dynamic Microtubules in Alzheimerâ€™s Disease: Association with Dendritic Spine Pathology. Biochemistry (Moscow), 2018, 83, 1068-1074.	0.7	18
611	Laboratory diagnostics in dementia. Laboratoriums Medizin, 2018, 42, 121-130.	0.1	1
612	cPLA2 and desaturases underlie the tau hyperphosphorylation offset induced by BACE knock-down in neuronal primary cultures. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 3696-3707.	1.8	4
613	Etersalate prevents the formations of 6AÎ²16-22 oligomer: An in silico study. PLoS ONE, 2018, 13, e0204026.	1.1	11
614	Passive AÎ² Immunotherapy: Current Achievements and Future Perspectives. Molecules, 2018, 23, 1068.	1.7	41
615	Eriodictyol Attenuates LPS-Induced Neuroinflammation, Amyloidogenesis, and Cognitive Impairments via the Inhibition of NF-Î¹B in Male C57BL/6J Mice and BV2 Microglial Cells. Journal of Agricultural and Food Chemistry, 2018, 66, 10205-10214.	2.4	79
616	Navigating Genetic Influences on the Topography of Alzheimerâ€™s Disease. Biological Psychiatry, 2018, 84, 476-477.	0.7	0
617	The many disguises of the signalling endosome. FEBS Letters, 2018, 592, 3615-3632.	1.3	37

#	Article	IF	Citations
618	A Unified View of Assessing the Proâ€oxidant versus Antioxidant Nature of Amyloid Beta Conformers. ChemBioChem, 2018, 19, 2360-2371.	1.3	11
619	Setbacks and promises for drugs against Alzheimer's disease. EMBO Reports, 2018, 19, .	2.0	10
620	Usefulness of Dual-Point Amyloid PET Scans in Appropriate Use Criteria: A Multicenter Study. Journal of Alzheimer's Disease, 2018, 65, 765-779.	1.2	14
621	Phosphorylation of the Amyloid-Beta Peptide Inhibits Zinc-Dependent Aggregation, Prevents Na,K-ATPase Inhibition, and Reduces Cerebral Plaque Deposition. Frontiers in Molecular Neuroscience, 2018, 11, 302.	1.4	33
622	Mitochondria at the Base of Neuronal Innate Immunity in Alzheimerâ€™s and Parkinsonâ€™s Diseases. , 2018, , .		1
623	Biophenols: Enzymes (Î²-secretase, Cholinesterases, histone deacetylase and tyrosinase) inhibitors from olive (Olea europaea L.). FÃ¬toterapÃ¬Ã¢, 2018, 128, 118-129.	1.1	59
624	The effect of Vâ€‹scp›ATP‹/scp›ase function defects in pathogenesis of Alzheimer's disease. CNS Neuroscience and Therapeutics, 2018, 24, 837-840.	1.9	6
625	Involvement of extrasynaptic glutamate in physiological and pathophysiological changes of neuronal excitability. Cellular and Molecular Life Sciences, 2018, 75, 2917-2949.	2.4	99
626	Changes in concentrations of tau-reactive antibodies are dependent on sex in Alzheimer's disease patients. Journal of Neuroimmunology, 2018, 322, 1-8.	1.1	9
627	Fucosterol inhibits the cholinesterase activities and reduces the release of pro-inflammatory mediators in lipopolysaccharide and amyloid-induced microglial cells. Journal of Applied Phycology, 2018, 30, 3261-3270.	1.5	27
628	Reaction rate theory for supramolecular kinetics: application to protein aggregation. Molecular Physics, 2018, 116, 3055-3065.	0.8	19
629	Compound CID 9998128 Is a Potential Multitarget Drug for Alzheimerâ€™s Disease. ACS Chemical Neuroscience, 2018, 9, 2588-2598.	1.7	17
630	Free-floating adult human brain-derived slice cultures as a model to study the neuronal impact of Alzheimerâ€™s disease-associated AÎ² oligomers. Journal of Neuroscience Methods, 2018, 307, 203-209.	1.3	27
631	Understanding amyloid fibril formation using protein fragments: structural investigations via vibrational spectroscopy and solid-state NMR. Biophysical Reviews, 2018, 10, 1133-1149.	1.5	28
632	In vivo MR in the drug pipeline. Journal of Magnetic Resonance, 2018, 292, 117-128.	1.2	4
633	Established amyloidâ€Î² pathology is unaffected by chronic treatment with the selective serotonin reuptake inhibitor paroxetine. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 215-223.	1.8	29
634	Interactions between elastin-like peptides and an insulating poly(ortho-aminophenol) membrane investigated by AFM and XPS. Analytical and Bioanalytical Chemistry, 2018, 410, 4925-4941.	1.9	5
635	Early minor stimulation of microglial TLR2 and TLR4 receptors attenuates Alzheimer's diseaseâ€“related cognitive deficit in rats: behavioral, molecular, and electrophysiological evidence. Neurobiology of Aging, 2018, 70, 203-216.	1.5	55

#	Article	IF	Citations
636	Benzo[<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M1"><mml:mi>g</mml:mi></mml:math>]coumarin-Based Fluorescent Probes for Bioimaging Applications. Journal of Analytical Methods in Chemistry, 2018, 2018, 1-11.	0.7	48
637	Proton Pump Inhibitors and Dementia: Physiopathological Mechanisms and Clinical Consequences. Neural Plasticity, 2018, 2018, 1-9.	1.0	56
638	Novel monoclonal antibodies targeting the microtubule-binding domain of human tau. PLoS ONE, 2018, 13, e0195211.	1.1	12
639	Synaptic modification by L-theanine, a natural constituent in green tea, rescues the impairment of hippocampal long-term potentiation and memory in AD mice. Neuropharmacology, 2018, 138, 331-340.	2.0	36
640	The Transcriptional Regulatory Properties of Amyloid Beta 1â€“42 may Include Regulation of Genes Related to Neurodegeneration. NeuroMolecular Medicine, 2018, 20, 363-375.	1.8	16
641	Clinical Research on Alzheimerâ€™s Disease: Progress and Perspectives. Neuroscience Bulletin, 2018, 34, 1111-1118.	1.5	100
642	Consequences of Pharmacological BACE Inhibition on Synaptic Structure and Function. Biological Psychiatry, 2018, 84, 478-487.	0.7	41
643	UsingDrosophilaModels of Amyloid Toxicity to Study Autophagy in the Pathogenesis of Alzheimerâ€™s Disease. BioMed Research International, 2018, 2018, 1-14.	0.9	15
644	Amyloid-Î²/Drug Interactions from Computer Simulations and Cell-Based Assays. Journal of Alzheimer's Disease, 2018, 64, S659-S672.	1.2	5
645	Relevance of N-terminal residues for amyloid-Î² binding to platelet integrin Î± IIb Î² 3 , integrin outside-in signaling and amyloid-Î² fibril formation. Cellular Signalling, 2018, 50, 121-130.	1.7	17
646	Disorder at the Tips of a Disease-Relevant AÎ²42 Amyloid Fibril: A Molecular Dynamics Study. Journal of Physical Chemistry B, 2018, 122, 11072-11082.	1.2	24
647	Dissecting conformational changes in APPâ€™s transmembrane domain linked to Îµ-efficiency in familial Alzheimerâ€™s disease. PLoS ONE, 2018, 13, e0200077.	1.1	13
648	Bone-Marrow-Derived Microglia-Like Cells Ameliorate Brain Amyloid Pathology and Cognitive Impairment in a Mouse Model of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2018, 64, 563-585.	1.2	32
649	Translational opportunities for amyloid-targeting fluorophores. Chemical Communications, 2018, 54, 9107-9118.	2.2	27
650	Current progress, challenges and future prospects of diagnostic and therapeutic interventions in Alzheimer's disease. RSC Advances, 2018, 8, 23780-23804.	1.7	105
651	Insulin-signaling Pathway Regulates the Degradation of Amyloid Î²-protein via Astrocytes. Neuroscience, 2018, 385, 227-236.	1.1	44
652	Early Intervention with a Multi-Ingredient Dietary Supplement Improves Mood and Spatial Memory in a Triple Transgenic Mouse Model of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2018, 64, 835-857.	1.2	10
653	Heme Oxygenase-1 Activity as a Correlate to Exercise-Mediated Amelioration of Cognitive Decline and Neuropathological Alterations in an Aging Rat Model of Dementia. BioMed Research International, 2018, 2018, 1-13.	0.9	24

#	Article	IF	Citations
654	Innate Immune and Fungal Model of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease Reports, 2018, 2, 139-152.	1.2	20
655	Adenosine Receptors in Alzheimerâ€™s Disease. , 2018, , 259-280.		5
656	Adenosine Receptors and Neuroinflammation. , 2018, , 217-237.		2
657	The effect of dexmedetomidine on inflammatory inhibition and microglial polarization in BV-2 cells. Neurological Research, 2018, 40, 838-846.	0.6	14
658	Towards a Novel Class of Multitarget-Directed Ligands: Dual P2X7â€“NMDA Receptor Antagonists. Molecules, 2018, 23, 230.	1.7	20
659	Probing Backbone Hydrogen Bonds in Proteins by Amideâ€toâ€Ester Mutations. ChemBioChem, 2018, 19, 2136-2145.	1.3	11
660	Î²-Sheet Breaker Peptide-HPYD for the Treatment of Alzheimer's Disease: Primary Studies on Behavioral Test and Transcriptional Profiling. Frontiers in Pharmacology, 2018, 8, 969.	1.6	15
661	A Computational Systems Pharmacology Approach to Investigate Molecular Mechanisms of Herbal Formula Tian-Ma-Gou-Teng-Yin for Treatment of Alzheimerâ€™s Disease. Frontiers in Pharmacology, 2018, 9, 668.	1.6	43
662	Effects of n-3 PUFA enriched and n-3 PUFA deficient diets in naÃ¯ve and AÎ²-treated female rats. Biochemical Pharmacology, 2018, 155, 326-335.	2.0	16
663	EphBs and ephrin-Bs: Trans-synaptic organizers of synapse development and function. Molecular and Cellular Neurosciences, 2018, 91, 108-121.	1.0	48
664	Immunotherapy to improve cognition and reduce pathological species in an Alzheimerâ€™s disease mouse model. Alzheimer's Research and Therapy, 2018, 10, 54.	3.0	24
665	Alzheimer's disease and blood-based biomarkers – potential contexts of use. Neuropsychiatric Disease and Treatment, 2018, Volume 14, 1877-1882.	1.0	32
666	Introduction of pathogenic mutations into the mouse Psen1 gene by Base Editor and Target-AID. Nature Communications, 2018, 9, 2892.	5.8	52
667	Histological and Behavioral Phenotypes of a Novel Mutated APP Knock-In Mouse. Journal of Alzheimer's Disease, 2018, 65, 165-180.	1.2	4
668	Intraneuronal accumulation of C99 contributes to synaptic alterations, apathy-like behavior, and spatial learning deficits in 3Ã—TgAD and 2Ã—TgAD mice. Neurobiology of Aging, 2018, 71, 21-31.	1.5	40
669	Evidence supporting oxidative stress in a moderately affected area of the brain in Alzheimerâ€™s disease. Scientific Reports, 2018, 8, 11553.	1.6	67
670	In Vivo Two Photon Imaging of Astrocytic Structure and Function in Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2018, 10, 219.	1.7	16
671	The Role of Genetics in Advancing Precision Medicine for Alzheimerâ€™s Diseaseâ€”A Narrative Review. Frontiers in Medicine, 2018, 5, 108.	1.2	61

#	Article	IF	Citations
672	U1 snRNP Alteration and Neuronal Cell Cycle Reentry in Alzheimer Disease. Frontiers in Aging Neuroscience, 2018, 10, 75.	1.7	16
673	Influence of APOE and RNF219 on Behavioral and Cognitive Features of Female Patients Affected by Mild Cognitive Impairment or Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2018, 10, 92.	1.7	8
674	Differential Hyperphosphorylation of Tau-S199, -T231 and -S396 in Organotypic Brain Slices of Alzheimer Mice. A Model to Study Early Tau Hyperphosphorylation Using Okadaic Acid. Frontiers in Aging Neuroscience, 2018, 10, 113.	1.7	39
675	Integrative Analysis of Hippocampus Gene Expression Profiles Identifies Network Alterations in Aging and Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2018, 10, 153.	1.7	58
676	An Inflammation-Centric View of Neurological Disease: Beyond the Neuron. Frontiers in Cellular Neuroscience, 2018, 12, 72.	1.8	320
677	Ryanodine Receptors in Autophagy: Implications for Neurodegenerative Diseases?. Frontiers in Cellular Neuroscience, 2018, 12, 89.	1.8	13
678	Classification of Alzheimer's Disease, Mild Cognitive Impairment, and Cognitively Unimpaired Individuals Using Multi-feature Kernel Discriminant Dictionary Learning. Frontiers in Computational Neuroscience, 2017, 11, 117.	1.2	22
679	The Quest for an Alzheimer Therapy. Frontiers in Neurology, 2018, 9, 108.	1.1	19
680	Challenges for Alzheimer's Disease Therapy: Insights from Novel Mechanisms Beyond Memory Defects. Frontiers in Neuroscience, 2018, 12, 37.	1.4	132
681	Antibody Engineering for Optimized Immunotherapy in Alzheimer's Disease. Frontiers in Neuroscience, 2018, 12, 254.	1.4	17
682	Sleep Disorders Associated With Alzheimer's Disease: A Perspective. Frontiers in Neuroscience, 2018, 12, 330.	1.4	99
683	Hypothalamic Alterations in Neurodegenerative Diseases and Their Relation to Abnormal Energy Metabolism. Frontiers in Molecular Neuroscience, 2018, 11, 2.	1.4	113
684	On the Role of Store-Operated Calcium Entry in Acute and Chronic Neurodegenerative Diseases. Frontiers in Molecular Neuroscience, 2018, 11, 87.	1.4	77
685	Î³-Secretase promotes membrane insertion of the human papillomavirus L2 capsid protein during virus infection. Journal of Cell Biology, 2018, 217, 3545-3559.	2.3	39
686	Site-specific structural order in Alzheimer's AÎ²42 fibrils. Royal Society Open Science, 2018, 5, 180166.	1.1	11
687	Chinese Herbal Medicine Xueshuantong Enhances Cerebral Blood Flow and Improves Neural Functions in Alzheimerâ€™s Disease Mice. Journal of Alzheimer's Disease, 2018, 63, 1089-1107.	1.2	20
688	Î²-barrel Oligomers as Common Intermediates of Peptides Self-Assembling into Cross-Î² Aggregates. Scientific Reports, 2018, 8, 10353.	1.6	62
689	What Happens with the Circuit in Alzheimer's Disease in Mice and Humans?. Annual Review of Neuroscience, 2018, 41, 277-297.	5.0	154

#	Article	IF	Citations
690	MK-0677, a Ghrelin Agonist, Alleviates Amyloid Beta-Related Pathology in 5XFAD Mice, an Animal Model of Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2018, 19, 1800.	1.8	32
691	Cellular Receptors of Amyloid Î² Oligomers (AÎ²Os) in Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2018, 19, 1884.	1.8	66
692	Results of Beta Secretase-Inhibitor Clinical Trials Support Amyloid Precursor Protein-Independent Generation of Beta Amyloid in Sporadic Alzheimerâ€™s Disease. Medical Sciences (Basel, Switzerland), 2018, 6, 45.	1.3	25
693	A Systematic Review of Antiamyloidogenic and Metal-Chelating Peptoids: Two Structural Motifs for the Treatment of Alzheimerâ€™s Disease. Molecules, 2018, 23, 296.	1.7	12
694	Design, Synthesis, and Biological Evaluation of 2-(Benzylamino-2-Hydroxyalkyl)Isoindoline-1,3-Diones Derivatives as Potential Disease-Modifying Multifunctional Anti-Alzheimer Agents. Molecules, 2018, 23, 347.	1.7	27
695	The Implication of the Brain Insulin Receptor in Late Onset Alzheimerâ€™s Disease Dementia. Pharmaceuticals, 2018, 11, 11.	1.7	45
696	In vitro neuroprotective effects of naringenin nanoemulsion against Î²-amyloid toxicity through the regulation of amyloidogenesis and tau phosphorylation. International Journal of Biological Macromolecules, 2018, 118, 1211-1219.	3.6	86
697	A Review on the Relationship between Tocotrienol and Alzheimer Disease. Nutrients, 2018, 10, 881.	1.7	28
698	Modelling Alzheimer's disease: Insights fromin vivotoin vitrothree-dimensional culture platforms. Journal of Tissue Engineering and Regenerative Medicine, 2018, 12, 1944-1958.	1.3	18
699	The TRPM2 channel nexus from oxidative damage to Alzheimerâ€™s pathologies: An emerging novel intervention target for age-related dementia. Ageing Research Reviews, 2018, 47, 67-79.	5.0	39
700	A discrete mathematical model for the aggregation of Î²-Amyloid. PLoS ONE, 2018, 13, e0196402.	1.1	24
701	An in vitro paradigm to assess potential anti-AÎ² antibodies for Alzheimerâ€™s disease. Nature Communications, 2018, 9, 2676.	5.8	50
702	Chiral supramolecular coordination cages as high-performance inhibitors against amyloid-Î² aggregation. Chemical Communications, 2018, 54, 8725-8728.	2.2	16
703	Honokiol Ameliorates Amyloidosis and Neuroinflammation and Improves Cognitive Impairment in Alzheimerâ€™s Disease Transgenic Mice. Journal of Pharmacology and Experimental Therapeutics, 2018, 366, 470-478.	1.3	31
704	Recent advancements toward therapeutic vaccines against Alzheimerâ€™s disease. Expert Review of Vaccines, 2018, 17, 707-721.	2.0	46
705	Amyloid-Î² Peptide Triggers Membrane Remodeling in Supported Lipid Bilayers Depending on Their Hydrophobic Thickness. Langmuir, 2018, 34, 9548-9560.	1.6	18
706	The spectrum of preclinical Alzheimer's disease pathology and its modulation by ApoE genotype. Neurobiology of Aging, 2018, 71, 72-80.	1.5	42
707	Conserved S/T Residues of the Human Chaperone DNAJB6 Are Required for Effective Inhibition of AÎ²42 Amyloid Fibril Formation. Biochemistry, 2018, 57, 4891-4902.	1.2	52

#	Article	IF	Citations
708	Highâ€density lipoprotein mimetic peptide 4F mitigates amyloidâ€Î²â€induced inhibition of apolipoprotein E secretion and lipidation in primary astrocytes and microglia. Journal of Neurochemistry, 2018, 147, 647-662.	2.1	31
709	Integration of Drosophila and Human Genetics to Understand Notch Signaling Related Diseases. Advances in Experimental Medicine and Biology, 2018, 1066, 141-185.	0.8	35
710	Highlights in BACE1 Inhibitors for Alzheimer's Disease Treatment. Frontiers in Chemistry, 2018, 6, 178.	1.8	126
711	Physiological AÎ² Concentrations Produce a More Biomimetic Representation of the Alzheimerâ€™s Disease Phenotype in iPSC Derived Human Neurons. ACS Chemical Neuroscience, 2018, 9, 1693-1701.	1.7	12
712	Anti-Î²-sheet conformation monoclonal antibody reduces tau and AÎ² oligomer pathology in an Alzheimerâ€™s disease model. Alzheimer's Research and Therapy, 2018, 10, 10.	3.0	23
713	Novel botanical drug DA-9803 prevents deficits in Alzheimerâ€™s mouse models. Alzheimer's Research and Therapy, 2018, 10, 11.	3.0	14
714	Pyroglutamate and Isoaspartate modified Amyloid-Beta in ageing and Alzheimerâ€™s disease. Acta Neuropathologica Communications, 2018, 6, 3.	2.4	69
715	White matter changes in Alzheimerâ€™s disease: a focus on myelin and oligodendrocytes. Acta Neuropathologica Communications, 2018, 6, 22.	2.4	412
717	An inorganic overview of natural AÎ² fragments: Copper(II) and zinc(II)-mediated pathways. Coordination Chemistry Reviews, 2018, 369, 1-14.	9.5	14
718	Residueâ€Specific Dynamics and Local Environmental Changes in AÎ²40 Oligomer and Fibril Formation. Angewandte Chemie - International Edition, 2018, 57, 8017-8021.	7.2	16
719	Dual-therapy strategy for modification of adiponectin receptor signaling in aging-associated chronic diseases. Drug Discovery Today, 2018, 23, 1305-1311.	3.2	13
720	Reduced penetrance of the PSEN1 H163Y autosomal dominant Alzheimer mutation: a 22-year follow-up study. Alzheimer's Research and Therapy, 2018, 10, 45.	3.0	11
721	A novel detection method of cleaved plasma highâ€molecularâ€weight kininogen reveals its correlation with Alzheimer's pathology and cognitive impairment. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 480-489.	1.2	27
722	Enriched environment enhances Î²â€adrenergic signaling to prevent microglia inflammation byÂamyloidâ€Î². EMBO Molecular Medicine, 2018, 10, .	3.3	50
723	BACE1 Inhibitor MK-8931 Alters Formation but Not Stability of Dendritic Spines. Frontiers in Aging Neuroscience, 2018, 10, 229.	1.7	27
724	Adrenergic Î² receptor activation in the basolateral amygdala, which is intracellular Zn2+-dependent, rescues amyloid Î²1-42-induced attenuation of dentate gyrus LTP. Neurochemistry International, 2018, 120, 43-48.	1.9	5
725	A mathematical model for the effects of amyloid beta on intracellular calcium. PLoS ONE, 2018, 13, e0202503.	1.1	28
726	Ginkgo biloba L. (Ginkgoaceae) Leaf Extract Medications From Different Providers Exhibit Differential Functional Effects on Mouse Frontal Cortex Neuronal Networks. Frontiers in Pharmacology, 2018, 9, 848.	1.6	10

#	Article	IF	Citations
727	Residueâ€Specific Dynamics and Local Environmental Changes in AÎ²40 Oligomer and Fibril Formation. Angewandte Chemie, 2018, 130, 8149-8153.	1.6	1
728	A d-enantiomeric peptide interferes with heteroassociation of amyloid-Î² oligomers and prion protein. Journal of Biological Chemistry, 2018, 293, 15748-15764.	1.6	21
729	Cholesterol and ApoE in Alzheimerâ€™s disease. OCL - Oilseeds and Fats, Crops and Lipids, 2018, 25, D407.	0.6	1
730	Ultrasensitive photoelectrochemical immunosensor for the detection of amyloid Î²-protein based on SnO2/SnS2/Ag2S nanocomposites. Biosensors and Bioelectronics, 2018, 120, 1-7.	5.3	77
731	Key Residues for the Formation of AÎ²42 Amyloid Fibrils. ACS Omega, 2018, 3, 8401-8407.	1.6	26
732	Enalaprilat Inhibits Zinc-Dependent Oligomerization of Metal-Binding Domain of Amyloid-beta Isoforms and Protects Human Neuroblastoma Cells from Toxic Action of these Isoforms. Molecular Biology, 2018, 52, 590-597.	0.4	9
733	Application of nanodiagnostics and nanotherapy to CNS diseases. Nanomedicine, 2018, 13, 2341-2371.	1.7	37
734	Resident brain neural precursor cells develop age-dependent loss of therapeutic functions in Alzheimer's mice. Neurobiology of Aging, 2018, 72, 40-52.	1.5	15
735	Paradoxical effects of mutant ubiquitin on AÎ² plaque formation in an Alzheimer mouse model. Neurobiology of Aging, 2018, 72, 62-71.	1.5	9
736	Increased Prevalence of Obesity/Type 2 Diabetes and Lower Levels of Lithium in Rural Texas Counties May Explain Greater Alzheimerâ€™s Disease Risk. Journal of Alzheimer's Disease, 2018, 64, 303-308.	1.2	13
737	The Involvement of AÎ²42 and Tau in Nucleolar and Protein Synthesis Machinery Dysfunction. Frontiers in Cellular Neuroscience, 2018, 12, 220.	1.8	29
738	The Amyloid-Î² Oligomer Hypothesis: Beginning of the Third Decade. Journal of Alzheimer's Disease, 2018, 64, S567-S610.	1.2	572
739	[18F]-Flutemetamol Uptake in Cortex and White Matter: Comparison with Cerebrospinal Fluid Biomarkers and [18F]-Fludeoxyglucose. Journal of Alzheimer's Disease, 2018, 62, 1595-1607.	1.2	16
740	The Fate of Nascent APP in Hippocampal Neurons: A Live Cell Imaging Study. ACS Chemical Neuroscience, 2018, 9, 2225-2232.	1.7	3
741	Graphene-based enzyme-modified field-effect transistor biosensor for monitoring drug effects in Alzheimerâ€™s disease treatment. Sensors and Actuators B: Chemical, 2018, 272, 448-458.	4.0	56
742	Prophylactic and Therapeutic Applications of Catalytic Immunoglobulin Gene Delivery in a Mouse Model of Alzheimerâ€™s Disease. , 2018, , 139-161.		1
743	Dysregulation of Intracellular Calcium Signaling in Alzheimer's Disease. Antioxidants and Redox Signaling, 2018, 29, 1176-1188.	2.5	71
744	Selective targeting of 3 repeat Tau with brain penetrating single chain antibodies for the treatment of neurodegenerative disorders. Acta Neuropathologica, 2018, 136, 69-87.	3.9	23

#	Article	IF	Citations
745	Recent progress in metalâ€“organic frameworks for precaution and diagnosis of Alzheimerâ€™s disease. Polyhedron, 2018, 151, 554-567.	1.0	13
746	Rhenium Complexes of Bis(benzothiazole)â€Based Tetraarylethylenes as Selective Luminescent Probes for Amyloid Fibrils. Chemistry - A European Journal, 2018, 24, 11729-11737.	1.7	23
747	Melatonin induces mechanisms of brain resilience against neurodegeneration. Journal of Pineal Research, 2018, 65, e12515.	3.4	59
748	Update on biomarkers for amyloid pathology in Alzheimer's disease. Biomarkers in Medicine, 2018, 12, 799-812.	0.6	59
749	Alzheimerâ€™s Dementia Drug Discovery. , 2018, , 587-591.		0
750	Sub-chronic celecoxib prevents soluble beta amyloid-induced depressive-like behaviour in rats. Journal of Affective Disorders, 2018, 238, 118-121.	2.0	17
751	The influences of E22Q mutant on solvated 3AÎ² 11-40 peptide: A REMD study. Journal of Molecular Graphics and Modelling, 2018, 83, 122-128.	1.3	6
752	Epigenetic Regulation in Neurodegenerative Diseases. Trends in Neurosciences, 2018, 41, 587-598.	4.2	248
753	Prion-like mechanisms in Alzheimer disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 153, 303-319.	1.0	42
754	Vaccination strategies. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 153, 419-430.	1.0	5
755	In Vivo Imaging of Tauopathy in Mice. Methods in Molecular Biology, 2018, 1779, 513-526.	0.4	12
756	Molecular Aspects of Ischemic Injury. , 2018, , 41-87.		1
757	Development of an Effective Alzheimerâ€™s Vaccine. , 2018, , 149-169.		2
758	Alzheimer's disease in the omics era. Clinical Biochemistry, 2018, 59, 9-16.	0.8	76
759	Modulating Protein Phosphatase 2A Rescues Disease Phenotype in Neurodegenerative Tauopathies. ACS Chemical Neuroscience, 2018, 9, 2731-2740.	1.7	16
760	Resveratrol Induces Brain Resilience Against Alzheimer Neurodegeneration Through Proteostasis Enhancement. Molecular Neurobiology, 2019, 56, 1502-1516.	1.9	104
761	Mass spectrometry is a multifaceted weapon to be used in the battle against Alzheimer's disease: Amyloid beta peptides and beyond. Mass Spectrometry Reviews, 2019, 38, 34-48.	2.8	23
762	Investigation of intermolecular interactions and stability of verubecestat in the active site of BACE1: Development of first model from QM/MM-based charge density and MD analysis. Journal of Biomolecular Structure and Dynamics, 2019, 37, 2339-2354.	2.0	15

#	Article	IF	Citations
763	Near-infrared Fluorescence Ocular Imaging (NIRFOI) of Alzheimerâ€™s Disease. Molecular Imaging and Biology, 2019, 21, 35-43.	1.3	31
764	The Prion Protein Regulates Synaptic Transmission by Controlling the Expression of Proteins Key to Synaptic Vesicle Recycling and Exocytosis. Molecular Neurobiology, 2019, 56, 3420-3436.	1.9	9
765	RPS23RG1 Is Required for Synaptic Integrity andÂRescues Alzheimerâ€™s Diseaseâ€“Associated CognitiveÂDeficits. Biological Psychiatry, 2019, 86, 171-184.	0.7	38
766	Progression of Alzheimerâ€™s disease, tau propagation, and its modifiable risk factors. Neuroscience Research, 2019, 141, 36-42.	1.0	50
767	Effect and Safety of Huannao Yicong Formula (è¿˜è„‘ç›Šèªæ–¹) in Patients with Mild-to-Moderate Alzheimerâ€™s Disease: A Randomized, Double-Blinded, Donepezil-Controlled Trial. Chinese Journal of Integrative Medicine, 2019, 25, 574-581.	0.7	16
768	Pathophysiological Roles of Intracellular Proteases in Neuronal Development and Neurological Diseases. Molecular Neurobiology, 2019, 56, 3090-3112.	1.9	39
769	Early compensatory responses against neuronal injury: A new therapeutic window of opportunity for Alzheimer's Disease?. CNS Neuroscience and Therapeutics, 2019, 25, 5-13.	1.9	43
770	Effects of Prion Protein on AÎ²42 and Pyroglutamate-Modified AÎ²pÎ•3-42 Oligomerization and Toxicity. Molecular Neurobiology, 2019, 56, 1957-1971.	1.9	13
771	AÎ² Oligomer Elimination Restores Cognition in Transgenic Alzheimerâ€™s Mice with Full-blown Pathology. Molecular Neurobiology, 2019, 56, 2211-2223.	1.9	29
772	Drug development for Alzheimerâ€™s disease: review. Journal of Drug Targeting, 2019, 27, 164-173.	2.1	60
773	A Candidate Regulatory Variant at the TREM Gene Cluster Confer Alzheimerâ€™s Disease Risk by Modulating Both Amyloid-Î² Pathology and Neuronal Degeneration. Frontiers in Neuroscience, 2019, 13, 742.	1.4	2
774	Mental Disorders in Young Adults from Families with the Presenilin-1 Gene Mutation E280A in the Preclinical Stage of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2019, , 1-10.	1.2	0
775	Dementia associated with disorders of the basal ganglia. Journal of Neuroscience Research, 2019, 97, 1728-1741.	1.3	10
776	The basis of cellular and regional vulnerability in Alzheimerâ€™s disease. Acta Neuropathologica, 2019, 138, 729-749.	3.9	73
777	A vicious cycle of Î² amyloidâ€“dependent neuronal hyperactivation. Science, 2019, 365, 559-565.	6.0	407
778	Bacopa monnieri, a Neuroprotective Lead in Alzheimer Disease: A Review on Its Properties, Mechanisms of Action, and Preclinical and Clinical Studies. Drug Target Insights, 2019, 13, 117739281986641.	0.9	71
779	C-Terminal Plays as the Possible Nucleation of the Self-Aggregation of the S-Shape AÎ²_{11â€“42} Tetramer in Solution: Intensive MD Study. ACS Omega, 2019, 4, 11066-11073.	1.6	8
780	Î²-amyloid pathology and hippocampal atrophy are independently associated with memory function in cognitively healthy elderly. Scientific Reports, 2019, 9, 11180.	1.6	28

#	Article	IF	Citations
781	EDITORIAL: FAILURE AFTER FAILURE. WHAT NEXT IN AD DRUG DEVELOPMENT?. journal of prevention of Alzheimer's disease, The, 2019, 6, 1-1.	1.5	18
782	Scanning ultrasound in the absence of blood-brain barrier opening is not sufficient to clear Î²-amyloid plaques in the APP23 mouse model of Alzheimer's disease. Brain Research Bulletin, 2019, 153, 8-14.	1.4	26
784	Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2019, 11, 68.	3.0	44
785	Superior Memory Reduces 8-year Risk of Mild Cognitive Impairment and Dementia But Not Amyloid Î²-Associated Cognitive Decline in Older Adults. Archives of Clinical Neuropsychology, 2019, 34, 585-598.	0.3	23
786	Unilateral Focused Ultrasound-Induced Blood-Brain Barrier Opening Reduces Phosphorylated Tau from The rTg4510 Mouse Model. Theranostics, 2019, 9, 5396-5411.	4.6	63
787	Modelling mitochondrial dysfunction in Alzheimer's disease using human induced pluripotent stem cells. World Journal of Stem Cells, 2019, 11, 236-253.	1.3	13
788	Hypothesis: cerebrospinal fluid protein markers suggest a pathway toward symptomatic resilience to AD pathology. Alzheimer's and Dementia, 2019, 15, 1160-1171.	0.4	12
789	Multiple BACE1 inhibitors abnormally increase the BACE1 protein level in neurons by prolonging its halfâ€life. Alzheimer's and Dementia, 2019, 15, 1183-1194.	0.4	17
790	Longitudinal analysis of risk factors for dementia based on Mild Cognitive Impairment Screen results and questionnaire responses from healthy Japanese individuals registered in an online database. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 347-353.	1.8	3
791	Linking Molecular Pathways and Large-Scale Computational Modeling to Assess Candidate Disease Mechanisms and Pharmacodynamics in Alzheimer's Disease. Frontiers in Computational Neuroscience, 2019, 13, 54.	1.2	83
792	Activities of mitochondrial respiratory chain complexes in platelets of patients with Alzheimer's disease and depressive disorder. Mitochondrion, 2019, 48, 67-77.	1.6	40
793	Decreased stimulus-driven connectivity of the primary visual cortex during visual motion stimulation in amnestic mild cognitive impairment: An fMRI study. Neuroscience Letters, 2019, 711, 134402.	1.0	1
794	Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. Nature Reviews Neurology, 2019, 15, 501-518.	4.9	734
795	1-Trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) Urea, a Selective and Potent Dual Inhibitor of Soluble Epoxide Hydrolase and p38 Kinase Intervenes in Alzheimerâ€™s Signaling in Human Nerve Cells. ACS Chemical Neuroscience, 2019, 10, 4018-4030.	1.7	23
796	Protein-Capped Metal Nanoparticles Inhibit Tau Aggregation in Alzheimerâ€™s Disease. ACS Omega, 2019, 4, 12833-12840.	1.6	100
797	Liver Dysfunction as a Novel Player in Alzheimerâ€™s Progression: Looking Outside the Brain. Frontiers in Aging Neuroscience, 2019, 11, 174.	1.7	93
798	Exploring the different environments effect of piperine via combined crystallographic, QM/MM and molecular dynamics simulation study. Journal of Molecular Graphics and Modelling, 2019, 92, 280-295.	1.3	7
799	Gamma secretase modulators and BACE inhibitors reduce AÎ² production without altering gene expression in Alzheimer's disease iPSC-derived neurons and mice. Molecular and Cellular Neurosciences, 2019, 100, 103392.	1.0	8

#	Article	IF	Citations
800	PPARÎ± Between Aspirin and Plaque Clearance. Journal of Alzheimer's Disease, 2019, 71, 389-397.	1.2	12
801	The role of mitophagy in selected neurodegenerative diseases. Postepy Psychiatrii I Neurologii, 2019, 28, 154-161.	0.2	2
802	Peripheral Blood Biomarkers Coupled with the Apolipoprotein E4 Genotype Are Strongly Associated with Semantic and Episodic Memory Impairments in Elderly Subjects with Amnestic Mild Cognitive Impairment and Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2019, 71, 797-811.	1.2	11
803	Decoding the Role of Platelets and Related MicroRNAs in Aging and Neurodegenerative Disorders. Frontiers in Aging Neuroscience, 2019, 11, 151.	1.7	34
804	Defining the binding interface of Amyloid Precursor Protein (APP) and Contactin3 (CNTN3) by site-directed mutagenesis. PLoS ONE, 2019, 14, e0219384.	1.1	3
805	Follow-up of active AÎ² immunization in Alzheimer disease. Nature Reviews Neurology, 2019, 15, 495-496.	4.9	9
806	Inhibition of Histone Methyltransferases EHMT1/2 Reverses Amyloid-Î²-Induced Loss of AMPAR Currents in Human Stem Cell-Derived Cortical Neurons. Journal of Alzheimer's Disease, 2019, 70, 1175-1185.	1.2	14
807	Characterization of the unique In Vitro effects of unsaturated fatty acids on the formation of amyloid Î² fibrils. PLoS ONE, 2019, 14, e0219465.	1.1	11
808	Tetrameric AÎ²40 and AÎ²42 Î²-Barrel Structures by Extensive Atomistic Simulations. II. In Aqueous Solution. Journal of Physical Chemistry B, 2019, 123, 6750-6756.	1.2	31
809	Alzheimer Disease Pathogenesis: Insights From Molecular and Cellular Biology Studies of Oligomeric AÎ² and Tau Species. Frontiers in Neuroscience, 2019, 13, 659.	1.4	198
810	Potential Benefits of Nobiletin, A Citrus Flavonoid, against Alzheimerâ€™s Disease and Parkinsonâ€™s Disease. International Journal of Molecular Sciences, 2019, 20, 3380.	1.8	126
811	Elevated levels of Secreted-Frizzled-Related-Protein 1 contribute to Alzheimerâ€™s disease pathogenesis. Nature Neuroscience, 2019, 22, 1258-1268.	7.1	48
812	Structure and dynamics of Î³-secretase with presenilin 2 compared to presenilin 1. RSC Advances, 2019, 9, 20901-20916.	1.7	24
813	Does Intraneuronal Accumulation of Carboxyl-terminal Fragments of the Amyloid Precursor Protein Trigger Early Neurotoxicity in Alzheimerâ€™s Disease?. Current Alzheimer Research, 2019, 16, 453-457.	0.7	41
814	Fluorescence Detection and Dissociation of Amyloidâ€Î² Species for the Treatment of Alzheimer's Disease. Advanced Therapeutics, 2019, 2, 1900054.	1.6	19
815	Solvent-Assisted Paper Spray Ionization Mass Spectrometry (SAPSI-MS) for the Analysis of Biomolecules and Biofluids. Scientific Reports, 2019, 9, 10296.	1.6	18
816	Structure of amyloid-Î² (20-34) with Alzheimerâ€™s-associated isomerization at Asp23 reveals a distinct protofilament interface. Nature Communications, 2019, 10, 3357.	5.8	45
817	Oxidative inactivation of amyloid beta-degrading proteases by cholesterol-enhanced mitochondrial stress. Redox Biology, 2019, 26, 101283.	3.9	27

#	Article	IF	Citations
818	Genes, pathways and risk prediction in Alzheimerâ€™s disease. Human Molecular Genetics, 2019, 28, R235-R240.	1.4	16
820	Optimal control strategies for inhibition of protein aggregation. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 14593-14598.	3.3	21
821	The Extent of Human Apolipoprotein A-I Lipidation Strongly Affects the Î²-Amyloid Efflux Across the Blood-Brain Barrier in vitro. Frontiers in Neuroscience, 2019, 13, 419.	1.4	42
822	Challenges in the treatment of Alzheimerâ€™s disease: recent progress and treatment strategies of pharmaceuticals targeting notable pathological factors. Expert Review of Neurotherapeutics, 2019, 19, 623-652.	1.4	17
823	Lessons Learned From Public Private Partnerships and Consortia: The ADNI Paradigm. Handbook of Behavioral Neuroscience, 2019, , 239-246.	0.7	0
824	Vascular Cognitive Impairment andÂDementia. Journal of the American College of Cardiology, 2019, 73, 3326-3344.	1.2	384
825	Alzheimerâ€™s disease: Key developments support promising perspectives for therapy. Pharmacological Research, 2019, 146, 104316.	3.1	17
826	Amyloid Beta 25â€“35 induces blood-brain barrier disruption in vitro. Metabolic Brain Disease, 2019, 34, 1365-1374.	1.4	35
827	Long-Term Pantethine Treatment Counteracts Pathologic Gene Dysregulation and Decreases Alzheimer's Disease Pathogenesis in a Transgenic Mouse Model. Neurotherapeutics, 2019, 16, 1237-1254.	2.1	9
828	Exosome-mediated therapeutic delivery: A new horizon for human neurodegenerative disordersâ€™ treatment (with a focus on siRNA delivery improvement). Process Biochemistry, 2019, 85, 164-174.	1.8	10
829	Common BACE2 Polymorphisms are Associated with Altered Risk for Alzheimerâ€™s Disease and CSF Amyloid Biomarkers in APOE Îµ4 Non-Carriers. Scientific Reports, 2019, 9, 9640.	1.6	14
830	Humanization of the entire murine Mapt gene provides a murine model of pathological human tau propagation. Journal of Biological Chemistry, 2019, 294, 12754-12765.	1.6	114
831	New insights into differential aggregation of enantiomerically pure and racemic AÎ²40 systems. Peptide Science, 2019, 111, e24139.	1.0	13
832	Molecular Basis of Neurodegeneration: Lessons from Alzheimerâ€™s and Parkinsonâ€™s Diseases. , 2019, , .		2
833	Mental Disorders in Young Adults from Families with the Presenilin-1 Gene Mutation E280A in the Preclinical Stage of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease Reports, 2019, 3, 241-250.	1.2	2
834	A combined miRNAâ€“piRNA signature to detect Alzheimerâ€™s disease. Translational Psychiatry, 2019, 9, 250.	2.4	74
835	Modulation of Proteome Profile in AÎ²PP/PS1 Mice Hippocampus, Medial Prefrontal Cortex, and Striatum by Palm Oil Derived Tocotrienol-Rich Fraction. Journal of Alzheimer's Disease, 2019, 72, 229-246.	1.2	12
836	Effects of Cu(II) on the aggregation of amyloid-Î². Journal of Biological Inorganic Chemistry, 2019, 24, 1197-1215.	1.1	30

#	Article	IF	Citations
837	Biological, Diagnostic and Therapeutic Advances in Alzheimer's Disease. , 2019, , .		6
838	Resveratrol in experimental Alzheimerâ€™s disease models: A systematic review of preclinical studies. Pharmacological Research, 2019, 150, 104476.	3.1	37
839	ASK1 and its role in cardiovascular and other disorders: available treatments and future prospects. Expert Review of Proteomics, 2019, 16, 857-870.	1.3	10
840	Amyloid-Î² peptides in cerebrospinal fluid of patients with dementia with Lewy bodies. Alzheimer's Research and Therapy, 2019, 11, 83.	3.0	23
841	Effects of the Novel IDO Inhibitor DWG-1036 on the Behavior of Male and Female 3xTg-AD Mice. Frontiers in Pharmacology, 2019, 10, 1044.	1.6	33
842	Nanoparticle-mediated approaches for Alzheimerâ€™s disease pathogenesis, diagnosis, and therapeutics. Journal of Controlled Release, 2019, 314, 125-140.	4.8	43
843	EEG time signature in AlzheimerÂ´s disease: Functional brain networks falling apart. NeuroImage: Clinical, 2019, 24, 102046.	1.4	43
844	The Development of Small Molecule Inhibitors of Glutaminyl Cyclase and Isoglutaminyl Cyclase for Alzheimer's Disease. ChemistrySelect, 2019, 4, 10591-10600.	0.7	5
845	Baicalein as a Potential Inhibitor against BACE1 and AChE: Mechanistic Comprehension through In Vitro and Computational Approaches. Nutrients, 2019, 11, 2694.	1.7	37
846	Future horizons in Alzheimer's disease research. Progress in Molecular Biology and Translational Science, 2019, 168, 223-241.	0.9	19
847	Hsp60 in Modifications of Nervous System Homeostasis and Neurodegeneration. Heat Shock Proteins, 2019, , 241-266.	0.2	2
849	Chronic traumatic encephalopathy neuropathology might not be inexorably progressive or unique to repetitive neurotrauma. Brain, 2019, 142, 3672-3693.	3.7	57
850	Heat Shock Protein 60 in Human Diseases and Disorders. Heat Shock Proteins, 2019, , .	0.2	6
851	Neuroprotective Dihydro-Î²-agarofuran-Type Sesquiterpenes from the Seeds of Euonymus maackii. Journal of Natural Products, 2019, 82, 3096-3103.	1.5	13
852	Flotillin is a Novel Diagnostic Blood Marker of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2019, 72, 1165-1176.	1.2	21
853	Albumin Exchange in Alzheimer's Disease: Might CSF Be an Alternative Route to Plasma?. Frontiers in Neurology, 2019, 10, 1036.	1.1	15
854	SERF engages in a fuzzy complex that accelerates primary nucleation of amyloid proteins. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 23040-23049.	3.3	25
856	Raloxifene alleviates amyloidâ€Î²â€induced cytotoxicity in HT22 neuronal cells via inhibiting oligomeric and fibrillar species formation. Journal of Biochemical and Molecular Toxicology, 2019, 33, e22395.	1.4	4

#	Article	IF	Citations
857	Using N-Terminal Coordination of Cu(II) and Ni(II) to Isolate the Coordination Environment of Cu(I) and Cu(II) Bound to His13 and His14 in Amyloid-Î²(4â€“16). Inorganic Chemistry, 2019, 58, 15138-15154.	1.9	16
858	A Human Embryonic Stem Cell Model of AÎ²-Dependent Chronic Progressive Neurodegeneration. Frontiers in Neuroscience, 2019, 13, 1007.	1.4	6
859	Synthesis and Evaluation of New Cyclodextrin Derivatives as Amyloidâ€Î² Aggregation Inhibitors. ChemistrySelect, 2019, 4, 10639-10642.	0.7	4
860	Exploring the relationship between physical activity, beta-amyloid and tau: A narrative review. Ageing Research Reviews, 2019, 50, 9-18.	5.0	67
861	Cryo-EM structure and polymorphism of AÎ² amyloid fibrils purified from Alzheimerâ€™s brain tissue. Nature Communications, 2019, 10, 4760.	5.8	411
862	Age-Related Changes of the Neurovascular Unit in the Cerebral Cortex of Alzheimer Disease Mouse Models: A Neuroanatomical and Molecular Study. Journal of Neuropathology and Experimental Neurology, 2019, 78, 101-112.	0.9	15
863	Designed Helical Peptides as Functional Probes for Î³-Secretase. Biochemistry, 2019, 58, 4398-4407.	1.2	4
864	Fluid dynamics of cerebrospinal fluid flow in perivascular spaces. Journal of the Royal Society Interface, 2019, 16, 20190572.	1.5	84
865	Age? It's in the Game. , 2019, , .		2
866	Age-Dependent Modification of Intracellular Zn²⁺ Buffering in the Hippocampus and Its Impact. Biological and Pharmaceutical Bulletin, 2019, 42, 1070-1075.	0.6	9
867	Cell size effects in the molecular dynamics of the intrinsically disordered AÎ² peptide. Journal of Chemical Physics, 2019, 151, 085101.	1.2	17
868	Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of PF-06751979, a Potent and Selective Oral BACE1 Inhibitor: Results from Phase I Studies in Healthy Adults and Healthy Older Subjects. Journal of Alzheimer's Disease, 2019, 71, 581-595.	1.2	16
869	Unravelling Alzheimer's Disease: It's Not the Whole Story, but AÎ² Still Matters. FASEB Journal, 2019, 33, 9701-9705.	0.2	5
870	EDITORIAL: IS NOW THE TIME FOR COMBINATION THERAPIES FOR ALZHEIMER DISEASE?. journal of prevention of Alzheimer's disease, The, 2019, 6, 1-2.	1.5	6
871	APPLICATION OF THE NIA-AA RESEARCH FRAMEWORK: TOWARDS A BIOLOGICAL DEFINITION OF ALZHEIMERâ€™S DISEASE USING CEREBROSPINAL FLUID BIOMARKERS IN THE AIBL STUDY. journal of prevention of Alzheimer's disease, The, 2019, 6, 1-8.	1.5	20
872	IMPLICATIONS FOR BACE1 INHIBITOR CLINICAL TRIALS: ADULT CONDITIONAL BACE1 KNOCKOUT MICE EXHIBIT AXONAL ORGANIZATION DEFECTS IN THE HIPPOCAMPUS. journal of prevention of Alzheimer's disease, The, 2019, 6, 1-7.	1.5	19
873	Overview of Transgenic Mouse Models for Alzheimer's Disease. Current Protocols in Neuroscience, 2019, 89, e81.	2.6	78
874	p35 Hemizygous Deletion in 5xFAD Mice Increases AÎ² Plaque Load in Males but Not in Females. Neuroscience, 2019, 417, 45-56.	1.1	4

#	Article	IF	Citations
875	Health benefits of dietary marine DHA/EPA-enriched glycerophospholipids. Progress in Lipid Research, 2019, 75, 100997.	5.3	195
876	Amyloid-Î² PETâ€"Correlation with cerebrospinal fluid biomarkers and prediction of AlzheimerÂ´s disease diagnosis in a memory clinic. PLoS ONE, 2019, 14, e0221365.	1.1	37
877	Abundant neuroprotective chaperone Lipocalin-type prostaglandin D synthase (L-PGDS) disassembles the Amyloid-Î² fibrils. Scientific Reports, 2019, 9, 12579.	1.6	31
878	Biomedical Implications of Autophagy in Macromolecule Storage Disorders. Frontiers in Cell and Developmental Biology, 2019, 7, 179.	1.8	22
879	The Involvement of Peripheral and Brain Insulin Resistance in Late Onset Alzheimerâ€™s Dementia. Frontiers in Aging Neuroscience, 2019, 11, 236.	1.7	40
880	Therapeutic potency of substituted chromones as Alzheimerâ€™s drug: Elucidation of acetylcholinesterase inhibitory activity through spectroscopic and molecular modelling investigation. BioImpacts, 2019, 9, 79-88.	0.7	12
881	Development of new treatments for Alzheimerâ€™s disease based on the modulation of translocator protein (TSPO). Ageing Research Reviews, 2019, 54, 100943.	5.0	10
882	Extracellular heat shock proteins in neurodegenerative diseases: New perspectives. Neuroscience Letters, 2019, 711, 134462.	1.0	31
883	Ageing as a risk factor for neurodegenerative disease. Nature Reviews Neurology, 2019, 15, 565-581.	4.9	1,578
884	Emerging Roles of Complement in Psychiatric Disorders. Frontiers in Psychiatry, 2019, 10, 573.	1.3	63
885	Patterned Amyloid Materials Integrating Robustness and Genetically Programmable Functionality. Nano Letters, 2019, 19, 8399-8408.	4.5	31
886	Microglia in Brain Development, Homeostasis, and Neurodegeneration. Annual Review of Genetics, 2019, 53, 263-288.	3.2	121
887	Plasmon-Activated Water Reduces Amyloid Burden and Improves Memory in Animals with Alzheimerâ€™s Disease. Scientific Reports, 2019, 9, 13252.	1.6	15
888	Hormesis in Health and Chronic Diseases. Trends in Endocrinology and Metabolism, 2019, 30, 944-958.	3.1	35
889	Acer okamotoanumand isoquercitrin improve cognitive functionviaattenuation of oxidative stress in high fat diet- and amyloid beta-induced mice. Food and Function, 2019, 10, 6803-6814.	2.1	22
890	Characterizing Individual Protein Aggregates by Infrared Nanospectroscopy and Atomic Force Microscopy. Journal of Visualized Experiments, 2019, , .	0.2	13
891	Non-invasive in vivo hyperspectral imaging of the retina for potential biomarker use in Alzheimerâ€™s disease. Nature Communications, 2019, 10, 4227.	5.8	157
892	Metal binding to the amyloid-Î² peptides in the presence of biomembranes: potential mechanisms of cell toxicity. Journal of Biological Inorganic Chemistry, 2019, 24, 1189-1196.	1.1	49

#	Article	IF	Citations
893	Type 2 Diabetes Mellitus Increases The Risk of Late-Onset Alzheimerâ€™s Disease: Ultrastructural Remodeling of the Neurovascular Unit and Diabetic Gliopathy. Brain Sciences, 2019, 9, 262.	1.1	48
894	Emerging Alternative Proteinases in APP Metabolism and Alzheimerâ€™s Disease Pathogenesis: A Focus on MT1-MMP and MT5-MMP. Frontiers in Aging Neuroscience, 2019, 11, 244.	1.7	46
895	Neuroglia in Neurodegenerative Diseases. Advances in Experimental Medicine and Biology, 2019, , .	0.8	18
896	M1 muscarinic receptor is a key target of neuroprotection, neuroregeneration and memory recovery by i-Extract from Withania somnifera. Scientific Reports, 2019, 9, 13990.	1.6	32
897	Risk Factors for Alzheimerâ€™s Disease: Focus on Stress. Frontiers in Pharmacology, 2019, 10, 976.	1.6	20
898	Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. Cell, 2019, 179, 312-339.	13.5	1,675
899	Critical evaluation of current Alzheimerâ€™s drug discovery (2018â€“19) & futuristic Alzheimer drug model approach. Bioorganic Chemistry, 2019, 93, 103299.	2.0	20
900	The mitochondria-targeted antioxidant MitoQ inhibits memory loss, neuropathology, and extends lifespan in aged 3xTg-AD mice. Molecular and Cellular Neurosciences, 2019, 101, 103409.	1.0	65
901	Discovery of an Extremely Potent Thiazine-Based Î²-Secretase Inhibitor with Reduced Cardiovascular and Liver Toxicity at a Low Projected Human Dose. Journal of Medicinal Chemistry, 2019, 62, 9331-9337.	2.9	7
902	Hexahydropyrrolo[2,3-b]indole Compounds as Potential Therapeutics for Alzheimerâ€™s Disease. ACS Chemical Neuroscience, 2019, 10, 4250-4263.	1.7	9
903	A catalytic antioxidant for limiting amyloid-beta peptide aggregation and reactive oxygen species generation. Chemical Science, 2019, 10, 1634-1643.	3.7	44
904	Blood-brain barrier at the interface of air pollution-associated neurotoxicity and neuroinflammation. Advances in Neurotoxicology, 2019, , 295-337.	0.7	3
905	Identification of fermented tea (Camellia sinensis) polyphenols and their inhibitory activities against amyloid-beta aggregation. Phytochemistry, 2019, 160, 11-18.	1.4	23
906	Photoactive chlorin e6 is a multifunctional modulator of amyloid-Î² aggregation and toxicity via specific interactions with its histidine residues. Chemical Science, 2019, 10, 208-217.	3.7	25
907	Tau and mTOR: The Hotspots for Multifarious Diseases in Alzheimer's Development. Frontiers in Neuroscience, 2018, 12, 1017.	1.4	65
908	Alanine Scanning Effects on the Biochemical and Biophysical Properties of Intrinsically Disordered Proteins: A Case Study of the Histidine to Alanine Mutations in Amyloid-Î²₄₂. Journal of Chemical Information and Modeling, 2019, 59, 871-884.	2.5	14
909	Molecular Mechanisms of TDP-43 Misfolding and Pathology in Amyotrophic Lateral Sclerosis. Frontiers in Molecular Neuroscience, 2019, 12, 25.	1.4	459
910	Prenatal noise stress aggravates cognitive decline and the onset and progression of beta amyloid pathology in a mouse model of Alzheimer's disease. Neurobiology of Aging, 2019, 77, 66-86.	1.5	36

#	Article	IF	Citations
911	Derivatives of Piperazines as Potential Therapeutic Agents for Alzheimerâ€™s Disease. Molecular Pharmacology, 2019, 95, 337-348.	1.0	26
912	Treatment Combinations for Alzheimerâ€™s Disease: Current and Future Pharmacotherapy Options. Journal of Alzheimer's Disease, 2019, 67, 779-794.	1.2	336
913	Olive Biophenols Reduces Alzheimerâ€™s Pathology in SH-SY5Y Cells and APPswe Mice. International Journal of Molecular Sciences, 2019, 20, 125.	1.8	43
914	TFEB-mediated Enhancement of the Autophagy-lysosomal Pathway Dually Modulates the Process of Amyloid Î²-Protein Generation in Neurons. Neuroscience, 2019, 402, 11-22.	1.1	12
915	Link between the unfolded protein response and dysregulation of mitochondrial bioenergetics in Alzheimerâ€™s disease. Cellular and Molecular Life Sciences, 2019, 76, 1419-1431.	2.4	37
916	Chitosan oligosaccharide (COS): An overview. International Journal of Biological Macromolecules, 2019, 129, 827-843.	3.6	313
917	Novel compound VB-037 inhibits AÎ² aggregation and promotes neurite outgrowth through enhancement of HSP27 and reduction of P38 and JNK-mediated inflammation in cell models for Alzheimer's disease. Neurochemistry International, 2019, 125, 175-186.	1.9	17
918	Free Energy Profile for Penetration of Pittsburgh Compound-B into the Amyloid Î² Fibril. ACS Chemical Neuroscience, 2019, 10, 1783-1790.	1.7	9
919	Optimized liposomes with transactivator of transcription peptide and anti-apoptotic drugs to target hippocampal neurons and prevent tau-hyperphosphorylated neurodegeneration. Acta Biomaterialia, 2019, 87, 207-222.	4.1	38
920	Tocotrienol Rich Fraction Supplementation Modulate Brain Hippocampal Gene Expression in APPswe/PS1dE9 Alzheimerâ€™s Disease Mouse Model. Journal of Alzheimer's Disease, 2019, 70, S239-S254.	1.2	17
921	Comparative studies of DHA-enriched phosphatidylcholine and recombination of DHA-ethyl ester with egg phosphatidylcholine on ameliorating memory and cognitive deficiency in SAMP8 mice. Food and Function, 2019, 10, 938-950.	2.1	50
922	Comparison of Intensity- and Polarization-based Contrast in Amyloid-beta Plaques as Observed by Optical Coherence Tomography. Applied Sciences (Switzerland), 2019, 9, 2100.	1.3	4
923	Inhibition of metal-induced amyloid Î²-peptide aggregation by a bloodâ€“brain barrier permeable silicaâ€“cyclen nanochelator. RSC Advances, 2019, 9, 14126-14131.	1.7	11
924	Long-term icariin treatment ameliorates cognitive deficits via CD4⁺ T cell-mediated immuno-inflammatory responses in APP/PS1 mice . Clinical Interventions in Aging, 2019, Volume 14, 817-826.	1.3	21
925	Modeling Alzheimerâ€™s disease with human iPS cells: advancements, lessons, and applications. Neurobiology of Disease, 2019, 130, 104503.	2.1	24
926	Alzheimer's disease-associated tau alters Drosophila circadian activity, sleep and clock neuron electrophysiology. Neurobiology of Disease, 2019, 130, 104507.	2.1	33
927	Hippocampal stem cells promotes synaptic resistance to the dysfunctional impact of amyloid beta oligomers via secreted exosomes. Molecular Neurodegeneration, 2019, 14, 25.	4.4	38
928	Interference with Amyloid-Î² Nucleation by Transient Ligand Interaction. Molecules, 2019, 24, 2129.	1.7	11

#	Article	IF	Citations
929	Influence of Matrix Metallopeptidase 9 on Beta-Amyloid Elimination Across the Blood-Brain Barrier. Molecular Neurobiology, 2019, 56, 8296-8305.	1.9	19
930	Glycosylation profiling of selected proteins in cerebrospinal fluid from Alzheimer's disease and healthy subjects. Analytical Methods, 2019, 11, 3331-3340.	1.3	7
931	CD4ÂT Cells Induce A Subset of MHCII-Expressing Microglia that Attenuates Alzheimer Pathology. IScience, 2019, 16, 298-311.	1.9	60
932	Copper-Targeting Approaches in Alzheimerâ€™s Disease: How To Improve the Fallouts Obtained from in Vitro Studies. Inorganic Chemistry, 2019, 58, 13509-13527.	1.9	61
933	Processing of Mutant Î²-Amyloid Precursor Protein and the Clinicopathological Features of Familial Alzheimerâ€™s Disease. , 2019, 10, 383.		27
934	The Alzheimer's Prevention Initiative Generation Program: Study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 216-227.	1.8	80
935	Can Healthy Diets, Regular Exercise, and Better Lifestyle Delay the Progression of Dementia in Elderly Individuals?. Journal of Alzheimer's Disease, 2019, 72, S37-S58.	1.2	36
936	Proteomic signatures of neuroinflammation in Alzheimerâ€™s disease, multiple sclerosis and ischemic stroke. Expert Review of Proteomics, 2019, 16, 601-611.	1.3	14
937	Four-repeat tauopathies. Progress in Neurobiology, 2019, 180, 101644.	2.8	141
938	Perspectives on drug discovery strategies based on IDPs. , 2019, , 275-327.		9
939	Two novel presenilin-1 mutations (I249L and P433S) in early onset Chinese Alzheimer's pedigrees and their functional characterization. Biochemical and Biophysical Research Communications, 2019, 516, 264-269.	1.0	10
940	Brains of rhesus monkeys display AÎ² deposits and glial pathology while lacking AÎ² dimers and other Alzheimer's pathologies. Aging Cell, 2019, 18, e12978.	3.0	17
941	Alzheimerâ€™s Disease Associated Genes Ankyrin and Tau Cause Shortened Lifespan and Memory Loss in Drosophila. Frontiers in Cellular Neuroscience, 2019, 13, 260.	1.8	32
942	Endolysosome and Autolysosome Dysfunction in Alzheimerâ€™s Disease: Where Intracellular and Extracellular Meet. CNS Drugs, 2019, 33, 639-648.	2.7	23
943	AÎ² oligomers promote oligodendrocyte differentiation and maturation via integrin Î²1 and Fyn kinase signaling. Cell Death and Disease, 2019, 10, 445.	2.7	49
944	Oral Immunization with Soybean Storage Protein Containing Amyloid-Î² 4â€“10 Prevents Spatial Learning Decline. Journal of Alzheimer's Disease, 2019, 70, 487-503.	1.2	4
945	Oxidative Stress in Neurodegenerative Diseases: From a Mitochondrial Point of View. Oxidative Medicine and Cellular Longevity, 2019, 2019, 1-18.	1.9	311
946	Amyloid Precursor Protein (APP) and GABAergic Neurotransmission. Cells, 2019, 8, 550.	1.8	24

#	Article	IF	Citations
947	Gemfibrozil, a Lipid-Lowering Drug, Lowers Amyloid Plaque Pathology and Enhances Memory in a Mouse Model of Alzheimerâ€™s Disease via Peroxisome Proliferator-Activated Receptor Î±. Journal of Alzheimer's Disease Reports, 2019, 3, 149-168.	1.2	37
948	Modulating Hinge Flexibility in the APP Transmembrane Domain Alters Î³-Secretase Cleavage. Biophysical Journal, 2019, 116, 2103-2120.	0.2	34
949	Native Ion Mobility-Mass Spectrometry Reveals the Formation of Î²-Barrel Shaped Amyloid-Î² Hexamers in a Membrane-Mimicking Environment. Journal of the American Chemical Society, 2019, 141, 10440-10450.	6.6	94
950	CD2-associated protein (CD2AP) overexpression accelerates amyloid precursor protein (APP) transfer from early endosomes to the lysosomal degradation pathway. Journal of Biological Chemistry, 2019, 294, 10886-10899.	1.6	28
951	Non-Alcoholic Fatty Liver Disease, and the Underlying Altered Fatty Acid Metabolism, Reveals Brain Hypoperfusion and Contributes to the Cognitive Decline in APP/PS1 Mice. Metabolites, 2019, 9, 104.	1.3	34
952	Electroacupuncture Mitigates Hippocampal Cognitive Impairments by Reducing BACE1 Deposition and Activating PKA in APP/PS1 Double Transgenic Mice. Neural Plasticity, 2019, 2019, 1-12.	1.0	19
953	Role of Cav-1 in HIV-1 Tat-Induced Dysfunction of Tight Junctions and AÎ²-Transferring Proteins. Oxidative Medicine and Cellular Longevity, 2019, 2019, 1-8.	1.9	11
954	Optimization of solid-phase extraction (SPE) in the preparation of [18F]D3FSP: A new PET imaging agent for mapping AÎ² plaques. Nuclear Medicine and Biology, 2019, 71, 54-64.	0.3	3
955	Persistent neuropathological effects 14 years following amyloid-Î² immunization in Alzheimerâ€™s disease. Brain, 2019, 142, 2113-2126.	3.7	127
956	Effects of Second Language Learning on the Plastic Aging Brain: Functional Connectivity, Cognitive Decline, and Reorganization. Frontiers in Neuroscience, 2019, 13, 423.	1.4	53
957	Wnt Signaling Upregulates Teneurin-3 Expression via Canonical and Non-canonical Wnt Pathway Crosstalk. Frontiers in Neuroscience, 2019, 13, 505.	1.4	6
958	Tau binding protein CAPON induces tau aggregation and neurodegeneration. Nature Communications, 2019, 10, 2394.	5.8	59
959	Cryo-EM of amyloid fibrils and cellular aggregates. Current Opinion in Structural Biology, 2019, 58, 34-42.	2.6	112
960	Familial L723P Mutation Can Shift the Distribution between the Alternative APP Transmembrane Domain Cleavage Cascades by Local Unfolding of the Î·-Cleavage Site Suggesting a Straightforward Mechanism of Alzheimerâ€™s Disease Pathogenesis. ACS Chemical Biology, 2019, 14, 1573-1582.	1.6	13
961	A Robust and Scalable High-Throughput Compatible Assay for Screening Amyloid-Î²-Binding Compounds. Journal of Alzheimer's Disease, 2019, 70, 187-197.	1.2	7
962	Pharmacological Potential of Cilostazol for Alzheimerâ€™s Disease. Frontiers in Pharmacology, 2019, 10, 559.	1.6	20
963	Metalloproteinases and their tissue inhibitors in Alzheimerâ€™s disease and other neurodegenerative disorders. Cellular and Molecular Life Sciences, 2019, 76, 3167-3191.	2.4	73
964	Moderateâ€•to highâ€intensity exercise does not modify cortical Î²â€amyloid in Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 208-215.	1.8	20

#	Article	IF	Citations
965	Î±-synuclein in the pathophysiology of Alzheimerâ€™s disease. Molecular Neurodegeneration, 2019, 14, 23.	4.4	197
966	Quercetin Regulates the Integrated Stress Response to Improve Memory. International Journal of Molecular Sciences, 2019, 20, 2761.	1.8	28
967	Astroglial Calcium Signaling in Aging and Alzheimer's Disease. Cold Spring Harbor Perspectives in Biology, 2019, 11, a035188.	2.3	56
968	Extracellular interface between APP and Nicastrin regulates AÎ² length and response to Î³â€secretase modulators. EMBO Journal, 2019, 38, .	3.5	45
969	Antibiotics, gut microbiota, and Alzheimerâ€™s disease. Journal of Neuroinflammation, 2019, 16, 108.	3.1	262
970	Age and sex differences in motivation and spatial working memory in 3xTg-AD mice in the Hebbâ€“Williams maze. Behavioural Brain Research, 2019, 370, 111937.	1.2	16
971	Exploring the Pathogenesis of Alzheimer Disease in Basal Forebrain Cholinergic Neurons: Converging Insights From Alternative Hypotheses. Frontiers in Neuroscience, 2019, 13, 446.	1.4	122
972	Molecular Connection Between Diabetes and Dementia. Advances in Experimental Medicine and Biology, 2019, 1128, 103-131.	0.8	9
973	Copper and zinc ions govern the transâ€directed dimerization of APP family members in multiple ways. Journal of Neurochemistry, 2019, 151, 626-641.	2.1	10
974	Multi-target design strategies for the improved treatment of Alzheimer's disease. European Journal of Medicinal Chemistry, 2019, 176, 228-247.	2.6	148
975	Microvesicles from cerebrospinal fluid of patients with Alzheimerâ€™s disease display reduced concentrations of tau and APP protein. Scientific Reports, 2019, 9, 7089.	1.6	30
976	Depression in Alzheimerâ€™s Disease: An Alternative Role for Selective Serotonin Reuptake Inhibitors?. Journal of Alzheimer's Disease, 2019, 69, 651-661.	1.2	37
977	Targeting Apolipoprotein E for Alzheimerâ€™s Disease: An Industry Perspective. International Journal of Molecular Sciences, 2019, 20, 2161.	1.8	27
979	Application of advanced brain positron emission tomographyâ€“based molecular imaging for a biological framework in neurodegenerative proteinopathies. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 327-332.	1.2	9
980	Natural Compounds for Alzheimerâ€™s Disease Therapy: A Systematic Review of Preclinical and Clinical Studies. International Journal of Molecular Sciences, 2019, 20, 2313.	1.8	148
981	Inhibitory effects of oxidovanadium complexes on the aggregation of human islet amyloid polypeptide and its fragments. Journal of Inorganic Biochemistry, 2019, 197, 110721.	1.5	9
982	The role of sleep deprivation and circadian rhythm disruption as risk factors of Alzheimerâ€™s disease. Frontiers in Neuroendocrinology, 2019, 54, 100764.	2.5	79
983	Hsp60 Protects against Amyloid Î² Oligomer Synaptic Toxicity via Modification of Toxic Oligomer Conformation. ACS Chemical Neuroscience, 2019, 10, 2858-2867.	1.7	19

#	Article	IF	Citations
986	Mesenchymal Stromal Cell Therapies for Neurodegenerative Diseases. Mayo Clinic Proceedings, 2019, 94, 892-905.	1.4	112
987	A metabolic perspective of late onset Alzheimerâ€™s disease. Pharmacological Research, 2019, 145, 104255.	3.1	19
988	COMBINATION THERAPY FOR ALZHEIMERâ€™S DISEASE: PERSPECTIVES OF THE EU/US CTAD TASK FORCE. journal of prevention of Alzheimer's disease, The, 2019, 6, 1-5.	1.5	29
989	A clinical dose of angiotensin-converting enzyme (ACE) inhibitor and heterozygous ACE deletion exacerbate Alzheimer's disease pathology in mice. Journal of Biological Chemistry, 2019, 294, 9760-9770.	1.6	32
990	Blood amyloid-Î² oligomerization associated with neurodegeneration of Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2019, 11, 40.	3.0	38
991	Exploring Amyloid-Î² Dimer Structure Using Molecular Dynamics Simulations. Journal of Physical Chemistry A, 2019, 123, 4658-4670.	1.1	13
992	High molecular weight amyloid Î² _{1â€42} oligomers induce neurotoxicity via plasma membrane damage. FASEB Journal, 2019, 33, 9220-9234.	0.2	72
993	Labelâ€free distribution of antiâ€amyloid Dâ€AIP in Drosophila melanogaster : prevention of AÎ²42â€induced toxicity without side effects in transgenic flies. Journal of Neurochemistry, 2019, 150, 74-87.	2.1	7
994	The Major Risk Factors for Alzheimerâ€™s Disease: Age, Sex, and Genes Modulate the Microglia Response to AÎ² Plaques. Cell Reports, 2019, 27, 1293-1306.e6.	2.9	527
995	HIV and Alzheimerâ€™s disease: complex interactions of HIV-Tat with amyloid Î² peptide and Tau protein. Journal of NeuroVirology, 2019, 25, 648-660.	1.0	29
996	Age-Associated Changes in the Immune System and Bloodâ€“Brain Barrier Functions. International Journal of Molecular Sciences, 2019, 20, 1632.	1.8	107
997	The BIN1 rs744373 SNP is associated with increased tau-PET levels and impaired memory. Nature Communications, 2019, 10, 1766.	5.8	68
998	Neurochemical Aspects of Alzheimerâ€™s Type of Dementia. , 2019, , 73-112.		1
999	Association of Cortical Î²-Amyloid Protein in the Absence of Insoluble Deposits With Alzheimer Disease. JAMA Neurology, 2019, 76, 818.	4.5	25
1000	Regulation of Neprilysin Activity and Cognitive Functions in Rats After Prenatal Hypoxia. Neurochemical Research, 2019, 44, 1387-1398.	1.6	17
1001	Cognitive Decline, Cerebral-Spleen Tryptophan Metabolism, Oxidative Stress, Cytokine Production, and Regulation of the Txnip Gene in a Triple Transgenic Mouse Model of Alzheimer Disease. American Journal of Pathology, 2019, 189, 1435-1450.	1.9	21
1002	New molecular approaches to Alzheimer's disease. Clinical Biochemistry, 2019, 72, 81-86.	0.8	18
1003	OPEP6: A New Constant-pH Molecular Dynamics Simulation Scheme with OPEP Coarse-Grained Force Field. Journal of Chemical Theory and Computation, 2019, 15, 3875-3888.	2.3	27

#	Article	IF	Citations
1004	Progesterone receptor membrane component 1 inhibits tumor necrosis factor alpha induction of gene expression in neural cells. PLoS ONE, 2019, 14, e0215389.	1.1	10
1005	Examination of Alzheimer's disease by a combination of electrostatic force and mechanical measurement. Journal of Microscopy, 2019, 275, 66-72.	0.8	4
1006	Insight into the internal structure of amyloid-Î² oligomers by isotope-edited Fourier transform infrared spectroscopy. Physical Chemistry Chemical Physics, 2019, 21, 8587-8597.	1.3	22
1007	Rivastigmine and metabolite analogues with putative Alzheimerâ€™s disease-modifying properties in a Caenorhabditis elegans model. Communications Chemistry, 2019, 2, .	2.0	25
1008	The vexing complexity of the amyloidogenic pathway. Protein Science, 2019, 28, 1177-1193.	3.1	25
1009	Modulation of Disordered Proteins with a Focus on Neurodegenerative Diseases and Other Pathologies. International Journal of Molecular Sciences, 2019, 20, 1322.	1.8	45
1010	Complex formation of APP with GABAB receptors links axonal trafficking to amyloidogenic processing. Nature Communications, 2019, 10, 1331.	5.8	92
1011	Semi-synthetic isoflavones as BACE-1 inhibitors against Alzheimerâ€™s disease. Bioorganic Chemistry, 2019, 87, 474-483.	2.0	24
1012	A Close Look at BACE1 Inhibitors for Alzheimerâ€™s Disease Treatment. CNS Drugs, 2019, 33, 251-263.	2.7	115
1013	What Is the â€œRelevantâ€•Amyloid Î²42 Concentration?. ChemBioChem, 2019, 20, 1725-1726.	1.3	20
1014	Novelty processing and memory impairment in Alzheimer's disease: A review. Neuroscience and Biobehavioral Reviews, 2019, 100, 237-249.	2.9	26
1015	Detection of Alzheimerâ€™s disease (AD) specific tau pathology with conformation-selective anti-tau monoclonal antibody in co-morbid frontotemporal lobar degeneration-tau (FTLD-tau). Acta Neuropathologica Communications, 2019, 7, 34.	2.4	27
1016	Probable Transmembrane Amyloid Î±-Helix Bundles Capable of Conducting Ca²⁺ Ions. Journal of Physical Chemistry B, 2019, 123, 2645-2653.	1.2	26
1017	Pharmacological inhibition of Bax-induced cell death: Bax-inhibiting peptides and small compounds inhibiting Bax. Experimental Biology and Medicine, 2019, 244, 621-629.	1.1	35
1018	Structural analysis of copper(I) interaction with amyloid Î² peptide. Journal of Inorganic Biochemistry, 2019, 195, 31-38.	1.5	25
1019	ApoE-fragment/AÎ² heteromers in the brain of patients with Alzheimerâ€™s disease. Scientific Reports, 2019, 9, 3989.	1.6	24
1020	Systemic peptide mediated delivery of an siRNA targeting Î±-syn in the CNS ameliorates the neurodegenerative process in a transgenic model of Lewy body disease. Neurobiology of Disease, 2019, 127, 163-177.	2.1	30
1021	PKR knockout in the 5xFAD model of Alzheimer's disease reveals beneficial effects on spatial memory and brain lesions. Aging Cell, 2019, 18, e12887.	3.0	28

#	Article	IF	Citations
1022	Human cerebrospinal fluid 6E10-immunoreactive protein species contain amyloid precursor protein fragments. PLoS ONE, 2019, 14, e0212815.	1.1	12
1023	Amyloidogenic Nanoplaques in Blood Serum of Patients with Alzheimerâ€™s Disease Revealed by Time-Resolved Thioflavin T Fluorescence Intensity Fluctuation Analysis. Journal of Alzheimer's Disease, 2019, 68, 571-582.	1.2	21
1024	Salidroside protects PC-12 cells against amyloid Î²-induced apoptosis by activation of theï¿½ERK1/2 and AKT signaling pathways. International Journal of Molecular Medicine, 2019, 43, 1769-1777.	1.8	17
1025	Free d-aspartate triggers NMDA receptor-dependent cell death in primary cortical neurons and perturbs JNK activation, Tau phosphorylation, and protein SUMOylation in the cerebral cortex of mice lacking d-aspartate oxidase activity. Experimental Neurology, 2019, 317, 51-65.	2.0	24
1026	The Dichotomy of Alzheimerâ€™s Disease Pathology: Amyloid-Î² and Tau. Journal of Alzheimer's Disease, 2019, 68, 77-83.	1.2	14
1027	Liraglutide and its Neuroprotective Propertiesâ€”Focus on Possible Biochemical Mechanisms in Alzheimerâ€™s Disease and Cerebral Ischemic Events. International Journal of Molecular Sciences, 2019, 20, 1050.	1.8	50
1028	Soluble tau aggregates inhibit synaptic long-term depression and amyloid Î²-facilitated LTD in vivo. Neurobiology of Disease, 2019, 127, 582-590.	2.1	25
1029	Endo-lysosomal pathway and ubiquitin-proteasome system dysfunction in Alzheimer's disease pathogenesis. Neuroscience Letters, 2019, 703, 68-78.	1.0	56
1030	Development of an Efficient Manufacturing Process for E2212 toward Rapid Clinical Introduction. Organic Process Research and Development, 2019, 23, 603-613.	1.3	3
1031	Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry. Journal of Visualized Experiments, 2019, , .	0.2	16
1032	Reply to: Major Clinical Trials Failed the Amyloid Hypothesis of Alzheimer's Disease. Journal of the American Geriatrics Society, 2019, 67, 848-849.	1.3	2
1033	Analysis of convective and diffusive transport in the brain interstitium. Fluids and Barriers of the CNS, 2019, 16, 6.	2.4	102
1034	Involvement of RhoA/ROCK Signaling in AÎ²-Induced Chemotaxis, Cytotoxicity and Inflammatory Response of Microglial BV2 Cells. Cellular and Molecular Neurobiology, 2019, 39, 637-650.	1.7	20
1035	Nr <scp>CAM</scp> is a marker for substrateâ€selective activation of <scp>ADAM</scp> 10 in Alzheimer's disease. EMBO Molecular Medicine, 2019, 11, .	3.3	38
1036	A small molecule Nec-1 directly induces amyloid clearance in the brains of aged APP/PS1 mice. Scientific Reports, 2019, 9, 4183.	1.6	27
1037	Autism genes and the leukocyte transcriptome in autistic toddlers relate to pathogen interactomes, infection and the immune system. A role for excess neurotrophic sAPPÎ± and reduced antimicrobial AÎ². Neurochemistry International, 2019, 126, 36-58.	1.9	13
1038	Contribution of syndecans to cellular internalization and fibrillation of amyloid-Î²(1â€“42). Scientific Reports, 2019, 9, 1393.	1.6	33
1039	Recurrent herpes simplex virus-1 infection induces hallmarks of neurodegeneration and cognitive deficits in mice. PLoS Pathogens, 2019, 15, e1007617.	2.1	160

#	Article	IF	Citations
1040	Understanding the Amyloid Hypothesis in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2019, 68, 493-510.	1.2	77
1041	DNA Aptamers Targeting BACE1 Reduce Amyloid Levels and Rescue Neuronal Deficiency in Cultured Cells. Molecular Therapy - Nucleic Acids, 2019, 16, 302-312.	2.3	9
1042	Amyloid-Î² oligomers have a profound detergent-like effect on lipid membrane bilayers, imaged by atomic force and electron microscopy. Journal of Biological Chemistry, 2019, 294, 7566-7572.	1.6	112
1043	Epigenetic Modulation on Tau Phosphorylation in Alzheimerâ€™s Disease. Neural Plasticity, 2019, 2019, 1-12.	1.0	18
1044	Differential effects of diet- and genetically-induced brain insulin resistance on amyloid pathology in a mouse model of Alzheimerâ€™s disease. Molecular Neurodegeneration, 2019, 14, 15.	4.4	74
1045	Nanowired delivery of cerebrolysin with neprilysin and p-Tau antibodies induces superior neuroprotection in Alzheimer's disease. Progress in Brain Research, 2019, 245, 145-200.	0.9	30
1046	A Novel PSEN1 M139L Mutation Found in a Chinese Pedigree with Early-Onset Alzheimerâ€™s Disease Increases AÎ²42/AÎ²40 ratio. Journal of Alzheimer's Disease, 2019, 69, 199-212.	1.2	11
1047	Randomized Trial of Verubecestat for Prodromal Alzheimerâ€™s Disease. New England Journal of Medicine, 2019, 380, 1408-1420.	13.9	397
1048	Quantitative assessment of oligomeric amyloid Î² peptide binding to Î±7 nicotinic receptor. British Journal of Pharmacology, 2019, 176, 3475-3488.	2.7	20
1049	Simulation Studies of Amyloidogenic Polypeptides and Their Aggregates. Chemical Reviews, 2019, 119, 6956-6993.	23.0	138
1050	Tetrameric AÎ²40 and AÎ²42 Î²-Barrel Structures by Extensive Atomistic Simulations. I. In a Bilayer Mimicking a Neuronal Membrane. Journal of Physical Chemistry B, 2019, 123, 3643-3648.	1.2	42
1051	The anaesthetic xenon partially restores an amyloid beta-induced impairment in murine hippocampal synaptic plasticity. Neuropharmacology, 2019, 151, 21-32.	2.0	7
1052	The potential of memory enhancement through modulation of perineuronal nets. British Journal of Pharmacology, 2019, 176, 3611-3621.	2.7	27
1053	The Potential Influence of Bone-Derived Modulators on the Progression of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2019, 69, 59-70.	1.2	30
1054	Determining the Protein Stability of Alzheimerâ€™s Disease Protein, Amyloid Precursor Protein. Protein Journal, 2019, 38, 419-424.	0.7	5
1055	The New Application of UHPLC-DAD-TOF/MS in Identification of Inhibitors on Î²-Amyloid Fibrillation From Scutellaria baicalensis. Frontiers in Pharmacology, 2019, 10, 194.	1.6	16
1056	Increased H-Bond Stability Relates to Altered Îµ-Cleavage Efficiency and AÎ² Levels in the I45T Familial Alzheimerâ€™s Disease Mutant of APP. Scientific Reports, 2019, 9, 5321.	1.6	20
1057	Glatiramer acetate reduces infarct volume in diabetic mice with cerebral ischemia and prevents long-term memory loss. Brain, Behavior, and Immunity, 2019, 80, 315-327.	2.0	18

#	Article	IF	Citations
1058	Metabolic resistance of the D-peptide RD2 developed for direct elimination of amyloid-Î² oligomers. Scientific Reports, 2019, 9, 5715.	1.6	25
1059	Autophagy Activator Drugs: A New Opportunity in Neuroprotection from Misfolded Protein Toxicity. International Journal of Molecular Sciences, 2019, 20, 901.	1.8	81
1060	GM6 Attenuates Alzheimerâ€™s Disease Pathology in APP Mice. Molecular Neurobiology, 2019, 56, 6386-6396.	1.9	4
1061	Late Effects. , 2019, , 496-554.		0
1062	Identification of Pre-symptomatic Gene Signatures That Predict Resilience to Cognitive Decline in the Genetically Diverse AD-BXD Model. Frontiers in Genetics, 2019, 10, 35.	1.1	22
1063	Iron treatment inhibits AÎ²42 deposition inÂvivo and reduces AÎ²42/AÎ²40 ratio. Biochemical and Biophysical Research Communications, 2019, 512, 653-658.	1.0	6
1064	Ginsenoside compound K attenuates cognitive deficits in vascular dementia rats by reducing the AÎ² deposition. Journal of Pharmacological Sciences, 2019, 139, 223-230.	1.1	44
1065	Innovative Therapy for Alzheimerâ€™s Disease-With Focus on Biodelivery of NGF. Frontiers in Neuroscience, 2019, 13, 38.	1.4	103
1066	A phase 1 clinical trial of the sigmaâ€2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 20-26.	1.8	73
1067	Amyloid Î² perturbs elevated heme flux induced with neuronal development. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 27-37.	1.8	8
1068	Dementia in Down syndrome: unique insights for Alzheimer diseaseÂresearch. Nature Reviews Neurology, 2019, 15, 135-147.	4.9	223
1069	[¹⁸F]Amylovis as a Potential PET Probe for Î²-Amyloid Plaque: Synthesis, In Silico, In vitro and In vivo Evaluations. Current Radiopharmaceuticals, 2019, 12, 58-71.	0.3	7
1070	A walk through tau therapeutic strategies. Acta Neuropathologica Communications, 2019, 7, 22.	2.4	211
1071	Remarkable Brain Penetration of Cyclopentadienyl M(CO)₃⁺ (M =) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Application as Diagnostic, with Single-Photon-Emission Computed Tomography (SPECT), and Therapeutic Agents for Alzheimerâ€™s Disease. Journal of Medicinal Chemistry, 2019, 62, 2638-2650.	2.9	22
1072	Vitamin D-binding protein-loaded PLGA nanoparticles suppress Alzheimer's disease-related pathology in 5XFAD mice. Nanomedicine: Nanotechnology, Biology, and Medicine, 2019, 17, 297-307.	1.7	76
1073	Elucidating the inhibitory potential of Vitamin A against fibrillation and amyloid associated cytotoxicity. International Journal of Biological Macromolecules, 2019, 129, 333-338.	3.6	23
1074	Atomic force microscopy for single molecule characterisation of protein aggregation. Archives of Biochemistry and Biophysics, 2019, 664, 134-148.	1.4	109
1075	Fresh evidence for major brain gangliosides as a target for the treatment of Alzheimer's disease. Neurobiology of Aging, 2019, 77, 128-143.	1.5	28

#	Article	IF	Citations
1076	Associations Between Gut Microbiota and Alzheimerâ€™s Disease: Current Evidences and Future Therapeutic and Diagnostic Perspectives. Journal of Alzheimer's Disease, 2019, 68, 25-31.	1.2	21
1077	Novel tacrine-tryptophan hybrids: Multi-target directed ligands as potential treatment for Alzheimer's disease. European Journal of Medicinal Chemistry, 2019, 168, 491-514.	2.6	75
1078	Regulation of AÎ²PP Glycosylation Modification and Roles of Glycosylation on AÎ²PP Cleavage in Alzheimerâ€™s Disease. ACS Chemical Neuroscience, 2019, 10, 2115-2124.	1.7	12
1079	Structure of amyloid Î²25â€“35 in lipid environment and cholesterol-dependent membrane pore formation. Scientific Reports, 2019, 9, 2689.	1.6	43
1080	Sodium rutin ameliorates Alzheimerâ€™s diseaseâ€“like pathology by enhancing microglial amyloid-Î² clearance. Science Advances, 2019, 5, eaau6328.	4.7	163
1081	A DFTâ€Assisted Topological Analysis of Four Polymorphic, Sâ€Shaped AÎ²42 Fibril Structures. ChemBioChem, 2019, 20, 1722-1724.	1.3	5
1082	Amyloid-Î²(29â€“42) Dimeric Conformations in Membranes Rich in Omega-3 and Omega-6 Polyunsaturated Fatty Acids. Journal of Physical Chemistry B, 2019, 123, 2687-2696.	1.2	14
1083	Small Molecule Amyloid-Î² Protein Precursor Processing Modulators Lower Amyloid-Î² Peptide Levels via cKit Signaling. Journal of Alzheimer's Disease, 2019, 67, 1089-1106.	1.2	6
1084	Genetic Risk Factors for Alzheimer Disease: Emerging Roles of Microglia in Disease Pathomechanisms. Advances in Experimental Medicine and Biology, 2019, 1118, 83-116.	0.8	34
1085	Synthesis and evaluation of novel GSK-3Î² inhibitors as multifunctional agents against Alzheimer's disease. European Journal of Medicinal Chemistry, 2019, 167, 211-225.	2.6	34
1086	Cerebrovascular Reactivity Impairment in Preclinical Alzheimer's Disease. Journal of Neuroimaging, 2019, 29, 493-498.	1.0	14
1087	The amyloid cascade and Alzheimer's disease therapeutics: theory versus observation. Laboratory Investigation, 2019, 99, 958-970.	1.7	82
1088	ACE gene missense mutation in a case with early-onset, rapid progressing dementia. Annals of General Psychiatry, 2019, 32, e100028.	1.1	5
1089	Alzheimerâ€™s-like pathology in aging rhesus macaques: Unique opportunity to study the etiology and treatment of Alzheimerâ€™s disease. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 26230-26238.	3.3	46
1091	Donepezil Derivatives Targeting Amyloid-Î² Cascade in Alzheimer's Disease. Current Alzheimer Research, 2019, 16, 772-800.	0.7	18
1092	Hematologic safety of chronic brainâ€penetrating erythropoietin dosing in APP/PS1 mice. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 627-636.	1.8	13
1093	Mitochondria and Alzheimerâ€™s Disease: An Electron Microscopy Study. , 2019, , .		4
1094	Oligomeric AÎ² in the monkey brain impacts synaptic integrity and induces accelerated cortical aging. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 26239-26246.	3.3	67

#	Article	IF	Citations
1095	Alzheimerâ€™s disease: A clinical perspective and future nonhuman primate research opportunities. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 26224-26229.	3.3	61
1096	A Brief Review of Paradigm Shifts in Prevention of Alzheimerâ€™s Disease: From Cognitive Reserve to Precision Medicine. Frontiers in Psychiatry, 2019, 10, 786.	1.3	6
1097	Different aspects of Alzheimerâ€™s disease-related amyloid Î²-peptide pathology and their relationship to amyloid positron emission tomography imaging and dementia. Acta Neuropathologica Communications, 2019, 7, 178.	2.4	29
1098	Amyloid Beta Oligomers Target to Extracellular and Intracellular Neuronal Synaptic Proteins in Alzheimer's Disease. Frontiers in Neurology, 2019, 10, 1140.	1.1	46
1099	Deep proteome profiling of the hippocampus in the 5XFAD mouse model reveals biological process alterations and a novel biomarker of Alzheimerâ€™s disease. Experimental and Molecular Medicine, 2019, 51, 1-17.	3.2	56
1100	Membrane domain modulation of AÎ²_{1â€“42} oligomer interactions with supported lipid bilayers: an atomic force microscopy investigation. Nanoscale, 2019, 11, 20857-20867.	2.8	34
1101	Calcium Signaling in ÃŸ-cell Physiology and Pathology: A Revisit. International Journal of Molecular Sciences, 2019, 20, 6110.	1.8	56
1102	A fingerprint of amyloid plaques in a bitransgenic animal model of Alzheimer's disease obtained by statistical unmixing analysis of hyperspectral Raman data. Analyst, The, 2019, 144, 7049-7056.	1.7	14
1103	The gut-brain axis: microglia in the spotlight. Neuroforum, 2019, 25, 205-212.	0.2	5
1104	Restoring Wnt/Î²-catenin signaling is a promising therapeutic strategy for Alzheimerâ€™s disease. Molecular Brain, 2019, 12, 104.	1.3	172
1105	Early-life Pb exposure as a potential risk factor for Alzheimerâ€™s disease: are there hazards for the Mexican population?. Journal of Biological Inorganic Chemistry, 2019, 24, 1285-1303.	1.1	11
1106	Supersaturated proteins are enriched at synapses and underlie cell and tissue vulnerability in Alzheimer's disease. Heliyon, 2019, 5, e02589.	1.4	23
1107	The search for improved animal models of Alzheimer's disease and novel strategies for therapeutic intervention. Future Medicinal Chemistry, 2019, 11, 1853-1857.	1.1	7
1108	Epidemiological pathology of AÎ² deposition in the ageing brain in CFAS: addition of multiple AÎ²-derived measures does not improve dementia assessment using logistic regression and machine learning approaches. Acta Neuropathologica Communications, 2019, 7, 198.	2.4	14
1109	The Rules of Engagement: Do Microglia Seal the Fate in the Inverse Relation of Glioma and Alzheimerâ€™s Disease?. Frontiers in Cellular Neuroscience, 2019, 13, 522.	1.8	6
1110	The Environment Is a Key Factor in Determining the Anti-Amyloid Efficacy of EGCG. Biomolecules, 2019, 9, 855.	1.8	32
1111	Neurophysiological Markers of Alzheimerâ€™s Disease: Quantitative EEG Approach. Neurology and Therapy, 2019, 8, 37-55.	1.4	60
1112	Tracking down a missing trigger for Alzheimer's disease by mass spectrometric imaging based on brain network analysis. Progress in Molecular Biology and Translational Science, 2019, 168, 25-55.	0.9	1

#	Article	IF	Citations
1113	Role of Adenosine A_{2A}Receptors in the Central Fatigue of Neurodegenerative Diseases. Journal of Caffeine and Adenosine Research, 2019, 9, 145-156.	0.8	9
1114	Impact of amyloid-PET in daily clinical management of patients with cognitive impairment fulfilling appropriate use criteria. Medicine (United States), 2019, 98, e16509.	0.4	6
1115	The amyloid-Î² degradation intermediate AÎ²34 is pericyte-associated and reduced in brain capillaries of patients with Alzheimerâ€™s disease. Acta Neuropathologica Communications, 2019, 7, 194.	2.4	20
1116	Dreaming of a New World Where Alzheimerâ€™s Is a Treatable Disorder. Frontiers in Aging Neuroscience, 2019, 11, 317.	1.7	14
1117	Neutral Endopeptidase (Neprilysin) in Therapy and Diagnostics: Yin and Yang. Biochemistry (Moscow), 2019, 84, 1346-1358.	0.7	17
1118	Organotypic brain slice cultures to model neurodegenerative proteinopathies. Molecular Neurodegeneration, 2019, 14, 45.	4.4	69
1119	Characterization of the selective in vitro and in vivo binding properties of crenezumab to oligomeric AÎ². Alzheimer's Research and Therapy, 2019, 11, 97.	3.0	22
1120	Gantenerumab reduces amyloid-Î² plaques in patients with prodromal to moderate Alzheimerâ€™s disease: a PET substudy interim analysis. Alzheimer's Research and Therapy, 2019, 11, 101.	3.0	131
1121	Early Cognitive and Behavioral Deficits in Mouse Models for Tauopathy and Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2019, 11, 335.	1.7	28
1122	Small-Molecule Amyloid Beta-Aggregation Inhibitors in Alzheimer's Disease Drug Development. Pharmaceutical Fronts, 2019, 01, e22-e32.	0.4	2
1123	In vitroandin silicodetermination of glutaminyl cyclase inhibitors. RSC Advances, 2019, 9, 29619-29627.	1.7	14
1124	Single molecule sensing of amyloid-Î² aggregation by confined glass nanopores. Chemical Science, 2019, 10, 10728-10732.	3.7	60
1125	JBPOS0101 attenuates amyloid-Î² accumulation and memory loss in a mouse model of Alzheimerâ€™s disease. NeuroReport, 2019, 30, 741-747.	0.6	2
1126	Interactions of Selective Serotonin Reuptake Inhibitors with Î²-Amyloid. ACS Chemical Neuroscience, 2019, 10, 226-234.	1.7	16
1127	The leukotriene signaling pathway: a druggable target in Alzheimerâ€™s disease. Drug Discovery Today, 2019, 24, 505-516.	3.2	48
1128	Motor deficits in 16-month-old male and female 3xTg-AD mice. Behavioural Brain Research, 2019, 356, 305-313.	1.2	32
1129	Astrocytic changes with aging and Alzheimer's diseaseâ€type pathology in chimpanzees. Journal of Comparative Neurology, 2019, 527, 1179-1195.	0.9	30
1130	Tau Biology, Tauopathy, Traumatic Brain Injury, and Diagnostic Challenges. Journal of Alzheimer's Disease, 2019, 67, 447-467.	1.2	73

#	Article	IF	Citations
1131	VEGF receptorâ€1 modulates amyloid Î² 1â€“42 oligomerâ€induced senescence in brain endothelial cells. FASEB Journal, 2019, 33, 4626-4637.	0.2	27
1132	Effects of rising amyloidÎ² levels on hippocampal synaptic transmission, microglial response and cognition in APPSwe/PSEN1M146V transgenic mice. EBioMedicine, 2019, 39, 422-435.	2.7	16
1133	Acylguanidine-BACE1 complex: Insights of intermolecular interactions and dynamics. Journal of Theoretical Biology, 2019, 464, 33-49.	0.8	11
1134	A multiomic approach to characterize the temporal sequence in Alzheimer's disease-related pathology. Neurobiology of Disease, 2019, 124, 454-468.	2.1	41
1135	Alzheimerâ€™s Disease Clinical Trials: Moving Toward Successful Prevention. CNS Drugs, 2019, 33, 99-106.	2.7	33
1136	Bax inhibitor 1 is a Î³-secretaseâ€“independent presenilin-binding protein. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 141-147.	3.3	12
1137	Retinal ganglion cellâ€“inner plexiform layer thickness is nonlinearly associated with cognitive impairment in the communityâ€dwelling elderly. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 19-27.	1.2	21
1138	PrP-grafted antibodies bind certain amyloid Î²-protein aggregates, but do not prevent toxicity. Brain Research, 2019, 1710, 125-135.	1.1	14
1139	The ethanol extract of Zizyphus jujuba var. spinosa seeds ameliorates the memory deficits in Alzheimer's disease model mice. Journal of Ethnopharmacology, 2019, 233, 73-79.	2.0	20
1140	Pivotal role of carnosine in the modulation of brain cells activity: Multimodal mechanism of action and therapeutic potential in neurodegenerative disorders. Progress in Neurobiology, 2019, 175, 35-53.	2.8	72
1141	Comprehensive review of mechanisms of pathogenesis involved in Alzheimerâ€™s disease and potential therapeutic strategies. Progress in Neurobiology, 2019, 174, 53-89.	2.8	223
1142	A critical appraisal of amyloid-Î²-targeting therapies for AlzheimerÂdisease. Nature Reviews Neurology, 2019, 15, 73-88.	4.9	666
1143	Matriptase cleaves the amyloid-beta peptide 1â€“42 at Arg-5, Lys-16, and Lys-28. BMC Research Notes, 2019, 12, 5.	0.6	5
1144	Quantitative proteomics reveals distinct composition of amyloid plaques in Alzheimer's disease. Alzheimer's and Dementia, 2019, 15, 429-440.	0.4	69
1145	Evaluating the Role of Microglial Cells in Clearance of AÎ² from Alzheimerâ€™s Brain. ACS Chemical Neuroscience, 2019, 10, 1149-1156.	1.7	12
1146	Kalirinâ€7 prevents dendritic spine dysgenesis induced by amyloid betaâ€derived oligomers. European Journal of Neuroscience, 2019, 49, 1091-1101.	1.2	10
1147	Computational Study of the Driving Forces and Dynamics of Curcumin Binding to Amyloid-Î² Protofibrils. Journal of Physical Chemistry B, 2019, 123, 551-560.	1.2	21
1148	A novel crosslinking protocol stabilizes amyloid Î² oligomers capable of inducing Alzheimer'sâ€associated pathologies. Journal of Neurochemistry, 2019, 148, 822-836.	2.1	20

#	Article	IF	Citations
1149	Relating constructs of attention and working memory to social withdrawal in Alzheimerâ€™s disease and schizophrenia: issues regarding paradigm selection. Neuroscience and Biobehavioral Reviews, 2019, 97, 47-69.	2.9	22
1150	Alzheimer's AÎ²_{1â€40} peptide degradation by thermolysin: evidence of inhibition by a Câ€terminal AÎ² product. FEBS Letters, 2019, 593, 128-137.	1.3	6
1151	Deceleration of the neurodegenerative phenotype in pyroglutamate-AÎ² accumulating transgenic mice by oral treatment with the AÎ² oligomer eliminating compound RD2. Neurobiology of Disease, 2019, 124, 36-45.	2.1	13
1152	Amyloid beta soluble forms and plasminogen activation system in Alzheimerâ€™s disease: Consequences on extracellular maturation of brainâ€derived neurotrophic factor and therapeutic implications. CNS Neuroscience and Therapeutics, 2019, 25, 303-313.	1.9	40
1153	The metalloprotease ADAMTS4 generates N-truncated AÎ²4â€“x species and marks oligodendrocytes as a source of amyloidogenic peptides in Alzheimerâ€™s disease. Acta Neuropathologica, 2019, 137, 239-257.	3.9	44
1154	Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimerâ€™s Disease. Journal of Medicinal Chemistry, 2019, 62, 4252-4264.	2.9	40
1155	Nanocomposites Inhibit the Formation, Mitigate the Neurotoxicity, and Facilitate the Removal of Î²-Amyloid Aggregates in Alzheimerâ€™s Disease Mice. Nano Letters, 2019, 19, 674-683.	4.5	124
1156	Age-related diseases as vicious cycles. Ageing Research Reviews, 2019, 49, 11-26.	5.0	58
1157	Amyloid-ÃŸ promotes neurotoxicity by Cdk5-induced p53 stabilization. Neuropharmacology, 2019, 146, 19-27.	2.0	40
1158	New approaches for the treatment of Alzheimerâ€™s disease. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 125-133.	1.0	111
1159	Mechanisms of Hydrogen Sulfide against the Progression of Severe Alzheimerâ€™s Disease in Transgenic Mice at Different Ages. Pharmacology, 2019, 103, 50-60.	0.9	50
1160	Ablation of amyloid precursor protein increases insulin-degrading enzyme levels and activity in brain and peripheral tissues. American Journal of Physiology - Endocrinology and Metabolism, 2019, 316, E106-E120.	1.8	24
1161	Membrane-mimetic systems for biophysical studies of the amyloid-Î² peptide. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2019, 1867, 492-501.	1.1	34
1162	Novel upregulation of amyloid-Î² precursor protein (APP) by microRNA-346 via targeting of APP mRNA 5â€²-untranslated region: Implications in Alzheimerâ€™s disease. Molecular Psychiatry, 2019, 24, 345-363.	4.1	103
1163	The Anti-amyloid Compound DO1 Decreases Plaque Pathology and Neuroinflammation-Related Expression Changes in 5xFAD Transgenic Mice. Cell Chemical Biology, 2019, 26, 109-120.e7.	2.5	8
1164	Neuronal function of Alzheimer's protein. Science, 2019, 363, 123-124.	6.0	17
1165	Mutation screening in Chinese patients with familial Alzheimer's disease by whole-exome sequencing. Neurobiology of Aging, 2019, 76, 215.e15-215.e21.	1.5	30
1166	Neurotoxicity of air pollution: Role of neuroinflammation. Advances in Neurotoxicology, 2019, , 195-221.	0.7	1

#	Article	IF	Citations
1167	Emerging pathways to neurodegeneration: Dissecting the critical molecular mechanisms in Alzheimerâ€™s disease, Parkinsonâ€™s disease. Biomedicine and Pharmacotherapy, 2019, 111, 765-777.	2.5	88
1168	A pilot study on the effect of lactoferrin on Alzheimerâ€™s disease pathological sequelae: Impact of the p-Akt/PTEN pathway. Biomedicine and Pharmacotherapy, 2019, 111, 714-723.	2.5	50
1169	Interactions of polyunsaturated fatty acids with amyloid peptides AÎ²40 and AÎ²42. Archives of Biochemistry and Biophysics, 2019, 663, 34-43.	1.4	28
1170	Structural progression of amyloid-Î² Arctic mutant aggregation in cells revealed by multiparametric imaging. Journal of Biological Chemistry, 2019, 294, 1478-1487.	1.6	31
1171	Therapeutic Approaches to Alzheimerâ€™s Disease Through Modulation of NRF2. NeuroMolecular Medicine, 2019, 21, 1-11.	1.8	78
1172	A cellular complex of BACE1 and Î³-secretase sequentially generates AÎ² from its full-length precursor. Journal of Cell Biology, 2019, 218, 644-663.	2.3	57
1173	Amyloidâ€Î² immunotherapy for alzheimer disease: Is it now a long shot?. Annals of Neurology, 2019, 85, 303-315.	2.8	126
1174	Alkali ion influence on structure and stability of fibrillar amyloid-Î² oligomers. Journal of Molecular Modeling, 2019, 25, 37.	0.8	14
1175	Electrochemical approaches for the detection of amyloid-Î², tau, and Î±-synuclein. Current Opinion in Electrochemistry, 2019, 14, 89-95.	2.5	13
1176	Obstacles to translating the promise of nanoparticles into viable amyloid disease therapeutics. Physical Biology, 2019, 16, 021002.	0.8	2
1177	The role of membrane trafficking in the processing of amyloid precursor protein and production of amyloid peptides in Alzheimer's disease. Biochimica Et Biophysica Acta - Biomembranes, 2019, 1861, 697-712.	1.4	72
1178	Effects of chain length of saturated fatty acids on AÎ² generation in SH-SY5Y cells. Neuroscience Letters, 2019, 698, 169-172.	1.0	6
1179	Trodusquemine enhances AÎ²42 aggregation but suppresses its toxicity by displacing oligomers from cell membranes. Nature Communications, 2019, 10, 225.	5.8	111
1180	Potential Effects of Aspirin on Lysosomal Biogenesis and Amyloid-Î² Clearance: An Old Drug and Novel Insights in Alzheimer's Disease Therapy. Journal of Neuroscience, 2019, 39, 197-198.	1.7	5
1181	Identification and Preliminary Validation of a Plasma Profile Associated with Cognitive Decline in Dementia and At-Risk Individuals: A Retrospective Cohort Analysis. Journal of Alzheimer's Disease, 2019, 67, 327-341.	1.2	32
1182	An outline for the pharmacological effect of icariin in the nervous system. European Journal of Pharmacology, 2019, 842, 20-32.	1.7	73
1183	Pharmacokinetics and Pharmacodynamics of the BACE 1 Inhibitor Verubecestat (MK â€8931) in Healthy Japanese Adults: A Randomized, Placeboâ€Controlled Study. Clinical Pharmacology and Therapeutics, 2019, 105, 1234-1243.	2.3	15
1184	IgG Fc N-glycosylation: Alterations in neurologic diseases and potential therapeutic target?. Journal of Autoimmunity, 2019, 96, 14-23.	3.0	31

#	Article	IF	Citations
1185	A Numerical Study of Sensitivity Coefficients for a Model of Amyloid Precursor Protein and Tubulin-Associated Unit Protein Transport and Agglomeration in Neurons at the Onset of Alzheimer's Disease. Journal of Biomechanical Engineering, 2019, 141, .	0.6	5
1186	Activity-Induced Amyloid-Î² Oligomers Drive Compensatory Synaptic Rearrangements in Brain Circuits Controlling Memory of Presymptomatic Alzheimer's Disease Mice. Biological Psychiatry, 2019, 86, 185-195.	0.7	15
1187	High resolution approaches for the identification of amyloid fragments in brain. Journal of Neuroscience Methods, 2019, 319, 7-15.	1.3	2
1188	Photosensitizing materials and platforms for light-triggered modulation of Alzheimer's Î²-amyloid self-assembly. Biomaterials, 2019, 190-191, 121-132.	5.7	62
1189	Candidate-based screening via gene modulation in human neurons and astrocytes implicatesFERMT2in AÎ²and TAU proteostasis. Human Molecular Genetics, 2019, 28, 718-735.	1.4	33
1190	Hippocampal transcriptome profiling combined with protein-protein interaction analysis elucidates Alzheimer's disease pathways and genes. Neurobiology of Aging, 2019, 74, 225-233.	1.5	30
1191	Sleep and circadian rhythm disruption and stress intersect in Alzheimer's disease. Neurobiology of Stress, 2019, 10, 100133.	1.9	41
1192	Hydroxylated Single-Walled Carbon Nanotubes Inhibit AÎ²₄₂ Fibrillogenesis, Disaggregate Mature Fibrils, and Protect against AÎ²₄₂-Induced Cytotoxicity. ACS Chemical Neuroscience, 2019, 10, 588-598.	1.7	56
1193	Proamyloidogenic effects of membrane type 1 matrix metalloproteinase involve MMPâ€2 and BACEâ€1 activities, and the modulation of APP trafficking. FASEB Journal, 2019, 33, 2910-2927.	0.2	25
1194	Tau <scp>PET</scp> Imaging for Staging of Alzheimer's Disease in Down Syndrome. Developmental Neurobiology, 2019, 79, 711-715.	1.5	15
1195	Mouse models of Alzheimerâ€™s disease cause rarefaction of pial collaterals and increased severity of ischemic stroke. Angiogenesis, 2019, 22, 263-279.	3.7	48
1196	Chirality Dependence of Amyloidâ€…Î² Cellular Uptake and a New Mechanistic Perspective. ChemBioChem, 2019, 20, 1023-1026.	1.3	29
1197	A multifunctional compound ebselen reverses memory impairment, apoptosis and oxidative stress in a mouse model of sporadic Alzheimer's disease. Journal of Psychiatric Research, 2019, 109, 107-117.	1.5	66
1198	Alzheimerâ€™s Disease and Dementia. , 2019, , 25-82.		2
1199	Dysregulation of Transcription Factors: A Key Culprit Behind Neurodegenerative Disorders. Neuroscientist, 2019, 25, 548-565.	2.6	6
1200	Minocycline prevents the development of depression-like behavior and hippocampal inflammation in a rat model of Alzheimerâ€™s disease. Psychopharmacology, 2019, 236, 1281-1292.	1.5	43
1201	Neuroprotective Actions of Glucagon-Like Peptide-1 (GLP-1) Analogues in Alzheimerâ€™s and Parkinsonâ€™s Diseases. CNS Drugs, 2019, 33, 209-223.	2.7	49
1202	An immobilized acetylcholinesterase as test system to screen new inhibitor drugs to treat Alzheimerâ€™s disease. Sensors and Actuators B: Chemical, 2019, 278, 196-201.	4.0	9

#	Article	IF	Citations
1203	Specific mutations in presenilin 1 cause conformational changes in Î³-secretase to modulate amyloid Î² trimming. Journal of Biochemistry, 2019, 165, 37-46.	0.9	11
1204	Fucosterol exerts protection against amyloid Î²-induced neurotoxicity, reduces intracellular levels of amyloid Î² and enhances the mRNA expression of neuroglobin in amyloid Î²-induced SH-SY5Y cells. International Journal of Biological Macromolecules, 2019, 121, 207-213.	3.6	28
1205	In silico evidence of direct interaction between statins and Î²â€amyloid. Journal of Cellular Biochemistry, 2019, 120, 4710-4715.	1.2	16
1206	Detection of amyloid Î² oligomers toward early diagnosis of Alzheimer's disease. Analytical Biochemistry, 2019, 566, 40-45.	1.1	25
1207	GM1 locates to mature amyloid structures implicating a prominent role for glycolipid-protein interactions in Alzheimer pathology. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2019, 1867, 458-467.	1.1	30
1208	Positional proteomics for identification of secreted proteoforms released by site-specific processing of membrane proteins. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2019, 1867, 140138.	1.1	23
1209	Two new sesquineolignans from the seeds of Crataegus pinnatifida and their Î²-amyloid aggregation inhibitory activitiy. Natural Product Research, 2019, 33, 2446-2452.	1.0	10
1210	PET imaging of tau protein targets: a methodology perspective. Brain Imaging and Behavior, 2019, 13, 333-344.	1.1	43
1211	BRI2 as an anti-Alzheimer gene. Medical Molecular Morphology, 2019, 52, 1-7.	0.4	9
1212	Dysfunctional Î³-Secretase in Familial Alzheimerâ€™s Disease. Neurochemical Research, 2019, 44, 5-11.	1.6	26
1213	An outlook on the role of decaffeinated coffee in neurodegenerative diseases. Critical Reviews in Food Science and Nutrition, 2020, 60, 760-779.	5.4	28
1214	Discovery of new potential triplet acting inhibitor for Alzheimerâ€™s disease via X-ray crystallography, molecular docking and molecular dynamics. Journal of Biomolecular Structure and Dynamics, 2020, 38, 1903-1917.	2.0	8
1215	Identification of a novel PSEN1 Gly111Val missense mutation in a Chinese pedigree with early-onset Alzheimer's disease. Neurobiology of Aging, 2020, 85, 155.e1-155.e4.	1.5	9
1216	Medical image analysis of phosphorylated protein interaction extraction algorithm based on text mining technology. Multimedia Tools and Applications, 2020, 79, 10551-10579.	2.6	2
1217	Noise exposure accelerates the risk of cognitive impairment and Alzheimerâ€™s disease: Adulthood, gestational, and prenatal mechanistic evidence from animal studies. Neuroscience and Biobehavioral Reviews, 2020, 117, 110-128.	2.9	54
1218	Familial Alzheimerâ€™s disease patient-derived neurons reveal distinct mutation-specific effects on amyloid beta. Molecular Psychiatry, 2020, 25, 2919-2931.	4.1	99
1219	Improvements of symptoms of Alzheimer`s disease by inhibition of the angiotensin system. Pharmacological Research, 2020, 154, 104230.	3.1	37
1220	Activation of PPARA-mediated autophagy reduces Alzheimer disease-like pathology and cognitive decline in a murine model. Autophagy, 2020, 16, 52-69.	4.3	193

#	Article	IF	Citations
1221	Rationale for the development of an Alzheimerâ€™s disease vaccine. Human Vaccines and Immunotherapeutics, 2020, 16, 645-653.	1.4	16
1222	Understanding the complexity of the matrix metalloproteinase system and its relevance to age-related diseases: Age-related macular degeneration and Alzheimer's disease. Progress in Retinal and Eye Research, 2020, 74, 100775.	7.3	12
1223	Aminoacid substitutions in the glycine zipper affect the conformational stability of amyloid beta fibrils. Journal of Biomolecular Structure and Dynamics, 2020, 38, 3908-3915.	2.0	8
1224	New diagnostic method for Alzheimerâ€™s disease based on the toxic conformation theory of amyloid Î². Bioscience, Biotechnology and Biochemistry, 2020, 84, 1-16.	0.6	32
1225	What is strain in neurodegenerative diseases?. Cellular and Molecular Life Sciences, 2020, 77, 665-676.	2.4	12
1226	Macromolecular complex in recognition and proteolysis of amyloid precursor protein in Alzheimerâ€™s disease. Current Opinion in Structural Biology, 2020, 61, 1-8.	2.6	15
1227	MicroRNAâ€134â€5p inhibition rescues longâ€term plasticity and synaptic tagging/capture in an AÎ²(1â€“42)â€induced model of Alzheimerâ€™s disease. Aging Cell, 2020, 19, e13046.	3.0	41
1228	The Structure and Function of Î±, Î² and Î³-Secretase as Therapeutic Target Enzymes in the Development of Alzheimerâ€™s Disease: A Review. CNS and Neurological Disorders - Drug Targets, 2020, 18, 657-667.	0.8	11
1229	The interplay between agingâ€associated loss of protein homeostasis and extracellular vesicles in neurodegeneration. Journal of Neuroscience Research, 2020, 98, 262-283.	1.3	21
1230	Revisiting the intersection of amyloid, pathologically modified tau and iron in Alzheimerâ€™s disease from a ferroptosis perspective. Progress in Neurobiology, 2020, 184, 101716.	2.8	98
1231	NeuroDefend, a novel Chinese medicine, attenuates amyloid-Î² and tau pathology in experimental Alzheimer's disease models. Journal of Food and Drug Analysis, 2020, 28, 132-146.	0.9	34
1232	Calcium-Handling Defects and Neurodegenerative Disease. Cold Spring Harbor Perspectives in Biology, 2020, 12, a035212.	2.3	55
1233	Bidirectional relationship between sleep and Alzheimerâ€™s disease: role of amyloid, tau, and other factors. Neuropsychopharmacology, 2020, 45, 104-120.	2.8	280
1234	The rare and the common: scale and the genetic imaginary in Alzheimer's disease drug development. New Genetics and Society, 2020, 39, 101-126.	0.7	8
1235	ÂLife-Course Contribution of Prenatal Stress in Regulating the Neural Modulation Network Underlying the Prepulse Inhibition of the Acoustic Startle Reflex in Male Alzheimerâ€™s Disease Mice. Cerebral Cortex, 2020, 30, 311-325.	1.6	9
1236	Substrate recognition and processing by γ-secretase. Biochimica Et Biophysica Acta - Biomembranes, 2020, 1862, 183016.	1.4	29
1237	Apelin/APJ system: A novel promising target for neurodegenerative diseases. Journal of Cellular Physiology, 2020, 235, 638-657.	2.0	32
1238	Polymerâˆ’Peptide Conjugates Convert Amyloid into Protein Nanobundles through Fragmentation and Lateral Association. ACS Applied Nano Materials, 2020, 3, 937-945.	2.4	11

#	Article	IF	Citations
1239	Insights into membrane-bound presenilin 2 from all-atom molecular dynamics simulations. Journal of Biomolecular Structure and Dynamics, 2020, 38, 3196-3210.	2.0	24
1240	Nicastrin Deficiency Induces Tyrosinase-Dependent Depigmentation and Skin Inflammation. Journal of Investigative Dermatology, 2020, 140, 404-414.e13.	0.3	9
1241	Early Intervention in Alzheimerâ€™s Disease: How Early is Early Enough?. Neuroscience Bulletin, 2020, 36, 195-197.	1.5	29
1242	Disease-modifying strategies in primary tauopathies. Neuropharmacology, 2020, 167, 107842.	2.0	7
1243	Suboptimal validity of amyloid imaging-based diagnosis and management of Alzheimerâ€™s disease: why it is time to abandon the approach. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 225-230.	3.3	13
1244	N-terminal tau truncation in the pathogenesis of Alzheimer's disease (AD): Developing a novel diagnostic and therapeutic approach. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2020, 1866, 165584.	1.8	22
1245	Role of endolysosomes and inter-organellar signaling in brain disease. Neurobiology of Disease, 2020, 134, 104670.	2.1	18
1246	Alzheimer's disease risk SNPs show no strong effect on miRNA expression in human lymphoblastoid cell lines. Neurobiology of Aging, 2020, 86, 202.e1-202.e3.	1.5	1
1247	Ultrasmall superparamagnetic iron oxide nanoparticles-bound NIR dyes: Novel theranostic agents for Alzheimer's disease. Dyes and Pigments, 2020, 173, 107968.	2.0	29
1248	The Interaction Between Contactin and Amyloid Precursor Protein and Its Role in Alzheimerâ€™s Disease. Neuroscience, 2020, 424, 184-202.	1.1	23
1249	DL0410 ameliorates cognitive deficits in APP/PS1 transgenic mice by promoting synaptic transmission and reducing neuronal loss. Acta Pharmacologica Sinica, 2020, 41, 599-611.	2.8	7
1250	Saliva, an easily accessible fluid as diagnostic tool and potent stem cell source for Alzheimerâ€™s Disease: Present and future applications. Brain Research, 2020, 1727, 146535.	1.1	21
1251	A Î²-sheet-targeted theranostic agent for diagnosing and preventing aggregation of pathogenic peptides in Alzheimerâ€™s disease. Science China Chemistry, 2020, 63, 73-82.	4.2	23
1252	DJ-1 can form Î²-sheet structured aggregates that co-localize with pathological amyloid deposits. Neurobiology of Disease, 2020, 134, 104629.	2.1	13
1253	Corrupted ERâ€mitochondrial calcium homeostasis promotes the collapse of proteostasis. Aging Cell, 2020, 19, e13065.	3.0	18
1254	Polyphenols in the management of brain disorders: Modulation of the microbiota-gut-brain axis. Advances in Food and Nutrition Research, 2020, 91, 1-27.	1.5	32
1255	Emerging signal regulating potential of small molecule biflavonoids to combat neuropathological insults of Alzheimer's disease. Science of the Total Environment, 2020, 700, 134836.	3.9	67
1256	Neuron-glia interaction through Serotonin-BDNF-NGFR axis enables regenerative neurogenesis in Alzheimerâ€™s model of adult zebrafish brain. PLoS Biology, 2020, 18, e3000585.	2.6	73

#	Article	IF	Citations
1257	Mercury and Alzheimerâ€™s Disease: Hg(II) Ions Display Specific Binding to the Amyloid-Î² Peptide and Hinder Its Fibrillization. Biomolecules, 2020, 10, 44.	1.8	26
1258	A 20-Year Journey from Axonal Injury to Neurodegenerative Diseases and the Prospect of Immunotherapy for Combating Alzheimerâ€™s Disease. Journal of Immunology, 2020, 204, 243-250.	0.4	26
1259	Complement-Mediated Events in Alzheimerâ€™s Disease: Mechanisms and Potential Therapeutic Targets. Journal of Immunology, 2020, 204, 306-315.	0.4	61
1260	Biosensors on the road to early diagnostic and surveillance of Alzheimer's disease. Talanta, 2020, 211, 120700.	2.9	36
1261	Peptides Co-Assembling into Hydrangea-Like Microstructures. Journal of Nanoscience and Nanotechnology, 2020, 20, 3239-3245.	0.9	1
1262	Human Plasma Protein Corona of AÎ² Amyloid and Its Impact on Islet Amyloid Polypeptide Cross-Seeding. Biomacromolecules, 2020, 21, 988-998.	2.6	15
1263	Using mouse models to understand Alzheimer's disease mechanisms in the context of trisomy of chromosome 21. Progress in Brain Research, 2020, 251, 181-208.	0.9	1
1264	Aggregation of disease-related peptides. Progress in Molecular Biology and Translational Science, 2020, 170, 435-460.	0.9	19
1265	Advanced fluorescence imaging of in situ protein aggregation. Physical Biology, 2020, 17, 021001.	0.8	16
1266	A photoelectrochemical immunosensor based on CdS/CdTe-cosensitized SnO‹sub›2‹/sub› as a platform for the ultrasensitive detection of amyloid Î²-protein. Analyst, The, 2020, 145, 619-625.	1.7	19
1267	Highly specific detection of AÎ² oligomers in early Alzheimer's disease by a near-infrared fluorescent probe with a â€œV-shapedâ€•spatial conformation. Chemical Communications, 2020, 56, 583-586.	2.2	34
1268	Development of novel carbazole derivatives with effective multifunctional action against Alzheimerâ€™s diseases: Design, synthesis, in silico, in vitro and in vivo investigation. Bioorganic Chemistry, 2020, 95, 103524.	2.0	17
1269	Proteome-wide observation of the phenomenon of life on the edge of solubility. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 1015-1020.	3.3	115
1270	Glycan biomarkers for Alzheimer disease correlate with Tâ€¢tau and Pâ€¢tau in cerebrospinal fluid in subjective cognitive impairment. FEBS Journal, 2020, 287, 3221-3234.	2.2	36
1271	Phosphorylation Signaling in APP Processing in Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2020, 21, 209.	1.8	51
1272	Cleaning the sleeping brain â€“ the potential restorative function of the glymphatic system. Current Opinion in Physiology, 2020, 15, 1-6.	0.9	64
1273	Alterations of Transcription of Genes Coding Anti-oxidative and Mitochondria-Related Proteins in Amyloid Î² Toxicity: Relevance to Alzheimerâ€™s Disease. Molecular Neurobiology, 2020, 57, 1374-1388.	1.9	37
1274	In pursuit of a sensitive EEG functional connectivity outcome measure for clinical trials in Alzheimerâ€™s disease. Clinical Neurophysiology, 2020, 131, 88-95.	0.7	33

#	Article	IF	Citations
1275	Back to the origins: Human brain organoids to investigate neurodegeneration. Brain Research, 2020, 1727, 146561.	1.1	12
1276	NCIPLOT4 Guide for Biomolecules: An Analysis Tool for Noncovalent Interactions. Journal of Chemical Information and Modeling, 2020, 60, 6-10.	2.5	24
1277	The search for a unique Raman signature of amyloid-beta plaques in human brain tissue from Alzheimer's disease patients. Analyst, The, 2020, 145, 1724-1736.	1.7	27
1278	Pyrazolones Activate the Proteasome by Gating Mechanisms and Protect Neuronal Cells from Î²â€Amyloid Toxicity. ChemMedChem, 2020, 15, 302-316.	1.6	15
1279	Human subiculo-fornico-mamillary system in Alzheimerâ€™s disease: Tau seeding by the pillar of the fornix. Acta Neuropathologica, 2020, 139, 443-461.	3.9	10
1280	Dengzhan Shengmai capsules and their active component scutellarin prevent cognitive decline in APP/PS1 mice by accelerating AÎ² aggregation and reducing oligomers formation. Biomedicine and Pharmacotherapy, 2020, 121, 109682.	2.5	12
1281	Differential DNA methylation following chemotherapy for breast cancer is associated with lack of memory improvement at one year. Epigenetics, 2020, 15, 499-510.	1.3	20
1282	An update on fluid biomarkers for neurodegenerative diseases: recent success and challenges ahead. Current Opinion in Neurobiology, 2020, 61, 29-39.	2.0	67
1283	A Deep Learning Approach for Automated Diagnosis and Multi-Class Classification of Alzheimerâ€™s Disease Stages Using Resting-State fMRI and Residual Neural Networks. Journal of Medical Systems, 2020, 44, 37.	2.2	189
1284	Inactivation of GAP-43 due to the depletion of cellular calcium by the Pb and amyloid peptide induced toxicity: An in vitro approach. Chemico-Biological Interactions, 2020, 316, 108927.	1.7	15
1285	Dysregulated Fc gamma receptorâ€“mediated phagocytosis pathway in Alzheimer's disease: network-based gene expression analysis. Neurobiology of Aging, 2020, 88, 24-32.	1.5	28
1286	Peptide-Based Vaccines: Current Progress and Future Challenges. Chemical Reviews, 2020, 120, 3210-3229.	23.0	352
1287	Glucocorticoid receptors signaling impairment potentiates amyloidâ€Î² oligomersâ€induced pathology in an acute model of Alzheimerâ€™s disease. FASEB Journal, 2020, 34, 1150-1168.	0.2	23
1288	Amyloid, APP, and Electrical Activity of the Brain. Neuroscientist, 2020, 26, 231-251.	2.6	36
1289	Peripheral Blood-Derived Microglia-Like Cells Decrease Amyloid-Î² Burden and Ameliorate Cognitive Impairment in a Mouse Model of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2020, 73, 413-429.	1.2	10
1290	Pâ€glycoprotein: a role in the export of amyloidâ€Î² in Alzheimer's disease?. FEBS Journal, 2020, 287, 612-625.	2.2	62
1291	An â€œAmyloidâ€Î² Cleanerâ€•for the Treatment of Alzheimer's Disease by Normalizing Microglial Dysfunction. Advanced Science, 2020, 7, 1901555.	5.6	54
1292	Regional differences in Alzheimerâ€™s disease pathology confound behavioural rescue after amyloid-Î² attenuation. Brain, 2020, 143, 359-373.	3.7	41

#	Article	IF	Citations
1293	Structural dissection of amyloid aggregates of TDPâ€43 and its Câ€terminal fragments TDPâ€35 and TDPâ€16. FEBS Journal, 2020, 287, 2449-2467.	2.2	33
1294	Amyloid-Î²-independent regulators of tau pathology in Alzheimer disease. Nature Reviews Neuroscience, 2020, 21, 21-35.	4.9	338
1295	Destabilization of Î²â€amyloid aggregates by thrombin derived peptide: plausible role of thrombin in neuroprotection. FEBS Journal, 2020, 287, 2386-2413.	2.2	1
1296	1-Benzylpyrrolidine-3-amine-based BuChE inhibitors with anti-aggregating, antioxidant and metal-chelating properties as multifunctional agents against Alzheimerâ€™s disease. European Journal of Medicinal Chemistry, 2020, 187, 111916.	2.6	33
1297	Adenovirus-Mediated Transduction of Insulin-Like Growth Factor 1 Protects Hippocampal Neurons from the Toxicity of AÎ² Oligomers and Prevents Memory Loss in an Alzheimer Mouse Model. Molecular Neurobiology, 2020, 57, 1473-1483.	1.9	19
1298	Multilayered N-Glycoproteome Profiling Reveals Highly Heterogeneous and Dysregulated Protein N-Glycosylation Related to Alzheimerâ€™s Disease. Analytical Chemistry, 2020, 92, 867-874.	3.2	46
1299	Inhibition of amyloid fibrillation, enzymatic degradation and cytotoxicity of insulin at carboxyl tailored gold-aryl nanoparticles surface. Colloids and Surfaces A: Physicochemical and Engineering Aspects, 2020, 586, 124279.	2.3	12
1300	Direct investigation of current transport in cells by conductive atomic force microscopy. Journal of Microscopy, 2020, 277, 49-57.	0.8	6
1301	Hippocampal longâ€term synaptic depression and memory deficits induced in early amyloidopathy are prevented by enhancing Gâ€proteinâ€gated inwardly rectifying potassium channel activity. Journal of Neurochemistry, 2020, 153, 362-376.	2.1	36
1302	Dampened Slow Oscillation Connectivity Anticipates Amyloid Deposition in the PS2APP Mouse Model of Alzheimerâ€™s Disease. Cells, 2020, 9, 54.	1.8	17
1303	Microglia prevent beta-amyloid plaque formation in the early stage of an Alzheimerâ€™s disease mouse model with suppression of glymphatic clearance. Alzheimer's Research and Therapy, 2020, 12, 125.	3.0	70
1304	Peli1 impairs microglial AÎ² phagocytosis through promoting C/EBPÎ² degradation. PLoS Biology, 2020, 18, e3000837.	2.6	24
1305	Neurogenesis Makes a Crucial Contribution to the Neuropathology of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease Reports, 2020, 4, 365-371.	1.2	17
1306	Role of Wnt Signaling in Adult Hippocampal Neurogenesis in Health and Disease. Frontiers in Cell and Developmental Biology, 2020, 8, 860.	1.8	80
1307	Presenilin-2 and Calcium Handling: Molecules, Organelles, Cells and Brain Networks. Cells, 2020, 9, 2166.	1.8	21
1308	Circular RNA Encoded Amyloid Beta peptidesâ€”A Novel Putative Player in Alzheimerâ€™s Disease. Cells, 2020, 9, 2196.	1.8	33
1309	Smart treatment strategies for alleviating tauopathy and neuroinflammation to improve clinical outcome in Alzheimer's disease. Drug Discovery Today, 2020, 25, 2110-2129.	3.2	12
1310	The influence of AÎ²-dependent and independent pathways on TDP-43 proteinopathy in Alzheimerâ€™s disease: a possible connection to LATE-NC. Neurobiology of Aging, 2020, 95, 161-167.	1.5	5

#	Article	IF	Citations
1311	Phospholipase C families: Common themes and versatility in physiology and pathology. Progress in Lipid Research, 2020, 80, 101065.	5.3	48
1312	The microbiotaâ€“microglia axis in central nervous system disorders. Brain Pathology, 2020, 30, 1159-1177.	2.1	52
1313	An update on magnetic resonance imaging markers in AD. Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642094798.	1.5	6
1314	Self-Replication of Prion Protein Fragment 89-230 Amyloid Fibrils Accelerated by Prion Protein Fragment 107-143 Aggregates. International Journal of Molecular Sciences, 2020, 21, 7410.	1.8	3
1315	Activation of STAT3 Regulates Reactive Astrogliosis and Neuronal Death Induced by AÎ²O Neurotoxicity. International Journal of Molecular Sciences, 2020, 21, 7458.	1.8	23
1316	Advancing combination therapy for Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12073.	1.8	21
1317	Status and future directions of clinical trials in Alzheimer's disease. International Review of Neurobiology, 2020, 154, 3-50.	0.9	29
1318	Endocytosis Is a Key Mode of Interaction between Extracellular Î²-Amyloid and the Cell Membrane. Biophysical Journal, 2020, 119, 1078-1090.	0.2	7
1319	Alzheimer's disease: Recent treatment strategies. European Journal of Pharmacology, 2020, 887, 173554.	1.7	300
1320	The search for Alzheimer disease therapeutics â€" same targets, better trials?. Nature Reviews Neurology, 2020, 16, 597-598.	4.9	11
1321	Overdosing on iron: Elevated iron and degenerative brain disorders. Experimental Biology and Medicine, 2020, 245, 1444-1473.	1.1	26
1322	Afferent and Efferent Visual Markers of Alzheimerâ€™s Disease: A Review and Update in Early Stage Disease. Frontiers in Aging Neuroscience, 2020, 12, 572337.	1.7	15
1323	Research on Cognition Disorders. , 2020, , .		0
1324	Kinetic fingerprints differentiate the mechanisms of action of anti-AÎ² antibodies. Nature Structural and Molecular Biology, 2020, 27, 1125-1133.	3.6	123
1325	Neuroprotective effects of verbascoside against Alzheimerâ€™s disease via the relief of endoplasmic reticulum stress in AÎ²-exposed U251 cells and APP/PS1 mice. Journal of Neuroinflammation, 2020, 17, 309.	3.1	34
1326	Association of serum Apolipoprotein B with cerebrospinal fluid biomarkers of Alzheimerâ€™s pathology. Annals of Clinical and Translational Neurology, 2020, 7, 1766-1778.	1.7	13
1327	The potential role of nanoyttria in alleviating oxidative stress biomarkers: Implications for Alzheimer's disease therapy. Life Sciences, 2020, 259, 118287.	2.0	9
1328	Identification of a dysfunctional microglial population in human Alzheimerâ€™s disease cortex using novel single-cell histology image analysis. Acta Neuropathologica Communications, 2020, 8, 170.	2.4	47

#	Article	IF	Citations
1329	Emerging Microglia Biology Defines Novel Therapeutic Approaches for Alzheimerâ€™s Disease. Neuron, 2020, 108, 801-821.	3.8	132
1330	Endocannabinoid system alterations in Alzheimerâ€™s disease: A systematic review of human studies. Brain Research, 2020, 1749, 147135.	1.1	23
1331	Multi-target approach for Alzheimerâ€™s disease treatment: computational biomolecular modeling of cholinesterase enzymes with a novel 4-N-phenylaminoquinoline derivative reveal promising potentials. Journal of Biomolecular Structure and Dynamics, 2021, 39, 3825-3841.	2.0	6
1332	Anisotropic diffusion and traveling waves of toxic proteins in neurodegenerative diseases. Physics Letters, Section A: General, Atomic and Solid State Physics, 2020, 384, 126935.	0.9	5
1333	Cognitive outcomes in trials of two BACE inhibitors in Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, 1483-1492.	0.4	46
1334	Protein-protein interactions in neurodegenerative diseases: A conspiracy theory. PLoS Computational Biology, 2020, 16, e1008267.	1.5	35
1335	Soluble Prion Peptide 107â€“120 Protects Neuroblastoma SH-SY5Y Cells against Oligomers Associated with Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2020, 21, 7273.	1.8	2
1336	Influence of Woodsmoke Exposure on Molecular Mechanisms Underlying Alzheimerâ€™s Disease: Existing Literature and Gaps in Our Understanding. Epigenetics Insights, 2020, 13, 251686572095487.	0.6	15
1337	Nitrogenâ€Doped Carbonized Polymer Dots: A Potent Scavenger and Detector Targeting Alzheimer's Î²â€Amyloid Plaques. Small, 2020, 16, e2002804.	5.2	46
1338	Feasibility of a label-free X-ray method to estimate brain amyloid load in small animals. Journal of Neuroscience Methods, 2020, 343, 108822.	1.3	2
1339	Gene-environment interaction promotes Alzheimer's risk as revealed by synergy of repeated mild traumatic brain injury and mouse App knock-in. Neurobiology of Disease, 2020, 145, 105059.	2.1	2
1340	Alzheimer's disease â€“ the â€˜microbial hypothesisâ€™ from a clinical and neuroimaging perspective. Psychiatry Research - Neuroimaging, 2020, 306, 111181.	0.9	16
1341	An Isoquinolinium Dual Inhibitor of Cholinesterases and Amyloid Î² Aggregation Mitigates Neuropathological Changes in a Triple-Transgenic Mouse Model of Alzheimerâ€™s Disease. ACS Chemical Neuroscience, 2020, 11, 3346-3357.	1.7	7
1342	Phosphorylation Promotes AÎ²25â€“35 Peptide Aggregation within the DMPC Bilayer. ACS Chemical Neuroscience, 2020, 11, 3430-3441.	1.7	8
1343	CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2020, 12, 88.	3.0	20
1344	Environmental and Cognitive Enrichment in Childhood as Protective Factors in the Adult and Aging Brain. Frontiers in Psychology, 2020, 11, 1814.	1.1	16
1345	Rhodamine-Based Metal Chelator: A Potent Inhibitor of Metal-Catalyzed Amyloid Toxicity. ACS Omega, 2020, 5, 18958-18967.	1.6	14
1346	Capsaicin consumption reduces brain amyloid-beta generation and attenuates Alzheimerâ€™s disease-type pathology and cognitive deficits in APP/PS1 mice. Translational Psychiatry, 2020, 10, 230.	2.4	41

#	Article	IF	Citations
1347	Genomic mechanisms in Alzheimer's disease. Brain Pathology, 2020, 30, 966-977.	2.1	29
1348	Multifunctional Superparamagnetic Iron Oxide Nanoparticles Conjugated with AÎ² Oligomer-Specific scFv Antibody and Class A Scavenger Receptor Activator Show Early Diagnostic Potentials for Alzheimerâ€™s Disease . International Journal of Nanomedicine, 2020, Volume 15, 4919-4932.	3.3	34
1349	Evaluation of Amyloid Î²42 Aggregation Inhibitory Activity of Commercial Dressings by A Microliter-Scale High-Throughput Screening System Using Quantum-Dot Nanoprobes. Foods, 2020, 9, 825.	1.9	8
1350	Applying geneâ€editing technology to elucidate the functional consequence of genetic and epigenetic variation in Alzheimerâ€™s disease. Brain Pathology, 2020, 30, 992-1004.	2.1	8
1351	Human Induced Pluripotent Stem Cell Models of Neurodegenerative Disorders for Studying the Biomedical Implications of Autophagy. Journal of Molecular Biology, 2020, 432, 2754-2798.	2.0	15
1352	Blood cell-produced amyloid-Î² induces cerebral Alzheimer-type pathologies and behavioral deficits. Molecular Psychiatry, 2021, 26, 5568-5577.	4.1	32
1353	From beta amyloid to altered proteostasis in Alzheimerâ€™s disease. Ageing Research Reviews, 2020, 64, 101126.	5.0	31
1354	The role of the gut microbiota in the pathophysiology of mental and neurological disorders. Psychiatric Genetics, 2020, 30, 87-100.	0.6	7
1355	Targeting Neuroglial Sodium Channels in Neuroinflammatory Diseases. , 2020, , .		1
1356	Harnessing endophenotypes and network medicine for Alzheimer's drug repurposing. Medicinal Research Reviews, 2020, 40, 2386-2426.	5.0	61
1357	Quercetin Disaggregates Prion Fibrils and Decreases Fibril-Induced Cytotoxicity and Oxidative Stress. Pharmaceutics, 2020, 12, 1081.	2.0	4
1358	Fluid Candidate Biomarkers for Alzheimerâ€™s Disease: A Precision Medicine Approach. Journal of Personalized Medicine, 2020, 10, 221.	1.1	20
1359	Compound AD16 Reduces Amyloid Plaque Deposition and Modifies Microglia in a Transgenic Mouse Model of Alzheimerâ€™s Disease. ACS Pharmacology and Translational Science, 2020, 3, 1100-1110.	2.5	4
1360	Therapeutic Strategies to Reduce the Toxicity of Misfolded Protein Oligomers. International Journal of Molecular Sciences, 2020, 21, 8651.	1.8	23
1361	Melatonin regulates AÎ² production/clearance balance and AÎ² neurotoxicity: A potential therapeutic molecule for Alzheimerâ€™s disease. Biomedicine and Pharmacotherapy, 2020, 132, 110887.	2.5	93
1362	Acetylation of AMPA Receptors Regulates Receptor Trafficking and Rescues Memory Deficits in Alzheimer's Disease. IScience, 2020, 23, 101465.	1.9	6
1363	Alzheimerâ€™s Disease-Like Pathology Triggered by Porphyromonas gingivalis in Wild Type Rats Is Serotype Dependent. Frontiers in Immunology, 2020, 11, 588036.	2.2	38
1364	Manganese Exposure Aggravates Î²-Amyloid Pathology by Microglial Activation. Frontiers in Aging Neuroscience, 2020, 12, 556008.	1.7	20

#	Article	IF	Citations
1365	Amyloid-Î² Precursor Protein APP Down-Regulation Alters Actin Cytoskeleton-Interacting Proteins in Endothelial Cells. Cells, 2020, 9, 2506.	1.8	11
1366	Therapeutic Strategies to Target Calcium Dysregulation in Alzheimerâ€™s Disease. Cells, 2020, 9, 2513.	1.8	22
1367	The good, the bad, and the opportunities of the complement system in neurodegenerative disease. Journal of Neuroinflammation, 2020, 17, 354.	3.1	133
1368	Biophysical, Biochemical, and Behavioral Implications of ApoE3 Conjugated Donepezil Nanomedicine in a AÎ²_{1â€“42} Induced Alzheimerâ€™s Disease Rat Model. ACS Chemical Neuroscience, 2020, 11, 4139-4151.	1.7	22
1369	Design and Development of Cholinesterase Dual Inhibitors towards Alzheimer's Disease Treatment: A Focus on Recent Contributions from Computational and Theoretical Perspective. ChemistrySelect, 2020, 5, 14136-14152.	0.7	5
1370	Effects of Curcumin and Boric Acid Against Neurodegenerative Damage Induced by Amyloid Beta (1-42). Biological Trace Element Research, 2021, 199, 3793-3800.	1.9	10
1371	Preface. International Review of Neurobiology, 2020, 154, xv-xx.	0.9	0
1372	HSF1 physically neutralizes amyloid oligomers to empower overgrowth and bestow neuroprotection. Science Advances, 2020, 6, .	4.7	13
1373	p47phox deficiency improves cognitive impairment and attenuates tau hyperphosphorylation in mouse models of AD. Alzheimer's Research and Therapy, 2020, 12, 146.	3.0	10
1374	Neuronalâ€“Glial Interaction in a Triple-Transgenic Mouse Model of Alzheimerâ€™s Disease: Gene Ontology and Lithium Pathways. Frontiers in Neuroscience, 2020, 14, 579984.	1.4	7
1375	BODIPY Dyes as Probes and Sensors to Study Amyloid-Î²-Related Processes. Biosensors, 2020, 10, 192.	2.3	20
1376	Dysregulated Wnt Signalling in the Alzheimerâ€™s Brain. Brain Sciences, 2020, 10, 902.	1.1	28
1377	Alterations of the Endoplasmic Reticulum (ER) Calcium Signaling Molecular Components in Alzheimerâ€™s Disease. Cells, 2020, 9, 2577.	1.8	32
1378	Lipid-Chaperone Hypothesis: A Common Molecular Mechanism of Membrane Disruption by Intrinsically Disordered Proteins. ACS Chemical Neuroscience, 2020, 11, 4336-4350.	1.7	101
1379	Dihydrophthalazinediones accelerate amyloid Î² peptide aggregation to nontoxic species. Bulletin of Materials Science, 2020, 43, 1.	0.8	0
1380	Changes in neuronal excitability and synaptic transmission in nucleus accumbens in a transgenic Alzheimerâ€™s disease mouse model. Scientific Reports, 2020, 10, 19606.	1.6	14
1381	Human Herpesviruses 6A and 6B in Brain Diseases: Association versus Causation. Clinical Microbiology Reviews, 2020, 34, .	5.7	34
1382	Alzheimerâ€™s disease: from basic science to precision medicine approach. BMJ Neurology Open, 2020, 2, e000079.	0.7	19

#	Article	IF	Citations
1383	Targeting isoaspartate-modified AÎ² rescues behavioral deficits in transgenic mice with Alzheimerâ€™s disease-like pathology. Alzheimer's Research and Therapy, 2020, 12, 149.	3.0	10
1384	Impairments of Synaptic Plasticity Induction Threshold and Network Oscillatory Activity in the Hippocampus Underlie Memory Deficits in a Non-Transgenic Mouse Model of Amyloidosis. Biology, 2020, 9, 175.	1.3	16
1385	Defining and predicting transdiagnostic categories of neurodegenerative disease. Nature Biomedical Engineering, 2020, 4, 787-800.	11.6	22
1386	Atomic Structures of Amyloid-Î² Oligomers Illuminate a Neurotoxic Mechanism. Trends in Neurosciences, 2020, 43, 740-743.	4.2	10
1387	Transmissible Endosomal Intoxication: A Balance between Exosomes and Lysosomes at the Basis of Intercellular Amyloid Propagation. Biomedicines, 2020, 8, 272.	1.4	18
1388	Mathematical Model Shows How Sleep May Affect Amyloid-Î² Fibrillization. Biophysical Journal, 2020, 119, 862-872.	0.2	10
1389	The AÎ² aggregation modulator MRZ-99030 prevents and even reverses synaptotoxic effects of AÎ²1-42 on LTP even following serial dilution to a 500:1 stoichiometric excess of AÎ²1-42, suggesting a beneficial prion-like seeding mechanism. Neuropharmacology, 2020, 179, 108267.	2.0	5
1390	Analysis of Membrane Protein Deinsertion-Associated Currents with Nanoneedle-Supported Bilayers to Discover Pore Formation Mechanisms. Langmuir, 2020, 36, 10012-10021.	1.6	12
1391	Signaling via the p75 neurotrophin receptor facilitates amyloid-Î²-induced dendritic spine pathology. Scientific Reports, 2020, 10, 13322.	1.6	24
1392	The contribution of C. elegans neurogenetics to understanding neurodegenerative diseases. Journal of Neurogenetics, 2020, 34, 527-548.	0.6	21
1393	Design, synthesis and biological evaluation of edaravone derivatives bearing the N-benzyl pyridinium moiety as multifunctional anti-Alzheimerâ€™s agents. Journal of Enzyme Inhibition and Medicinal Chemistry, 2020, 35, 1596-1605.	2.5	8
1394	Selection of mutant Âµplasmin for amyloid-Î² cleavage in vivo. Scientific Reports, 2020, 10, 12117.	1.6	4
1395	Glibenclamide modulates microglial function and attenuates AÎ² deposition in 5XFAD mice. European Journal of Pharmacology, 2020, 884, 173416.	1.7	9
1396	Stepwise Design of Î³-Secretase Modulators with an Advanced Profile by Judicious Coordinated Structural Replacements and an Unconventional Phenyl Ring Bioisostere. Journal of Medicinal Chemistry, 2020, 63, 8534-8553.	2.9	11
1397	Treating Protein Misfolding Diseases: Therapeutic Successes Against Systemic Amyloidoses. Frontiers in Pharmacology, 2020, 11, 1024.	1.6	25
1398	Highâ€resolution structure of a partially folded insulin aggregation intermediate. Proteins: Structure, Function and Bioinformatics, 2020, 88, 1648-1659.	1.5	13
1399	Engulfment of Toxic Amyloid Î²-protein in Neurons and Astrocytes Mediated by MEGF10. Neuroscience, 2020, 443, 1-7.	1.1	14
1400	Plant-Derived Antioxidants Protect the Nervous System From Aging by Inhibiting Oxidative Stress. Frontiers in Aging Neuroscience, 2020, 12, 209.	1.7	54

#	Article	IF	Citations
1401	Slow Wave Sleep Is a Promising Intervention Target for Alzheimerâ€™s Disease. Frontiers in Neuroscience, 2020, 14, 705.	1.4	55
1402	Advantages and Pitfalls in Fluid Biomarkers for Diagnosis of Alzheimerâ€™s Disease. Journal of Personalized Medicine, 2020, 10, 63.	1.1	13
1403	Emerging Roles of Inhibitor of Differentiation-1 in Alzheimerâ€™s Disease: Cell Cycle Reentry and Beyond. Cells, 2020, 9, 1746.	1.8	15
1404	Increased blood COASY DNA methylation levels a potential biomarker for early pathology of Alzheimerâ€™s disease. Scientific Reports, 2020, 10, 12217.	1.6	17
1405	Effects of IL-34 on Macrophage Immunological Profile in Response to Alzheimer's-Related AÎ²42 Assemblies. Frontiers in Immunology, 2020, 11, 1449.	2.2	15
1406	Early-Onset Familial Alzheimer Disease Variant PSEN2 N141I Heterozygosity is Associated with Altered Microglia Phenotype. Journal of Alzheimer's Disease, 2020, 77, 675-688.	1.2	18
1407	ORAI2 Down-Regulation Potentiates SOCE and Decreases AÎ²42 Accumulation in Human Neuroglioma Cells. International Journal of Molecular Sciences, 2020, 21, 5288.	1.8	14
1408	Design and synthesis of Î²-strand-fixed peptides inhibiting aggregation of amyloid Î²-protein. Bioorganic and Medicinal Chemistry, 2020, 28, 115676.	1.4	8
1409	Dissolving microneedles for transdermal delivery of huperzine A for the treatment of Alzheimer's disease. Drug Delivery, 2020, 27, 1147-1155.	2.5	32
1410	Phosphorylated AÎ² peptides in human Down syndrome brain and different Alzheimerâ€™s-like mouse models. Acta Neuropathologica Communications, 2020, 8, 118.	2.4	14
1411	Microglia facilitate loss of perineuronal nets in the Alzheimer's disease brain. EBioMedicine, 2020, 58, 102919.	2.7	123
1412	The collagen receptor glycoprotein VI promotes platelet-mediated aggregation of Î²-amyloid. Science Signaling, 2020, 13, .	1.6	15
1413	The existence of AÎ² strains and their potential for driving phenotypic heterogeneity in Alzheimerâ€™s disease. Acta Neuropathologica, 2021, 142, 17-39.	3.9	35
1414	Neuropathological assessment of the Alzheimer spectrum. Journal of Neural Transmission, 2020, 127, 1229-1256.	1.4	34
1415	Generation of Leads for Î³-Secretase Modulation. Journal of Medicinal Chemistry, 2020, 63, 8216-8230.	2.9	7
1416	Multifunctional roles of zinc in Alzheimerâ€™s disease. NeuroToxicology, 2020, 80, 112-123.	1.4	40
1417	Significance of cytosolic cathepsin D in Alzheimer's disease pathology: Protective cellular effects of PLGA nanoparticles against Î²â€amyloidâ€toxicity. Neuropathology and Applied Neurobiology, 2020, 46, 686-706.	1.8	14
1418	Integrated analysis of ultra-deep proteomes in cortex, cerebrospinal fluid and serum reveals a mitochondrial signature in Alzheimerâ€™s disease. Molecular Neurodegeneration, 2020, 15, 43.	4.4	104

#	Article	IF	Citations
1419	In silico exploration of the fingerprints triggering modulation of glutaminyl cyclase inhibition for the treatment of Alzheimerâ€™s disease using SMILES based attributes in Monte Carlo optimization. Journal of Biomolecular Structure and Dynamics, 2021, 39, 7181-7193.	2.0	10
1420	Higher CSF sTREM2 and microglia activation are associated with slower rates of betaâ€amyloid accumulation. EMBO Molecular Medicine, 2020, 12, e12308.	3.3	73
1421	A new naphthalene derivative with anti-amyloidogenic activity as potential therapeutic agent for Alzheimer's disease. Bioorganic and Medicinal Chemistry, 2020, 28, 115700.	1.4	6
1422	Noncanonical function of an autophagy protein prevents spontaneous Alzheimerâ€™s disease. Science Advances, 2020, 6, eabb9036.	4.7	62
1423	Nrf2: a dark horse in Alzheimer's disease treatment. Ageing Research Reviews, 2020, 64, 101206.	5.0	131
1424	Mitochondria and cellular redox state on the route from ageing to Alzheimerâ€™s disease. Mechanisms of Ageing and Development, 2020, 192, 111385.	2.2	30
1425	Investigating the Effects of Molecular Crowding on the Kinetics of Protein Aggregation. Journal of Physical Chemistry B, 2020, 124, 9829-9839.	1.2	22
1426	Increased Levels of Coagulation Factor XI in Plasma Are Related to Alzheimerâ€™s Disease Diagnosis. Journal of Alzheimer's Disease, 2020, 77, 375-386.	1.2	12
1427	Cobalt(III) Schiff base complexes stabilize non-fibrillar amyloid-Î² aggregates with reduced toxicity. Journal of Inorganic Biochemistry, 2020, 213, 111265.	1.5	5
1428	A computer-simulated mechanism of familial Alzheimerâ€™s disease: Mutations enhance thermal dynamics and favor looser substrate-binding to Î³-secretase. Journal of Structural Biology, 2020, 212, 107648.	1.3	18
1429	Hyaluronan-carnosine conjugates inhibit AÎ² aggregation and toxicity. Scientific Reports, 2020, 10, 15998.	1.6	17
1430	On the Role of Platelet-Generated Amyloid Beta Peptides in Certain Amyloidosis Health Complications. Frontiers in Immunology, 2020, 11, 571083.	2.2	22
1431	Tau Oligomers and Fibrils Exhibit Differential Patterns of Seeding and Association With RNA Binding Proteins. Frontiers in Neurology, 2020, 11, 579434.	1.1	21
1432	Attenuation of Oxidative Stress by Cannabinoids and Cannabis Extracts in Differentiated Neuronal Cells. Pharmaceuticals, 2020, 13, 328.	1.7	20
1433	Computational Investigation of Gantenerumab and Crenezumab Recognition of AÎ² Fibrils in Alzheimerâ€™s Disease Brain Tissue. ACS Chemical Neuroscience, 2020, 11, 3233-3244.	1.7	12
1434	Impact of Hyperhomocysteinemia and Different Dietary Interventions on Cognitive Performance in a Knock-in Mouse Model for Alzheimerâ€™s Disease. Nutrients, 2020, 12, 3248.	1.7	8
1435	Pre-clinical dose-ranging efficacy, pharmacokinetics, tissue biodistribution, and toxicity of a targeted contrast agent for MRI of amyloid deposition in Alzheimerâ€™s disease. Scientific Reports, 2020, 10, 16185.	1.6	10
1436	A Coordinated Approach by Public Domain Bioinformatics Resources to Aid the Fight Against Alzheimerâ€™s Disease Through Expert Curation of Key Protein Targets. Journal of Alzheimer's Disease, 2020, 77, 257-273.	1.2	7

#	Article	IF	Citations
1437	Further Studies on Triazinoindoles as Potential Novel Multitarget-Directed Anti-Alzheimerâ€™s Agents. ACS Chemical Neuroscience, 2020, 11, 3557-3574.	1.7	15
1438	Regional Disconnection in Alzheimer Dementia and Amyloid-Positive Mild Cognitive Impairment: Association Between EEG Functional Connectivity and Brain Glucose Metabolism. Brain Connectivity, 2020, 10, 555-565.	0.8	18
1439	Retinal Functional and Structural Changes in the 5xFAD Mouse Model of Alzheimerâ€™s Disease. Frontiers in Neuroscience, 2020, 14, 862.	1.4	32
1440	Fluorescent Dopamineâ€“Tryptophan Nanocomposites as Dual-Imaging and Antiaggregation Agents: New Generation of Amyloid Theranostics with Trimeric Effects. ACS Applied Materials & Interfaces, 2020, 12, 44180-44194.	4.0	12
1441	Amyloid-Î² regulates gap junction protein connexin 43 trafficking in cultured primary astrocytes. Journal of Biological Chemistry, 2020, 295, 15097-15111.	1.6	16
1442	High-fat diet exacerbates cognitive and metabolic abnormalities in neuronal BACE1 knock-in mice â€“ partial prevention by Fenretinide. Nutritional Neuroscience, 2022, 25, 719-736.	1.5	4
1443	The two faces of synaptic failure in AppNL-G-F knock-in mice. Alzheimer's Research and Therapy, 2020, 12, 100.	3.0	25
1444	Increased levels of Stress-inducible phosphoprotein-1 accelerates amyloid-Î² deposition in a mouse model of Alzheimerâ€™s disease. Acta Neuropathologica Communications, 2020, 8, 143.	2.4	13
1445	Internalisation and toxicity of amyloidâ€Î² 1â€42 are influenced by its conformation and assembly state rather than size. FEBS Letters, 2020, 594, 3490-3503.	1.3	27
1446	Delta-secretase cleavage of Tau mediates its pathology and propagation in Alzheimerâ€™s disease. Experimental and Molecular Medicine, 2020, 52, 1275-1287.	3.2	17
1447	Feasibility of dualâ€task gait to estimate Alzheimer's related cognitive decline in Down syndrome. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12092.	1.2	2
1448	Adenosine triphosphate Binding Cassette subfamily C member 1 (ABCC1) overexpression reduces APP processing and increases alpha- versus beta-secretase activity, in vitro. Biology Open, 2021, 10, .	0.6	2
1449	A rationally designed bicyclic peptide remodels Aβ42 aggregation in vitro and reduces its toxicity in a worm model of Alzheimerâ€™s disease. Scientific Reports, 2020, 10, 15280.	1.6	15
1450	Antenatal Hypoxia Accelerates the Onset of Alzheimerâ€™s Disease Pathology in 5xFAD Mouse Model. Frontiers in Aging Neuroscience, 2020, 12, 251.	1.7	12
1451	Two boron-containing compounds affect the cellular viability of SH-SY5Y cells in an in vitro amyloid-beta toxicity model. Turkish Journal of Biology, 2020, 44, 208-214.	2.1	7
1452	Klotho overexpression improves amyloidâ€β clearance and cognition in the APP/PS1 mouse model of Alzheimer's disease. Aging Cell, 2020, 19, e13239.	3.0	51
1453	Familial Alzheimerâ€™s disease mutations at position 22 of the amyloid β-peptide sequence differentially affect synaptic loss, tau phosphorylation and neuronal cell death in an ex vivo system. PLoS ONE, 2020, 15, e0239584.	1.1	15
1454	Human Pluripotent Stem Cell-Derived Neural Cells as a Relevant Platform for Drug Screening in Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2020, 21, 6867.	1.8	26

#	Article	IF	Citations
1456	The role of the cellular prion protein in the uptake and toxic signaling of pathological neurodegenerative aggregates. Progress in Molecular Biology and Translational Science, 2020, 175, 297-323.	0.9	5
1457	The neutrophil-to-lymphocyte ratio in Alzheimer's disease: Current understanding and potential applications. Journal of Neuroimmunology, 2020, 349, 577398.	1.1	42
1458	The Role of Lipid Environment in Ganglioside GM1-Induced Amyloid Î² Aggregation. Membranes, 2020, 10, 226.	1.4	25
1459	Rhizolutin, a Novel 7/10/6â€Tricyclic Dilactone, Dissociates Misfolded Protein Aggregates and Reduces Apoptosis/Inflammation Associated with Alzheimer's Disease. Angewandte Chemie, 2020, 132, 23194-23198.	1.6	6
1460	Side-by-side comparison of Notch- and C83 binding to Î³-secretase in a complete membrane model at physiological temperature. RSC Advances, 2020, 10, 31215-31232.	1.7	21
1461	Challenges in demonstrating the value of disease-modifying therapies for Alzheimerâ€™s disease. Expert Review of Pharmacoeconomics and Outcomes Research, 2020, 20, 563-570.	0.7	14
1462	Tau-Mediated Dysregulation of Neuroplasticity and Glial Plasticity. Frontiers in Molecular Neuroscience, 2020, 13, 151.	1.4	11
1463	Circuitry and Synaptic Dysfunction in Alzheimerâ€™s Disease: A New Tau Hypothesis. Neural Plasticity, 2020, 2020, 1-11.	1.0	19
1464	Cerebrolysin in the therapy of mild cognitive impairment and dementia due to Alzheimer's disease: 30 years of clinical use. Medicinal Research Reviews, 2021, 41, 2775-2803.	5.0	39
1465	Gut Microbiota and Dysbiosis in Alzheimerâ€™s Disease: Implications for Pathogenesis and Treatment. Molecular Neurobiology, 2020, 57, 5026-5043.	1.9	191
1466	Myeloproliferative blood cancers as a human neuroinflammation model for development of Alzheimerâ€™s disease: evidences and perspectives. Journal of Neuroinflammation, 2020, 17, 248.	3.1	8
1467	The Effects of Alpha-Linolenic Acid on the Secretory Activity of Astrocytes and Î² Amyloid-Associated Neurodegeneration in Differentiated SH-SY5Y Cells: Alpha-Linolenic Acid Protects the SH-SY5Y cells against Î² Amyloid Toxicity. Oxidative Medicine and Cellular Longevity, 2020, 2020, 1-20.	1.9	20
1468	Rhizolutin, a Novel 7/10/6â€Tricyclic Dilactone, Dissociates Misfolded Protein Aggregates and Reduces Apoptosis/Inflammation Associated with Alzheimer's Disease. Angewandte Chemie - International Edition, 2020, 59, 22994-22998.	7.2	15
1469	Effect of Herbal Medicinal Compounds on Alzheimerâ€™s Disease Pathology in APP/PS1 Transgenic Mouse Model. Natural Product Communications, 2020, 15, 1934578X2094898.	0.2	1
1470	Dynamic Blood Concentrations of AÎ²1â€“40 and AÎ²1â€“42 in Alzheimerâ€™s Disease. Frontiers in Cell and Developmental Biology, 2020, 8, 768.	1.8	14
1471	Nicotinamide, a Poly [ADP-Ribose] Polymerase 1 (PARP-1) Inhibitor, as an Adjunctive Therapy for the Treatment of Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2020, 12, 255.	1.7	47
1472	Recent developments of small molecule Î³-secretase modulators for Alzheimer's disease. RSC Medicinal Chemistry, 2020, 11, 1003-1022.	1.7	31
1473	Mechanisms of Pathogenic Tau and AÎ² Protein Spreading in Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2020, 12, 265.	1.7	78

#	Article	IF	Citations
1474	Proteomic Profiling of Extracellular Vesicles Derived from Cerebrospinal Fluid of Alzheimerâ€™s Disease Patients: A Pilot Study. Cells, 2020, 9, 1959.	1.8	75
1475	Impact of COVID-19 on Alzheimerâ€™s Disease Risk: Viewpoint for Research Action. Healthcare (Switzerland), 2020, 8, 286.	1.0	35
1476	Hydrogen sulfide signalling in the CNS â€•Comparison with NO. British Journal of Pharmacology, 2020, 177, 5031-5045.	2.7	23
1477	Significance of Blood and Cerebrospinal Fluid Biomarkers for Alzheimerâ€™s Disease: Sensitivity, Specificity and Potential for Clinical Use. Journal of Personalized Medicine, 2020, 10, 116.	1.1	26
1478	Thermodynamic and kinetic design principles for amyloid-aggregation inhibitors. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 24251-24257.	3.3	49
1479	Behavioral and neural network abnormalities in human APP transgenic mice resemble those of App knock-in mice and are modulated by familial Alzheimerâ€™s disease mutations but not by inhibition of BACE1. Molecular Neurodegeneration, 2020, 15, 53.	4.4	44
1480	Contribution of iron and AÎ² to age differences in entorhinal and hippocampal subfield volume. Neurology, 2020, 95, e2586-e2594.	1.5	11
1481	Ubiquitin, Autophagy and Neurodegenerative Diseases. Cells, 2020, 9, 2022.	1.8	44
1482	Adiponectin: The Potential Regulator and Therapeutic Target of Obesity and Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2020, 21, 6419.	1.8	31
1483	Amyloidosis increase is not attenuated by long-term calorie restriction or related to neuron density in the prefrontal cortex of extremely aged rhesus macaques. GeroScience, 2020, 42, 1733-1749.	2.1	17
1484	AÎ²43â€producing <scp>PS</scp>1 <scp>FAD</scp> mutants cause altered substrate interactions and respond to Î³â€secretase modulation. EMBO Reports, 2020, 21, e47996.	2.0	24
1485	The Other Side of Alzheimerâ€™s Disease: Influence of Metabolic Disorder Features for Novel Diagnostic Biomarkers. Journal of Personalized Medicine, 2020, 10, 115.	1.1	8
1486	T2 heterogeneity: a novel marker of microstructural integrity associated with cognitive decline in people with mild cognitive impairment. Alzheimer's Research and Therapy, 2020, 12, 105.	3.0	16
1487	Somatostatin, an In Vivo Binder to AÎ² Oligomers, Binds to Î²PFO_{AÎ²(1â€“42)} Tetramers. ACS Chemical Neuroscience, 2020, 11, 3358-3365.	1.7	7
1488	Pre-symptomatic Caspase-1 inhibitor delays cognitive decline in a mouse model of Alzheimer disease and aging. Nature Communications, 2020, 11, 4571.	5.8	50
1489	A Pentacyclic Triterpene from Ligustrum lucidum Targets Î³-Secretase. ACS Chemical Neuroscience, 2020, 11, 2827-2835.	1.7	4
1490	Identifying the molecular systems that influence cognitive resilience to Alzheimer's disease in genetically diverse mice. Learning and Memory, 2020, 27, 355-371.	0.5	15
1491	Emodin inhibits aggregation of amyloidâ€Î² peptide 1â€“42 and improves cognitive deficits in Alzheimer's disease transgenic mice. Journal of Neurochemistry, 2021, 157, 1992-2007.	2.1	17

#	Article	IF	Citations
1492	Current Biomarkers for Alzheimerâ€™s Disease: From CSF to Blood. Journal of Personalized Medicine, 2020, 10, 85.	1.1	42
1493	CanToxoplasma gondiiPave the Road for Dementia?. Journal of Parasitology Research, 2020, 2020, 1-13.	0.5	3
1494	Trodusquemine displaces protein misfolded oligomers from cell membranes and abrogates their cytotoxicity through a generic mechanism. Communications Biology, 2020, 3, 435.	2.0	44
1495	Oral Treatment with Iododiflunisal Delays Hippocampal Amyloid-Î² Formation in a Transgenic Mouse Model of Alzheimerâ€™s Disease: A Longitudinal in vivo Molecular Imaging Study1. Journal of Alzheimer's Disease, 2020, 77, 99-112.	1.2	6
1496	MicroRNAs in Alzheimerâ€™s Disease: Function and Potential Applications as Diagnostic Biomarkers. Frontiers in Molecular Neuroscience, 2020, 13, 160.	1.4	57
1497	Cotinine and 6-Hydroxy-L-Nicotine Reverses Memory Deficits and Reduces Oxidative Stress in AÎ²25-35-Induced Rat Model of Alzheimerâ€™s Disease. Antioxidants, 2020, 9, 768.	2.2	17
1499	Luteolin Protects Pheochromocytoma (PC-12) Cells against AÎ²25-35-Induced Cell Apoptosis through the ER/ERK/MAPK Signalling Pathway. Evidence-based Complementary and Alternative Medicine, 2020, 2020, 1-8.	0.5	6
1500	Editorial: Using Small Molecules to Treat Macromolecule Storage Disorders. Frontiers in Cell and Developmental Biology, 2020, 8, 623613.	1.8	2
1501	Experimental Evidence of the Benefits of Acupuncture for Alzheimer's Disease: An Updated Review. Frontiers in Neuroscience, 2020, 14, 549772.	1.4	24
1502	Natural Compounds as Inhibitors of AÎ² Peptide Aggregation: Chemical Requirements and Molecular Mechanisms. Frontiers in Neuroscience, 2020, 14, 619667.	1.4	59
1503	Evaluating the Effects of Grain of Isogenic Wheat Lines Differing in the Content of Anthocyanins in Mouse Models of Neurodegenerative Disorders. Nutrients, 2020, 12, 3877.	1.7	27
1504	Pharmacological Strategies to Improve Dendritic Spines in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2021, 82, S91-S107.	1.2	13
1505	Targeting Mitophagy in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2020, 78, 1273-1297.	1.2	6
1506	Vaccination against Î²-Amyloid as a Strategy for the Prevention of Alzheimerâ€™s Disease. Biology, 2020, 9, 425.	1.3	26
1507	Indian Medicinal Herbs and Formulations for Alzheimerâ€™s Disease, from Traditional Knowledge to Scientific Assessment. Brain Sciences, 2020, 10, 964.	1.1	36
1508	Transcriptional, Behavioral and Biochemical Profiling in the 3xTg-AD Mouse Model Reveals a Specific Signature of Amyloid Deposition and Functional Decline in Alzheimerâ€™s Disease. Frontiers in Neuroscience, 2020, 14, 602642.	1.4	3
1509	Self-Protecting Biomimetic Nanozyme for Selective and Synergistic Clearance of Peripheral Amyloid-Î² in an Alzheimerâ€™s Disease Model. Journal of the American Chemical Society, 2020, 142, 21702-21711.	6.6	96
1510	An insight into the in vivo imaging potential of curcumin analogues as fluorescence probes. Asian Journal of Pharmaceutical Sciences, 2021, 16, 419-431.	4.3	16

#	Article	IF	Citations
1511	The variability of functional MRI brain signal increases in Alzheimer's disease at cardiorespiratory frequencies. Scientific Reports, 2020, 10, 21559.	1.6	28
1512	Biomarkers: Our Path Towards a Cure for Alzheimer Disease. Biomarker Insights, 2020, 15, 117727192097636.	1.0	21
1513	Collagenous Alzheimer amyloid plaque component impacts on the compaction of amyloid-Î² plaques. Acta Neuropathologica Communications, 2020, 8, 212.	2.4	13
1514	Celecoxib Exerts Neuroprotective Effects in Î²-Amyloid-Treated SH-SY5Y Cells Through the Regulation of Heme Oxygenase-1: Novel Insights for an Old Drug. Frontiers in Cell and Developmental Biology, 2020, 8, 561179.	1.8	16
1515	Neuromodulation in the Treatment of Alzheimerâ€™s Disease: Current and Emerging Approaches. Journal of Alzheimer's Disease, 2020, 78, 1299-1313.	1.2	7
1516	An Overview of Astrocyte Responses in Genetically Induced Alzheimerâ€™s Disease Mouse Models. Cells, 2020, 9, 2415.	1.8	18
1517	Alzheimerâ€™s amyloid Î² heterogeneous species differentially affect brain endothelial cell viability, bloodâ€brain barrier integrity, and angiogenesis. Aging Cell, 2020, 19, e13258.	3.0	39
1518	Metal- and UV- Catalyzed Oxidation Results in Trapped Amyloid-Î² Intermediates Revealing that Self-Assembly Is Required for AÎ²-Induced Cytotoxicity. IScience, 2020, 23, 101537.	1.9	18
1519	Synthesis and biological evaluation of 2â€²-Aminochalcone: A multi-target approach to find drug candidates to treat Alzheimerâ€™s disease. Bioorganic Chemistry, 2020, 103, 104201.	2.0	8
1520	Common aspects between glaucoma and brain neurodegeneration. Mutation Research - Reviews in Mutation Research, 2020, 786, 108323.	2.4	8
1521	APOE2: protective mechanism and therapeutic implications for Alzheimerâ€™s disease. Molecular Neurodegeneration, 2020, 15, 63.	4.4	110
1522	Superparamagnetic iron oxide nanoparticles conjugated with AÎ² oligomer-specific scFv antibody and class A scavenger receptor activator show therapeutic potentials for Alzheimerâ€™s Disease. Journal of Nanobiotechnology, 2020, 18, 160.	4.2	24
1523	Contributions of Molecular and Optical Techniques to the Clinical Diagnosis of Alzheimerâ€™s Disease. Brain Sciences, 2020, 10, 815.	1.1	6
1524	TRPM2 channel-mediated cell death: An important mechanism linking oxidative stress-inducing pathological factors to associated pathological conditions. Redox Biology, 2020, 37, 101755.	3.9	71
1525	Astaxanthin Ameliorated Parvalbumin-Positive Neuron Deficits and Alzheimerâ€™s Disease-Related Pathological Progression in the Hippocampus of AppNL-G-F/NL-G-F Mice. Frontiers in Pharmacology, 2020, 11, 307.	1.6	27
1526	Conformational Selection as the Driving Force of Amyloid Î² Chiral Inactivation. ChemBioChem, 2020, 21, 2945-2949.	1.3	8
1527	Identification of Structural Calcium Binding Sites in Membrane-Bound Presenilin 1 and 2. Journal of Physical Chemistry B, 2020, 124, 4697-4711.	1.2	6
1528	Anodal Transcranial Direct Current Stimulation Can Improve Spatial Learning and Memory and Attenuate AÎ²42 Burden at the Early Stage of Alzheimerâ€™s Disease in APP/PS1 Transgenic Mice. Frontiers in Aging Neuroscience, 2020, 12, 134.	1.7	31

#	Article	IF	Citations
1529	Alzheimerâ€™s Disease, a Lipid Story: Involvement of Peroxisome Proliferator-Activated Receptor Î±. Cells, 2020, 9, 1215.	1.8	30
1530	Intracellular Trafficking Mechanisms of Synaptic Dysfunction in Alzheimerâ€™s Disease. Frontiers in Cellular Neuroscience, 2020, 14, 72.	1.8	31
1531	The Role of Rac GTPase in Dendritic Spine Morphogenesis and Memory. Frontiers in Synaptic Neuroscience, 2020, 12, 12.	1.3	34
1532	Mosaic Somatic Gene Recombination as a Potentially Unifying Hypothesis for Alzheimerâ€™s Disease. Frontiers in Genetics, 2020, 11, 390.	1.1	14
1533	Peripheral clearance of brain-derived AÎ² in Alzheimer's disease: pathophysiology and therapeutic perspectives. Translational Neurodegeneration, 2020, 9, 16.	3.6	83
1534	Proteomic Profiling of Plasma and Brain Tissue from Alzheimerâ€™s Disease Patients Reveals Candidate Network of Plasma Biomarkers. Journal of Alzheimer's Disease, 2020, 76, 349-368.	1.2	31
1535	The Positive Side of the Alzheimerâ€™s Disease Amyloid Cross-Interactions: The Case of the AÎ² 1-42 Peptide with Tau, TTR, CysC, and ApoA1. Molecules, 2020, 25, 2439.	1.7	37
1536	CD8+ T-cells infiltrate Alzheimerâ€™s disease brains and regulate neuronal- and synapse-related gene expression in APP-PS1 transgenic mice. Brain, Behavior, and Immunity, 2020, 89, 67-86.	2.0	112
1537	A novel pectin from Polygala tenuifolia blocks AÎ²42 aggregation and production by enhancing insulin-degradation enzyme and neprilysin. International Journal of Biological Macromolecules, 2020, 161, 35-43.	3.6	15
1538	Xingnaojing ameliorates synaptic plasticity and memory deficits in an AÎ²1â€“42 induced mouse model of Alzheimer's disease. Journal of Pharmacological Sciences, 2020, 143, 245-254.	1.1	8
1539	Perindopril ameliorates experimental Alzheimerâ€™s disease progression: role of amyloid Î² degradation, central estrogen receptor and hyperlipidemic-lipid raft signaling. Inflammopharmacology, 2020, 28, 1343-1364.	1.9	18
1540	Functionalized Mesoporous Silicas Direct Structural Polymorphism of Amyloid-Î² Fibrils. Langmuir, 2020, 36, 7345-7355.	1.6	3
1541	Opposite Roles of Î´- and Î¼-Opioid Receptors in BACE1 Regulation and Alzheimerâ€™s Injury. Frontiers in Cellular Neuroscience, 2020, 14, 88.	1.8	10
1542	Endo/Lysosomeâ€Escapable Delivery Depot for Improving BBB Transcytosis and Neuron Targeted Therapy of Alzheimer's Disease. Advanced Functional Materials, 2020, 30, 1909999.	7.8	71
1543	Optimization of Solid-Phase Synthesis of the 1-40 Beta-Amyloid and Preparation of Antibodies Revealing It under Immunoblotting Conditions. Russian Journal of Bioorganic Chemistry, 2020, 46, 217-222.	0.3	1
1544	Safflower Yellow Improves the Synaptic Structural Plasticity by Ameliorating the Disorder of Glutamate Circulation in AÎ²1-42-induced AD Model Rats. Neurochemical Research, 2020, 45, 1870-1887.	1.6	9
1545	Insulin resistance and sleep apnea. , 2020, , 157-206.		0
1546	Out-of-Register Parallel Î²-Sheets and Antiparallel Î²-Sheets Coexist in 150-kDa Oligomers Formed by Amyloid-Î²(1â€“42). Journal of Molecular Biology, 2020, 432, 4388-4407.	2.0	27

#	Article	IF	Citations
1547	Partial reduction of amyloid Î² production by Î²-secretase inhibitors does not decrease synaptic transmission. Alzheimer's Research and Therapy, 2020, 12, 63.	3.0	21
1548	Mitochondrial Dysfunctions: A Red Thread across Neurodegenerative Diseases. International Journal of Molecular Sciences, 2020, 21, 3719.	1.8	61
1550	Novel carbazole-stilbene hybrids as multifunctional anti-Alzheimer agents. Bioorganic Chemistry, 2020, 101, 103977.	2.0	27
1551	Signal Peptide Peptidase-Type Proteases: Versatile Regulators with Functions Ranging from Limited Proteolysis to Protein Degradation. Journal of Molecular Biology, 2020, 432, 5063-5078.	2.0	10
1552	The Use of Patient-Derived Induced Pluripotent Stem Cells for Alzheimerâ€™s Disease Modeling. Progress in Neurobiology, 2020, 192, 101804.	2.8	15
1553	Neuronâ€glia interactions: Molecular basis of alzheimerâ€™s disease and applications of neuroproteomics. European Journal of Neuroscience, 2020, 52, 2931-2943.	1.2	32
1554	The Alzheimerâ€™s Prevention Initiative Composite Cognitive Test: a practical measure for tracking cognitive decline in preclinical Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2020, 12, 66.	3.0	19
1555	Amyloid Î² induces interneuron-specific changes in the hippocampus of APPNL-F mice. PLoS ONE, 2020, 15, e0233700.	1.1	17
1556	A Role of Low-Density Lipoprotein Receptor-Related Protein 4 (LRP4) in Astrocytic AÎ² Clearance. Journal of Neuroscience, 2020, 40, 5347-5361.	1.7	35
1557	Amyloid-Î² (AÎ²42) Peptide Aggregation Rate and Mechanism on Surfaces with Widely Varied Properties: Insights from Brownian Dynamics Simulations. Journal of Physical Chemistry B, 2020, 124, 5549-5558.	1.2	7
1558	Integrin adhesion in brain assembly: From molecular structure to neuropsychiatric disorders. European Journal of Neuroscience, 2021, 53, 3831-3850.	1.2	42
1559	Mouse Bone Marrow-derived Microglia-like Cells Secrete Transforming Growth Factor-Î²1 and Promote Microglial AÎ² Phagocytosis and Reduction of Brain AÎ². Neuroscience, 2020, 438, 217-228.	1.1	15
1560	Lack of association between LGMN and Alzheimerâ€™s disease in the Southern Han Chinese population. European Journal of Neuroscience, 2020, 52, 4009-4017.	1.2	4
1561	Mini Nutritional Assessment May Identify a Dual Pattern of Perturbed Plasma Amino Acids in Patients with Alzheimerâ€™s Disease: A Window to Metabolic and Physical Rehabilitation?. Nutrients, 2020, 12, 1845.	1.7	19
1562	Heart and Brain: Complex Relationships for Left Ventricular Dysfunction. Current Cardiology Reports, 2020, 22, 72.	1.3	16
1563	Amyloid precursor protein-b facilitates cell adhesion during early development in zebrafish. Scientific Reports, 2020, 10, 10127.	1.6	18
1564	Popular three-dimensional models: Advantages for cancer, Alzheimerâ€™s and cardiovascular diseases. Tissue and Cell, 2020, 65, 101367.	1.0	1
1565	Biophysical studies of protein misfolding and aggregation inin vivomodels of Alzheimer's and Parkinson's diseases. Quarterly Reviews of Biophysics, 2020, 53, e22.	2.4	13

#	Article	IF	Citations
1566	Binding modes of thioflavin T and Congo red to the fibril structure of amyloid-Î²(1â€“42). Chemical Communications, 2020, 56, 7589-7592.	2.2	38
1567	Effects of N-Terminal Residues on the Assembly of Constrained Î²-Hairpin Peptides Derived from AÎ². Journal of the American Chemical Society, 2020, 142, 11593-11601.	6.6	12
1568	Yeast Î²-glucan alleviates cognitive deficit by regulating gut microbiota and metabolites in AÎ²1â€“42-induced AD-like mice. International Journal of Biological Macromolecules, 2020, 161, 258-270.	3.6	79
1569	Cognitive Decline and Modulation of Alzheimerâ€™s Disease-Related Genes After Inhibition of MicroRNA-101 in Mouse Hippocampal Neurons. Molecular Neurobiology, 2020, 57, 3183-3194.	1.9	20
1570	Piezoelectric materials for ultrasound-driven dissociation of Alzheimer's Î²-amyloid aggregate structure. Biomaterials, 2020, 255, 120165.	5.7	47
1571	AÎ²(1-42) tetramer and octamer structures reveal edge conductivity pores as a mechanism for membrane damage. Nature Communications, 2020, 11, 3014.	5.8	162
1572	Protective Role of Cerebrospinal Fluid Inflammatory Cytokines in Patients with Amnestic Mild Cognitive Impairment and Early Alzheimerâ€™s Disease Carrying Apolipoprotein E4 Genotype. Journal of Alzheimer's Disease, 2020, 76, 681-689.	1.2	27
1573	RISK FACTORS AND CURRENT STRATEGIES TO OVERCOME ALZHEIMERâ€™S DISEASE: A REVIEW. International Journal of Research in Ayurveda and Pharmacy, 2020, 11, 115-123.	0.0	0
1574	Exploring the Role of PSEN Mutations in the Pathogenesis of Alzheimerâ€™s Disease. Neurotoxicity Research, 2020, 38, 833-849.	1.3	30
1575	Amyloidosis is associated with thicker myelin and increased oligodendrogenesis in the adult mouse brain. Journal of Neuroscience Research, 2020, 98, 1905-1932.	1.3	20
1576	AÎ²-Amyloid Fibrils Are Self-Triggered by the Interfacial Lipid Environment and Low Peptide Content. Langmuir, 2020, 36, 8056-8065.	1.6	10
1577	Copper stabilizes antiparallel Î²-sheet fibrils of the amyloid Î²40 (AÎ²40)-Iowa variant. Journal of Biological Chemistry, 2020, 295, 8914-8927.	1.6	7
1578	Link between Diabetes and Alzheimerâ€™s Disease Due to the Shared Amyloid Aggregation and Deposition Involving Both Neurodegenerative Changes and Neurovascular Damages. Journal of Clinical Medicine, 2020, 9, 1713.	1.0	56
1579	Can Infections Cause Alzheimer Disease?. JAMA - Journal of the American Medical Association, 2020, 324, 239.	3.8	23
1580	Two new compounds from the stewed Polygonatum cyrtonema Hua and their protective effect against AÎ²₂₅₋₃₅ induced cytotoxicity and oxidative stress damage. Natural Product Research, 2021, 35, 4945-4952.	1.0	7
1581	Plasma transferrin and hemopexin are associated with altered AÎ² uptake and cognitive decline in Alzheimerâ€™s disease pathology. Alzheimer's Research and Therapy, 2020, 12, 72.	3.0	19
1582	Senescence as an Amyloid Cascade: The Amyloid Senescence Hypothesis. Frontiers in Cellular Neuroscience, 2020, 14, 129.	1.8	35
1583	Nanoliposomes as a Therapeutic Tool for Alzheimerâ€™s Disease. Frontiers in Synaptic Neuroscience, 2020, 12, 20.	1.3	24

#	Article	IF	Citations
1584	Upregulation of RIN3 induces endosomal dysfunction in Alzheimerâ€™s disease. Translational Neurodegeneration, 2020, 9, 26.	3.6	37
1585	A Novel Compound YS-5-23 Exhibits Neuroprotective Effect by Reducing Î²-Site Amyloid Precursor Protein Cleaving Enzyme 1â€™s Expression and H2O2-Induced Cytotoxicity in SH-SY5Y Cells. Neurochemical Research, 2020, 45, 2113-2127.	1.6	2
1586	The Novel Role of PPAR Alpha in the Brain: Promising Target in Therapy of Alzheimerâ€™s Disease and Other Neurodegenerative Disorders. Neurochemical Research, 2020, 45, 972-988.	1.6	161
1587	Amyloid-Î²42/40 ratio drives tau pathology in 3D human neural cell culture models of Alzheimerâ€™s disease. Nature Communications, 2020, 11, 1377.	5.8	88
1588	Editorial: Alzheimerâ€™s Disease: Original Mechanisms and Translational Impact. Frontiers in Pharmacology, 2020, 11, 157.	1.6	0
1589	Molecular mechanisms underlying actions of certain long noncoding RNAs in Alzheimerâ€™s disease. Metabolic Brain Disease, 2020, 35, 681-693.	1.4	20
1590	A mechanistic hypothesis for the impairment of synaptic plasticity by soluble AÎ² oligomers from Alzheimerâ€™s brain. Journal of Neurochemistry, 2020, 154, 583-597.	2.1	158
1591	Synaptic Activity and (Neuro)Inflammation in Alzheimerâ€™s Disease: Could Exosomes be an Additional Link?. Journal of Alzheimer's Disease, 2020, 74, 1029-1043.	1.2	11
1592	Potential Role of Venular Amyloid in Alzheimerâ€™s Disease Pathogenesis. International Journal of Molecular Sciences, 2020, 21, 1985.	1.8	28
1593	The Impact of Natural Compounds on S-Shaped AÎ²42 Fibril: From Molecular Docking to Biophysical Characterization. International Journal of Molecular Sciences, 2020, 21, 2017.	1.8	18
1594	Machine Learning Predictive Models Can Improve Efficacy of Clinical Trials for Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2020, 74, 55-63.	1.2	18
1595	Discovery of small molecules for the treatment of Alzheimerâ€™s disease. , 2020, , 289-322.		1
1596	Metal complexes that bind to the amyloid-Î² peptide of relevance to Alzheimerâ€™s disease. Coordination Chemistry Reviews, 2020, 412, 213255.	9.5	54
1597	The clinical promise of biomarkers of synapse damage or loss in Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2020, 12, 21.	3.0	183
1598	CRANAD-28: A Robust Fluorescent Compound for Visualization of Amyloid Beta Plaques. Molecules, 2020, 25, 863.	1.7	10
1599	Control of the toxic conformation of amyloid Î²42 by intramolecular disulfide bond formation. Chemical Communications, 2020, 56, 4118-4121.	2.2	15
1600	Computational studies of protein aggregation mediated by amyloid: Fibril elongation and secondary nucleation. Progress in Molecular Biology and Translational Science, 2020, 170, 461-504.	0.9	12
1601	Tacrine-hydroxamate derivatives as multitarget-directed ligands for the treatment of Alzheimerâ€™s disease: Design, synthesis, and biological evaluation. Bioorganic Chemistry, 2020, 98, 103721.	2.0	21

#	Article	IF	Citations
1602	A Cell- and Tissue-Specific Weakness of the Protein Homeostasis System Underlies Brain Vulnerability to Protein Aggregation. IScience, 2020, 23, 100934.	1.9	9
1603	Benzothiazolyl Ureas are Low Micromolar and Uncompetitive Inhibitors of 17Î²-HSD10 with Implications to Alzheimerâ€™s Disease Treatment. International Journal of Molecular Sciences, 2020, 21, 2059.	1.8	14
1604	Real-time nanoscale organization of amyloid precursor protein. Nanoscale, 2020, 12, 8200-8215.	2.8	19
1605	Magnetic Nanoparticles as In Vivo Tracers for Alzheimerâ€™s Disease. Magnetochemistry, 2020, 6, 13.	1.0	12
1606	Antioxidant Berberine-Derivative Inhibits Multifaceted Amyloid Toxicity. IScience, 2020, 23, 101005.	1.9	63
1607	Functional Brain Network Connectivity Patterns Associated With Normal Cognition at Old-Age, Local Î²-amyloid, Tau, and APOE4. Frontiers in Aging Neuroscience, 2020, 12, 46.	1.7	21
1608	Brain lipid peroxidation and alzheimer disease: Synergy between the Butterfield and Mattson laboratories. Ageing Research Reviews, 2020, 64, 101049.	5.0	45
1609	Fecal Microbiota Transplantation in Neurological Disorders. Frontiers in Cellular and Infection Microbiology, 2020, 10, 98.	1.8	221
1610	Tau R3â€“R4 Domain Dimer of the Wild Type and Phosphorylated Ser356 Sequences. I. In Solution by Atomistic Simulations. Journal of Physical Chemistry B, 2020, 124, 2975-2983.	1.2	30
1611	Complexity in Lipid Membrane Composition Induces Resilience to AÎ²₄₂ Aggregation. ACS Chemical Neuroscience, 2020, 11, 1347-1352.	1.7	22
1612	A Positive Feedback Loop of Hippo- and c-Jun-Amino-Terminal Kinase Signaling Pathways Regulates Amyloid-Beta-Mediated Neurodegeneration. Frontiers in Cell and Developmental Biology, 2020, 8, 117.	1.8	39
1613	Neuropathological Mechanisms Associated with Pesticides in Alzheimerâ€™s Disease. Toxics, 2020, 8, 21.	1.6	40
1614	Discovery of Chemicals to Either Clear or Indicate Amyloid Aggregates by Targeting Memoryâ€Impairing Antiâ€Parallel AÎ² Dimers. Angewandte Chemie - International Edition, 2020, 59, 11491-11500.	7.2	15
1615	The design and development of covalent protein-protein interaction inhibitors for cancer treatment. Journal of Hematology and Oncology, 2020, 13, 26.	6.9	50
1616	A Unique GSK-3Î² inhibitor B10 Has a Direct Effect on AÎ², Targets Tau and Metal Dyshomeostasis, and Promotes Neuronal Neurite Outgrowth. Cells, 2020, 9, 649.	1.8	17
1617	Research Progress on Alzheimer's Disease and Resveratrol. Neurochemical Research, 2020, 45, 989-1006.	1.6	55
1618	Effects of air pollution on the nervous system and its possible role in neurodevelopmental and neurodegenerative disorders. , 2020, 210, 107523.		206
1619	Identifying Fibrillization State of AÎ² Protein via Near-Field THz Conductance Measurement. ACS Nano, 2020, 14, 6548-6558.	7.3	25

#	Article	IF	Citations
1620	The Bewildering Effect of AMPK Activators in Alzheimerâ€™s Disease: Review of the Current Evidence. BioMed Research International, 2020, 2020, 1-18.	0.9	31
1621	Alzheimerâ€™s Disease: From Amyloid to Autoimmune Hypothesis. Neuroscientist, 2020, 26, 455-470.	2.6	17
1622	Rhynchophylline Loaded-mPEG-PLGA Nanoparticles Coated with Tween-80 for Preliminary Study in Alzheimerâ€™s Disease . International Journal of Nanomedicine, 2020, Volume 15, 1149-1160.	3.3	50
1623	Predisposition to Alzheimerâ€™s and Age-Related Brain Pathologies by PM2.5 Exposure: Perspective on the Roles of Oxidative Stress and TRPM2 Channel. Frontiers in Physiology, 2020, 11, 155.	1.3	26
1624	What Are the Molecular Mechanisms by Which Functional Bacterial Amyloids Influence Amyloid Beta Deposition and Neuroinflammation in Neurodegenerative Disorders?. International Journal of Molecular Sciences, 2020, 21, 1652.	1.8	34
1625	Contributions of DNA Damage to Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2020, 21, 1666.	1.8	60
1626	Dihydroartemisinin Ameliorates Learning and Memory in Alzheimerâ€™s Disease Through Promoting Autophagosome-Lysosome Fusion and Autolysosomal Degradation for AÎ² Clearance. Frontiers in Aging Neuroscience, 2020, 12, 47.	1.7	27
1627	Engineering probiotics as living diagnostics and therapeutics for improving human health. Microbial Cell Factories, 2020, 19, 56.	1.9	71
1628	Alzheimer's disease: A need for personalized therapeutic approaches. Drug Development Research, 2020, 81, 141-143.	1.4	5
1629	Coarse-grained MD simulations reveal beta-amyloid fibrils of various sizes bind to interfacial liquid-ordered and liquid-disordered regions in phase separated lipid rafts with diverse membrane-bound conformational states. Biophysical Chemistry, 2020, 260, 106355.	1.5	28
1630	Calorimetric Studies of Binary and Ternary Molecular Interactions between Transthyretin, AÎ² Peptides, and Small-Molecule Chaperones toward an Alternative Strategy for Alzheimerâ€™s Disease Drug Discovery. Journal of Medicinal Chemistry, 2020, 63, 3205-3214.	2.9	22
1631	Amyloid-beta modulates the association between neurofilament light chain and brain atrophy in Alzheimerâ€™s disease. Molecular Psychiatry, 2021, 26, 5989-6001.	4.1	28
1632	Toll-Like Receptors (TLRs) in Neurodegeneration: Integrative Approach to TLR Cascades in Alzheimerâ€™s and Parkinsonâ€™s Diseases. , 2020, , .		2
1633	Application of electrochemical method to a comparative study of spontaneous aggregation of amyloid-Î² isoforms. Journal of Electroanalytical Chemistry, 2020, 861, 113938.	1.9	7
1634	To Keto or Not to Keto? A Systematic Review of Randomized Controlled Trials Assessing the Effects of Ketogenic Therapy on Alzheimer Disease. Advances in Nutrition, 2020, 11, 1583-1602.	2.9	36
1635	New BACE1 Chimeric Peptide InhibitorsÂSelectively Prevent AÎ²PP-Î² Cleavage Decreasing Amyloid-Î² Production and Accumulation in Alzheimerâ€™s Disease Models. Journal of Alzheimer's Disease, 2020, 76, 1317-1337.	1.2	6
1636	Counteracting role of nuclear factor erythroid 2-related factor 2 pathway in Alzheimer's disease. Biomedicine and Pharmacotherapy, 2020, 129, 110373.	2.5	56
1637	Alzheimerâ€™s Disease: The Link Between Amyloid-Î² and Neurovascular Dysfunction. Journal of Alzheimer's Disease, 2020, 76, 1179-1198.	1.2	76

#	Article	IF	Citations
1638	GABAergic Inhibitory Interneuron Deficits in Alzheimerâ€™s Disease: Implications for Treatment. Frontiers in Neuroscience, 2020, 14, 660.	1.4	111
1639	The involvement of neuronal chloride transporter deficiencies in epilepsy. , 2020, , 329-366.		3
1640	The role of CREB and BDNF in neurobiology and treatment of Alzheimer's disease. Life Sciences, 2020, 257, 118020.	2.0	198
1641	The Toxicity and Polymorphism of Î²-Amyloid Oligomers. International Journal of Molecular Sciences, 2020, 21, 4477.	1.8	80
1642	Apolipoprotein E isoforms differentially regulate matrix metallopeptidase 9 function in Alzheimerâ€™s disease. Neurobiology of Aging, 2020, 95, 56-68.	1.5	13
1643	Half a century of amyloids: past, present and future. Chemical Society Reviews, 2020, 49, 5473-5509.	18.7	345
1644	Interaction of Oxidative Stress and Misfolded Proteins in the Mechanism of Neurodegeneration. Life, 2020, 10, 101.	1.1	53
1645	The pathophysiology of neurodegenerative disease: Disturbing the balance between phase separation and irreversible aggregation. Progress in Molecular Biology and Translational Science, 2020, 174, 187-223.	0.9	16
1646	Tau Ser208 phosphorylation promotes aggregation and reveals neuropathologic diversity in Alzheimerâ€™s disease and other tauopathies. Acta Neuropathologica Communications, 2020, 8, 88.	2.4	52
1647	Polyphenols as Potential Metal Chelation Compounds Against Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2021, 82, S335-S357.	1.2	65
1648	Abnormal Mitochondrial Quality Control in Neurodegenerative Diseases. Frontiers in Cellular Neuroscience, 2020, 14, 138.	1.8	42
1649	Rationally Designed Antibodies as Research Tools to Study the Structureâ€“Toxicity Relationship of Amyloid-Î² Oligomers. International Journal of Molecular Sciences, 2020, 21, 4542.	1.8	12
1650	A Pooled Analysis of Three Randomized Phase I/IIa Clinical Trials Confirms Absence of a Clinically Relevant Effect on the QTc Interval by Umibecestat. Clinical and Translational Science, 2020, 13, 1316-1326.	1.5	6
1651	The role of innate immunity in Alzheimer's disease. Immunological Reviews, 2020, 297, 225-246.	2.8	70
1652	Age-Specific Retinal and Cerebral Immunodetection of Amyloid-Î² Plaques and Oligomers in a Rodent Model of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2020, 76, 1135-1150.	1.2	26
1653	Hybrid PET/MRI enables high-spatial resolution, quantitative imaging of amyloid plaques in an Alzheimerâ€™s disease mouse model. Scientific Reports, 2020, 10, 10379.	1.6	15
1654	Multiple Herpes Simplex Virus-1 (HSV-1) Reactivations Induce Protein Oxidative Damage in Mouse Brain: Novel Mechanisms for Alzheimerâ€™s Disease Progression. Microorganisms, 2020, 8, 972.	1.6	17
1655	Structures of the intrinsically disordered AÎ², tau and Î±-synuclein proteins in aqueous solution from computer simulations. Biophysical Chemistry, 2020, 264, 106421.	1.5	85

#	Article	IF	Citations
1656	Mechanisms of Î³-Secretase Activation and Substrate Processing. ACS Central Science, 2020, 6, 969-983.	5.3	34
1657	Pharmacological Treatment of Alzheimerâ€™s Disease: Insights from Drosophila melanogaster. International Journal of Molecular Sciences, 2020, 21, 4621.	1.8	15
1658	C. elegans to model autophagy-related human disorders. Progress in Molecular Biology and Translational Science, 2020, 172, 325-373.	0.9	10
1659	Astrocytic palmitoylethanolamide pre-exposure exerts neuroprotective effects in astrocyte-neuron co-cultures from a triple transgenic mouse model of Alzheimer's disease. Life Sciences, 2020, 257, 118037.	2.0	14
1660	Chemical sensing platforms for detecting trace-level Alzheimer's core biomarkers. Chemical Society Reviews, 2020, 49, 5446-5472.	18.7	56
1661	Protective Effects of Compounds from Cimicifuga dahurica against Amyloid Beta Production in Vitro and Scopolamine-Induced Memory Impairment in Vivo. Journal of Natural Products, 2020, 83, 223-230.	1.5	3
1662	Negative evidence for a role of APH1B T27I variant in Alzheimerâ€™s disease. Human Molecular Genetics, 2020, 29, 955-966.	1.4	6
1663	Amyloid-Î², tau, and the cholinergic system in Alzheimerâ€™s disease: seeking direction in a tangle of clues. Reviews in the Neurosciences, 2020, 31, 391-413.	1.4	56
1664	APOE-amyloid interaction: Therapeutic targets. Neurobiology of Disease, 2020, 138, 104784.	2.1	65
1665	Protofibrils of Amyloid-Î² are Important Targets of a Disease-Modifying Approach for Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2020, 21, 952.	1.8	41
1666	Vaccines targeting the primary amino acid sequence and conformational epitope of amyloidâ€Î² had distinct effects on neuropathology and cognitive deficits in EAE/AD mice. British Journal of Pharmacology, 2020, 177, 2860-2871.	2.7	7
1667	Nicotinamide attenuates the decrease in dendritic spine density in hippocampal primary neurons from 5xFAD mice, an Alzheimerâ€™s disease animal model. Molecular Brain, 2020, 13, 17.	1.3	17
1668	Chronic Oral Palmitoylethanolamide Administration Rescues Cognitive Deficit and Reduces Neuroinflammation, Oxidative Stress, and Glutamate Levels in A Transgenic Murine Model of Alzheimerâ€™s Disease. Journal of Clinical Medicine, 2020, 9, 428.	1.0	26
1669	Brain injury-induced dysfunction of the blood brain barrier as a risk for dementia. Experimental Neurology, 2020, 328, 113257.	2.0	50
1670	Development of the clinical candidate PBD-C06, a humanized pGlu3-AÎ²-specific antibody against Alzheimerâ€™s disease with reduced complement activation. Scientific Reports, 2020, 10, 3294.	1.6	17
1671	Pathogenic AÎ² generation in familial Alzheimerâ€™s disease: novel mechanistic insights and therapeutic implications. Current Opinion in Neurobiology, 2020, 61, 73-81.	2.0	22
1672	Impact of the Astaxanthin, Betanin, and EGCG Compounds on Small Oligomers of Amyloid AÎ²₄₀ Peptide. Journal of Chemical Information and Modeling, 2020, 60, 1399-1408.	2.5	17
1673	An overview of spirooxindole as a promising scaffold for novel drug discovery. Expert Opinion on Drug Discovery, 2020, 15, 603-625.	2.5	157

#	Article	IF	Citations
1674	Mechanistic insights into the deleterious roles of Nasu-Hakola disease associated TREM2 variants. Scientific Reports, 2020, 10, 3663.	1.6	24
1675	A Proteotranscriptomic-Based Computational Drug-Repositioning Method for Alzheimerâ€™s Disease. Frontiers in Pharmacology, 2019, 10, 1653.	1.6	18
1676	Melatonin affects the release of exosomes and tau-content in in vitro amyloid-beta toxicity model. Journal of Clinical Neuroscience, 2020, 73, 237-244.	0.8	18
1677	Neurophysiological alterations in the nucleus reuniens of a mouse model of Alzheimer's disease. Neurobiology of Aging, 2020, 88, 1-10.	1.5	5
1678	Rivastigmine modifies the Î±-secretase pathway and potentially early Alzheimerâ€™s disease. Translational Psychiatry, 2020, 10, 47.	2.4	44
1680	Acetylcholinesterase inhibitory activity and neuroprotection in vitro, molecular docking, and improved learning and memory functions of demethylcurcumin in scopolamine-induced amnesia ICR mice. Food and Function, 2020, 11, 2328-2338.	2.1	14
1681	5-Caffeoylquinic Acid Ameliorates Cognitive Decline and Reduces AÎ² Deposition by Modulating AÎ² Clearance Pathways in APP/PS2 Transgenic Mice. Nutrients, 2020, 12, 494.	1.7	34
1682	Uncertainty in Pharmacology. Boston Studies in the Philosophy and History of Science, 2020, , .	0.4	1
1683	Pharmacological effects of icariin. Advances in Pharmacology, 2020, 87, 179-203.	1.2	103
1684	Alzheimer's disease pathology in APOE transgenic mouse models: The Who, What, When, Where, Why, and How. Neurobiology of Disease, 2020, 139, 104811.	2.1	44
1685	Neurodegenerative pathways as targets for acquired epilepsy therapy development. Epilepsia Open, 2020, 5, 138-154.	1.3	33
1686	Baicalein protects PC12 cells from AÎ²25â€“35-induced cytotoxicity via inhibition of apoptosis and metabolic disorders. Life Sciences, 2020, 248, 117471.	2.0	30
1687	Validation of a novel and accurate ApoE4 assay for automated chemistry analyzers. Scientific Reports, 2020, 10, 2138.	1.6	5
1688	Transition metal complexes as imaging or therapeutic agents for neurodegenerative diseases. Journal of Materials Chemistry B, 2020, 8, 4715-4725.	2.9	28
1689	Exercise Training Results in Lower Amyloid Plaque Load and Greater Cognitive Function in an Intensity Dependent Manner in the Tg2576 Mouse Model of Alzheimerâ€™s Disease. Brain Sciences, 2020, 10, 88.	1.1	10
1690	Aggregation Mechanism of Alzheimerâ€™s Amyloid Î²-Peptide Mediated by Î±-Strand/Î±-Sheet Structure. International Journal of Molecular Sciences, 2020, 21, 1094.	1.8	12
1691	Impact of A2T and D23N Mutations on Tetrameric AÎ²42 Barrel within a Dipalmitoylphosphatidylcholine Lipid Bilayer Membrane by Replica Exchange Molecular Dynamics. Journal of Physical Chemistry B, 2020, 124, 1175-1182.	1.2	18
1692	FMN reduces Amyloid-Î² toxicity in yeast by regulating redox status and cellular metabolism. Nature Communications, 2020, 11, 867.	5.8	50

#	Article	IF	Citations
1693	Diphtheria toxoid nanoparticles improve learning and memory impairment in animal model of Alzheimerâ€™s disease. Pharmacological Reports, 2020, 72, 814-826.	1.5	8
1694	Central and Peripheral Metabolic Defects Contribute to the Pathogenesis of Alzheimer's Disease: Targeting Mitochondria for Diagnosis and Prevention. Antioxidants and Redox Signaling, 2020, 32, 1188-1236.	2.5	61
1695	Targeting Hsc70-based autophagy to eliminate amyloid Î² oligomers. Biochemical and Biophysical Research Communications, 2020, 524, 923-928.	1.0	29
1696	Plasma levels of Interleukin 18 but not amyloid-Î² or Tau are elevated in female depressive patients. Comprehensive Psychiatry, 2020, 97, 152159.	1.5	7
1697	Elucidating the Effect of Static Electric Field on Amyloid Beta 1â€“42 Supramolecular Assembly. Journal of Molecular Graphics and Modelling, 2020, 96, 107535.	1.3	14
1698	Stability of AÎ²11â€“40 Trimers with Parallel and Antiparallel Î²-Sheet Organizations in a Membrane-Mimicking Environment by Replica Exchange Molecular Dynamics Simulation. Journal of Physical Chemistry B, 2020, 124, 617-626.	1.2	21
1699	Î²-amyloid redirects norepinephrine signaling to activate the pathogenic GSK3Î²/tau cascade. Science Translational Medicine, 2020, 12, .	5.8	86
1700	Resistance Exercise Decreases Amyloid Load and Modulates Inflammatory Responses in the APP/PS1 Mouse Model for Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2020, 73, 1525-1539.	1.2	25
1701	Clinical trials of new drugs for Alzheimer disease. Journal of Biomedical Science, 2020, 27, 18.	2.6	453
1702	Photo-controlled delivery of very long chain fatty acids to cell membranes and modulation of membrane protein function. Biochimica Et Biophysica Acta - Biomembranes, 2020, 1862, 183200.	1.4	8
1703	Making sense out of missense mutations: Mechanistic dissection of Notch receptors through structureâ€function studies in Drosophila. Development Growth and Differentiation, 2020, 62, 15-34.	0.6	14
1704	Biological evaluation and interaction mechanism of beta-site APP cleaving enzyme 1 inhibitory pentapeptide from egg albumin. Food Science and Human Wellness, 2020, 9, 162-167.	2.2	9
1705	Near-Infrared Responsive Dopamine/Melatonin-Derived Nanocomposites Abrogating in Situ Amyloid Î² Nucleation, Propagation, and Ameliorate Neuronal Functions. ACS Applied Materials & Interfaces, 2020, 12, 5658-5670.	4.0	19
1706	â€œAmyloidâ€beta accumulation cycleâ€•as a prevention and/or therapy target for Alzheimer's disease. Aging Cell, 2020, 19, e13109.	3.0	37
1707	Differences Between Human and Murine Tau at the N-terminal End. Frontiers in Aging Neuroscience, 2020, 12, 11.	1.7	38
1708	Kv1.3 Channel as a Key Therapeutic Target for Neuroinflammatory Diseases: State of the Art and Beyond. Frontiers in Neuroscience, 2019, 13, 1393.	1.4	61
1709	Augmentation of Bri2 molecular chaperone activity against amyloid-Î² reduces neurotoxicity in mouse hippocampus in vitro. Communications Biology, 2020, 3, 32.	2.0	42
1710	Intracerebral seeding of amyloid-Î² and tau pathology in mice: Factors underlying prion-like spreading and comparisons with Î±-synuclein. Neuroscience and Biobehavioral Reviews, 2020, 112, 1-27.	2.9	31

#	Article	IF	Citations
1711	Functional brain architecture is associated with the rate of tau accumulation in Alzheimerâ€™s disease. Nature Communications, 2020, 11, 347.	5.8	185
1712	Reduced Influence of apoE on AÎ²43 Aggregation and Reduced Vascular AÎ²43 Toxicity as Compared with AÎ²40 and AÎ²42. Molecular Neurobiology, 2020, 57, 2131-2141.	1.9	6
1713	Alterations of aqueous humor AÎ² levels in AÎ²-infused and transgenic mouse models of Alzheimer disease. PLoS ONE, 2020, 15, e0227618.	1.1	15
1714	An update on human astrocytes and their role in development and disease. Glia, 2020, 68, 685-704.	2.5	46
1715	Tau/AÎ² chimera peptides: Evaluating the dual function of metal coordination and membrane interaction in one sequence. Journal of Inorganic Biochemistry, 2020, 205, 110996.	1.5	7
1716	Neuroprotection of SAK3 on scopolamine-induced cholinergic dysfunction in human neuroblastoma SH-SY5Y cells. Cytotechnology, 2020, 72, 155-164.	0.7	4
1717	Renin-Angiotensin System and Alzheimerâ€™s Disease Pathophysiology: From the Potential Interactions to Therapeutic Perspectives. Protein and Peptide Letters, 2020, 27, 484-511.	0.4	25
1718	Substrate interaction inhibits Î³-secretase production of amyloid-Î² peptides. Chemical Communications, 2020, 56, 2578-2581.	2.2	3
1719	Galectin 3â€“binding protein suppresses amyloid-Î² production by modulating Î²-cleavage of amyloid precursor protein. Journal of Biological Chemistry, 2020, 295, 3678-3691.	1.6	29
1720	Transthyretin Inhibits Primary and Secondary Nucleations of Amyloid-Î² Peptide Aggregation and Reduces the Toxicity of Its Oligomers. Biomacromolecules, 2020, 21, 1112-1125.	2.6	59
1721	Korean Red Ginseng Inhibits Amyloid-Î²-Induced Apoptosis and Nucling Expression in Human Neuronal Cells. Pharmacology, 2020, 105, 586-597.	0.9	10
1722	University College London/University of Gothenburg PhD course â€œBiomarkers in neurodegenerative diseasesâ€•2019â€”course organisation. Alzheimer's Research and Therapy, 2020, 12, 18.	3.0	0
1723	Alzheimerâ€™s Disease Genetics: Review of Novel Loci Associated with Disease. Current Genetic Medicine Reports, 2020, 8, 1-16.	1.9	20
1724	Insulin resistance and impaired lipid metabolism as a potential link between diabetes and Alzheimer's disease. Drug Development Research, 2020, 81, 194-205.	1.4	16
1725	Immunotherapies for Aging-Related Neurodegenerative Diseasesâ€”Emerging Perspectives and New Targets. Neurotherapeutics, 2020, 17, 935-954.	2.1	40
1726	Imaging biomarkers in neurodegeneration: current and future practices. Alzheimer's Research and Therapy, 2020, 12, 49.	3.0	96
1727	An Affibody Molecule Is Actively Transported into the Cerebrospinal Fluid via Binding to the Transferrin Receptor. International Journal of Molecular Sciences, 2020, 21, 2999.	1.8	12
1728	Amyloid Î²-protein and beyond: the path forward in Alzheimerâ€™s disease. Current Opinion in Neurobiology, 2020, 61, 116-124.	2.0	87

#	Article	IF	Citations
1729	Exploring the multifaceted neuroprotective actions of gallic acid: a review. International Journal of Food Properties, 2020, 23, 736-752.	1.3	47
1730	Plasma Amyloid Concentration in Alzheimerâ€™s Disease: Performance of a High-Throughput Amyloid Assay in Distinguishing Alzheimerâ€™s Disease Cases from Controls. Journal of Alzheimer's Disease, 2020, 74, 1285-1294.	1.2	20
1731	Dual Neutral Sphingomyelinase-2/Acetylcholinesterase Inhibitors for the Treatment of Alzheimerâ€™s Disease. ACS Chemical Biology, 2020, 15, 1671-1684.	1.6	17
1732	Current understanding of metal ions in the pathogenesis of Alzheimerâ€™s disease. Translational Neurodegeneration, 2020, 9, 10.	3.6	219
1733	Suvorexant ameliorates cognitive impairments and pathology in APP/PS1 transgenic mice. Neurobiology of Aging, 2020, 91, 66-75.	1.5	34
1734	N-Amino peptide scanning reveals inhibitors of AÎ²₄₂aggregation. RSC Advances, 2020, 10, 14331-14336.	1.7	8
1735	Assessing Reproducibility in Amyloid Î² Research: Impact of AÎ² Sources on Experimental Outcomes. ChemBioChem, 2020, 21, 2425-2430.	1.3	8
1736	Significant combination of AÎ² aggregation inhibitory and neuroprotective properties in silico, in vitro and in vivo by bis(propyl)-cognitin, a multifunctional anti-Alzheimerâ€™s agent. European Journal of Pharmacology, 2020, 876, 173065.	1.7	7
1737	Periphery-confined particulate systems for the management of neurodegenerative diseases and toxicity: Avoiding the blood-brain-barrier challenge. Journal of Controlled Release, 2020, 322, 286-299.	4.8	9
1738	Leveraging preclinical models for the development of Alzheimer disease therapeutics. Nature Reviews Drug Discovery, 2020, 19, 447-462.	21.5	73
1740	Design principles and fundamental understanding of biosensors for amyloid-Î² detection. Journal of Materials Chemistry B, 2020, 8, 6179-6196.	2.9	39
1741	Heparan Sulfate Proteoglycans Undergo Differential Expression Alterations in Alzheimer Disease Brains. Journal of Neuropathology and Experimental Neurology, 2020, 79, 474-483.	0.9	25
1742	What works and what does not work in Alzheimerâ€™s disease? From interventions on risk factors to antiâ€amyloid trials. Journal of Neurochemistry, 2020, 155, 120-136.	2.1	26
1743	Apolipoprotein E Facilitates Amyloid-Î² Oligomer-Induced Tau Phosphorylation. Journal of Alzheimer's Disease, 2020, 74, 521-534.	1.2	9
1744	Small heat shock proteins in neurodegenerative diseases. Cell Stress and Chaperones, 2020, 25, 679-699.	1.2	57
1745	Inhibition of formyl peptide receptors improves the outcome in a mouse model of Alzheimer disease. Journal of Neuroinflammation, 2020, 17, 131.	3.1	27
1746	Substrate recruitment by Î³-secretase. Seminars in Cell and Developmental Biology, 2020, 105, 54-63.	2.3	13
1747	Identification and Analysis of Components in Yizhi Granule and Cynomolgus Monkey Plasma after Oral Administration by UPLC/ESI-Q-TOF MS and Their Protective Effects on PC12 Cells. Journal of Analytical Methods in Chemistry, 2020, 2020, 1-14.	0.7	5

#	Article	IF	Citations
1748	Utility of spontaneous animal models of Alzheimerâ€™s disease in preclinical efficacy studies. Cell and Tissue Research, 2020, 380, 273-286.	1.5	10
1749	Successive cleavage of Î²-amyloid precursor protein by Î³-secretase. Seminars in Cell and Developmental Biology, 2020, 105, 64-74.	2.3	29
1750	Systems Pharmacology Approach to Investigate the Mechanism of Kai-Xin-San in Alzheimerâ€™s Disease. Frontiers in Pharmacology, 2020, 11, 381.	1.6	27
1751	Dysfunction of ABC transporters at the blood-brain barrier: Role in neurological disorders. , 2020, 213, 107554.		83
1752	2-Hydroxy-Docosahexaenoic Acid Is Converted Into Heneicosapentaenoic Acid via Î±-Oxidation: Implications for Alzheimerâ€™s Disease Therapy. Frontiers in Cell and Developmental Biology, 2020, 8, 164.	1.8	6
1753	Traditional Chinese Medicine: Role in Reducing Î²-Amyloid, Apoptosis, Autophagy, Neuroinflammation, Oxidative Stress, and Mitochondrial Dysfunction of Alzheimerâ€™s Disease. Frontiers in Pharmacology, 2020, 11, 497.	1.6	64
1754	Discovery of Chemicals to Either Clear or Indicate Amyloid Aggregates by Targeting Memoryâ€Impairing Antiâ€Parallel Aβ2 Dimers. Angewandte Chemie, 2020, 132, 11588-11597.	1.6	3
1755	Beta-Amyloid-Dependent miRNAs as Circulating Biomarkers in Alzheimerâ€™s Disease: a Preliminary Report. Journal of Molecular Neuroscience, 2020, 70, 871-877.	1.1	9
1756	Targeting the Wnt/Î²-catenin pathway in neurodegenerative diseases: recent approaches and current challenges. Expert Opinion on Drug Discovery, 2020, 15, 803-822.	2.5	37
1757	Mitochondrial and Nuclear DNA Oxidative Damage in Physiological and Pathological Aging. DNA and Cell Biology, 2020, 39, 1410-1420.	0.9	69
1758	Proteostasis Failure in Neurodegenerative Diseases: Focus on Oxidative Stress. Oxidative Medicine and Cellular Longevity, 2020, 2020, 1-21.	1.9	88
1759	Interaction between Angiotensin Receptor and Î²-Adrenergic Receptor Regulates the Production of Amyloid Î²-Protein. Biological and Pharmaceutical Bulletin, 2020, 43, 731-735.	0.6	1
1760	Oxidative Stress Targeting Amyloid Beta Accumulation and Clearance in Alzheimerâ€™s Disease: Insight into Pathological Mechanisms and Therapeutic Strategies. Current Psychopharmacology, 2020, 9, 22-42.	0.1	3
1761	Is Alzheimerâ€™s Disease a Liver Disease of the Brain?. Journal of Alzheimer's Disease, 2020, 75, 1-14.	1.2	58
1762	Amyloid-Î² in Alzheimerâ€™s Disease: A Study of Citation Practices of the Amyloid Cascade Hypothesis Between 1992 and 2019. Journal of Alzheimer's Disease, 2020, 74, 1309-1317.	1.2	15
1763	Low-Dose Phosphodiesterase III Inhibitor Reduces the Vascular Amyloid Burden in Amyloid-Î² Protein Precursor Transgenic Mice. International Journal of Molecular Sciences, 2020, 21, 2295.	1.8	6
1764	Oligomerization and Conformational Change Turn Monomeric Î²-Amyloid and Tau Proteins Toxic: Their Role in Alzheimerâ€™s Pathogenesis. Molecules, 2020, 25, 1659.	1.7	60
1765	Action of low doses of Aspirin in Inflammation and Oxidative Stress induced by aÎ²₁₋₄₂ on Astrocytes in primary culture. International Journal of Medical Sciences, 2020, 17, 834-843.	1.1	23

#	Article	IF	Citations
1766	Preclinical evaluation of [18F]D3FSP, deuterated AV-45, for imaging of Î²-amyloid in the brain. Nuclear Medicine and Biology, 2021, 92, 97-106.	0.3	7
1767	Biomarkers for Alzheimerâ€™s diseaseâ€”preparing for a new era of disease-modifying therapies. Molecular Psychiatry, 2021, 26, 296-308.	4.1	205
1768	Role of Microglia in Regulating Cholesterol and Tau Pathology in Alzheimerâ€™s Disease. Cellular and Molecular Neurobiology, 2021, 41, 651-668.	1.7	10
1769	Abelson Kinases Mediate the Depression of Spontaneous Synaptic Activity Induced by Amyloid Beta 1â€“42 Peptides. Cellular and Molecular Neurobiology, 2021, 41, 431-448.	1.7	5
1770	Feasibility of imaging amyloid in the brain using small-angle x-ray scattering. Biomedical Physics and Engineering Express, 2021, 7, 015008.	0.6	9
1771	Î´-Secretase-cleaved Tau stimulates AÎ² production via upregulating STAT1-BACE1 signaling in Alzheimerâ€™s disease. Molecular Psychiatry, 2021, 26, 586-603.	4.1	54
1772	Mitochondria and Calcium in Alzheimerâ€™s Disease: From Cell Signaling to Neuronal Cell Death. Trends in Neurosciences, 2021, 44, 136-151.	4.2	119
1773	Associations of the Rate of Change in Geriatric Depression Scale with Amyloid and Cerebral Glucose Metabolism in Cognitively Normal Older Adults: A Longitudinal Study. Journal of Affective Disorders, 2021, 280, 77-84.	2.0	10
1774	Multifunctional compounds for the treatment of Alzheimerâ€™s disease. Canadian Journal of Chemistry, 2021, 99, 1-9.	0.6	12
1775	From Venom to AChE Inhibitor: Design, Molecular Modeling, and Synthesis of a Peptidic Inhibitor of AChE. International Journal of Peptide Research and Therapeutics, 2021, 27, 463-474.	0.9	3
1776	Remodeling without destruction: non-proteolytic ubiquitin chains in neural function and brain disorders. Molecular Psychiatry, 2021, 26, 247-264.	4.1	17
1777	Intranasal delivery of mesenchymal stem cell secretome repairs the brain of Alzheimerâ€™s mice. Cell Death and Differentiation, 2021, 28, 203-218.	5.0	63
1778	Roles of glutamate receptors in a novel in vitro model of early, comorbid cerebrovascular, and Alzheimerâ€™s diseases. Journal of Neurochemistry, 2021, 156, 539-552.	2.1	4
1779	Î²-amyloid pathology is not associated with depression in a large community sample autopsy study. Journal of Affective Disorders, 2021, 278, 372-381.	2.0	12
1780	Alzheimerâ€™s protection effect of A673T mutation may be driven by lower AÎ² oligomer binding affinity. Journal of Neurochemistry, 2021, 157, 1316-1330.	2.1	20
1781	The extended scope of neuroimaging and prospects in brain atrophy mitigation: A systematic review. Interdisciplinary Neurosurgery: Advanced Techniques and Case Management, 2021, 23, 100875.	0.2	2
1782	Retinal changes in Alzheimer's diseaseâ€” integrated prospects of imaging, functional and molecular advances. Progress in Retinal and Eye Research, 2021, 82, 100899.	7.3	71
1783	Identification of phytochemicals from North African plants for treating Alzheimerâ€™s diseases and of their molecular targets by in silico network pharmacology approach. Journal of Traditional and Complementary Medicine, 2021, 11, 268-278.	1.5	5

#	Article	IF	Citations
1784	Protofibrilâ€“Fibril Interactions Inhibit Amyloid Fibril Assembly by Obstructing Secondary Nucleation. Angewandte Chemie - International Edition, 2021, 60, 3016-3021.	7.2	21
1785	Selective autophagy as a therapeutic target for neurological diseases. Cellular and Molecular Life Sciences, 2021, 78, 1369-1392.	2.4	45
1786	Genistein attenuates amyloid-beta-induced cognitive impairment in rats by modulation of hippocampal synaptotoxicity and hyperphosphorylation of Tau. Journal of Nutritional Biochemistry, 2021, 87, 108525.	1.9	27
1787	Sigma ligands as potent inhibitors of AÎ² and AÎ²Os in neurons and promising therapeutic agents of Alzheimer's disease. Neuropharmacology, 2021, 190, 108342.	2.0	8
1788	miR-204-3p/Nox4 Mediates Memory Deficits in a Mouse Model of Alzheimerâ€™s Disease. Molecular Therapy, 2021, 29, 396-408.	3.7	43
1789	Prediction of Alzheimer's disease using multi-variants from a Chinese genome-wide association study. Brain, 2021, 144, 924-937.	3.7	30
1790	Early detection and personalized medicine: Future strategies against Alzheimer's disease. Progress in Molecular Biology and Translational Science, 2021, 177, 157-173.	0.9	9
1791	Modeling AÎ²42 Accumulation in Response to Herpes Simplex Virus 1 Infection: Two Dimensional or Three Dimensional?. Journal of Virology, 2021, 95, .	1.5	12
1792	Oral absorption enhancement of the amyloid-Î² oligomer eliminating compound RD2 by conjugation with folic acid. European Journal of Pharmaceutical Sciences, 2021, 156, 105581.	1.9	2
1793	Oxidative Damage and Antioxidant Response in Frontal Cortex of Demented and Nondemented Individuals with Alzheimer's Neuropathology. Journal of Neuroscience, 2021, 41, 538-554.	1.7	41
1794	Lipopolysaccharide-Induced Exosomal miR-146a Is Involved in Altered Expression of Alzheimerâ€™s Risk Genes Via Suppression of TLR4 Signaling. Journal of Molecular Neuroscience, 2021, 71, 1245-1255.	1.1	13
1795	The interaction of AÎ²42 peptide in monomer, oligomer or fibril forms with sphingomyelin/cholesterol/ganglioside bilayers. International Journal of Biological Macromolecules, 2021, 168, 611-619.	3.6	12
1796	ATP Impedes the Inhibitory Effect of Hsp90 on AÎ²40 Fibrillation. Journal of Molecular Biology, 2021, 433, 166717.	2.0	11
1797	Recent Insights on the Role of PPAR-Î²/Î´ in Neuroinflammation and Neurodegeneration, and Its Potential Target for Therapy. NeuroMolecular Medicine, 2021, 23, 86-98.	1.8	52
1798	Protective Activity of AÎ² on Cell Cultures (PC12 and THP-1 after Differentiation) Preincubated with Lipopolysaccharide (LPS). Molecular Neurobiology, 2021, 58, 1453-1464.	1.9	17
1799	Resveratrol confers neuroprotection against high-fat diet in a mouse model of Alzheimer's disease via modulation of proteolytic mechanisms. Journal of Nutritional Biochemistry, 2021, 89, 108569.	1.9	28
1800	Harpertrioate A, an A,B,D-seco-Limonoid with Promising Biological Activity against Alzheimerâ€™s Disease from Twigs of Harrisonia perforata (Blanco) Merr.. Organic Letters, 2021, 23, 262-267.	2.4	15
1801	Changes in the brain transcriptome after DNA AÎ²42 trimer immunization in a 3xTg-AD mouse model. Neurobiology of Disease, 2021, 148, 105221.	2.1	9

#	Article	IF	Citations
1802	Pulse-Chase Proteomics of the App Knockin Mouse Models of Alzheimerâ€™s Disease Reveals that Synaptic Dysfunction Originates in Presynaptic Terminals. Cell Systems, 2021, 12, 141-158.e9.	2.9	32
1803	2-Propargylamino-naphthoquinone derivatives as multipotent agents for the treatment of Alzheimerâ€™s disease. European Journal of Medicinal Chemistry, 2021, 211, 113112.	2.6	19
1804	Comparison of AÎ² (1â€“40, 1â€“28, 11â€“22, and 29â€“40) aggregation processes and inhibition of toxic species generated in early stages of aggregation by a water-soluble ruthenium complex. Journal of Inorganic Biochemistry, 2021, 215, 111314.	1.5	7
1805	The effects of antimony on Alzheimer's disease-like pathological changes in mice brain. Science of the Total Environment, 2021, 760, 143235.	3.9	15
1806	Glycogen Synthase Kinase 3Î²: A New Gold Rush in Anti-Alzheimerâ€™s Disease Multitarget Drug Discovery?. Journal of Medicinal Chemistry, 2021, 64, 26-41.	2.9	46
1807	18F-labeled 2-phenylbenzoheterocycles with chiral dihydroxyl side chains as Î²-amyloid imaging probes. Bioorganic and Medicinal Chemistry, 2021, 29, 115884.	1.4	3
1808	TDMQ20, a Specific Copper Chelator, Reduces Memory Impairments in Alzheimerâ€™s Disease Mouse Models. ACS Chemical Neuroscience, 2021, 12, 140-149.	1.7	26
1809	Singular cases of Alzheimerâ€™s disease disclose new and old genetic â€œacquaintancesâ€• Neurological Sciences, 2021, 42, 2021-2029.	0.9	4
1810	Alterations of GABA B receptors in the APP/PS1 mouse model of Alzheimer's disease. Neurobiology of Aging, 2021, 97, 129-143.	1.5	10
1811	Ligustilide alleviates neurotoxicity in <scp>SHâ€•SY5Y</scp> cells induced by AÎ²_{25â€•35} via regulating endoplasmic reticulum stress and autophagy. Phytotherapy Research, 2021, 35, 1572-1584.	2.8	7
1812	Critical thinking on amyloid-beta-targeted therapy: challenges and perspectives. Science China Life Sciences, 2021, 64, 926-937.	2.3	12
1813	Computational prediction and molecular mechanism of Î³-secretase modulators. European Journal of Pharmaceutical Sciences, 2021, 157, 105626.	1.9	6
1814	Identification of truncated Câ€•terminal fragments of the Alzheimerâ€™s disease amyloid protein precursor derived from sequential proteolytic pathways. Journal of Neurochemistry, 2021, 156, 943-956.	2.1	1
1815	Additional methodological considerations regarding optimization of the dose of intracerebroventricular streptozotocin A response to: â€œOptimization of intracerebroventricular streptozotocin dose for the induction of neuroinflammation and memory impairments in ratsâ€• by Ghosh et al., Metab Brain Dis 2020 July 21. Metabolic Brain Disease, 2021, 36, 97-102.	1.4	14
1816	Protofibrilâ€“Fibril Interactions Inhibit Amyloid Fibril Assembly by Obstructing Secondary Nucleation. Angewandte Chemie, 2021, 133, 3053-3058.	1.6	2
1817	Novel biomarkers in Alzheimerâ€™s disease using high resolution proteomics and metabolomics: miRNAS, proteins and metabolites. Critical Reviews in Clinical Laboratory Sciences, 2021, 58, 167-179.	2.7	9
1818	Membrane dynamics of Î³â€•secretase with the anterior pharynxâ€•defective 1B subunit. Journal of Cellular Biochemistry, 2021, 122, 69-85.	1.2	10
1819	Comparison between touchscreen operant chambers and water maze to detect early prefrontal dysfunction in mice. Genes, Brain and Behavior, 2021, 20, e12695.	1.1	10

#	Article	IF	Citations
1820	Novel Targets for Alzheimer's Disease: A View Beyond Amyloid. Annual Review of Medicine, 2021, 72, 15-28.	5.0	22
1821	Systems-based proteomics to resolve the biology of Alzheimerâ€™s disease beyond amyloid and tau. Neuropsychopharmacology, 2021, 46, 98-115.	2.8	70
1822	Alzheimerâ€™s disease neuropathology in the hippocampus and brainstem of people with obstructive sleep apnea. Sleep, 2021, 44, .	0.6	30
1823	Targeting increased levels of APP in Down syndrome: Posiphenâ€mediated reductions in APP and its products reverse endosomal phenotypes in the Ts65Dn mouse model. Alzheimer's and Dementia, 2021, 17, 271-292.	0.4	25
1824	Grey zone amyloid burden affects memory function: the SCIENCe project. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 747-756.	3.3	5
1825	Multi-Target Drug Candidates for Multifactorial Alzheimerâ€™s Disease: AChE and NMDAR as Molecular Targets. Molecular Neurobiology, 2021, 58, 281-303.	1.9	53
1826	Amyloid, tau and risk of Alzheimerâ€™s disease: a Mendelian randomization study. European Journal of Epidemiology, 2021, 36, 81-88.	2.5	19
1827	Vaccination with (1â€“11)E2 in alum efficiently induces an antibody response to Î²-amyloid without affecting brain Î²-amyloid load and microglia activation in 3xTg mice. Aging Clinical and Experimental Research, 2021, 33, 1383-1387.	1.4	3
1828	Hippo signaling: bridging the gap between cancer and neurodegenerative disorders. Neural Regeneration Research, 2021, 16, 643.	1.6	18
1829	Î²-Amyloid Orchestrates Factor XII and Platelet Activation Leading to Endothelial Dysfunction and Abnormal Fibrinolysis in Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2021, 35, 91-97.	0.6	3
1830	Degenerative Diseases of the CNS. , 2021, , 353-389.		0
1831	Conformation-specific perturbation of membrane dynamics by structurally distinct oligomers of Alzheimer's amyloid-Î² peptide. Physical Chemistry Chemical Physics, 2021, 23, 9686-9694.	1.3	9
1832	Probing Mechanisms and Therapeutic Potential of Î³-Secretase in Alzheimerâ€™s Disease. Molecules, 2021, 26, 388.	1.7	15
1833	Nanodelivery of oxiracetam enhances memory, functional recovery and induces neuroprotection following concussive head injury. Progress in Brain Research, 2021, 265, 139-230.	0.9	9
1834	Novel Phosphorylation-State Specific Antibodies Reveal Differential Deposition of Ser26 Phosphorylated AÎ² Species in a Mouse Model of Alzheimerâ€™s Disease. Frontiers in Molecular Neuroscience, 2020, 13, 619639.	1.4	7
1835	The Application of Omics Technologies in the Research of Neurotoxicology. Methods in Molecular Biology, 2021, 2326, 143-154.	0.4	0
1836	Comparison of Cerebrospinal Fluid Amyloidogenic Nanoplaques With Core Biomarkers of Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2020, 12, 608628.	1.7	3
1837	Progress in Metal-Organic Supramolecular System Based on Subcomponent Self-Assembly. Chinese Journal of Organic Chemistry, 2021, 41, 2261.	0.6	0

#	Article	IF	Citations
1838	3D Alzheimer's disease in a dish: Implications for drug discovery. , 2021, , 311-331.		1
1839	Calcium Signalling in Alzheimerâ€™s Disease: From Pathophysiological Regulation to Therapeutic Approaches. Cells, 2021, 10, 140.	1.8	6
1840	Amyloid and APOE Status of Screened Subjects in the Elenbecestat MissionAD Phase 3 Program. journal of prevention of Alzheimer's disease, The, 2021, 8, 1-6.	1.5	8
1841	Targeting Age-Related Neurodegenerative Diseases byÂAAV-Mediated Gene Therapy. Advances in Experimental Medicine and Biology, 2021, 1286, 213-223.	0.8	1
1842	Drug Discovery in CNS: Finding a Target for What?. , 2021, , 25-33.		0
1843	Rare genetic variants prioritize molecular pathways for semaphorin interactions in Alzheimerâ€™s disease patients. Biotechnology and Biotechnological Equipment, 2021, 35, 1256-1262.	0.5	3
1844	Changes of blood-brain-barrier function and transfer of amyloid beta in rats with collagen-induced arthritis. Journal of Neuroinflammation, 2021, 18, 35.	3.1	12
1845	Disruption of Endoplasmic Reticulum Proteostasis in Age-Related Nervous System Disorders. Progress in Molecular and Subcellular Biology, 2021, 59, 239-278.	0.9	2
1846	Screening of Synthetic Isoxazolone Derivative Role in Alzheimerâ€™s Disease: Computational and Pharmacological Approach. Neurochemical Research, 2021, 46, 905-920.	1.6	18
1847	Soluble amyloid beta-containing aggregates are present throughout the brain at early stages of Alzheimerâ€™s disease. Brain Communications, 2021, 3, fcab147.	1.5	32
1848	The C99 domain of the amyloid precursor protein resides in the disordered membrane phase. Journal of Biological Chemistry, 2021, 296, 100652.	1.6	9
1849	Is Î³-secretase a beneficial inactivating enzyme of the toxic APP C-terminal fragment C99?. Journal of Biological Chemistry, 2021, 296, 100489.	1.6	32
1850	A sensitivity analysis of a mathematical model for the synergistic interplay of amyloid beta and tau on the dynamics of Alzheimerâ€™s disease. Brain Multiphysics, 2021, 2, 100020.	0.8	11
1851	The Pathogenesis Mechanism, Structure Properties, Potential Drugs and Therapeutic Nanoparticles against the Small Oligomers of Amyloid-Î². Current Topics in Medicinal Chemistry, 2021, 21, 151-167.	1.0	5
1852	Klinik der Demenzen. , 2021, , 59-92.		0
1853	Alzheimer's disease neuropathology is exacerbated following traumatic brain injury. Neuroprotection by co-administration of nanowired mesenchymal stem cells and cerebrolysin with monoclonal antibodies to amyloid beta peptide. Progress in Brain Research, 2021, 265, 1-97.	0.9	8
1854	Spatiotemporal processing of neural cell adhesion molecules 1 and 2 by BACE1 inÂvivo. Journal of Biological Chemistry, 2021, 296, 100372.	1.6	13
1855	Selective coactivation of Î±7- and Î±4Î²2-nicotinic acetylcholine receptors reverses beta-amyloidâ€“induced synaptic dysfunction. Journal of Biological Chemistry, 2021, 296, 100402.	1.6	30

#	Article	IF	Citations
1856	Amyloid-PET imaging offers small improvements in predictions of future cognitive trajectories. NeuroImage: Clinical, 2021, 31, 102713.	1.4	6
1857	Longitudinal evaluation of a novel BChE PET tracer as an early in vivo biomarker in the brain of a mouse model for Alzheimer disease. Theranostics, 2021, 11, 6542-6559.	4.6	12
1858	Modeling the Self-navigation Behavior of Patients with Alzheimerâ€™s Disease in Virtual Reality. Communications in Computer and Information Science, 2021, , 121-136.	0.4	0
1859	Quantifying the dose-dependent impact of intracellular amyloid beta in a mathematical model of calcium regulation in xenopus oocyte. PLoS ONE, 2021, 16, e0246116.	1.1	8
1860	Mechanisms of Intranasal Deferoxamine in Neurodegenerative and Neurovascular Disease. Pharmaceuticals, 2021, 14, 95.	1.7	27
1861	Bioactive 3D structures of naturally occurring peptides and their application in drug design. Bioscience, Biotechnology and Biochemistry, 2021, 85, 24-32.	0.6	2
1862	Restoration of the reduced CLSP activity alleviates memory impairment in Alzheimer disease. Translational Psychiatry, 2021, 11, 44.	2.4	2
1863	Mendelian and Sporadic FTD: Disease Risk and Avenues from Genetics to Disease Pathways Through In Silico Modelling. Advances in Experimental Medicine and Biology, 2021, 1281, 283-296.	0.8	1
1864	Positron emission tomography imaging agents for evaluating the pathologic features of Alzheimer's disease and drug development. , 2021, , 367-412.		0
1865	Soluble Î²-amyloid impaired the GABA inhibition by mediating KCC2 in early APP/PS1 mice. BioScience Trends, 2021, 15, 330-340.	1.1	7
1866	Monoclonal Antibodies as Neurological Therapeutics. Pharmaceuticals, 2021, 14, 92.	1.7	35
1867	Association of naturally occurring antibodies to Î²-amyloid with cognitive decline and cerebral amyloidosis in Alzheimerâ€™s disease. Science Advances, 2021, 7, .	4.7	26
1869	A continuous-time mathematical model and discrete approximations for the aggregation of Î²-Amyloid. Journal of Biological Dynamics, 2021, 15, 109-136.	0.8	5
1870	Microvascular Alterations in Alzheimer's Disease. Frontiers in Cellular Neuroscience, 2020, 14, 618986.	1.8	41
1871	Defining the Neuropathological Aggresome across in Silico, in Vitro, and ex Vivo Experiments. Journal of Physical Chemistry B, 2021, 125, 1974-1996.	1.2	5
1872	Design of carboxylated single-walled carbon nanotubes as highly efficient inhibitors against AÎ²40 fibrillation based on the HyBER mechanism. Journal of Materials Chemistry B, 2021, 9, 6902-6914.	2.9	13
1873	Extracellular Vesicles in Premature Aging and Diseases in Adulthood Due to Developmental Exposures. , 2021, 12, 1516.		8
1874	Laboratory evolution of a sortase enzyme that modifies amyloid-Î² protein. Nature Chemical Biology, 2021, 17, 317-325.	3.9	34

#	Article	IF	Citations
1875	Acetylcholinesterase inhibitors and nanoparticles on Alzheimerâ€™s disease: a review. Journal of Nanoparticle Research, 2021, 23, 1.	0.8	3
1876	An integrated strategy using LC-MS/MS combined with in vivo microdialysis for the simultaneous determination of lignans of Schisandra chinensis (Turcz.) Baill. Fructus and endogenous neurotransmitters: application in pharmacokinetic and pharmacodynamic studies. Food and Function, 2021, 12, 8932-8945.	2.1	6
1877	Micro-Raman spectroscopy of lipid halo and dense-core amyloid plaques: aging process characterization in the Alzheimer's disease APPswePS1Î”E9 mouse model. Analyst, The, 2021, 146, 6014-6025.	1.7	4
1878	Association of AÎ² deposition and regional synaptic density in early Alzheimerâ€™s disease: a PET imaging study with [11C]UCB-J. Alzheimer's Research and Therapy, 2021, 13, 11.	3.0	53
1879	Molecular Simulations and Alzheimer×³s Disease. , 2021, , 54-70.		0
1882	The cellular machinery of post-endocytic APP trafficking in Alzheimer's disease: A future target for therapeutic intervention?. Progress in Molecular Biology and Translational Science, 2021, 177, 109-122.	0.9	3
1883	Retinal Optical Coherence Tomography Metrics Are Unchanged in Verubecestat Alzheimerâ€™s Disease Clinical Trial but Correlate with Baseline Regional Brain Atrophy. Journal of Alzheimer's Disease, 2021, 79, 275-287.	1.2	7
1884	Cholinergic neurodegeneration in Alzheimer disease mouse models. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2021, 182, 191-209.	1.0	12
1885	Management of Patients with Dementia: An Introduction. , 2021, , 1-18.		1
1886	RNA Modifications in Neurodegenerations. RNA Technologies, 2021, , 23-77.	0.2	1
1887	Presence of a mutation in PSEN1 or PSEN2 gene is associated with an impaired brain endothelial cell phenotype in vitro. Fluids and Barriers of the CNS, 2021, 18, 3.	2.4	25
1888	Spatial memory deficiency early in 6xTg Alzheimerâ€™s disease mouse model. Scientific Reports, 2021, 11, 1334.	1.6	24
1889	Targeting the APP-Mint2 Proteinâ€“Protein Interaction with a Peptide-Based Inhibitor Reduces Amyloid-Î² Formation. Journal of the American Chemical Society, 2021, 143, 891-901.	6.6	15
1890	The Membrane Interactions of Synuclein: Physiology and Pathology. Annual Review of Pathology: Mechanisms of Disease, 2021, 16, 465-485.	9.6	32
1891	Epigenetics of Alzheimerâ€™s Disease. Biomolecules, 2021, 11, 195.	1.8	74
1892	Structural details of amyloid Î² oligomers in complex with human prion protein as revealed by solid-state MAS NMR spectroscopy. Journal of Biological Chemistry, 2021, 296, 100499.	1.6	23
1893	Modification of amyloid-beta peptide aggregation via photoactivation of strained Ru(<scp>ii</scp>) polypyridyl complexes. Chemical Science, 2021, 12, 7510-7520.	3.7	15
1894	3D-visualization of amyloid-Î² oligomer interactions with lipid membranes by cryo-electron tomography. Chemical Science, 2021, 12, 6896-6907.	3.7	31

#	Article	IF	Citations
1895	Alzheimerâ€™s Diseaseâ€”Molecular Defect, Public Perceptions and Stigma in South Africa. , 2021, , 63-99.		1
1896	Chinese nutraceuticals and physical activity; their role in neurodegenerative tauopathies. Chinese Medicine, 2021, 16, 1.	1.6	24
1897	Tauroursodeoxycholic Acid Attenuates Diet-Induced and Age-Related Peripheral Endoplasmic Reticulum Stress and Cerebral Amyloid Pathology in a Mouse Model of Alzheimerâ€™s Disease. journal of prevention of Alzheimer's disease, The, 2021, 8, 1-12.	1.5	6
1898	Design, synthesis, and evaluation of 3,7-substituted coumarin derivatives as multifunctional Alzheimerâ€™s disease agents. Journal of Enzyme Inhibition and Medicinal Chemistry, 2021, 36, 1606-1620.	2.5	11
1899	Transcriptional downregulation of FAM3C/ILEI in the Alzheimerâ€™s brain. Human Molecular Genetics, 2021, 31, 122-132.	1.4	14
1900	Sex differences in microglia as a risk factor for Alzheimerâ€™s disease. , 2021, , 79-104.		1
1901	Ablating Adult Neural Stem Cells Improves Synaptic and Cognitive Functions in Alzheimer Models. Stem Cell Reports, 2021, 16, 89-105.	2.3	18
1902	Therapeutic Potential of Neu1 in Alzheimerâ€™s Disease Via the Immune System. American Journal of Alzheimer's Disease and Other Dementias, 2021, 36, 153331752199614.	0.9	10
1903	Modified Snake Î±-Neurotoxin Averts Î²-Amyloid Binding to Î±7 Nicotinic Acetylcholine Receptor and Reverses Cognitive Deficits in Alzheimerâ€™s Disease Mice. Molecular Neurobiology, 2021, 58, 2322-2341.	1.9	6
1905	Rationally Designed Bicyclic Peptides Prevent the Conversion of AÎ²42 Assemblies Into Fibrillar Structures. Frontiers in Neuroscience, 2021, 15, 623097.	1.4	6
1906	Quantifying misfolded protein oligomers as drug targets and biomarkers in Alzheimer and Parkinson diseases. Nature Reviews Chemistry, 2021, 5, 277-294.	13.8	56
1908	From Combinations to Single-Molecule Polypharmacologyâ€”Cromolyn-Ibuprofen Conjugates for Alzheimerâ€™s Disease. Molecules, 2021, 26, 1112.	1.7	6
1909	Correction of eIF2-dependent defects in brain protein synthesis, synaptic plasticity, and memory in mouse models of Alzheimerâ€™s disease. Science Signaling, 2021, 14, .	1.6	75
1910	Enrichment of Neurodegenerative Microglia Signature in Brain-Derived Extracellular Vesicles Isolated from Alzheimerâ€™s Disease Mouse Models. Journal of Proteome Research, 2021, 20, 1733-1743.	1.8	34
1911	Genetics of Alzheimerâ€™s disease. Wiener Medizinische Wochenschrift, 2021, 171, 249-256.	0.5	11
1912	Estrogen deficiency exacerbates learning and memory deficits associated with glucose metabolism disorder in APP/PS1 double transgenic female mice. Genes and Diseases, 2022, 9, 1315-1331.	1.5	7
1913	Isoliquiritigenin Confers Neuroprotection and Alleviates Amyloid-Î²42-Induced Neuroinflammation in Microglia by Regulating the Nrf2/NF-ÎºB Signaling. Frontiers in Neuroscience, 2021, 15, 638772.	1.4	22
1914	AÎ² Oligomers Dysregulate Calcium Homeostasis by Mechanosensitive Activation of AMPA and NMDA Receptors. ACS Chemical Neuroscience, 2021, 12, 766-781.	1.7	35

#	Article	IF	Citations
1915	Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis. BMJ, The, 2021, 372, n156.	3.0	113
1916	Amyloid Oligomers: A Joint Experimental/Computational Perspective on Alzheimerâ€™s Disease, Parkinsonâ€™s Disease, Type II Diabetes, and Amyotrophic Lateral Sclerosis. Chemical Reviews, 2021, 121, 2545-2647.	23.0	406
1917	Moving fluid biomarkers for Alzheimerâ€™s disease from research tools to routine clinical diagnostics. Molecular Neurodegeneration, 2021, 16, 10.	4.4	101
1918	Reactive astrocytes as treatment targets in Alzheimer's diseaseâ€”Systematic review of studies using the <scp>APPswePS1dE9</scp> mouse model. Glia, 2021, 69, 1852-1881.	2.5	37
1919	A Toxic Synergy between Aluminium and Amyloid Beta in Yeast. International Journal of Molecular Sciences, 2021, 22, 1835.	1.8	14
1920	Interleukin-1Î² mediates alterations in mitochondrial fusion/fission proteins and memory impairment induced by amyloid-Î² oligomers. Journal of Neuroinflammation, 2021, 18, 54.	3.1	40
1921	Dispersion as a waste-clearance mechanism in flow through penetrating perivascular spaces in the brain. Scientific Reports, 2021, 11, 4595.	1.6	20
1922	Structural analysis of the Î²â€sheet edge of peptide selfâ€assembly using a model protein. Proteins: Structure, Function and Bioinformatics, 2021, 89, 845-852.	1.5	3
1923	Cerebrospinal Fluid Biomarkers of Alzheimerâ€™s Disease: Current Evidence and Future Perspectives. Brain Sciences, 2021, 11, 215.	1.1	58
1924	Implication of Nicotinamide Adenine Dinucleotide Phosphate (NADPH) Oxidase and Its Inhibitors in Alzheimerâ€™s Disease Murine Models. Antioxidants, 2021, 10, 218.	2.2	15
1925	Compartmentalized Signaling in Aging and Neurodegeneration. Cells, 2021, 10, 464.	1.8	17
1926	Ameliorative effects of astaxanthin on brain tissues of alzheimerâ€™s disease-like model: cross talk between neuronal-specific microRNA-124 and related pathways. Molecular and Cellular Biochemistry, 2021, 476, 2233-2249.	1.4	17
1927	Mutual structural effects of unmodified and pyroglutamylated amyloid Î² peptides during aggregation. Journal of Peptide Science, 2021, 27, e3312.	0.8	3
1928	Oxidative Stress Boosts the Uptake of Cerium Oxide Nanoparticles by Changing Brain Endothelium Microvilli Pattern. Antioxidants, 2021, 10, 266.	2.2	7
1930	Imaging Techniques in Alzheimerâ€™s Disease: A Review of Applications in Early Diagnosis and Longitudinal Monitoring. International Journal of Molecular Sciences, 2021, 22, 2110.	1.8	79
1931	Metformin attenuates plaque-associated tau pathology and reduces amyloid-Î² burden in APP/PS1 mice. Alzheimer's Research and Therapy, 2021, 13, 40.	3.0	53
1932	Lysozyme Fibrils Alter the Mechanism of Insulin Amyloid Aggregation. International Journal of Molecular Sciences, 2021, 22, 1775.	1.8	7
1933	A survey on functional and cognitive assessment for diagnosing neurodegenerative disorders. Materials Today: Proceedings, 2021, , .	0.9	0

#	Article	IF	Citations
1934	Synthesis of Alkyl Bridgedâ€Trisâ€Î±â€Amino Acids as C₃â€Symmetric and Linear Linkers. European Journal of Organic Chemistry, 2021, 2021, 1370-1377.	1.2	3
1935	Entering a new era of quantifying glutamate clearance in health and disease. Journal of Neuroscience Research, 2021, 99, 1598-1617.	1.3	13
1937	Using stable isotope labeling to advance our understanding of Alzheimerâ€™s disease etiology and pathology. Journal of Neurochemistry, 2021, 159, 318-329.	2.1	7
1938	Antibody-Free Determinations of Low-Mass, Soluble Oligomers of AÎ²₄₂ and AÎ²₄₀ by Planar Bilayer Lipid Membrane-Based Electrochemical Biosensor. Analytical Chemistry, 2021, 93, 3611-3617.	3.2	18
1939	Smallest Secondary Nucleation Competent AÎ² Aggregates Probed by an ATP-Independent Molecular Chaperone Domain. Biochemistry, 2021, 60, 678-688.	1.2	17
1940	Flavonoids and Polyphenolic Compounds as Potential Talented Agents for the Treatment of Alzheimerâ€™s Disease and their Antioxidant Activities. Current Pharmaceutical Design, 2021, 27, 345-356.	0.9	21
1941	The role of microbial infection in the pathogenesis of Alzheimerâ€™s disease and the opportunity for protection by anti-microbial peptides. Critical Reviews in Microbiology, 2021, 47, 240-253.	2.7	19
1942	CAUSES OF ALZHEIMER'S DISEASE (Alz) AND POTENTIAL REMEDIES. , 2021, , 41-48.		0
1943	Computational modelling of potent Î²-secretase (BACE1) inhibitors towards Alzheimer's disease treatment. Biophysical Chemistry, 2021, 270, 106536.	1.5	14
1944	Ethics of Early Intervention in Alzheimerâ€™s Disease. AJOB Neuroscience, 2021, 12, 212-223.	0.6	16
1945	Evaluating Infectious, Neoplastic, Immunological, and Degenerative Diseases of the Central Nervous System with Cerebrospinal Fluid-Based Next-Generation Sequencing. Molecular Diagnosis and Therapy, 2021, 25, 207-229.	1.6	10
1946	New Trajectory of Clinical and Biomarker Changes in Sporadic Alzheimerâ€™s Disease. Cerebral Cortex, 2021, 31, 3363-3373.	1.6	4
1947	Alzheimer Disease Clinical Trials Targeting Amyloid. Neurologist, 2021, 26, 52-61.	0.4	19
1948	Insight Into Seeded Tau Fibril Growth From Molecular Dynamics Simulation of the Alzheimerâ€™s Disease Protofibril Core. Frontiers in Molecular Biosciences, 2021, 8, 624302.	1.6	17
1951	Animal and Cellular Models of Alzheimerâ€™s Disease: Progress, Promise, and Future Approaches. Neuroscientist, 2022, 28, 572-593.	2.6	11
1953	The role of clearance mechanisms in the kinetics of pathological protein aggregation involved in neurodegenerative diseases. Journal of Chemical Physics, 2021, 154, 125101.	1.2	14
1954	Advances in the development paradigm of biosampleâ€based biosensors for early ultrasensitive detection of alzheimerâ€™s disease. Journal of Nanobiotechnology, 2021, 19, 72.	4.2	18
1955	An Open Question: Is the A2A Adenosine Receptor a Novel Target for Alzheimerâ€™s Disease Treatment?. Frontiers in Pharmacology, 2021, 12, 652455.	1.6	15

#	Article	IF	Citations
1956	Exploring the origins of nucleation. ELife, 2021, 10, .	2.8	0
1957	Evaluation of Fluorinated Cromolyn Derivatives as Potential Therapeutics for Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2021, 80, 775-786.	1.2	6
1958	Can blood amyloid levels be used as a biomarker for Alzheimerâ€™s disease?. Brain Science Advances, 2021, 7, 17-25.	0.3	4
1959	Chalcone and its analogs: Therapeutic and diagnostic applications in Alzheimerâ€™s disease. Bioorganic Chemistry, 2021, 108, 104681.	2.0	71
1960	Deep Brain Stimulation for Alzheimer's Disease: Stimulation Parameters and Potential Mechanisms of Action. Frontiers in Aging Neuroscience, 2021, 13, 619543.	1.7	39
1961	Onset of Preclinical Alzheimer Disease in Monozygotic Twins. Annals of Neurology, 2021, 89, 987-1000.	2.8	20
1963	The PKR/P38/RIPK1 Signaling Pathway as a Therapeutic Target in Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2021, 22, 3136.	1.8	17
1964	Linalool Alleviates AÎ²42-Induced Neurodegeneration via Suppressing ROS Production and Inflammation in Fly and Rat Models of Alzheimerâ€™s Disease. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-10.	1.9	27
1965	Cathepsin D: A Candidate Link between Amyloid ?-protein and Tauopathy in Alzheimer Disease. , 2021, 2, .		3
1966	Practical recommendations for timely, accurate diagnosis of symptomatic Alzheimerâ€™s disease (MCI) Tj ETQq1 1 0.784314 rgBT /Ove	2.7	77
1967	Plasmonic Nanoparticles as Optical Sensing Probes for the Detection of Alzheimerâ€™s Disease. Sensors, 2021, 21, 2067.	2.1	19
1968	Astrocytes in Alzheimerâ€™s Disease: Pathological Significance and Molecular Pathways. Cells, 2021, 10, 540.	1.8	62
1969	Urea titration of a lipase from Pseudomonas sp. reveals four different conformational states, with a stable partially folded state explaining its high aggregation propensity. International Journal of Biological Macromolecules, 2021, 174, 32-41.	3.6	5
1970	Ferulic Acid Ameliorates Alzheimer's Disease-like Pathology and Repairs Cognitive Decline by Preventing Capillary Hypofunction in APP/PS1 Mice. Neurotherapeutics, 2021, 18, 1064-1080.	2.1	29
1971	TUFM is involved in Alzheimerâ€™s diseaseâ€like pathologies that are associated with ROS. FASEB Journal, 2021, 35, e21445.	0.2	10
1972	Fluorine-19 Magnetic Resonance Imaging for Detection of Amyloid Î² Oligomers Using a Keto Form of Curcumin Derivative in a Mouse Model of Alzheimerâ€™s Disease. Molecules, 2021, 26, 1362.	1.7	10
1973	Racemization in Post-Translational Modifications Relevance to Protein Aging, Aggregation and Neurodegeneration: Tip of the Iceberg. Symmetry, 2021, 13, 455.	1.1	9
1974	Genetic Approaches Using Zebrafish to Study the Microbiotaâ€“Gutâ€“Brain Axis in Neurological Disorders. Cells, 2021, 10, 566.	1.8	26

#	Article	IF	Citations
1975	Liver X Receptor Activation with an Intranasal Polymer Therapeutic Prevents Cognitive Decline without Altering Lipid Levels. ACS Nano, 2021, 15, 4678-4687.	7.3	17
1976	Polymorphic SERPINA3 prolongs oligomeric state of amyloid beta. PLoS ONE, 2021, 16, e0248027.	1.1	7
1977	Accelerating Alzheimerâ€™s disease drug discovery and development: whatâ€™s the way forward?. Expert Opinion on Drug Discovery, 2021, 16, 727-735.	2.5	9
1978	Defining the mechanism of PDI interaction with disulfide-free amyloidogenic proteins: Implications for exogenous protein expression and neurodegenerative disease. International Journal of Biological Macromolecules, 2021, 174, 175-184.	3.6	5
1979	Anti-tuberculotic thionamide antibiotics show antioxidative and neuronal cytoprotective nature by inhibiting amyloid formation in human insulin and amyloid Î²-42. Journal of Molecular Liquids, 2021, 326, 115396.	2.3	6
1980	Viral Involvement in Alzheimerâ€™s Disease. ACS Chemical Neuroscience, 2021, 12, 1049-1060.	1.7	38
1981	Mitophagy impairment in neurodegenerative diseases: Pathogenesis and therapeutic interventions. Mitochondrion, 2021, 57, 270-293.	1.6	17
1982	Keto form of curcumin derivatives strongly binds to AÎ² oligomers but not fibrils. Biomaterials, 2021, 270, 120686.	5.7	21
1983	Phenotyping Neuropsychiatric Symptoms Profiles of Alzheimerâ€™s Disease Using Cluster Analysis on EEG Power. Frontiers in Aging Neuroscience, 2021, 13, 623930.	1.7	4
1984	18Fâ€“THKâ€“5351, Fluorodeoxyglucose, and Florbetaben PET Images in Atypical Alzheimerâ€™s Disease: A Pictorial Insight into Disease Pathophysiology. Brain Sciences, 2021, 11, 465.	1.1	2
1985	Reward motivation and cognitive flexibility in tau null-mutation mice. Neurobiology of Aging, 2021, 100, 106-117.	1.5	1
1986	Artemisinin-treatment in pre-symptomatic APP-PS1 mice increases gephyrin phosphorylation at Ser270: a modification regulating postsynaptic GABA_AR density. Biological Chemistry, 2022, 403, 73-87.	1.2	4
1987	The aging endothelium. Vascular Biology (Bristol, England), 2021, 3, R35-R47.	1.2	20
1988	Bifidobacterium Lactis Probio-M8 regulates gut microbiota to alleviate Alzheimerâ€™s disease in the APP/PS1 mouse model. European Journal of Nutrition, 2021, 60, 3757-3769.	1.8	37
1989	Multi-target inhibition ability of neohesperidin dictates its neuroprotective activity: Implication in Alzheimer's disease therapeutics. International Journal of Biological Macromolecules, 2021, 176, 315-324.	3.6	13
1990	Combating deleterious phase transitions in neurodegenerative disease. Biochimica Et Biophysica Acta - Molecular Cell Research, 2021, 1868, 118984.	1.9	52
1991	Trem2 restrains the enhancement of tau accumulation and neurodegeneration by Î²-amyloid pathology. Neuron, 2021, 109, 1283-1301.e6.	3.8	137
1992	Peripheral Markers of Vascular Endothelial Dysfunction Show Independent but Additive Relationships with Brain-Based Biomarkers in Association with Functional Impairment in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2021, 80, 1553-1565.	1.2	16

#	Article	IF	Citations
1995	Unraveling the Speciation of Î²-Amyloid Peptides during the Aggregation Process by Taylor Dispersion Analysis. Analytical Chemistry, 2021, 93, 6523-6533.	3.2	19
1996	Recent advances in pre-clinical diagnosis of Alzheimerâ€™s disease. Metabolic Brain Disease, 2021, , 1.	1.4	3
1997	The Role of Chronic Infection in Alzheimerâ€™s Disease: Instigators, Co-conspirators, or Bystanders?. Current Clinical Microbiology Reports, 2021, 8, 199-212.	1.8	11
1998	Insoluble Vascular Amyloid Deposits Trigger Disruption of the Neurovascular Unit in Alzheimerâ€™s Disease Brains. International Journal of Molecular Sciences, 2021, 22, 3654.	1.8	16
1999	Elucidating the Neuropathologic Mechanisms of SARS-CoV-2 Infection. Frontiers in Neurology, 2021, 12, 660087.	1.1	46
2000	Neuropathology of the Brainstem to Mechanistically Understand and to Treat Alzheimerâ€™s Disease. Journal of Clinical Medicine, 2021, 10, 1555.	1.0	9
2001	Research progress on transient receptor potential melastatin 2 channel in nervous system diseases. Zhejiang Da Xue Xue Bao Yi Xue Ban = Journal of Zhejiang University Medical Sciences, 2021, 50, 267-276.	0.1	2
2002	Balancing potency and basicity by incorporating fluoropyridine moieties: Discovery of a 1-amino-3,4-dihydro-2,6-naphthyridine BACE1 inhibitor that affords robust and sustained central AÎ² reduction. European Journal of Medicinal Chemistry, 2021, 216, 113270.	2.6	7
2003	A Mechanism for the Inhibition of Tau Neurotoxicity: Studies with Artificial Membranes, Isolated Mitochondria, and Intact Cells. ACS Chemical Neuroscience, 2021, 12, 1563-1577.	1.7	1
2004	Neuroprotective Herbs for the Management of Alzheimerâ€™s Disease. Biomolecules, 2021, 11, 543.	1.8	79
2005	Cytokine signaling convergence regulates the microglial state transition in Alzheimerâ€™s disease. Cellular and Molecular Life Sciences, 2021, 78, 4703-4712.	2.4	23
2007	Amyloid Î² Clearance Is Disrupted by Depletion of Low-Density Lipoprotein Receptor-Related Protein 4 (LRP4) in Astrocytes. Journal of Neuroscience, 2021, 41, 3749-3751.	1.7	3
2008	Type II nuclear receptors with potential role in Alzheimer disease. Molecular Aspects of Medicine, 2021, 78, 100940.	2.7	5
2009	Photo-oxygenation by a biocompatible catalyst reduces amyloid-Î² levels in Alzheimerâ€™s disease mice. Brain, 2021, 144, 1884-1897.	3.7	28
2010	Synergistic Association between Plasma AÎ²_{1â€“42} and p-tau in Alzheimerâ€™s Disease but Not in Parkinsonâ€™s Disease or Frontotemporal Dementia. ACS Chemical Neuroscience, 2021, 12, 1376-1383.	1.7	9
2011	Alternative Targets to Fight Alzheimerâ€™s Disease: Focus on Astrocytes. Biomolecules, 2021, 11, 600.	1.8	16
2012	Targeting Adenosine Receptors in Neurological Diseases. Cellular Reprogramming, 2021, 23, 57-72.	0.5	10
2013	SIRT1-Dependent Upregulation of BDNF in Human Microglia Challenged with AÎ²: An Early but Transient Response Rescued by Melatonin. Biomedicines, 2021, 9, 466.	1.4	16

#	Article	IF	Citations
2015	Phytochemical Differentiation of Saffron (Crocus sativus L.) by High Resolution Mass Spectrometry Metabolomic Studies. Molecules, 2021, 26, 2180.	1.7	11
2016	Identification of highest neurotoxic amyloid-Î² plaque type showing reduced contact with astrocytes. Biochemical and Biophysical Research Communications, 2021, 549, 67-74.	1.0	4
2017	Phenothiazine-Tacrine Heterodimers: Pursuing Multitarget Directed Approach in Alzheimerâ€™s Disease. ACS Chemical Neuroscience, 2021, 12, 1698-1715.	1.7	16
2018	Bridging Scales in Alzheimer's Disease: Biological Framework for Brain Simulation With The Virtual Brain. Frontiers in Neuroinformatics, 2021, 15, 630172.	1.3	20
2019	Amyloid-Mediated Mechanisms of Membrane Disruption. Biophysica, 2021, 1, 137-156.	0.6	14
2020	Alzheimerâ€™s Disease: New Concepts on the Role of Autoimmunity and NLRP3 Inflammasome in the Pathogenesis of the Disease. Current Neuropharmacology, 2021, 19, 498-512.	1.4	16
2021	Anti-Alzheimerâ€™s Molecules Derived from Marine Life: Understanding Molecular Mechanisms and Therapeutic Potential. Marine Drugs, 2021, 19, 251.	2.2	31
2022	Increasing the confidence of 18F-Florbetaben PET interpretations: Machine learning quantitative approximation. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2022, 41, 153-163.	0.1	1
2023	Loss of TREM2 facilitates tau accumulation, spreading, and brain atrophy, but only in the presence of amyloid pathology. Neuron, 2021, 109, 1243-1245.	3.8	9
2024	Haemodynamic impairment along the Alzheimerâ€™s disease continuum. European Journal of Neurology, 2021, 28, 2168-2173.	1.7	7
2025	Sequential conformational changes in transmembrane domains of presenilin 1 in AÎ²42 downregulation. Journal of Biochemistry, 2021, 170, 215-227.	0.9	2
2026	Aluminum and Tau in Neurofibrillary Tangles in Familial Alzheimerâ€™s Disease. Journal of Alzheimer's Disease Reports, 2021, 5, 283-294.	1.2	19
2027	Defining the Landscape of the Pauling-Corey Rippled Sheet: An Orphaned Motif Finding New Homes. Accounts of Chemical Research, 2021, 54, 2488-2501.	7.6	21
2028	Upregulation of Cortical A2A Adenosine Receptors Is Reflected in Platelets of Patients with Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2021, 80, 1105-1117.	1.2	21
2029	A review on Î±-mangostin as a potential multi-target-directed ligand for Alzheimer's disease. European Journal of Pharmacology, 2021, 897, 173950.	1.7	19
2030	Near-Infrared-Active Copper Molybdenum Sulfide Nanocubes for Phonon-Mediated Clearance of Alzheimerâ€™s Î²-Amyloid Aggregates. ACS Applied Materials & Interfaces, 2021, 13, 18581-18593.	4.0	19
2031	A Comprehensive Machine Learning Framework for the Exact Prediction of the Age of Onset in Familial and Sporadic Alzheimerâ€™s Disease. Diagnostics, 2021, 11, 887.	1.3	2
2032	P2X7 receptors in the central nervous system. Biochemical Pharmacology, 2021, 187, 114472.	2.0	14

#	Article	IF	Citations
2033	Hypothesis: JNK signaling is a therapeutic target of neurodegenerative diseases. Alzheimer's and Dementia, 2022, 18, 152-158.	0.4	22
2034	Increased hippocampal excitability in miR-324-null mice. Scientific Reports, 2021, 11, 10452.	1.6	10
2035	Neuronal loss and microgliosis are restricted to the core of AÎ² deposits in mouse models of Alzheimer's disease. Aging Cell, 2021, 20, e13380.	3.0	16
2036	Astrocytes and Adenosine A2A Receptors: Active Players in Alzheimerâ€™s Disease. Frontiers in Neuroscience, 2021, 15, 666710.	1.4	19
2037	The application of multifunctional nanomaterials in Alzheimerâ€™s disease: A potential theranostics strategy. Biomedicine and Pharmacotherapy, 2021, 137, 111360.	2.5	15
2038	Neuroinflammation in Alzheimerâ€™s Disease. Biomedicines, 2021, 9, 524.	1.4	120
2039	Preventing neurodegenerative disease. Brain, 2021, 144, 1279-1280.	3.7	6
2040	Repurposing beta-3 adrenergic receptor agonists for Alzheimerâ€™s disease: beneficial effects in a mouse model. Alzheimer's Research and Therapy, 2021, 13, 103.	3.0	17
2041	Systematic in silico analysis of clinically tested drugs for reducing amyloidâ€beta plaque accumulation in Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, 1487-1498.	0.4	22
2042	Some Candidate Drugs for Pharmacotherapy of Alzheimerâ€™s Disease. Pharmaceuticals, 2021, 14, 458.	1.7	18
2044	Postâ€transcriptional regulation of Î±7 nAChR expression by miRâ€98â€5p modulates cognition and neuroinflammation in an animal model of Alzheimer's disease. FASEB Journal, 2021, 35, e21658.	0.2	7
2045	The role of alpha-helix on the structure-targeting drug design of amyloidogenic proteins. Chemistry and Physics of Lipids, 2021, 236, 105061.	1.5	7
2046	Luminescent lanthanide complexes for reactive oxygen species biosensing and possible application in Alzheimerâ€™s diseases. FEBS Journal, 2022, 289, 2516-2539.	2.2	12
2047	When Good Kinases Go Rogue: GSK3, p38 MAPK and CDKs as Therapeutic Targets for Alzheimerâ€™s and Huntingtonâ€™s Disease. International Journal of Molecular Sciences, 2021, 22, 5911.	1.8	36
2048	Towards developing a rhesus monkey model of early Alzheimer's disease focusing on women's health. American Journal of Primatology, 2021, 83, e23289.	0.8	8
2049	Cerebrospinal Fluid C18 Ceramide Associates with Markers of Alzheimerâ€™s Disease and Inflammation at the Pre- and Early Stages of Dementia. Journal of Alzheimer's Disease, 2021, 81, 231-244.	1.2	19
2050	In vivo brain imaging of mitochondrial Ca2+ in neurodegenerative diseases with multiphoton microscopy. Biochimica Et Biophysica Acta - Molecular Cell Research, 2021, 1868, 118998.	1.9	8
2051	Donanemab in Early Alzheimerâ€™s Disease. New England Journal of Medicine, 2021, 384, 1691-1704.	13.9	633

#	Article	IF	Citations
2052	Insights into the cross-amyloid aggregation of AÎ²40 and its N-terminal truncated peptide AÎ²11-40 affected by epigallocatechin gallate. Chinese Journal of Chemical Engineering, 2022, 45, 284-293.	1.7	4
2053	Nanodroplet Oligomers (NanDOs) of AÎ²40. Biochemistry, 2021, 60, 2691-2703.	1.2	4
2054	Polyphenol-Peptide Interactions in Mitigation of Alzheimerâ€™s Disease: Role of Biosurface-Induced Aggregation. Journal of Alzheimer's Disease, 2021, 81, 33-55.	1.2	4
2055	Bacterial sepsis increases hippocampal fibrillar amyloid plaque load and neuroinflammation in a mouse model of Alzheimer's disease. Neurobiology of Disease, 2021, 152, 105292.	2.1	21
2056	AÎ²43 aggregates exhibit enhanced prion-like seeding activity in mice. Acta Neuropathologica Communications, 2021, 9, 83.	2.4	14
2057	Exploring the Impact of Glyoxal Glycation on Î²-Amyloid Peptide (AÎ²) Aggregation in Alzheimerâ€™s Disease. Journal of Physical Chemistry B, 2021, 125, 5559-5571.	1.2	6
2058	Bladder Cancer Immunotherapy by BCG Is Associated with a Significantly Reduced Risk of Alzheimerâ€™s Disease and Parkinsonâ€™s Disease. Vaccines, 2021, 9, 491.	2.1	37
2059	Structural Studies Providing Insights into Production and Conformational Behavior of Amyloid-Î² Peptide Associated with Alzheimerâ€™s Disease Development. Molecules, 2021, 26, 2897.	1.7	15
2060	Helix-coil transition and conformational deformity in AÎ²₄₂-monomer: a case study using the Zn²⁺ cation. Journal of Biomolecular Structure and Dynamics, 2022, 40, 8949-8960.	2.0	1
2061	Azetidine-Bearing Non-Ribosomal Peptides, Bonnevillamides D and E, Isolated from a Carrion Beetle-Associated Actinomycete. Journal of Organic Chemistry, 2021, 86, 11149-11159.	1.7	10
2062	Calcium Dyshomeostasis in Alzheimerâ€™s Disease Pathogenesis. International Journal of Molecular Sciences, 2021, 22, 4914.	1.8	76
2063	Recent Progress in the Drug Development for the Treatment of Alzheimerâ€™s Disease Especially on Inhibition of Amyloid-peptide Aggregation. Mini-Reviews in Medicinal Chemistry, 2021, 21, 969-990.	1.1	6
2064	Dietary cis-9, trans-11-conjugated linoleic acid reduces amyloid Î²-protein accumulation and upregulates anti-inflammatory cytokines in an Alzheimerâ€™s disease mouse model. Scientific Reports, 2021, 11, 9749.	1.6	9
2065	Cognitive Go/No-Go decision-making criteria in Alzheimerâ€™s disease drug development. Drug Discovery Today, 2021, 26, 1330-1336.	3.2	3
2066	Gambir catechins modulates amyloid-Î² concentration in cerebrospinal fluid of Alzheimerâ€™s model rat. IOP Conference Series: Earth and Environmental Science, 2021, 741, 012068.	0.2	0
2067	Systemic Actions of SGLT2 Inhibition on Chronic mTOR Activation as a Shared Pathogenic Mechanism between Alzheimerâ€™s Disease and Diabetes. Biomedicines, 2021, 9, 576.	1.4	18
2068	The interplay between lipid and AÎ² amyloid homeostasis in Alzheimerâ€™s Disease: risk factors and therapeutic opportunities. Chemistry and Physics of Lipids, 2021, 236, 105072.	1.5	16
2070	Modulation of Î³-Secretase Activity by a Carborane-Based Flurbiprofen Analogue. Molecules, 2021, 26, 2843.	1.7	10

#	Article	IF	Citations
2071	Synchrotron X-ray Fluorescence and FTIR Signatures for Amyloid Fibrillary and Nonfibrillary Plaques. ACS Chemical Neuroscience, 2021, 12, 1961-1971.	1.7	11
2072	Inhibitory Effects of Sulfated Polysaccharides from the Sea CucumberCucumaria Frondosaagainst AÎ²40 Aggregation and Cytotoxicity. ACS Chemical Neuroscience, 2021, 12, 1854-1859.	1.7	9
2073	Construction of Long Noncoding RNA-Associated ceRNA Networks Reveals Potential Biomarkers in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2021, 82, 169-183.	1.2	11
2074	Alzheimer and Purinergic Signaling: Just a Matter of Inflammation?. Cells, 2021, 10, 1267.	1.8	15
2075	Upregulation of APP endocytosis by neuronal aging drives amyloid-dependent synapse loss. Journal of Cell Science, 2021, 134, .	1.2	29
2076	Re-emphasizing early Alzheimerâ€™s disease pathology starting in select entorhinal neurons, with a special focus on mitophagy. Ageing Research Reviews, 2021, 67, 101307.	5.0	62
2077	Mutations in the COPI coatomer subunit Î±-COP induce release of AÎ²-42 and amyloid precursor protein intracellular domain and increase tau oligomerization and release. Neurobiology of Aging, 2021, 101, 57-69.	1.5	6
2078	Exploiting formyl peptide receptor 2 to promote microglial resolution: a new approach to Alzheimerâ€™s disease treatment. FEBS Journal, 2022, 289, 1801-1822.	2.2	6
2079	Differential Influence of Amyloid-Î² on the Kinetics of Dopamine Release in the Dorsal and Ventral Striatum of Rats. Neurotoxicity Research, 2021, 39, 1285-1292.	1.3	3
2080	Hydrogen Sulfide Ameliorates Lipopolysaccharide-Induced Memory Impairment in Mice by Reducing Apoptosis, Oxidative, and Inflammatory Effects. Neurotoxicity Research, 2021, 39, 1310-1322.	1.3	14
2081	Inflammasome NLRP3 Potentially Links Obesity-Associated Low-Grade Systemic Inflammation and Insulin Resistance with Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2021, 22, 5603.	1.8	25
2083	MIND diet and cognitive performance in older adults: a systematic review. Critical Reviews in Food Science and Nutrition, 2022, 62, 8059-8077.	5.4	45
2084	Mediterranean Diet, Alzheimer Disease Biomarkers, and Brain Atrophy in Old Age. Neurology, 2021, 96, .	1.5	72
2085	Modeling Amyloid Aggregation Kinetics: A Case Study with Sup35NM. Journal of Physical Chemistry B, 2021, 125, 4955-4963.	1.2	3
2086	Misfolding and Self-Assembly Dynamics of Microtubule-Binding Repeats of the Alzheimer-Related Protein Tau. Journal of Chemical Information and Modeling, 2021, 61, 2916-2925.	2.5	24
2087	Therapeutic efficacy of novel memantine nitrate MNâ€08 in animal models of Alzheimerâ€™s disease. Aging Cell, 2021, 20, e13371.	3.0	11
2088	Neuronal Hyperexcitability in APPSWE/PS1dE9 Mouse Models of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2021, 81, 855-869.	1.2	14
2089	Neurotrophins and Neurotrophic Therapy (Based on the Cerebrolysin Model) in the Treatment of Elderly Patients with Cognitive Disorders and Depression. Part 1. Psychiatry, 2021, 19, 87-103.	0.2	2

#	Article	IF	Citations
2090	Peptides Derived from Growth Factors to Treat Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2021, 22, 6071.	1.8	10
2091	Molecular dynamics study of water channels in natural and synthetic amyloid-Î² fibrils. Journal of Chemical Physics, 2021, 154, 235102.	1.2	0
2092	Artesunate restores the levels of inhibitory synapse proteins and reduces amyloid-Î² and C-terminal fragments (CTFs) of the amyloid precursor protein in an AD-mouse model. Molecular and Cellular Neurosciences, 2021, 113, 103624.	1.0	9
2093	mTOR in Alzheimer disease and its earlier stages: Links to oxidative damage in the progression of this dementing disorder. Free Radical Biology and Medicine, 2021, 169, 382-396.	1.3	58
2094	Early Impairment in the Ventral Visual Pathway Can Predict Conversion to Dementia in Patients With Amyloid-negative Amnestic Mild Cognitive Impairment. Alzheimer Disease and Associated Disorders, 2021, Publish Ahead of Print, 298-305.	0.6	4
2095	A meta-analysis of cohort studies: Traumatic brain injury and risk of Alzheimerâ€™s Disease. PLoS ONE, 2021, 16, e0253206.	1.1	13
2096	An evaluation of the self-assembly enhancing properties of cell-derived hexameric amyloid-Î². Scientific Reports, 2021, 11, 11570.	1.6	9
2097	Emerging insights into the role of albumin with plasma exchange in Alzheimerâ€™s disease management. Transfusion and Apheresis Science, 2021, 60, 103164.	0.5	12
2098	Early Effects of the Soluble Amyloid Î²25-35 Peptide in Rat Cortical Neurons: Modulation of Signal Transduction Mediated by Adenosine and Group I Metabotropic Glutamate Receptors. International Journal of Molecular Sciences, 2021, 22, 6577.	1.8	9
2099	Amyloid-Î² Impairs Dendritic Trafficking of Golgi-Like Organelles in the Early Phase Preceding Neurite Atrophy: Rescue by Mirtazapine. Frontiers in Molecular Neuroscience, 2021, 14, 661728.	1.4	3
2100	Rutin prevents tau pathology and neuroinflammation in a mouse model of Alzheimerâ€™s disease. Journal of Neuroinflammation, 2021, 18, 131.	3.1	78
2101	MT5â€MMP controls APP and Î²â€CTF/C99 metabolism through proteolyticâ€dependent and â€independent mechanisms relevant for Alzheimer's disease. FASEB Journal, 2021, 35, e21727.	0.2	6
2102	Modifications of physical and functional integrity of the blood-brain barrier in an inducible mouse model of neurodegeneration. Neuropharmacology, 2021, 191, 108588.	2.0	3
2103	Reversible GABAergic dysfunction involved in hippocampal hyperactivity predicts early-stage Alzheimer disease in a mouse model. Alzheimer's Research and Therapy, 2021, 13, 114.	3.0	23
2104	The BIN1 rs744373 Alzheimer's disease risk SNP is associated with faster AÎ²â€associated tau accumulation and cognitive decline. Alzheimer's and Dementia, 2022, 18, 103-115.	0.4	24
2105	Plasma ILâ€12/IFNâ€Î³ axis predicts cognitive trajectories in cognitively unimpaired older adults. Alzheimer's and Dementia, 2022, 18, 645-653.	0.4	39
2106	Deletion of Dcf1 Reduces Amyloid-Î² Aggregation and Mitigates Memory Deficits. Journal of Alzheimer's Disease, 2021, 81, 1181-1194.	1.2	2
2107	Associations of cerebrospinal fluid amyloidogenic nanoplaques with cytokines in Alzheimerâ€™s disease. Translational Neurodegeneration, 2021, 10, 18.	3.6	6

#	Article	IF	Citations
2108	BACE1 controls synaptic function through modulating release of synaptic vesicles. Molecular Psychiatry, 2021, 26, 6394-6410.	4.1	20
2109	Polymorphic SERPINA3-R124C reduces pathogenesis of its wild type by shortening the lifetime of oligomeric AÎ². Bioscience, Biotechnology and Biochemistry, 2021, 85, 1861-1868.	0.6	1
2110	The p53/NF-kappaB-dependent induction of sestrin2 by amyloid-beta peptides exerts antioxidative actions in neurons. Free Radical Biology and Medicine, 2021, 169, 36-61.	1.3	5
2111	Chronic stress and <scp>A</scp>lzheimer's disease: theâ€‰interplay between the hypothalamicâ€“pituitaryâ€“adrenal axis, genetics and microglia. Biological Reviews, 2021, 96, 2209-2228.	4.7	37
2112	A New Highly Deuterated [¹⁸F]AV-45, [¹⁸F]D15FSP, for Imaging Î²-Amyloid Plaques in the Brain. ACS Medicinal Chemistry Letters, 2021, 12, 1086-1092.	1.3	10
2113	Nicking and fragmentation are responsible for Î±â€lactalbumin amyloid fibril formation at acidic <scp>pH</scp> and elevated temperature. Protein Science, 2021, 30, 1919-1934.	3.1	13
2114	Impact of Alcohol Abuse on Susceptibility to Rare Neurodegenerative Diseases. Frontiers in Molecular Biosciences, 2021, 8, 643273.	1.6	7
2116	CK1Î´-Derived Peptides as Novel Tools Inhibiting the Interactions between CK1Î´ and APP695 to Modulate the Pathogenic Metabolism of APP. International Journal of Molecular Sciences, 2021, 22, 6423.	1.8	1
2117	The neural economics of brain aging. Scientific Reports, 2021, 11, 12167.	1.6	0
2118	Effects of Vitamin B12 Deficiency on Amyloid-Î² Toxicity in Caenorhabditis elegans. Antioxidants, 2021, 10, 962.	2.2	12
2119	Synaptic Plasticity and Oscillations in Alzheimerâ€™s Disease: A Complex Picture of a Multifaceted Disease. Frontiers in Molecular Neuroscience, 2021, 14, 696476.	1.4	16
2120	Analysis of Age-Dependent Alterations in Excitability Properties of CA1 Pyramidal Neurons in an APPPS1 Model of Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2021, 13, 668948.	1.7	12
2121	TREM2-mediated activation of microglia breaks link between amyloid and tau. Lancet Neurology, The, 2021, 20, 416-417.	4.9	11
2122	In Vitro and In Vivo Efficacies of the Linear and the Cyclic Version of an All-d-Enantiomeric Peptide Developed for the Treatment of Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2021, 22, 6553.	1.8	6
2123	APP, PSEN1, and PSEN2 Variants in Alzheimerâ€™s Disease: Systematic Re-evaluation According to ACMG Guidelines. Frontiers in Aging Neuroscience, 2021, 13, 695808.	1.7	33
2124	Axonal Transport and Local Translation of mRNA in Neurodegenerative Diseases. Frontiers in Molecular Neuroscience, 2021, 14, 697973.	1.4	15
2126	Sanweidoukou decoction, a Chinese herbal formula, ameliorates Î²-amyloid protein-induced neuronal insult via modulating MAPK/NF-ÎºB signaling pathways: Studies in vivo and in vitro. Journal of Ethnopharmacology, 2021, 273, 114002.	2.0	12
2127	Towards development of a novel screening method for identifying Alzheimerâ€™s disease risk: Raman spectroscopy of blood serum and machine learning. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2021, 254, 119603.	2.0	17

#	Article	IF	Citations
2128	Subcommissural Organ-Spondin-Derived Peptide Restores Memory in a Mouse Model of Alzheimerâ€™s Disease. Frontiers in Neuroscience, 2021, 15, 651094.	1.4	6
2129	An Overview of Î²-Amyloid Cleaving Enzyme 1 (BACE1) in Alzheimer's Disease Therapy: Elucidating its Exosite-Binding Antibody and Allosteric Inhibitor. Current Medicinal Chemistry, 2022, 29, 114-135.	1.2	4
2130	Immunohistochemical evidence of P2X7R, P2X4R and CaMKK2 in pyramidal neurons of frontal cortex does not align with Alzheimer's disease. Experimental and Molecular Pathology, 2021, 120, 104636.	0.9	4
2131	Absolute Quantitation of Tryptophan-Containing Peptides and Amyloid Î²-Peptide Fragments by Coulometric Mass Spectrometry. Journal of the American Society for Mass Spectrometry, 2021, 32, 1771-1779.	1.2	4
2132	A Review on SARS-CoV-2-Induced Neuroinflammation, Neurodevelopmental Complications, and Recent Updates on the Vaccine Development. Molecular Neurobiology, 2021, 58, 4535-4563.	1.9	31
2133	Retinal Ganglion Cells Functional Changes in a Mouse Model of Alzheimerâ€™s Disease Are Linked with Neurotransmitter Alterations. Journal of Alzheimer's Disease, 2021, 82, S5-S18.	1.2	6
2134	Phospholipids of APOE lipoproteins activate microglia in an isoform-specific manner in preclinical models of Alzheimerâ€™s disease. Nature Communications, 2021, 12, 3416.	5.8	57
2135	Parp mutations protect from mitochondrial toxicity in Alzheimerâ€™s disease. Cell Death and Disease, 2021, 12, 651.	2.7	20
2136	Plasma amyloid-Î² oligomerization assay as a pre-screening test for amyloid status. Alzheimer's Research and Therapy, 2021, 13, 133.	3.0	19
2137	The informed road map to prevention of Alzheimer Disease: A call to arms. Molecular Neurodegeneration, 2021, 16, 49.	4.4	43
2138	Genomic Mosaicism Formed by Somatic Variation in the Aging and Diseased Brain. Genes, 2021, 12, 1071.	1.0	17
2139	Insulin Resistance Exacerbates Alzheimer Disease via Multiple Mechanisms. Frontiers in Neuroscience, 2021, 15, 687157.	1.4	40
2140	Bolstered Neuronal Antioxidant Response May Confer Resistance to Development of Dementia in Individuals with Alzheimer's Neuropathology by Ameliorating Amyloid-Î²-Induced Oxidative Stress. Journal of Neuroscience, 2021, 41, 6187-6189.	1.7	1
2141	A Novel Cardenolide Glycoside Isolated from Xysmalobium undulatum Reduces Levels of the Alzheimerâ€™s Disease-Associated Î²-Amyloid Peptides AÎ²42 In Vitro. Pharmaceuticals, 2021, 14, 743.	1.7	2
2142	Assembly of Î³-secretase occurs through stable dimers after exit from the endoplasmic reticulum. Journal of Cell Biology, 2021, 220, .	2.3	5
2143	A simple methyl substitution of 3-acetylcoumarin thiosemicarbazone enhances cellular autophagy flux, reduces inflammation and ameliorates rough eye phenotype in the Drosophila model of Alzheimer's disease. Journal of Molecular Structure, 2021, 1235, 130265.	1.8	7
2144	Correlative optical photothermal infrared and X-ray fluorescence for chemical imaging of trace elements and relevant molecular structures directly in neurons. Light: Science and Applications, 2021, 10, 151.	7.7	24
2145	Inhibition of Smad3 in macrophages promotes AÎ² efflux from the brain and thereby ameliorates Alzheimer's pathology. Brain, Behavior, and Immunity, 2021, 95, 154-167.	2.0	7

#	Article	IF	Citations
2146	Relationship Between Amyloid-Î² Deposition and Bloodâ€“Brain Barrier Dysfunction in Alzheimerâ€™s Disease. Frontiers in Cellular Neuroscience, 2021, 15, 695479.	1.8	71
2147	Pharmacological implications of ipriflavone against environmental metalâ€“induced neurodegeneration and dementia in rats. Environmental Science and Pollution Research, 2021, 28, 65349-65362.	2.7	6
2148	The Link between Exercise and Homocysteine in the Alzheimerâ€™s Disease: A Bioinformatic Network Model. CNS and Neurological Disorders - Drug Targets, 2021, 20, 814-821.	0.8	0
2149	Amyloid Î² production along the neuronal secretory pathway: Dangerous liaisons in the Golgi?. Traffic, 2021, 22, 319-327.	1.3	12
2150	From Kinase Inhibitors to Multitarget Ligands as Powerful Drug Leads for Alzheimer's Disease using Proteinâ€Templated Synthesis. Angewandte Chemie, 2021, 133, 19493-19503.	1.6	2
2151	Effects of Functional Fitness Enhancement through Taekwondo Training on Physical Characteristics and Risk Factors of Dementia in Elderly Women with Depression. International Journal of Environmental Research and Public Health, 2021, 18, 7961.	1.2	8
2152	Insulin Fibril Formation Caused by Mechanical Shock and Cavitation. Journal of Physical Chemistry B, 2021, 125, 8021-8027.	1.2	6
2153	Novel Rare SORL1 Variants in Early-Onset Dementia. Journal of Alzheimer's Disease, 2021, 82, 761-770.	1.2	2
2154	Association of Gut Microbiome Dysbiosis with Neurodegeneration: Can Gut Microbe-Modifying Diet Prevent or Alleviate the Symptoms of Neurodegenerative Diseases?. Life, 2021, 11, 698.	1.1	11
2155	<scp>ErbB4</scp> mediates amyloid Î²â€induced neurotoxicity through <scp>JNK</scp>/tau pathway activation: Implications for Alzheimer's disease. Journal of Comparative Neurology, 2021, 529, 3497-3512.	0.9	17
2156	Innate immune memory mediates increased susceptibility to Alzheimerâ€™s disease-like pathology in sepsis surviving mice. Brain, Behavior, and Immunity, 2021, 95, 287-298.	2.0	18
2157	Tau/AÎ² chimera peptides: A Thioflavin-T and MALDI-TOF study of AÎ² amyloidosis in the presence of Cu(II) or Zn(II) ions and total lipid brain extract (TLBE) vesicles. Chemistry and Physics of Lipids, 2021, 237, 105085.	1.5	6
2158	Basal Forebrain Cholinergic Neurons: Linking Down Syndrome and Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2021, 13, 703876.	1.7	13
2159	Passive immunotherapy with a novel antibody against 3pE-modified AÎ² demonstrates potential for enhanced efficacy and favorable safety in combination with BACE inhibitor treatment in plaque-depositing mice. Neurobiology of Disease, 2021, 154, 105365.	2.1	5
2160	Two human metabolites rescue a C. elegans model of Alzheimerâ€™s disease via a cytosolic unfolded protein response. Communications Biology, 2021, 4, 843.	2.0	6
2161	Exploring the Early Stages of the Amyloid AÎ²(1â€“42) Peptide Aggregation Process: An NMR Study. Pharmaceuticals, 2021, 14, 732.	1.7	13
2162	A novel presenilin 1 duplication mutation (Ile168dup) causing Alzheimer's disease associated with myoclonus, seizures and pyramidal features. Neurobiology of Aging, 2021, 103, 137.e1-137.e5.	1.5	1
2163	NNC 26-9100 increases AÎ²1-42 phagocytosis, inhibits nitric oxide production and decreases calcium in BV2 microglia cells. PLoS ONE, 2021, 16, e0254242.	1.1	6

#	Article	IF	Citations
2164	Modeling the mature CNS: A predictive screening platform for neurodegenerative disease drug discovery. Journal of Neuroscience Methods, 2021, 358, 109180.	1.3	6
2165	Investigation of the peripheral inflammation (neutrophilâ€“lymphocyte ratio) in two neurodegenerative diseases of the central nervous system. Neurological Sciences, 2022, 43, 1799-1807.	0.9	29
2166	Promising tacrine/huperzine Aâ€based dimeric acetylcholinesterase inhibitors for neurodegenerative disorders: From relieving symptoms to modifying diseases through multitarget. Journal of Neurochemistry, 2021, 158, 1381-1393.	2.1	13
2167	The critical roles of histone deacetylase 3 in the pathogenesis of solid organ injury. Cell Death and Disease, 2021, 12, 734.	2.7	19
2168	Tetrahydrocurcumin ameliorates Alzheimer's pathological phenotypes by inhibition of microglial cell cycle arrest and apoptosis via Ras/ERK signaling. Biomedicine and Pharmacotherapy, 2021, 139, 111651.	2.5	22
2169	NLRP3 Inflammasome Mediates Neurodegeneration in Rats with Chronic Neuropathic Pain. Shock, 2021, 56, 840-849.	1.0	11
2170	Amyloid-Î²: A double agent in Alzheimer's disease?. Biomedicine and Pharmacotherapy, 2021, 139, 111575.	2.5	32
2171	Platelet APP Processing: Is It a Tool to Explore the Pathophysiology of Alzheimerâ€™s Disease? A Systematic Review. Life, 2021, 11, 750.	1.1	0
2172	Potential therapeutic natural products against Alzheimer's disease with Reference of Acetylcholinesterase. Biomedicine and Pharmacotherapy, 2021, 139, 111609.	2.5	54
2173	Exogenous misfolded protein oligomers can cross the intestinal barrier and cause a disease phenotype in C. elegans. Scientific Reports, 2021, 11, 14391.	1.6	6
2174	Amyloid-Î² precursor protein processing and oxidative stress are altered in human iPSC-derived neuron and astrocyte co-cultures carrying presenillin-1 gene mutations following spontaneous differentiation. Molecular and Cellular Neurosciences, 2021, 114, 103631.	1.0	9
2175	From Kinase Inhibitors to Multitarget Ligands as Powerful Drug Leads for Alzheimer's Disease using Proteinâ€Templated Synthesis. Angewandte Chemie - International Edition, 2021, 60, 19344-19354.	7.2	9
2176	Memory Potential Herb: A Review. World Journal of Current Medical and Pharmaceutical Research, 0, , 68-73.	0.2	0
2177	Effects of monoclonal antibodies against amyloid-Î² on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimerâ€™s disease. Ageing Research Reviews, 2021, 68, 101339.	5.0	118
2178	Brain-wide Cas9-mediated cleavage of a gene causing familial Alzheimerâ€™s disease alleviates amyloid-related pathologies in mice. Nature Biomedical Engineering, 2022, 6, 168-180.	11.6	27
2179	Role of the English (H6R) Mutation on the Structural Properties of AÎ²40 and AÎ²42 Owing to the Histidine Tautomeric Effect. ACS Chemical Neuroscience, 2021, 12, 2705-2711.	1.7	2
2180	Reappraisal of metabolic dysfunction in neurodegeneration: Focus on mitochondrial function and calcium signaling. Acta Neuropathologica Communications, 2021, 9, 124.	2.4	33
2181	Current Nosology of Neural Autoantibody-Associated Dementia. Frontiers in Aging Neuroscience, 2021, 13, 711195.	1.7	10

#	Article	IF	Citations
2182	Thiopheneâ€Ïâ€Cyanoacetamides Show Intense and Tauâ€selective Turnâ€on Fluorescence in the Nearâ€Infrared Region. Bulletin of the Korean Chemical Society, 2021, 42, 1285-1288.	1.0	5
2183	EVOO Polyphenols Relieve Synergistically Autophagy Dysregulation in a Cellular Model of Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2021, 22, 7225.	1.8	13
2184	Quantifying scaling exponents for neurite morphology of in vitro-cultured human iPSC-derived neurons using discrete Loewner evolution: A statisticalâ^physical approach to the neuropathology in Alzheimer's disease. Chaos, 2021, 31, 073140.	1.0	3
2185	Endo-lysosomal AÎ² concentration and pH trigger formation of AÎ² oligomers that potently induce Tau missorting. Nature Communications, 2021, 12, 4634.	5.8	59
2186	Cognitive reserve and Alzheimer's biological continuum: clues for prediction and prevention of dementia. Minerva Medica, 2021, 112, 441-447.	0.3	10
2187	Estradiol exerts a neuroprotective effect on SHâ€5Y5Y cells through the miRâ€106bâ€5p/TXNIP axis. Journal of Biochemical and Molecular Toxicology, 2021, 35, e22861.	1.4	9
2188	Inhibition of Amyloid Aggregation and Toxicity with Janus Iron Oxide Nanoparticles. Chemistry of Materials, 2021, 33, 6484-6500.	3.2	25
2189	Therapeutic Potential of Multifunctional Derivatives of Cholinesterase Inhibitors. Current Neuropharmacology, 2021, 19, 1323-1344.	1.4	14
2190	Synthesis of BACE1 Inhibitors E2609/E2071 via Oximeâ€“Olefin Cycloaddition Following a Process Risk Mitigation Strategy. Organic Process Research and Development, 2022, 26, 804-816.	1.3	3
2191	Myricetin prevents high molecular weight AÎ²1-42 oligomer-induced neurotoxicity through antioxidant effects in cell membranes and mitochondria. Free Radical Biology and Medicine, 2021, 171, 232-244.	1.3	27
2192	Tau-related grey matter network breakdown across the Alzheimerâ€™s disease continuum. Alzheimer's Research and Therapy, 2021, 13, 138.	3.0	10
2193	Therapeutic Effects of Aripiprazole in the 5xFAD Alzheimerâ€™s Disease Mouse Model. International Journal of Molecular Sciences, 2021, 22, 9374.	1.8	7
2194	Preclinical in vivo longitudinal assessment of KG207-M as a disease-modifying Alzheimerâ€™s disease therapeutic. Journal of Cerebral Blood Flow and Metabolism, 2022, 42, 788-801.	2.4	8
2195	Imaging protein aggregates in the serum and cerebrospinal fluid in Parkinsonâ€™s disease. Brain, 2022, 145, 632-643.	3.7	20
2197	Significance of Oligomeric and Fibrillar Species in Amyloidosis: Insights into Pathophysiology and Treatment. Molecules, 2021, 26, 5091.	1.7	23
2198	High cerebrospinal amyloid-Î² 42 is associated with normal cognition in individuals with brain amyloidosis. EClinicalMedicine, 2021, 38, 100988.	3.2	69
2200	Reduced Levels of miR-342-5p in Plasma Are Associated With Worse Cognitive Evolution in Patients With Mild Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2021, 13, 705989.	1.7	9
2201	Triggering Innate Immune Receptors as New Therapies in Alzheimerâ€™s Disease and Multiple Sclerosis. Cells, 2021, 10, 2164.	1.8	3

#	Article	IF	Citations
2202	Early Divergence in Misfolding Pathways of Amyloidâ€Beta Peptides. ChemPhysChem, 2021, 22, 2158-2163.	1.0	4
2204	Age-Dependency of Total Tau in the Cerebrospinal Fluid Is Corrected by Amyloid-Î² 1â€“40: A Correlational Study in Healthy Adults. Journal of Alzheimer's Disease, 2021, 83, 155-162.	1.2	1
2205	Discovery of Investigational Drug CT1812, an Antagonist of the Sigma-2 Receptor Complex for Alzheimerâ€™s Disease. ACS Medicinal Chemistry Letters, 2021, 12, 1389-1395.	1.3	19
2206	Proteomic landscape of Alzheimerâ€™s Disease: novel insights into pathogenesis and biomarker discovery. Molecular Neurodegeneration, 2021, 16, 55.	4.4	95
2207	Casein Kinase 2 dependent phosphorylation of eIF4B regulates BACE1 expression in Alzheimerâ€™s disease. Cell Death and Disease, 2021, 12, 769.	2.7	8
2208	Scavenging amyloid oligomers from neurons with silica nanobowls: Implications for amyloid diseases. Biophysical Journal, 2021, 120, 3329-3340.	0.2	3
2209	Segmented Linear Mixed Model Analysis Reveals Association of the APOE É›4 Allele with Faster Rate of Alzheimerâ€™s Disease Dementia Progression. Journal of Alzheimer's Disease, 2021, 82, 921-937.	1.2	13
2210	Apolipoprotein E and Alzheimer's Disease: Findings, Hypotheses, and Potential Mechanisms. Annual Review of Pathology: Mechanisms of Disease, 2022, 17, 73-99.	9.6	81
2211	Inhibition of miR-96-5p May Reduce AÎ²42/AÎ²40 Ratio via Regulating ATP-binding cassette transporter A1. Journal of Alzheimer's Disease, 2021, 83, 367-377.	1.2	3
2212	Constraints on the Structure of Fibrils Formed by a Racemic Mixture of Amyloid-Î² Peptides from Solid-State NMR, Electron Microscopy, and Theory. Journal of the American Chemical Society, 2021, 143, 13299-13313.	6.6	17
2213	A large-scale brain network mechanism for increased seizure propensity in Alzheimerâ€™s disease. PLoS Computational Biology, 2021, 17, e1009252.	1.5	13
2214	Neutrophil Granule Proteins Inhibit Amyloid Beta Aggregation and Neurotoxicity. Current Alzheimer Research, 2021, 18, 414-427.	0.7	7
2215	Treatments for Alzheimer's disease emerge. Science, 2021, 373, 624-626.	6.0	75
2216	Immune-microbiome interplay and its implications in neurodegenerative disorders. Metabolic Brain Disease, 2022, 37, 17-37.	1.4	5
2217	Tau Protein Interaction Partners and Their Roles in Alzheimerâ€™s Disease and Other Tauopathies. International Journal of Molecular Sciences, 2021, 22, 9207.	1.8	50
2218	Plexin-A4 mediates amyloid-Î²â€“induced tau pathology in Alzheimerâ€™s disease animal model. Progress in Neurobiology, 2021, 203, 102075.	2.8	5
2219	Oxorhenium(V) and Oxotechnetium(V) Complexes of N₃S Tetradentate Ligands with a Styrylpyridyl Functional Group: Toward Imaging Agents to Assist in the Diagnosis of Alzheimerâ€™s Disease. Inorganic Chemistry, 2021, 60, 13669-13680.	1.9	5
2220	Met35 Oxidation Hinders AÎ²25-35 Peptide Aggregation within the Dimyristoylphosphatidylcholine Bilayer. ACS Chemical Neuroscience, 2021, 12, 3225-3236.	1.7	7

#	Article	IF	Citations
2221	Planar cell polarity signaling components are a direct target of Î²-amyloidâ€“associated degeneration of glutamatergic synapses. Science Advances, 2021, 7, .	4.7	14
2223	Differential interaction with <scp>TREM2</scp> modulates microglial uptake of modified AÎ² species. Glia, 2021, 69, 2917-2932.	2.5	9
2224	The amyloid-inhibiting NCAM-PrP peptide targets AÎ² peptide aggregation in membrane-mimetic environments. IScience, 2021, 24, 102852.	1.9	15
2226	Dual Role of Phenyl Amides from Hempseed on BACE 1, PPARÎ³, and PGC-1Î± in N2a-APP Cells. Journal of Natural Products, 2021, 84, 2447-2453.	1.5	3
2227	The Uppsala APP deletion causes early onset autosomal dominant Alzheimerâ€™s disease by altering APP processing and increasing amyloid Î² fibril formation. Science Translational Medicine, 2021, 13, .	5.8	23
2228	Effects of Mild Excitotoxic Stimulus on Mitochondria Ca2+ Handling in Hippocampal Cultures of a Mouse Model of Alzheimerâ€™s Disease. Cells, 2021, 10, 2046.	1.8	8
2229	Amyloid-Targeting Drugs for the Treatment of Alzheimer Disease. Journal of the Korean Neurological Association, 2021, 39, 134-140.	0.0	2
2230	Early detection of redox imbalance in the APPswe/PS1dE9 mouse model of Alzheimerâ€™s disease by in vivo electron paramagnetic resonance imaging. Free Radical Biology and Medicine, 2021, 172, 9-18.	1.3	7
2231	Aggregate Trends of Apolipoprotein E on Cognition in Transgenic Alzheimerâ€™s Disease Mice. Journal of Alzheimer's Disease, 2021, 83, 435-450.	1.2	4
2232	Looking at Alzheimerâ€™s Disease Pathogenesis from the Nuclear Side. Biomolecules, 2021, 11, 1261.	1.8	3
2233	Copper Imbalance in Alzheimerâ€™s Disease and Its Link with the Amyloid Hypothesis: Towards a Combined Clinical, Chemical, and Genetic Etiology. Journal of Alzheimer's Disease, 2021, 83, 23-41.	1.2	31
2234	Searching for Natural Products That Delay Nucleation Phase and Promote Elongation Phase of Amyloid Î²42 toward Alzheimerâ€™s Disease Therapeutics. ACS Chemical Neuroscience, 2021, 12, 3467-3476.	1.7	3
2235	Characterization of a Conformation-Restricted Amyloid Î² Peptide and Immunoreactivity of Its Antibody in Human AD brain. ACS Chemical Neuroscience, 2021, 12, 3418-3432.	1.7	13
2237	Tau-PET and in vivo Braak-staging as prognostic markers of future cognitive decline in cognitively normal to demented individuals. Alzheimer's Research and Therapy, 2021, 13, 137.	3.0	59
2238	A Primer on the Evolution of Aducanumab: The First Antibody Approved for Treatment of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2021, 83, 1537-1552.	1.2	38
2239	Kinetic and thermodynamic insights into the interaction of AÎ²1â€“42 with astaxanthin and aggregation behavior of AÎ²1â€“42: Surface plasmon resonance, microscopic, and molecular docking studies. Biophysical Chemistry, 2021, 275, 106612.	1.5	5
2240	CSF in Epileptic Prodromal Alzheimer's Disease: No Diagnostic Contribution but a Pathophysiological One. Frontiers in Neurology, 2021, 12, 623777.	1.1	3
2241	Differential Effects of Polyphenols on Insulin Proteolysis by the Insulin-Degrading Enzyme. Antioxidants, 2021, 10, 1342.	2.2	5

#	Article	IF	Citations
2242	Anxiety and Alzheimerâ€™s disease: Behavioral analysis and neural basis in rodent models of Alzheimerâ€™s-related neuropathology. Neuroscience and Biobehavioral Reviews, 2021, 127, 647-658.	2.9	31
2243	Role of Oxidative Damage in Alzheimerâ€™s Disease and Neurodegeneration: From Pathogenic Mechanisms to Biomarker Discovery. Antioxidants, 2021, 10, 1353.	2.2	57
2244	Stem Cells: Innovative Therapeutic Options for Neurodegenerative Diseases?. Cells, 2021, 10, 1992.	1.8	18
2245	Regulation of PPARÎ± by APP in Alzheimer disease affects the pharmacological modulation of synaptic activity. JCI Insight, 2021, 6, .	2.3	8
2246	Indoles as essential mediators in the gut-brain axis. Their role in Alzheimer's disease. Neurobiology of Disease, 2021, 156, 105403.	2.1	39
2248	The Amyloid-Î² Pathway in Alzheimerâ€™s Disease. Molecular Psychiatry, 2021, 26, 5481-5503.	4.1	478
2249	Long-Term Treatment of Cuban Policosanol Attenuates Abnormal Oxidative Stress and Inflammatory Response via Amyloid Plaques Reduction in 5xFAD Mice. Antioxidants, 2021, 10, 1321.	2.2	9
2250	Implications of FBXW7 in Neurodevelopment and Neurodegeneration: Molecular Mechanisms and Therapeutic Potential. Frontiers in Cellular Neuroscience, 2021, 15, 736008.	1.8	14
2251	Synaptic dysregulation and hyperexcitability induced by intracellular amyloid beta oligomers. Aging Cell, 2021, 20, e13455.	3.0	16
2253	Dietary Regulation of Oxidative Stress in Chronic Metabolic Diseases. Foods, 2021, 10, 1854.	1.9	54
2254	Prediction and verification of the AD-FTLD common pathomechanism based on dynamic molecular network analysis. Communications Biology, 2021, 4, 961.	2.0	2
2255	<scp>DSCR1</scp> upregulation enhances dural meningeal lymphatic drainage to attenuate amyloid pathology of <scp>A</scp>lzheimer's disease. Journal of Pathology, 2021, 255, 296-310.	2.1	14
2256	Hydrolysable Tannins Exhibit Acetylcholinesterase Inhibitory and Anti-Glycation Activities In Vitro and Learning and Memory Function Improvements in Scopolamine-Induced Amnesiac Mice. Biomedicines, 2021, 9, 1066.	1.4	5
2258	Regulation of beta-amyloid production in neurons by astrocyte-derived cholesterol. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	138
2259	Brain Somatic Mutation in Aging and Alzheimer's Disease. Annual Review of Genomics and Human Genetics, 2021, 22, 239-256.	2.5	32
2260	Amaryllidaceae Alkaloids of Norbelladine-Type as Inspiration for Development of Highly Selective Butyrylcholinesterase Inhibitors: Synthesis, Biological Activity Evaluation, and Docking Studies. International Journal of Molecular Sciences, 2021, 22, 8308.	1.8	5
2262	Metallobiology and therapeutic chelation of biometals (copper, zinc and iron) in Alzheimerâ€™s disease: Limitations, and current and future perspectives. Journal of Trace Elements in Medicine and Biology, 2021, 67, 126779.	1.5	60
2263	Inverse Correlation Between Alzheimerâ€™s Disease and Cancer: Short Overview. Molecular Neurobiology, 2021, 58, 6335-6349.	1.9	26

#	Article	IF	Citations
2264	Association Between Adenosine A2A Receptors and Connexin 43 Regulates Hemichannels Activity and ATP Release in Astrocytes Exposed to Amyloid-Î² Peptides. Molecular Neurobiology, 2021, 58, 6232-6248.	1.9	21
2265	Ca2+ handling at the mitochondria-ER contact sites in neurodegeneration. Cell Calcium, 2021, 98, 102453.	1.1	49
2266	Structure and biological action of analogs and derivatives of biogenic polyamines. Fine Chemical Technologies, 2021, 16, 287-306.	0.1	0
2267	Diagnosis and Treatment of Alzheimerâ€™s Disease:. Delaware Journal of Public Health, 2021, 7, 74-85.	0.2	8
2268	Distinct conformers of amyloid beta accumulate in the neocortex of patients with rapidly progressive Alzheimer's disease. Journal of Biological Chemistry, 2021, 297, 101267.	1.6	25
2269	Immunization with AÎ²3-10-KLH vaccine improves cognitive function and ameliorates mitochondrial dysfunction and reduces Alzheimerâ€™s disease-like pathology in Tg-APPswe/PSEN1dE9 mice. Brain Research Bulletin, 2021, 174, 31-40.	1.4	7
2270	Impact of Amyloid-Î² on Platelet Mitochondrial Function and Plateletâ€“Mediated Amyloid Aggregation in Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2021, 22, 9633.	1.8	14
2271	Effects of AÎ²-derived peptide fragments on fibrillogenesis of AÎ². Scientific Reports, 2021, 11, 19262.	1.6	10
2272	Nano-Infrared Imaging of Primary Neurons. Cells, 2021, 10, 2559.	1.8	14
2274	AÎ²_{31â€“35} Decreases Neprilysin-Mediated Alzheimerâ€™s Amyloid-Î² Peptide Degradation. ACS Chemical Neuroscience, 2021, 12, 3708-3718.	1.7	4
2275	Mutations in the Amyloid-Î² Protein Precursor Reduce Mitochondrial Function and Alter Gene Expression Independent of 42-Residue Amyloid-Î² Peptide. Journal of Alzheimer's Disease, 2021, 83, 1039-1049.	1.2	5
2277	The localization of amyloid precursor protein to ependymal cilia in vertebrates and its role in ciliogenesis and brain development in zebrafish. Scientific Reports, 2021, 11, 19115.	1.6	4
2278	The curvature of gold nanoparticles influences the exposure of amyloid-Î² and modulates its aggregation process. Materials Science and Engineering C, 2021, 128, 112269.	3.8	8
2279	Improvement of electroacupuncture on <scp>APP</scp>/<scp>PS1</scp> transgenic mice in behavioral probably due to reducing deposition of AÎ² in hippocampus. Anatomical Record, 2021, 304, 2521-2530.	0.8	8
2280	Meningeal lymphatic endothelial cells fulfill scavenger endothelial cell function and cooperate with microglia in waste removal from the brain. Glia, 2022, 70, 35-49.	2.5	11
2281	In situ identification and G4-PPI-His-Mal-dendrimer-induced reduction of early-stage amyloid aggregates in Alzheimerâ€™s disease transgenic mice using synchrotron-based infrared imaging. Scientific Reports, 2021, 11, 18368.	1.6	9
2282	Exogenous AÎ² seeds induce AÎ² depositions in the blood vessels rather than the brain parenchyma, independently of AÎ² strain-specific information. Acta Neuropathologica Communications, 2021, 9, 151.	2.4	6
2283	Apolipoprotein E isoform-dependent effects on the processing of Alzheimer's amyloid-Î². Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2021, 1866, 158980.	1.2	14

#	Article	IF	Citations
2285	Dysregulation of the secretory pathway connects Alzheimerâ€™s disease genetics to aggregate formation. Cell Systems, 2021, 12, 873-884.e4.	2.9	11
2286	Retinal Vasculopathy in Alzheimerâ€™s Disease. Frontiers in Neuroscience, 2021, 15, 731614.	1.4	40
2287	Effects of Peroral Omega-3 Fatty Acid Supplementation on Cerebrospinal Fluid Biomarkers in Patients with Alzheimerâ€™s Disease: A Randomized Controlled Trialâ€”The OmegAD Study. Journal of Alzheimer's Disease, 2021, 83, 1291-1301.	1.2	10
2288	Brain energy metabolism and neurodegeneration: hints from CSF lactate levels in dementias. Neurobiology of Aging, 2021, 105, 333-339.	1.5	14
2290	Curcumin Complex Analogues as Near-Infrared Fluorescent Probes for Monitoring all AÎ² Species in the Early Alzheimerâ€™s Disease Model. ACS Chemical Neuroscience, 2021, 12, 3683-3689.	1.7	13
2291	The amyloid precursor protein is a conserved Wnt receptor. ELife, 2021, 10, .	2.8	22
2292	Pregabalin Treatment does not Affect Amyloid Pathology in 5XFAD Mice. Current Alzheimer Research, 2021, 18, 283-297.	0.7	3
2293	A Super-Resolved View of the Alzheimerâ€™s Disease-Related Amyloidogenic Pathway in Hippocampal Neurons. Journal of Alzheimer's Disease, 2021, 83, 833-852.	1.2	5
2294	A third-generation mouse model of Alzheimer's disease shows early and increased cored plaque pathology composed of wild-type human amyloid Î² peptide. Journal of Biological Chemistry, 2021, 297, 101004.	1.6	16
2295	Solubility of AÎ²40 peptide. Jcis Open, 2021, 4, 100024.	1.5	5
2296	Peripheral Nerve Impairment in a Mouse Model of Alzheimerâ€™s Disease. Brain Sciences, 2021, 11, 1245.	1.1	11
2298	Immune modulations and immunotherapies for Alzheimerâ€™s disease: a comprehensive review. Reviews in the Neurosciences, 2022, 33, 365-381.	1.4	5
2299	The role of the immune system in Alzheimerâ€™s disease. Ageing Research Reviews, 2021, 70, 101409.	5.0	57
2300	Inflammatory Cascade in Alzheimerâ€™s Disease Pathogenesis: A Review of Experimental Findings. Cells, 2021, 10, 2581.	1.8	42
2301	The Janus-like Association between Proton Pump Inhibitors and Dementia. Current Alzheimer Research, 2021, 18, 453-469.	0.7	3
2302	Insulin and Insulin Resistance in Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2021, 22, 9987.	1.8	97
2303	Transferrin Biosynthesized in the Brain Is a Novel Biomarker for Alzheimerâ€™s Disease. Metabolites, 2021, 11, 616.	1.3	16
2304	Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease. Alzheimer's and Dementia, 2022, 18, 824-857.	0.4	56

#	Article	IF	Citations
2305	Neuroprotective Effects of Ceftriaxone Involve the Reduction of AÎ² Burden and Neuroinflammatory Response in a Mouse Model of Alzheimerâ€™s Disease. Frontiers in Neuroscience, 2021, 15, 736786.	1.4	14
2306	Amyloid toxicity in a Drosophila Alzheimer's model is ameliorated by autophagy activation. Neurobiology of Aging, 2021, 105, 137-147.	1.5	5
2307	Cerebrovascular alterations in NAFLD: Is it increasing our risk of Alzheimer's disease?. Analytical Biochemistry, 2022, 636, 114387.	1.1	12
2308	Bile acid receptors and signaling crosstalk in the liver, gut and brain. Liver Research, 2021, 5, 105-118.	0.5	19
2309	The case for low-level BACE1 inhibition for the prevention of Alzheimer disease. Nature Reviews Neurology, 2021, 17, 703-714.	4.9	65
2310	Stem cell-derived neurons reflect features of protein networks, neuropathology, and cognitive outcome of their aged human donors. Neuron, 2021, 109, 3402-3420.e9.	3.8	75
2311	T2 heterogeneity as an in vivo marker of microstructural integrity in medial temporal lobe subfields in ageing and mild cognitive impairment. NeuroImage, 2021, 238, 118214.	2.1	1
2312	An Overview of the Nrf2/ARE Pathway and Its Role in Neurodegenerative Diseases. International Journal of Molecular Sciences, 2021, 22, 9592.	1.8	62
2313	A2A Adenosine Receptor as a Potential Biomarker and a Possible Therapeutic Target in Alzheimerâ€™s Disease. Cells, 2021, 10, 2344.	1.8	15
2314	Exploring amyloid oligomers with peptide model systems. Current Opinion in Chemical Biology, 2021, 64, 106-115.	2.8	23
2315	TSPO deficiency accelerates amyloid pathology and neuroinflammation by impairing microglial phagocytosis. Neurobiology of Aging, 2021, 106, 292-303.	1.5	10
2316	Comprehensive analysis of O-glycosylation of amyloid precursor protein (APP) using targeted and multi-fragmentation MS strategy. Biochimica Et Biophysica Acta - General Subjects, 2021, 1865, 129954.	1.1	6
2317	Liquidâ€“liquid phase separation: a principal organizer of the cellâ€™s biochemical activity architecture. Trends in Pharmacological Sciences, 2021, 42, 845-856.	4.0	28
2318	Aducanumab: evidence from clinical trial data and controversies. Drugs in Context, 2021, 10, 1-9.	1.0	96
2319	The role of microRNA-34 family in Alzheimerâ€™s disease: A potential molecular link between neurodegeneration and metabolic disorders. Pharmacological Research, 2021, 172, 105805.	3.1	23
2320	Improvement of cognitive performance by a nutraceutical formulation: Underlying mechanisms revealed by laboratory studies. Free Radical Biology and Medicine, 2021, 174, 281-304.	1.3	3
2321	Emerging two-dimensional materials-based diagnosis of neurodegenerative diseases: Status and challenges. Nano Today, 2021, 40, 101284.	6.2	12
2322	The transmembrane amyloid precursor C99 protein exhibits non-specific interaction with tau. Biochemical and Biophysical Research Communications, 2021, 576, 48-52.	1.0	2

#	Article	IF	Citations
2323	Regulation of Microglia for the Treatment of Glioma. World Neurosurgery, 2021, 154, 222-227.	0.7	1
2324	Synthesis and approbation of new neuroprotective chemicals of pyrrolyl- and indolylazine classes in a cell model of Alzheimer's disease. European Journal of Medicinal Chemistry, 2021, 222, 113577.	2.6	10
2325	Attenuation of Pb-induced AÎ² generation and autophagic dysfunction via activation of SIRT1: Neuroprotective properties of resveratrol. Ecotoxicology and Environmental Safety, 2021, 222, 112511.	2.9	19
2326	Dual targeting of acetylcholinesterase and tau aggregation: Design, synthesis and evaluation of multifunctional deoxyvasicinone analogues for Alzheimerâ€™s disease. Bioorganic Chemistry, 2021, 116, 105354.	2.0	13
2327	Genetic deletion of Î±7 nicotinic acetylcholine receptors induces an age-dependent Alzheimerâ€™s disease-like pathology. Progress in Neurobiology, 2021, 206, 102154.	2.8	21
2328	Dysregulated CRTC1-BDNF signaling pathway in the hippocampus contributes to AÎ² oligomer-induced long-term synaptic plasticity and memory impairment. Experimental Neurology, 2021, 345, 113812.	2.0	9
2329	Differential involvement of insulin receptor substrate (IRS)-1 and IRS-2 in brain insulin signaling is associated with the effects on amyloid pathology in a mouse model of Alzheimer's disease. Neurobiology of Disease, 2021, 159, 105510.	2.1	9
2330	CRISPR-activated patient fibroblasts for modeling of familial Alzheimer's disease. Neuroscience Research, 2021, 172, 7-12.	1.0	2
2331	Spectroscopic, calorimetric and in silico insight into the molecular interactions of Memantine with human transferrin: Implications of Alzheimer's drugs. International Journal of Biological Macromolecules, 2021, 190, 660-666.	3.6	8
2332	Can platelet activation result in increased plasma AÎ² levels and contribute to the pathogenesis of Alzheimerâ€™s disease?. Ageing Research Reviews, 2021, 71, 101420.	5.0	15
2333	Bri2 BRICHOS chaperone rescues impaired fast-spiking interneuron behavior and neuronal network dynamics in an AD mouse model in vitro. Neurobiology of Disease, 2021, 159, 105514.	2.1	12
2334	The role of amyloids in Alzheimer's and Parkinson's diseases. International Journal of Biological Macromolecules, 2021, 190, 44-55.	3.6	33
2335	Abnormal amyloid beta metabolism in systemic abnormalities and Alzheimerâ€™s pathology: Insights and therapeutic approaches from periphery. Ageing Research Reviews, 2021, 71, 101451.	5.0	20
2336	GABAA receptor agonist muscimol rescues inhibitory microcircuit defects in the olfactory bulb and improves olfactory function in APP/PS1 transgenic mice. Neurobiology of Aging, 2021, 108, 47-57.	1.5	6
2337	Autophagy in Alzheimerâ€™s disease pathogenesis: Therapeutic potential and future perspectives. Ageing Research Reviews, 2021, 72, 101464.	5.0	99
2338	Development and crystallography-aided SAR studies of multifunctional BuChE inhibitors and 5-HT6R antagonists with Î²-amyloid anti-aggregation properties. European Journal of Medicinal Chemistry, 2021, 225, 113792.	2.6	13
2339	Mimosine functionalized gold nanoparticles (Mimo-AuNPs) suppress Î²-amyloid aggregation and neuronal toxicity. Bioactive Materials, 2021, 6, 4491-4505.	8.6	19
2340	The effect of Î±-tocopherol, Î±- and Î³-tocotrienols on amyloid-Î² aggregation and disaggregation in vitro. Biochemistry and Biophysics Reports, 2021, 28, 101131.	0.7	2

#	Article	IF	Citations
2341	Pathological mechanisms and therapeutic strategies for Alzheimerâ€™s disease. Neural Regeneration Research, 2022, 17, 543.	1.6	146
2342	Heat shock factor 1 is a direct anti-amyloid factor: connecting neurodegeneration and uncontrolled growth. Neural Regeneration Research, 2022, 17, 559.	1.6	0
2343	Overexpression of miR-132-3p contributes to neuronal protection in in vitro and in vivo models of Alzheimerâ€™s disease. Behavioural Brain Research, 2022, 417, 113584.	1.2	14
2344	Significance of mitochondrial activity in neurogenesis and neurodegenerative diseases. Neural Regeneration Research, 2022, 17, 741.	1.6	13
2345	Gangliosides smelt nanostructured amyloid AÎ²(1â€“40) fibrils in a membrane lipid environment. Biochimica Et Biophysica Acta - Biomembranes, 2022, 1864, 183749.	1.4	1
2346	Insulin and aging. Vitamins and Hormones, 2021, 115, 185-219.	0.7	14
2347	From uncovering the mechanism of transthyretin aggregation to the drug tafamidis for ameliorating neurodegeneration and cardiomyopathy. , 2021, , 65-103.		1
2348	Microglial Turnover in Ageing-Related Neurodegeneration: Therapeutic Avenue to Intervene in Disease Progression. Cells, 2021, 10, 150.	1.8	23
2349	Effects of Alzheimer-Like Pathology on Homocysteine and Homocysteic Acid Levelsâ€”An Exploratory In Vivo Kinetic Study. International Journal of Molecular Sciences, 2021, 22, 927.	1.8	5
2350	Prior activation state shapes the microglia response to antihuman TREM2 in a mouse model of Alzheimerâ€™s disease. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	66
2351	The Burden of Dementia due to Down Syndrome, Parkinsonâ€™s Disease, Stroke, and Traumatic Brain Injury: A Systematic Analysis for the Global Burden of Disease Study 2019. Neuroepidemiology, 2021, 55, 286-296.	1.1	24
2352	Amyloid binding and beyond: a new approach for Alzheimer's disease drug discovery targeting Aî²oâ€“PrP^Cbinding and downstream pathways. Chemical Science, 2021, 12, 3768-3785.	3.7	6
2353	Structural basis of Î³-secretase inhibition and modulation by small molecule drugs. Cell, 2021, 184, 521-533.e14.	13.5	100
2354	Combined treatment with valproic acid and estrogen has neuroprotective effects in ovariectomized mice with Alzheimerâ€™s disease. Neural Regeneration Research, 2021, 16, 2078.	1.6	6
2355	Exercise-Mediated Autophagy and Alzheimerâ€™s Disease. , 2021, , 127-154.		0
2356	Familial Alzheimerâ€™s Disease Mutations in PSEN1 Lead to Premature Human Stem Cell Neurogenesis. Cell Reports, 2021, 34, 108615.	2.9	53
2357	The search for novel targets in Alzheimer's diseaseâ€”The 90s redux. Progress in Molecular Biology and Translational Science, 2021, 177, 123-135.	0.9	1
2359	Alzheimerâ€™s disease: neuropathology, neuropsychological differential diagnosis, and treatment. , 2021, , 57-128.		0

#	Article	IF	Citations
2360	Synthesis and structureâ€“activity relationships of 3,4,5-trisubstituted-1,2,4-triazoles: high affinity and selective somatostatin receptor-4 agonists for Alzheimer's disease treatment. RSC Medicinal Chemistry, 2021, 12, 1352-1365.	1.7	3
2361	Occurrence of Morpholine in Central Nervous System Drug Discovery. ACS Chemical Neuroscience, 2021, 12, 378-390.	1.7	30
2362	A conformation-specific antibody against oligomeric Î²-amyloid restores neuronal integrity in a mouse model of Alzheimer's disease. Journal of Biological Chemistry, 2021, 296, 100241.	1.6	4
2363	Extracellular GAPDH Promotes Alzheimer Disease Progression by Enhancing Amyloid-Î² Aggregation and Cytotoxicity. , 2021, 12, 1223.		16
2364	A dopamine metabolite stabilizes neurotoxic amyloid-Î² oligomers. Communications Biology, 2021, 4, 19.	2.0	25
2365	Design, synthesis and comparison of water-soluble phthalocyanine/porphyrin analogues and their inhibition effects on AÎ²₄₂ fibrillization. Inorganic Chemistry Frontiers, 2021, 8, 3501-3513.	3.0	6
2366	Chronic traumatic encephalopathy and the nucleus basalis of Meynert. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2021, 182, 9-29.	1.0	2
2367	Quantification of the Trans-Synaptic Partners Neuroligin-Neurexin in CSF of Neurodegenerative Diseases by Parallel Reaction Monitoring Mass Spectrometry. SSRN Electronic Journal, 0, , .	0.4	0
2368	Animal Models of Metabolic Disorders in the Study of Neurodegenerative Diseases: An Overview. Frontiers in Neuroscience, 2020, 14, 604150.	1.4	31
2369	The association of circulating amylin with Î²â€amyloid in familial Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12130.	1.8	21
2370	Predicting sporadic Alzheimer's disease progression via inherited Alzheimer's diseaseâ€informed machineâ€learning. Alzheimer's and Dementia, 2020, 16, 501-511.	0.4	47
2371	Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification. Alzheimer's and Dementia, 2021, 17, 1365-1382.	0.4	43
2372	Staining and Quantification of Î²-Amyloid Pathology in Transgenic Mouse Models of Alzheimerâ€™s Disease. Methods in Molecular Biology, 2020, 2144, 211-221.	0.4	5
2373	Using Fluorescence In Situ Hybridization (FISH) Analysis to Measure Chromosome Instability and Mosaic Aneuploidy in Neurodegenerative Diseases. Neuromethods, 2017, , 329-359.	0.2	2
2374	SMPL Synaptic Membranes: Nanodisc-Mediated Synaptic Membrane Mimetics Expand the Toolkit for Drug Discovery and the Molecular Cell Biology of Synapses. Neuromethods, 2018, , 227-250.	0.2	1
2375	Golgi Structure and Function in Health, Stress, and Diseases. Results and Problems in Cell Differentiation, 2019, 67, 441-485.	0.2	69
2376	Targeting Purinergic Signaling and Cell Therapy in Cardiovascular and Neurodegenerative Diseases. Advances in Experimental Medicine and Biology, 2019, 1201, 275-353.	0.8	8
2377	Therapeutic Efficacy of Plasmalogens for Alzheimerâ€™s Disease, Mild Cognitive Impairment, and Parkinsonâ€™s Disease in Conjunction with a New Hypothesis for the Etiology of Alzheimerâ€™s Disease. Advances in Experimental Medicine and Biology, 2020, 1299, 195-212.	0.8	15

#	Article	IF	Citations
2378	Role of Drebrin in Synaptic Plasticity. Advances in Experimental Medicine and Biology, 2017, 1006, 183-201.	0.8	17
2379	Unraveling Alzheimerâ€™s Disease Using Drosophila. , 2019, , 251-277.		10
2380	Neurobiological Mechanisms Involved in the Pathogenesis of Alzheimerâ€™s Disease. , 2019, , 235-269.		2
2381	Oligodendroglial Cells in Alzheimerâ€™s Disease. Advances in Experimental Medicine and Biology, 2019, 1175, 325-333.	0.8	59
2382	Tau Interacting Proteins: Gaining Insight into the Roles of Tau in Health and Disease. Advances in Experimental Medicine and Biology, 2019, 1184, 145-166.	0.8	11
2383	Investigating surrogate cerebrospinal fluid matrix compositions for use in quantitative LC-MS analysis of therapeutic antibodies in the cerebrospinal fluid. Analytical and Bioanalytical Chemistry, 2020, 412, 1653-1661.	1.9	8
2384	Insulin resistance: a connecting link between Alzheimerâ€™s disease and metabolic disorder. Metabolic Brain Disease, 2021, 36, 67-83.	1.4	23
2385	Heat Shock Proteins and Protein Quality Control in Alzheimerâ€™s Disease. , 2018, , 269-298.		5
2386	Cognitive behavioral therapy use in Alzheimer's disease. , 2020, , 793-809.		1
2387	Synthesis of morpholine derivatives using the Castagnoli-Cushman reaction as BACE1 inhibitors: Unexpected binding activity of cyclic thioamides. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127211.	1.0	4
2388	Stress and Alzheimerâ€™s disease: A senescence link?. Neuroscience and Biobehavioral Reviews, 2020, 115, 285-298.	2.9	29
2389	TSPO ligand PK11195 improves Alzheimer-related outcomes in aged female 3xTg-AD mice. Neuroscience Letters, 2018, 683, 7-12.	1.0	28
2390	Seeds of Destruction: New Mechanistic Insights into the Role of Apolipoprotein E4 in Alzheimerâ€™s Disease. Neuron, 2017, 96, 953-955.	3.8	4
2391	Pituitary adenylate cyclase-activating polypeptide (PACAP) protects against mitoxantrone-induced cardiac injury in mice. Peptides, 2017, 95, 25-32.	1.2	7
2392	VPS10P Domain Receptors: Sorting Out Brain Health and Disease. Trends in Neurosciences, 2020, 43, 870-885.	4.2	30
2393	A Perspective on Multi-target Drugs for Alzheimerâ€™s Disease. Trends in Pharmacological Sciences, 2020, 41, 434-445.	4.0	148
2394	Green Tea Extracts EGCG and EGC Display Distinct Mechanisms in Disrupting AÎ²₄₂ Protofibril. ACS Chemical Neuroscience, 2020, 11, 1841-1851.	1.7	73
2395	Component of Cannabis, Cannabidiol, as a Possible Drug against the Cytotoxicity of AÎ²(31â€“35) and AÎ²(25â€“35) Peptides: An Investigation by Molecular Dynamics and Well-Tempered Metadynamics Simulations. ACS Chemical Neuroscience, 2021, 12, 660-674.	1.7	12

#	Article	IF	Citations
2396	A meta-analysis of gene expression data highlights synaptic dysfunction in the hippocampus of brains with Alzheimerâ€™s disease. Scientific Reports, 2020, 10, 8384.	1.6	22
2397	Amphipathic molecules modulate PIEZO1 activity. Biochemical Society Transactions, 2019, 47, 1833-1842.	1.6	26
2398	On the role of the cellular prion protein in the uptake and signaling of pathological aggregates in neurodegenerative diseases. Prion, 2020, 14, 257-270.	0.9	15
2399	From Reproducibility to Translation in Neurodegenerative Disease. ILAR Journal, 2017, 58, 106-114.	1.8	11
2400	AÎ² monomer induces phosphorylation of Tau at Serâ€214 through Î²2ARâ€PKAâ€JNK signaling pathway. FASEB Journal, 2020, 34, 5092-5105.	0.2	17
2401	The aroylhydrazone INHHQ prevents memory impairment induced by Alzheimerâ€™s-linked amyloid-Î² oligomers in mice. Behavioural Pharmacology, 2020, 31, 738-747.	0.8	9
2431	Assessment of pathological features in Alzheimerâ€™s disease brain tissue with a large field-of-view visible-light optical coherence microscope. Neurophotonics, 2018, 5, 1.	1.7	20
2432	Alzheimer's Disease: Many Failed Trials, So Where Do We Go from Here?. Journal of Investigative Medicine, 2020, 68, 1135-1140.	0.7	17
2433	Transcranial optical imaging reveals a pathway for optimizing the delivery of immunotherapeutics to the brain. JCI Insight, 2018, 3, .	2.3	64
2434	Targeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation. Journal of Clinical Investigation, 2018, 128, 2144-2155.	3.9	105
2435	Blood will out: vascular contributions to Alzheimerâ€™s disease. Journal of Clinical Investigation, 2018, 128, 556-563.	3.9	73
2436	Can Antiâ€“Î²-amyloid Monoclonal Antibodies Work in Autosomal Dominant Alzheimer Disease?. Neurology: Genetics, 2021, 7, e535.	0.9	10
2437	Haplotype-based association analysis of general cognitive ability in Generation Scotland, the English Longitudinal Study of Ageing, and UK Biobank. Wellcome Open Research, 2017, 2, 61.	0.9	4
2438	The Drosophila amyloid precursor protein homologue mediates neuronal survival and neuroglial interactions. PLoS Biology, 2020, 18, e3000703.	2.6	10
2439	Role of the N-terminus for the stability of an amyloid-Î² fibril with three-fold symmetry. PLoS ONE, 2017, 12, e0186347.	1.1	31
2440	Eicosanoyl-5-hydroxytryptamide (EHT) prevents Alzheimerâ€™s disease-related cognitive and electrophysiological impairments in mice exposed to elevated concentrations of oligomeric beta-amyloid. PLoS ONE, 2017, 12, e0189413.	1.1	10
2441	DEFINING DISEASE MODIFYING THERAPY FOR ALZHEIMERâ€™S DISEASE. journal of prevention of Alzheimer's disease, The, 2017, 4, 1-7.	1.5	65
2442	THE FUTURE OF ANTI-AMYLOID TRIALS. journal of prevention of Alzheimer's disease, The, 2020, 7, 1-6.	1.5	34

#	Article	IF	Citations
2443	ApoE4-Induced Cholesterol Dysregulation and Its Brain Cell Type-Specific Implications in the Pathogenesis of Alzheimer's Disease. Molecules and Cells, 2019, 42, 739-746.	1.0	54
2444	Investigating Relationships Between Hypertension, Sleep, and Cognitive Risk in an Underserved Community. Online Journal of Rural Nursing and Health Care: the Official Journal of the Rural Nurse Organization, 2020, 20, 70-89.	0.4	2
2445	Platelet-generated amyloid beta peptides in Alzheimer's disease and glaucoma. Histology and Histopathology, 2019, 34, 843-856.	0.5	28
2446	Protective effect of sakuranetin in brain cells of dementia model rats. Cellular and Molecular Biology, 2019, 65, 54-58.	0.3	6
2447	Functional Amyloids and their Possible Influence on Alzheimer Disease. Discoveries, 2017, 5, e79.	1.5	9
2448	Inactive variants of death receptor p75 ^{NTR} reduce Alzheimerâ€™s neuropathology by interfering with APP internalization. EMBO Journal, 2021, 40, e104450.	3.5	11
2449	The diphenylpyrazole compound anle138b blocks AÎ² channels and rescues disease phenotypes in a mouse model for amyloid pathology. EMBO Molecular Medicine, 2018, 10, 32-47.	3.3	63
2451	Computational Investigations of the Transmembrane Italian-Mutant (E22K) 3A(eta_{11 - 40}) in Aqueous Solution. Communications in Physics, 2018, 28, 265.	0.0	3
2452	Alzheimerâ€™s disease: amyloid-based pathogenesis and potential therapies. Cell Stress, 2018, 2, 150-161.	1.4	27
2453	Innate immunity and inflammation in AlzheimerÂ´s disease pathogenesis. Arquivos De Neuro-Psiquiatria, 2017, 75, 607-608.	0.3	8
2454	Complement factor H levels are decreased and correlated with serum C-reactive protein in late-onset Alzheimer's disease. Arquivos De Neuro-Psiquiatria, 2020, 78, 76-80.	0.3	9
2456	AÎ² Plaques. Free Neuropathology, 2020, 1, .	2.4	21
2458	Brain precursor cells' failure in neurodegeneration. Aging, 2018, 10, 2539-2540.	1.4	1
2459	MicroRNA-181a protects against pericyte apoptosis via directly targeting FOXO1: implication for ameliorated cognitive deficits in APP/PS1 mice. Aging, 2019, 11, 6120-6133.	1.4	28
2460	The neuroprotective effects of SIRT1 in mice carrying the APP/PS1 double-transgenic mutation and in SH-SY5Y cells over-expressing human APP670/671 may involve elevated levels of Î±7 nicotinic acetylcholine receptors. Aging, 2020, 12, 1792-1807.	1.4	15
2461	Codonopsis pilosula polysaccharide attenuates AÎ² toxicity and cognitive defects in APP/PS1 mice. Aging, 2020, 12, 13422-13436.	1.4	33
2462	Alzheimerâ€™s disease as a systems network disorder: chronic stress/dyshomeostasis, innate immunity, and genetics. Aging, 2020, 12, 17815-17844.	1.4	9
2463	MicroRNA-338-5p alleviates neuronal apoptosis via directly targeting BCL2L11 in APP/PS1 mice. Aging, 2020, 12, 20728-20742.	1.4	23

#	Article	IF	Citations
2464	NEAT1 regulates microtubule stabilization via FZD3/GSK3Î²/P-tau pathway in SH-SY5Y cells and APP/PS1 mice. Aging, 2020, 12, 23233-23250.	1.4	15
2465	Anticoagulants inhibit proteolytic clearance of plasma amyloid beta. Oncotarget, 2018, 9, 5614-5626.	0.8	10
2466	Role of p27Kip1 as a transcriptional regulator. Oncotarget, 2018, 9, 26259-26278.	0.8	32
2467	Long-term behavioral, histological, biochemical and hematological evaluations of amyloid beta-induced Alzheimerâ€™s disease in rat. Acta Neurobiologiae Experimentalis, 2018, 78, 51-59.	0.4	4
2468	Chlorogenic Acid Alleviates Aβ₂₅₋₃₅-Induced Autophagy and Cognitive Impairment via the mTOR/TFEB Signaling Pathway . Drug Design, Development and Therapy, 2020, Volume 14, 1705-1716.	2.0	64
2469	Structure-based Approaches Targeting Parasite Cysteine Proteases. Current Medicinal Chemistry, 2019, 26, 4435-4453.	1.2	10
2470	A Chronological Review of Potential Disease-Modifying Therapeutic Strategies for Alzheimer's Disease. Current Pharmaceutical Design, 2020, 26, 1286-1299.	0.9	12
2471	Lipid Nanoparticles as Carriers for the Treatment of Neurodegeneration Associated with Alzheimerâ€™s Disease and Glaucoma: Present and Future Challenges. Current Pharmaceutical Design, 2020, 26, 1235-1250.	0.9	14
2472	AMPK: Potential Therapeutic Target for Alzheimer's Disease. Current Protein and Peptide Science, 2020, 21, 66-77.	0.7	25
2473	Tolfenamic Acid: A Modifier of the Tau Protein and its Role in Cognition and Tauopathy. Current Alzheimer Research, 2018, 15, 655-663.	0.7	14
2474	Therapeutic Strategies Targeting Amyloid-Î² in Alzheimerâ€™s Disease. Current Alzheimer Research, 2019, 16, 418-452.	0.7	88
2475	A Pilot Study of Exenatide Actions in Alzheimerâ€™s Disease. Current Alzheimer Research, 2019, 16, 741-752.	0.7	75
2476	Anti-Alzheimerâ€™s Materials Isolated from Marine Bio-resources: A Review. Current Alzheimer Research, 2019, 16, 895-906.	0.7	12
2477	Microglia in Alzheimerâ€™s Disease. Current Alzheimer Research, 2020, 17, 29-43.	0.7	13
2478	Targeting Post-Translational Remodeling of Ryanodine Receptor: A New Track for Alzheimer's Disease Therapy?. Current Alzheimer Research, 2020, 17, 313-323.	0.7	5
2479	Targeting Pathological Amyloid Aggregates with Conformation-Sensitive Antibodies. Current Alzheimer Research, 2020, 17, 722-734.	0.7	12
2480	Emerging Promise of Immunotherapy for Alzheimerâ€™s Disease: A New Hope for the Development of Alzheimerâ€™s Vaccine. Current Topics in Medicinal Chemistry, 2020, 20, 1214-1234.	1.0	22
2481	Combining in vitro and in silico Approaches to Find New Candidate Drugs Targeting the Pathological Proteins Related to the Alzheimer's Disease. Current Neuropharmacology, 2018, 16, 758-768.	1.4	12

#	Article	IF	Citations
2482	The Protective Roles and Molecular Mechanisms of Troxerutin (Vitamin P4) for the Treatment of Chronic Diseases: A Mechanistic Review. Current Neuropharmacology, 2020, 19, 97-110.	1.4	11
2483	Rhizoma Coptidis for Alzheimerâ€™s Disease and Vascular Dementia: A Literature Review. Current Vascular Pharmacology, 2020, 18, 358-368.	0.8	22
2484	A Pharmacological Appraisal of Neuroprotective and Neurorestorative Flavonoids Against Neurodegenerative Diseases. CNS and Neurological Disorders - Drug Targets, 2019, 18, 103-114.	0.8	15
2485	Yishen Huazhuo Decoction Induces Autophagy to Promote the Clearance of AÎ²1-42 in SAMP8 Mice: Mechanism Research of a Traditional Chinese Formula Against Alzheimerâ€™s Disease. CNS and Neurological Disorders - Drug Targets, 2020, 19, 276-289.	0.8	4
2486	The MMP-2/TIMP-2 System in Alzheimer Disease. CNS and Neurological Disorders - Drug Targets, 2020, 19, 402-416.	0.8	14
2487	Amyloid-Negative Dementia in the Elderly is Associated with High Accumulation of Tau in the Temporal Lobes. Open Biomedical Engineering Journal, 2019, 13, 55-66.	0.7	1
2488	Cerasus microcarpa and Amygdalus scoparia Methanolic Extract Protect Cultured Cerebellar Granule Neurons Against Î²-amyloid-induced Toxicity and Oxidative Stress. Journal of Advances in Medical and Biomedical Research, 2020, 28, 23-32.	0.1	4
2489	Role of neprilysin in synaptic plasticity and memory. Sechenov Physiological Journal, 2020, 106, 1191-1208.	0.8	6
2490	Alzheimerâ€™s Disease is Driven by Intraneuronally Retained Beta-Amyloid Produced in the AD-Specific, Î²APP-Independent Pathway: Current Perspective and Experimental Models for Tomorrow. Annals of Integrative Molecular Medicine, 2019, 2, 90-114.	0.0	14
2491	Cellular Senescence in Neurodegenerative Diseases. Frontiers in Cellular Neuroscience, 2020, 14, 16.	1.8	164
2492	Oxidatively Modified Proteins: Cause and Control of Diseases. Applied Sciences (Switzerland), 2020, 10, 6419.	1.3	12
2493	Alzheimerâ€™s Disease: An Overview of Major Hypotheses and Therapeutic Options in Nanotechnology. Nanomaterials, 2021, 11, 59.	1.9	14
2494	Effects of GrandFusion Diet on Cognitive Impairment in Transgenic Mouse Model of Alzheimerâ€™s Disease. Nutrients, 2021, 13, 117.	1.7	8
2495	Promising Results from Alzheimerâ€™s Disease Passive Immunotherapy Support the Development of a Preventive Vaccine. Research, 2019, 2019, 5341375.	2.8	18
2496	Grape Seed Oil as a Natural Therapy in Male Rats with Alzheimerâ€™s Diseases. Advanced Pharmaceutical Bulletin, 2020, 10, 430-436.	0.6	12
2497	Inhibition of HDAC6 expression decreases brain injury induced by APOE4 and AÎ² coâ€‘aggregation in rats. Molecular Medicine Reports, 2019, 20, 3363-3370.	1.1	2
2498	Is Stroke a Neurodegenerative Condition? A Critical Review of Secondary Neurodegeneration and Amyloid-beta Accumulation after Stroke. AIMS Medical Science, 2017, 4, 1-16.	0.2	36
2499	Regulated intramembrane proteolysis, innate immunity and therapeutic targets in Alzheimerâ€™s disease. AIMS Molecular Science, 2016, 3, 138-157.	0.3	2

#	Article	IF	Citations
2500	Alzheimerâ€²s disease: the silver tsunami of the 21stcentury. Neural Regeneration Research, 2016, 11, 693.	1.6	46
2501	Neuroprotective effect of the Chinese medicine Tiantai No. 1 and its molecular mechanism in the senescence-accelerated mouse prone 8. Neural Regeneration Research, 2017, 12, 301.	1.6	2
2502	Heparan sulfate proteoglycans and heparanases in Alzheimer's disease: current outlook and potential therapeutic targets. Neural Regeneration Research, 2017, 12, 914.	1.6	17
2503	Melastatin-related transient receptor potential 2 channel in AÎ²42-induced neuroinflammation: implications to Alzheimerâ€™s disease mechanism and development of therapeutics. Neural Regeneration Research, 2018, 13, 419.	1.6	3
2504	Synaptic dysfunction in Alzheimer's disease: the effects of amyloid beta on synaptic vesicle dynamics as a novel target for therapeutic intervention. Neural Regeneration Research, 2018, 13, 616.	1.6	106
2505	Role of presynaptic calcium stores for neural network dysfunction in Alzheimer's disease. Neural Regeneration Research, 2018, 13, 977.	1.6	2
2506	Loss of canonical Wnt signaling is involved in the pathogenesis of Alzheimer's disease. Neural Regeneration Research, 2018, 13, 1705.	1.6	100
2507	High-frequency (50 Hz) electroacupuncture ameliorates cognitive impairment in rats with amyloid beta 1â€“42-induced Alzheimer's disease. Neural Regeneration Research, 2018, 13, 1833.	1.6	35
2508	Cognitive deficits and Alzheimer-like neuropathological impairments during adolescence in a rat model of type 2 diabetes mellitus. Neural Regeneration Research, 2018, 13, 1995.	1.6	18
2509	Glutamate receptor delocalization in postsynaptic membrane and reduced hippocampal synaptic plasticity in the early stage of Alzheimerâ€™s disease. Neural Regeneration Research, 2019, 14, 1037.	1.6	17
2510	Exploring the efficacy of natural products in alleviating Alzheimerâ€™s disease. Neural Regeneration Research, 2019, 14, 1321.	1.6	66
2511	Knowledge domain and emerging trends in Alzheimerâ€™s disease: a scientometric review based on CiteSpace analysis. Neural Regeneration Research, 2019, 14, 1643.	1.6	102
2512	Physiological effects of amyloid precursor protein and its derivatives on neural stem cell biology and signaling pathways involved. Neural Regeneration Research, 2019, 14, 1661.	1.6	22
2513	The local mammalian target of rapamycin (mTOR) modulation: a promising strategy to counteract neurodegeneration. Neural Regeneration Research, 2019, 14, 1711.	1.6	3
2514	Early active immunization with AÎ²_{3â€“10}-KLH vaccine reduces tau phosphorylation in the hippocampus and protects cognition of mice. Neural Regeneration Research, 2020, 15, 519.	1.6	12
2515	Alzheimerâ€™s disease, neural stem cells and neurogenesis: cellular phase at single-cell level. Neural Regeneration Research, 2020, 15, 824.	1.6	29
2516	Recent advances on the role of long non-coding RNAs in Alzheimer's disease. Neural Regeneration Research, 2020, 15, 2253.	1.6	18
2517	Neuroprotective effects of ZL006 in AÎ²_{1â€“42}-treated neuronal cells. Neural Regeneration Research, 2020, 15, 2296.	1.6	6

#	Article	IF	Citations
2518	Physiological and Pathological Functions of Beta-Amyloid in the Brain and Alzheimer'S Disease. Chinese Journal of Physiology, 2020, 63, 95-100.	0.4	11
2519	Methyl-CpG Binding Protein 2 in Alzheimer Dementia. International Neurourology Journal, 2019, 23, S72-81.	0.5	20
2520	Emerging roles of 14-3-3Î³ in the brain disorder. BMB Reports, 2020, 53, 500-511.	1.1	20
2521	How Î³-secretase hits a moving target. ELife, 2016, 5, .	2.8	7
2522	Reversal of ApoE4-induced recycling block as a novel prevention approach for Alzheimerâ€™s disease. ELife, 2018, 7, .	2.8	62
2523	Endoplasmic reticulum-associated SKN-1A/Nrf1 mediates a cytoplasmic unfolded protein response and promotes longevity. ELife, 2019, 8, .	2.8	50
2524	Increased expression of heme-binding protein 1 early in Alzheimer's disease is linked to neurotoxicity. ELife, 2019, 8, .	2.8	27
2525	Presynaptic APP levels and synaptic homeostasis are regulated by Akt phosphorylation of huntingtin. ELife, 2020, 9, .	2.8	21
2526	Super-resolution microscopy reveals majorly mono- and dimeric presenilin1/Î³-secretase at the cell surface. ELife, 2020, 9, .	2.8	22
2527	Direct imaging of APP proteolysis in living cells. PeerJ, 2017, 5, e3086.	0.9	7
2528	Lipid-induced S-palmitoylation as a Vital Regulator of Cell Signaling and Disease Development. International Journal of Biological Sciences, 2021, 17, 4223-4237.	2.6	26
2529	An AÎ²3-10-KLH vaccine decreases AÎ² plaques and astrocytes and microglia activation in the brain of APP/PS1 transgenic mice. Acta Neurobiologiae Experimentalis, 2021, 81, 207-217.	0.4	0
2530	TNF-Î±-dependent neuronal necroptosis regulated in Alzheimer's disease by coordination of RIPK1-p62 complex with autophagic UVRAG. Theranostics, 2021, 11, 9452-9469.	4.6	56
2531	Predicting brain atrophy from tau pathology: a summary of clinical findings and their translation into personalized models. Brain Multiphysics, 2021, 2, 100039.	0.8	13
2532	Hippocampal CysLT1R overexpression or activation accelerates memory deficits, synaptic dysfunction, and amyloidogenesis in young APP/PS1 transgenic mice. Annals of Translational Medicine, 2021, 9, 1531-1531.	0.7	0
2533	Microglia in Neuroinflammation and Neurodegeneration: From Understanding to Therapy. Frontiers in Neuroscience, 2021, 15, 742065.	1.4	171
2534	Potential of Sorghum Polyphenols to Prevent and Treat Alzheimerâ€™s Disease: A Review Article. Frontiers in Aging Neuroscience, 2021, 13, 729949.	1.7	14
2535	Past, present and future of therapeutic strategies against amyloid-Î² peptides in Alzheimerâ€™s disease: a systematic review. Ageing Research Reviews, 2021, 72, 101496.	5.0	131

#	Article	IF	Citations
2536	Light Chain Stabilization: A Therapeutic Approach to Ameliorate AL Amyloidosis. Hemato, 2021, 2, 645-659.	0.2	9
2537	Design of Transmembrane Mimetic Structural Probes to Trap Different Stages of Î³-Secretaseâ€“Substrate Interaction. Journal of Medicinal Chemistry, 2021, 64, 15367-15378.	2.9	4
2538	Amyloidâ€dependent and amyloidâ€independent effects of Tau in individuals without dementia. Annals of Clinical and Translational Neurology, 2021, 8, 2083-2092.	1.7	7
2539	Decreased Global EEG Synchronization in Amyloid Positive Mild Cognitive Impairment and Alzheimerâ€™s Disease Patientsâ€”Relationship to APOE Îµ4. Brain Sciences, 2021, 11, 1359.	1.1	8
2540	Population pharmacokinetics and standard uptake value ratio of aducanumab, an amyloid plaqueâ€“removing agent, in patients with Alzheimerâ€™s disease. CPT: Pharmacometrics and Systems Pharmacology, 2022, 11, 7-19.	1.3	10
2541	Effects and mechanisms of natural products on Alzheimerâ€™s disease. Critical Reviews in Food Science and Nutrition, 2023, 63, 3168-3188.	5.4	10
2542	Gene Therapy Approach with an Emphasis on Growth Factors: Theoretical and Clinical Outcomes in Neurodegenerative Diseases. Molecular Neurobiology, 2022, 59, 191-233.	1.9	22
2543	The Role of Microglia in the Development of Neurodegenerative Diseases. Biomedicines, 2021, 9, 1449.	1.4	18
2544	Prolonged Volatile Anesthetic Exposure Exacerbates Cognitive Impairment and Neuropathology in the 5xFAD Mouse Model of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2021, , 1-12.	1.2	2
2545	Identification and drug-induced reversion of molecular signatures of Alzheimerâ€™s disease onset and progression in AppNL-G-F, AppNL-F, and 3xTg-AD mouse models. Genome Medicine, 2021, 13, 168.	3.6	7
2546	NGLY1: insights from Caenorhabditis elegans. Journal of Biochemistry, 2022, 171, 145-152.	0.9	4
2547	Mechanistic Understanding from Molecular Dynamics in Pharmaceutical Research 2: Lipid Membrane in Drug Design. Pharmaceuticals, 2021, 14, 1062.	1.7	23
2548	Restoration of Calmodulin-Like Skin Protein as Treatment for Alzheimer's Disease. Frontiers in Neurology, 2021, 12, 771856.	1.1	0
2549	Nanoscale organization of Nicastrin, the substrate receptor of the Î³-secretase complex, as independent molecular domains. Molecular Brain, 2021, 14, 158.	1.3	4
2550	Enhanced Expression of microRNA-1273g-3p Contributes to Alzheimerâ€™s Disease Pathogenesis by Regulating the Expression of Mitochondrial Genes. Cells, 2021, 10, 2697.	1.8	10
2551	Deep post-GWAS analysis identifies potential risk genes and risk variants for Alzheimerâ€™s disease, providing new insights into its disease mechanisms. Scientific Reports, 2021, 11, 20511.	1.6	16
2552	Combined High-Pressure and Multiquantum NMR and Molecular Simulation Propose a Role for N-Terminal Salt Bridges in Amyloid-Beta. Journal of Physical Chemistry Letters, 2021, 12, 9933-9939.	2.1	4
2553	Novel API Coated Catheter Removes Amyloid-Î² from Plasma of Patients with Alzheimerâ€™s Disease. Alzheimerâ€™s & Neurodegenerative Diseases, 2021, 7, 1-7.	0.1	0

#	Article	IF	Citations
2554	Probing the intermolecular interactions, binding affinity, charge density distribution and dynamics of silibinin in dual targets AChE and BACE1: QTAIM and molecular dynamics perspective. Journal of Biomolecular Structure and Dynamics, 2022, 40, 12880-12894.	2.0	5
2556	Structural characterization of polysaccharide purified from Hericium erinaceus fermented mycelium and its pharmacological basis for application in Alzheimer's disease: Oxidative stress related calcium homeostasis. International Journal of Biological Macromolecules, 2021, 193, 358-369.	3.6	19
2557	Inefficient quality control of ribosome stalling during APP synthesis generates CAT-tailed species that precipitate hallmarks of Alzheimerâ€™s disease. Acta Neuropathologica Communications, 2021, 9, 169.	2.4	28
2558	The Swedish dilemma - the almost exclusive use of APPswe-based mouse models impedes adequate evaluation of alternative Î²-secretases. Biochimica Et Biophysica Acta - Molecular Cell Research, 2021, , 119164.	1.9	13
2559	Aggregation and structure of amyloid Î²-protein. Neurochemistry International, 2021, 151, 105208.	1.9	19
2560	Transgene distribution and immune response after ultrasound delivery of rAAV9 and PHP.B to the brain in a mouse model of amyloidosis. Molecular Therapy - Methods and Clinical Development, 2021, 23, 390-405.	1.8	13
2561	(Neurobiology of) Dementia: Causes, Presentation and Management. Mental Health and Illness Worldwide, 2016, , 1-20.	0.1	0
2562	Viral Vector Gene Delivery to the Brain for Treating Neurogenetic Diseases. , 2017, , 89-125.		0
2563	(Neurobiology of) Dementia: Causes, Presentation, and Management. Mental Health and Illness Worldwide, 2017, , 85-104.	0.1	0
2564	The Impact of Ultrasound on APP/PS1 Model Mouse. , 2017, , .		1
2565	Verubecestat. , 2017, , 204-251.		0
2568	Alzheimer Disease. , 2017, , .		0
2572	Dynamics of changes in the content of thyroid hormones and some neurotransmitters in brain of rats with experimental Alzheimerâ€™s disease. Journal of Clinical Medicine of Kazakhstan, 2017, 4, 26-32.	0.1	0
2574	Prion-Like Propagation in Neurodegenerative Diseases. , 2018, , 189-242.		0
2575	Biomarqueurs du liquide cÃ©rÃ©brospinal dans la maladie dâ€™Alzheimer. Bulletin De L'Academie Nationale De Medecine, 2018, 202, 307-320.	0.0	1
2577	Long-Term Monoacylglycerol Lipase Inhibitor Treatment Decelerates Pathological Changes in APP/PS1-21 Mice, but Behavioral Improvements Require Early-Stage Treatment Onsetâ€”Short Report. World Journal of Neuroscience, 2018, 08, 157-170.	0.1	0
2578	Solving the Puzzle of Neurodegeneration. , 2018, , 1-22.		2
2581	Alzheimerio ligos gydymo metodÅ³ paieÅ¡ka: klinikiniÅ³ tyrimÅ³ kryptys. Neurologijos Seminarai, 2018, 22, 21-30.	0.0	0

#	Article	IF	Citations
2593	Therapeutic Vaccines Targeting Alzheimerâ€™s Disease. , 2019, , 9-20.		1
2594	Spectroscopic Characterization of the Interaction between Dopamine and Human Serum Albumin. Open Journal of Biophysics, 2019, 09, 110-130.	0.7	5
2596	Role of Hsp90 Interacting Molecular Chaperones on Tau and AÃŸ Processing in Alzheimerâ€™s Disease. Heat Shock Proteins, 2019, , 131-145.	0.2	0
2597	The Whole Picture: From Isolated to Global MRI Measures of Neurovascular and Neurodegenerative Disease. Advances in Experimental Medicine and Biology, 2019, 1205, 25-53.	0.8	1
2598	AD â€œStatinâ€• Alzheimerâ€™s Disorder is a â€œFastâ€•Disease Preventable by Therapeutic Intervention Initiated Even Late in Life and Reversible at the Early Stages. , 2019, 2, 75-89.		9
2599	Precursor-Independent Overproduction of Beta-Amyloid in AD: Mitochondrial Dysfunction as Possible Initiator of Asymmetric RNA-Dependent Î²APP mRNA Amplification. An Engine that Drives Alzheimerâ€™s Disease. , 2019, 1, .		10
2611	Chronic Traumatic Encephalopathy. , 2020, , 399-419.		0
2612	Synthesis and Structure-Function Analyses of the Toxic Dimer and Trimer Models of Amyloid Î². Yuki Gosei Kagaku Kyokaishi/Journal of Synthetic Organic Chemistry, 2019, 77, 1201-1208.	0.0	0
2613	Amyloid Î²-peptide interaction with GM1 containing model membrane. Advances in Biomembranes and Lipid Self-Assembly, 2020, 32, 1-24.	0.3	0
2614	Mild Cognitive Impairment and Early Dementia. , 2020, , 215-236.		0
2615	A Comprehensive Visual Rating Scale for Predicting Progression from Mild Cognitive Impairment to Dementia in Patients with Alzheimer's Pathology or Suspected Non-Alzheimer's Pathology. Dementia and Neurocognitive Disorders, 2020, 19, 129.	0.4	2
2627	Effect of Autranellacongolensis on Lipid Profile of Ratsâ€™ Brain with Experimentally Induced Alzheimerâ€™s Disease. Journal of Food Research, 2020, 9, 60.	0.1	1
2628	The Î²-Secretase Enzyme BACE1: A Biochemical Enigma for Alzheimerâ€™s Disease. CNS and Neurological Disorders - Drug Targets, 2020, 19, 184-194.	0.8	5
2629	Development of an Efficient Manufacturing Process for E2212 toward Rapid Clinical Introduction. Yuki Gosei Kagaku Kyokaishi/Journal of Synthetic Organic Chemistry, 2020, 78, 760-769.	0.0	0
2630	An Intense, But Ecologically Valid, Resistance Exercise Session Does Not Alter Growth Factors Associated With Cognitive Health. Journal of Aging and Physical Activity, 2020, 28, 605-612.	0.5	2
2632	Surface-enhanced Raman scattering sensing platform for detecting amyloid-Î² peptide interaction with an aggregation inhibitor. Applied Optics, 2020, 59, 7490.	0.9	3
2634	Ex-vivo Alzheimerâ€™s disease brain tissue investigation: a multiscale approach using 1060-nm swept source optical coherence tomography for a direct correlation to histology. Neurophotonics, 2020, 7, 035004.	1.7	1
2636	Herbal Drugs Used In Treatment Of Alzimerâ€™s Disease. American Journal of PharmTech Research, 2020, 10, 66-87.	0.2	0

#	Article	IF	Citations
2637	Analysis of Electrostatic Interaction between Dimer Complexes. Part II: Criteria and Conditions on Inhibitors of APP Protein Derivatives. Technical Physics, 2020, 65, 1313-1320.	0.2	0
2638	Glutamate and GABA in Microglia-Neuron Cross-Talk in Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2021, 22, 11677.	1.8	54
2639	Decoding the Inter-Relationship between Sleep Disorders and Alzheimerâ€™s Disease Pathogenesis. CNS and Neurological Disorders - Drug Targets, 2021, 20, 723-735.	0.8	2
2640	Genomics of Alzheimerâ€™s disease implicates the innate and adaptive immune systems. Cellular and Molecular Life Sciences, 2021, 78, 7397-7426.	2.4	32
2641	The Role of GM130 in Nervous System Diseases. Frontiers in Neurology, 2021, 12, 743787.	1.1	6
2642	Combination of the Glutaminyl Cyclase Inhibitor PQ912 (Varoglutamstat) and the Murine Monoclonal Antibody PBD-C06 (m6) Shows Additive Effects on Brain AÎ² Pathology in Transgenic Mice. International Journal of Molecular Sciences, 2021, 22, 11791.	1.8	10
2643	GluA3-containing AMPA receptors: From physiology to synaptic dysfunction in brain disorders. Neurobiology of Disease, 2021, 161, 105539.	2.1	8
2644	Alzheimerâ€™s Disease-Related Metabolic Pattern in Diverse Forms of Neurodegenerative Diseases. Diagnostics, 2021, 11, 2023.	1.3	9
2645	Systematic Search for a Predictor for the Clinical Observables of Alzheimerâ€™s Disease. Journal of Physical Chemistry B, 2021, 125, 12177-12186.	1.2	2
2646	Identification of hub genes associated with cognition in the hippocampus of Alzheimerâ€™s Disease. Bioengineered, 2021, 12, 9598-9609.	1.4	12
2648	Brain susceptibility to hypoxia/hypoxemia and metabolic dysfunction in Alzheimer's disease. , 2020, , 407-422.		0
2649	Multifunctional Ligand Approach: Search for Effective Therapy Against Alzheimerâ€™s Disease. , 0, , 181-203.		1
2650	In silico Probing Ca2+ And Zn2+ Permeable Transmembrane 4AÎ²1-42 Barrel. Communications in Physics, 2020, 31, .	0.0	0
2653	The ethics of innovation for Alzheimerâ€™s disease: the risk of overstating evidence for metabolic enhancement protocols. Theoretical Medicine and Bioethics, 2020, 41, 223-237.	0.4	15
2654	Alzheimerâ€™s Disease: Etiology, Neuropathology and Pathogenesis. , 0, , 1-22.		22
2655	Lysine acetyltransferase Tip60 acetylates the APP adaptor Fe65 to increase its transcriptional activity. Biological Chemistry, 2021, 402, 481-499.	1.2	4
2656	Immunotherapy Targeting Amyloid-ÃŸ Peptides in Alzheimerâ€™s Disease. , 0, , 23-49.		3
2657	Immunotherapy in Neurodegenerative Disorders. , 2021, , 117-136.		0

#	Article	IF	Citations
2659	Targeting Alzheimerâ€™s disease and related dementias with CRISPR and human pluripotent stem cell technologies. , 2022, , 65-80.		0
2660	Secretases in Alzheimer's disease: Novel insights into proteolysis of APP and TREM2. Current Opinion in Neurobiology, 2022, 72, 101-110.	2.0	28
2661	The Role of AÎ² in the Development of Alzheimerâ€™s Disease and its Mechanisms. E3S Web of Conferences, 2020, 218, 03041.	0.2	0
2662	Squalamine and trodusquemine: two natural products for neurodegenerative diseases, from physical chemistry to the clinic. Natural Product Reports, 2022, 39, 742-753.	5.2	27
2663	Alzheimerâ€™s Disease: The Role of Mutations in Protein Folding. Advances in Experimental Medicine and Biology, 2020, 1195, 227-236.	0.8	2
2664	Toward an integrative understanding of the neuroinflammatory molecular milieu in Alzheimer disease neurodegeneration. , 2020, , 163-176.		0
2665	Amyloid beta 1â€“42-induced animal model of dementia. , 2020, , 865-880.		1
2666	Butyrylcholinesterase as a biomarker in Alzheimerâ€™s disease. , 2020, , 263-280.		1
2668	Revisiting Alzheimerâ€™s Disease. , 2020, , 137-155.		0
2669	Robust Biomarkers: Methodologically Tracking Causal Processes in Alzheimerâ€™s Measurement. Boston Studies in the Philosophy and History of Science, 2020, , 289-318.	0.4	2
2670	Genomics of Alzheimerâ€™s disease. , 2020, , 3-18.		0
2671	A rapid absorbance-based growth assay to screen the toxicity of oligomer AÎ²₄₂ and protect against cell death in yeast. Neural Regeneration Research, 2020, 15, 1931.	1.6	3
2672	THE EU/US TASK FORCEâ€™S FUTURE FOR ANTI-AMYLOID TRIALS: FAITES VOS JEUX. journal of prevention of Alzheimer's disease, The, 2020, 7, 1-2.	1.5	1
2677	Comparative functional genomic analysis of Alzheimerâ€™s affected and naturally aging brains. PeerJ, 2020, 8, e8682.	0.9	3
2678	Switched AÎ²43 generation in familial Alzheimerâ€™s disease with presenilin 1 mutation. Translational Psychiatry, 2021, 11, 558.	2.4	5
2679	First Immunoassay for Measuring Isoaspartate in Human Serum Albumin. Molecules, 2021, 26, 6709.	1.7	9
2680	Multifunctional fluorescence sensor as a potential theranostic agent against Alzheimer's disease. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2022, 267, 120587.	2.0	6
2681	Discovery of aryl aminothiazole Î³-secretase modulators with novel effects on amyloid Î²-peptide production. Bioorganic and Medicinal Chemistry Letters, 2021, 54, 128446.	1.0	3

#	Article	IF	Citations
2682	All-d-Enantiomeric Peptide D3 Designed for Alzheimerâ€™s Disease Treatment Dynamically Interacts with Membrane-Bound Amyloid-Î² Precursors. Journal of Medicinal Chemistry, 2021, 64, 16464-16479.	2.9	7
2684	Lithium modulates multiple tau kinases with distinct effects in cortical and hippocampal neurons according to concentration ranges. Naunyn-Schmiedeberg's Archives of Pharmacology, 2022, 395, 105-113.	1.4	4
2685	Structural differences in amyloid-Î² fibrils from brains of nondemented elderly individuals and Alzheimer's disease patients. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	23
2686	DNA Methylation in Genetic and Sporadic Forms of Neurodegeneration: Lessons from Alzheimerâ€™s, Related Tauopathies and Genetic Tauopathies. Cells, 2021, 10, 3064.	1.8	12
2687	Reversing AÎ² Fibrillation and Inhibiting AÎ² Primary Neuronal Cell Toxicity Using Amphiphilic Polyphenylene Dendrons. Advanced Healthcare Materials, 2022, 11, e2101854.	3.9	8
2688	Potential implications of angiotensin-converting enzyme 2 blockades on neuroinflammation in SARS-CoV-2 infection. Current Drug Targets, 2021, 22, .	1.0	1
2689	Dysregulated expression levels of APH1B in peripheral blood are associated with brain atrophy and amyloid-Î² deposition in Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2021, 13, 183.	3.0	13
2691	Amyloid-Driven Tau Accumulation on Mitochondria Potentially Leads to Cognitive Deterioration in Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2021, 22, 11950.	1.8	7
2692	Peptide-Based Vaccines for Neurodegenerative Diseases: Recent Endeavors and Future Perspectives. Vaccines, 2021, 9, 1278.	2.1	13
2694	Differential Clearance of AÎ² Species from the Brain by Brain Lymphatic Endothelial Cells in Zebrafish. International Journal of Molecular Sciences, 2021, 22, 11883.	1.8	4
2695	Cognitive Impairment in Old Age. European Psychologist, 2020, 25, 174-185.	1.8	3
2697	Analysis of Electrostatic Interaction between Dimer Complexes. Part I: A Method for Selecting Inhibitors of APP Protein Derivatives. Technical Physics, 2020, 65, 1167-1174.	0.2	1
2698	MicroRNA-Mediated Inhibition of Amyloid Beta Protein Synthesis in Alzheimerâ€™s Disease: A Research Protocol. , 2020, 4, 1-7.		0
2712	Hypoxic Preconditioning Ameliorates Amyloid-Î² Pathology and Longterm Cognitive Decline in AÎ²PP/PS1 Transgenic Mice. Current Alzheimer Research, 2020, 17, 626-634.	0.7	4
2713	Amyloid-beta immunotherapy: the hope for Alzheimer disease?. Colombia Medica, 2016, 47, 203-212.	0.7	21
2714	Detection of Alzheimer's Disease. Yale Journal of Biology and Medicine, 2018, 91, 291-300.	0.2	21
2715	Precursor-Independent Overproduction of Beta-Amyloid in AD: Mitochondrial Dysfunction as Possible Initiator of Asymmetric RNA-Dependent Î²APP mRNA Amplification. An Engine that Drives Alzheimer's Disease. Annals of Integrative Molecular Medicine, 2019, 1, 61-74.	0.0	4
2716	Cathepsin D: A Candidate Link between Amyloid Î²-protein and Tauopathy in Alzheimer Disease. Journal of Experimental Neurology, 2021, 2, 10-15.	0.5	4

#	Article	IF	Citations
2717	Cell competition from development to neurodegeneration. DMM Disease Models and Mechanisms, 2021, 14, .	1.2	3
2718	Clustering of activated microglia occurs before the formation of dystrophic neurites in the evolution of AÎ² plaques in Alzheimer's disease. Free Neuropathology, 2020, 1, .	2.4	2
2719	Innate Immunity and Cell Death in Alzheimer's Disease. ASN Neuro, 2021, 13, 17590914211051908.	1.5	1
2720	Aluminum inhibits non-amyloid pathways via retinoic acid receptor. Journal of Trace Elements in Medicine and Biology, 2022, 69, 126902.	1.5	0
2721	Formaldehyde toxicity in age-related neurological dementia. Ageing Research Reviews, 2022, 73, 101512.	5.0	30
2722	Multiple-region grey matter atrophy as a predictor for the development of dementia in a community: the Hisayama Study. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 263-271.	0.9	11
2723	Prions and Neurodegenerative Diseases: A Focus on Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2022, 85, 503-518.	1.2	17
2724	Î±-Lipoic Acid Has the Potential to Normalize Copper Metabolism, Which Is Dysregulated in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2022, 85, 715-728.	1.2	7
2725	Advances in Proteasome Enhancement by Small Molecules. Biomolecules, 2021, 11, 1789.	1.8	13
2726	An App knock-in rat model for Alzheimerâ€™s disease exhibiting AÎ² and tau pathologies, neuronal death and cognitive impairments. Cell Research, 2022, 32, 157-175.	5.7	53
2727	Andrographolide promotes hippocampal neurogenesis and spatial memory in the APPswe/PS1Î”E9 mouse model of Alzheimerâ€™s disease. Scientific Reports, 2021, 11, 22904.	1.6	10
2728	Is Aducanumab for LMICs? Promises and Challenges. Brain Sciences, 2021, 11, 1547.	1.1	5
2729	Dimensional Changes in Lipid Rafts from Human Brain Cortex Associated to Development of Alzheimerâ€™s Disease. Predictions from an Agent-Based Mathematical Model. International Journal of Molecular Sciences, 2021, 22, 12181.	1.8	2
2730	Editorial: Advanced Sampling and Modeling in Molecular Simulations for Slow and Large-Scale Biomolecular Dynamics. Frontiers in Molecular Biosciences, 2021, 8, 795991.	1.6	2
2731	Revisit the Cellular Transmission and Emerging Techniques in Understanding the Mechanisms of Proteinopathies. Frontiers in Neuroscience, 2021, 15, 781722.	1.4	1
2732	Anti-Stroke Chinese Herbal Medicines Inhibit Abnormal Amyloid-Î² Protein Precursor Processing in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2022, 85, 261-272.	1.2	1
2733	Jacob, a Synapto-Nuclear Protein Messenger Linking N-methyl-D-aspartate Receptor Activation to Nuclear Gene Expression. Frontiers in Synaptic Neuroscience, 2021, 13, 787494.	1.3	7
2734	Recent High-Resolution Structures of Amyloids Involved in Neurodegenerative Diseases. Frontiers in Aging Neuroscience, 2021, 13, 782617.	1.7	8

#	Article	IF	Citations
2735	Amyloid Î² 42 fibril structure based on small-angle scattering. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	23
2736	Loss of C9orf72 in Microglia Drives Neuronal Injury by Enhancing Synaptic Pruning in Aged and Alzheimerâ€™s Disease Mice. Neuroscience Bulletin, 2022, 38, 327-330.	1.5	5
2737	Microglia contribute to the propagation of AÎ² into unaffected brain tissue. Nature Neuroscience, 2022, 25, 20-25.	7.1	89
2738	Aumento de la confianza en la interpretaciÃ³n del PET con 18F-Florbetaben: â€œmachine learningâ€•basado en la aproximaciÃ³n cuantitativa. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2022, 41, 153-163.	0.0	1
2739	Presenilin/Î³-Secretase Activity Is Located in Acidic Compartments of Live Neurons. Journal of Neuroscience, 2022, 42, 145-154.	1.7	19
2740	Does Data-Independent Acquisition Data Contain Hidden Gems? A Case Study Related to Alzheimerâ€™s Disease. Journal of Proteome Research, 2022, 21, 118-131.	1.8	15
2741	Exercise Reverses Amyloid Beta-Peptide-mediated Cognitive Deficits in Alzheimerâ€™s Disease Mice Expressing Mutant Presenilin-2. Medicine and Science in Sports and Exercise, 2021, Publish Ahead of Print, .	0.2	3
2742	Impact of increased APP gene dose in Down syndrome and the Dp16 mouse model. Alzheimer's and Dementia, 2022, 18, 1203-1234.	0.4	19
2743	Structural biology of cell surface receptors implicated in Alzheimerâ€™s disease. Biophysical Reviews, 2022, 14, 233-255.	1.5	5
2744	Down-regulation of cyclin D2 in amyloid Î² toxicity, inflammation, and Alzheimerâ€™s disease. PLoS ONE, 2021, 16, e0259740.	1.1	4
2745	Novel Brain-Penetrating Single Chain Antibodies Directed Against 3RTau for the Treatment of Alzheimerâ€™s Disease and Related Dementias. Methods in Molecular Biology, 2022, 2383, 447-457.	0.4	0
2746	WWOX-Related Neurodevelopmental Disorders: Models and Future Perspectives. Cells, 2021, 10, 3082.	1.8	8
2747	Immunosenescence and Alzheimerâ€™s Disease. Healthy Ageing and Longevity, 2022, , 177-199.	0.2	3
2748	Association of Superficial White Matter Alterations with Cerebrospinal Fluid Biomarkers and Cognitive Decline in Neurodegenerative Dementia. Journal of Alzheimer's Disease, 2022, 85, 431-442.	1.2	2
2749	Is Amyloid Burden Measured by 18F-Flutemetamol PET Associated with Progression in Clinical Alzheimerâ€™s Disease?. Journal of Alzheimer's Disease, 2021, , 1-9.	1.2	2
2750	4â€(2â€Hydroxyethyl)â€1â€piperazine ethane sulfonic acid repositioning: Amyloid disaggregating agent and its <scp>sustainedâ€release</scp> system. Bulletin of the Korean Chemical Society, 2022, 43, 78-82.	1.0	6
2751	The Potential Effect of Insulin on AChE and Its Interactions with Rivastigmine In Vitro. Pharmaceuticals, 2021, 14, 1136.	1.7	5
2752	The probabilistic model of Alzheimer disease: the amyloid hypothesis revised. Nature Reviews Neuroscience, 2022, 23, 53-66.	4.9	203

#	Article	IF	Citations
2753	Astrocytes in depression and Alzheimerâ€™s disease. Frontiers of Medicine, 2021, 15, 829-841.	1.5	16
2754	UBB+1 reduces amyloid-Î² cytotoxicity by activation of autophagy in yeast. Aging, 2021, 13, 23953-23980.	1.4	2
2755	Oligomeric AÎ²25â€“35 induces the tyrosine phosphorylation of PSD-95 by SrcPTKs in rat hippocampal CA1 subfield. International Journal of Neuroscience, 2023, 133, 888-895.	0.8	1
2756	Biological and methodological complexities of betaâ€amyloid peptide: Implications for Alzheimerâ€™s disease research. Journal of Neurochemistry, 2022, 160, 434-453.	2.1	12
2757	Time-Evolved SERS Signatures of DEP-Trapped AÎ² and Zn²⁺AÎ² Peptides Revealed by a Sub-10 nm Electrode Nanogap. Analytical Chemistry, 2021, 93, 16320-16329.	3.2	5
2758	Dietary Regulation of Gut-Brain Axis in Alzheimerâ€™s Disease: Importance of Microbiota Metabolites. Frontiers in Neuroscience, 2021, 15, 736814.	1.4	24
2759	Lead Exposure in Developmental Ages Promotes AÎ² Accumulation by Disturbing AÎ² Transportation in Blood-Cerebrospinal Fluid Barrier/Bloodâ€“Brain Barriers and Impairing AÎ² Clearance in the Liver. Biological Trace Element Research, 2022, 200, 3702-3711.	1.9	5
2760	Federated Morphometry Feature Selection for Hippocampal Morphometry Associated Beta-Amyloid and Tau Pathology. Frontiers in Neuroscience, 2021, 15, 762458.	1.4	5
2761	Modified Low-Temperature Extraction Method for Isolation of Bletilla striata Polysaccharide as Antioxidant for the Prevention of Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2021, 22, 12760.	1.8	11
2762	Amyloid-betaâ€“copper interaction studied by simultaneous nitrogen K and copper L2,3-edge soft X-ray absorption spectroscopy. IScience, 2021, 24, 103465.	1.9	2
2763	Redox Homeostasis in Alzheimerâ€™s Disease. Healthy Ageing and Longevity, 2022, , 323-348.	0.2	11
2764	Evidence against altered excitatory/inhibitory balance in the posteromedial cortex of young adult APOE E4 carriers: A resting state 1H-MRS study. NeuroImage Reports, 2021, 1, 100059.	0.5	0
2765	Development of a Low-Molecular-Weight AÎ²42 Detection System Using a Enzyme-Linked Peptide Assay. Biomolecules, 2021, 11, 1818.	1.8	5
2766	Engineering Surface Amphiphilicity of Polymer Nanostructures. Progress in Polymer Science, 2021, , 101489.	11.8	0
2767	Microtubule-modulating Agents in the Fight Against Neurodegeneration: Will it ever Work?. Current Neuropharmacology, 2022, 20, 782-798.	1.4	10
2769	Automatic Detection of Amyloid Beta Plaques in Somatosensory Cortex of an Alzheimerâ€™s Disease Mouse Using Deep Learning. IEEE Access, 2021, 9, 161926-161936.	2.6	3
2770	Innate Immunity and Cell Death in Alzheimer's Disease. ASN Neuro, 2021, 13, 175909142110519.	1.5	19
2771	Chronic Exposure to Environmentally Relevant Concentrations of Guanylurea Impairs the Behavior, Redox Status, Acetylcholinesterase Homeostasis,ÂÂAnd Expression of Antioxidant Defense-, Apoptosis-, and Neuronal Communication-Related Genes OfÂDanio RerioÂAdults. SSRN Electronic Journal, 0, , .	0.4	0

#	Article	IF	Citations
2772	Prenatal and Postnatal Pharmacotherapy in Down Syndrome: The Search to Prevent or Ameliorate Neurodevelopmental and Neurodegenerative Disorders. Annual Review of Pharmacology and Toxicology, 2022, 62, 211-233.	4.2	7
2773	A Protein Corona Modulates Interactions of Î±-Synuclein with Nanoparticles and Alters the Rates of the Microscopic Steps of Amyloid Formation. ACS Nano, 2022, 16, 1102-1118.	7.3	9
2774	Impact of Testosterone on Alzheimerâ€™s Disease. World Journal of Men?s Health, 2022, 40, 243.	1.7	16
2775	Specific Mutations in Aph1 Cause Î³-Secretase Activation. International Journal of Molecular Sciences, 2022, 23, 507.	1.8	5
2776	A fragment of cell adhesion molecule L1 reduces amyloid-Î² plaques in a mouse model of Alzheimerâ€™s disease. Cell Death and Disease, 2022, 13, 48.	2.7	16
2777	Surfactant Protein-G in Wildtype and 3xTg-AD Mice: Localization in the Forebrain, Age-Dependent Hippocampal Dot-like Deposits and Brain Content. Biomolecules, 2022, 12, 96.	1.8	3
2778	The Therapeutic and Diagnostic Potential of Amyloid Î² Oligomers Selective Antibodies to Treat Alzheimerâ€™s Disease. Frontiers in Neuroscience, 2021, 15, 768646.	1.4	10
2779	Quantification of the trans-synaptic partners neurexin-neuroligin in CSF of neurodegenerative diseases by parallel reaction monitoring mass spectrometry. EBioMedicine, 2022, 75, 103793.	2.7	4
2780	Combating amyloid-induced cellular toxicity and stiffness by designer peptidomimetics. RSC Chemical Biology, 2022, 3, 220-226.	2.0	13
2781	Reactive astrocytes acquire neuroprotective as well as deleterious signatures in response to Tau and AÃŸ pathology. Nature Communications, 2022, 13, 135.	5.8	97
2783	Transcriptomic and functional analysis of AÎ²1-42 oligomer-stimulated human monocyte-derived microglia-like cells. Brain, Behavior, and Immunity, 2022, 100, 219-230.	2.0	4
2784	Protection against Amyloid-Î² Oligomer Neurotoxicity by Small Molecules with Antioxidative Properties: Potential for the Prevention of Alzheimerâ€™s Disease Dementia. Antioxidants, 2022, 11, 132.	2.2	9
2785	Paeoniflorin is a promising natural monomer for neurodegenerative diseases via modulation of Ca2+ and ROS homeostasis. Current Opinion in Pharmacology, 2022, 62, 97-102.	1.7	23
2786	Impacts of oxidants and antioxidants on the emergence and progression of Alzheimer's disease. Neurochemistry International, 2022, 153, 105268.	1.9	21
2787	Associations of circulating C-reactive proteins, APOE Îµ4, and brain markers for Alzheimerâ€™s disease in healthy samples across the lifespan. Brain, Behavior, and Immunity, 2022, 100, 243-253.	2.0	12
2788	Investigations of the electronic-molecular structure of bio-inorganic systems using modern methods of quantum chemistry. Inorganica Chimica Acta, 2022, 532, 120728.	1.2	1
2789	Photo-Oxygenation: An Innovative New Therapeutic Approach Against Amyloidoses. Advances in Experimental Medicine and Biology, 2021, 1339, 415-422.	0.8	2
2790	How does excess phenylalanine affect the packing density and fluidity of a lipid membrane?. Physical Chemistry Chemical Physics, 2021, 23, 27294-27303.	1.3	4

#	Article	IF	Citations
2791	Enzyme inhibitors as controllers of neurodegenerative diseases: An update of in vitro effects of medicinal plants. Lekovite Sirovine, 2021, , 72-105.	0.8	1
2792	Comparative Analysis of Aducanumab, Zagotenemab and Pioglitazone as Targeted Treatment Strategies for Alzheimerâ€™s Disease. , 2021, 12, 1964.		35
2793	Effects of <italic><bold>Radix Rehmanniae</bold></italic> on behavior and blood-brain barrier in Alzheimer’s disease mice. Zhejiang Da Xue Xue Bao Yi Xue Ban = Journal of Zhejiang University Medical Sciences, 2021, 50, 553-560.	0.1	1
2795	Activation of Microglial Genes and Crosstalk with Micro-environment in Modulating Immunological Pathology in Alzheimer's Disease. , 2021, , .		0
2796	Genome Editing Technology for the Study and Correction of Neurodegenerative Diseases. Neurochemical Journal, 2021, 15, 339-352.	0.2	1
2797	Anchoring of Amyloid-Î² onto Polyunsaturated Phospholipid Membranes. Journal of Biomolecular Structure and Dynamics, 2021, , 1-11.	2.0	0
2798	Chronic Glucocorticoids Consumption Triggers and Worsens Experimental Alzheimerâ€™s Disease-Like Pathology by Detrimental Immune Modulations. Neuroendocrinology, 2022, 112, 982-997.	1.2	5
2799	Synapses, Microglia, and Lipids in Alzheimerâ€™s Disease. Frontiers in Neuroscience, 2021, 15, 778822.	1.4	10
2800	Icariin Ameliorates Alzheimerâ€™s Disease Pathology by Alleviating Myelin Injury in 3â€‰Ã—â€‰Tg-AD Mice. Neurochemical Research, 2022, 47, 1049-1059.	1.6	13
2801	Synaptic dysfunction in early phases of Alzheimer's Disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2022, 184, 417-438.	1.0	27
2802	Nanocarrier mediated drug delivery as an impeccable therapeutic approach against Alzheimerâ€™s disease. Journal of Controlled Release, 2022, 343, 528-550.	4.8	25
2803	Amyloid-beta peptide and tau protein crosstalk in Alzheimerâ€™s disease. Neural Regeneration Research, 2022, 17, 1666.	1.6	87
2804	The microRNA-455 Null Mouse Has Memory Deficit and Increased Anxiety, Targeting Key Genes Involved in Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2022, 23, 554.	1.8	9
2805	Protein degradation-associated mechanisms that are affected in AlzheimerÂ´s disease. Molecular and Cellular Biochemistry, 2022, 477, 915-925.	1.4	9
2806	The Effect of Ethanol on Disassembly of Amyloid-Î²1-42 Pentamer Revealed by Atomic Force Microscopy and Gel Electrophoresis. International Journal of Molecular Sciences, 2022, 23, 889.	1.8	2
2807	Specificity of Adaptive Immune Responses in Central Nervous System Health, Aging and Diseases. Frontiers in Neuroscience, 2021, 15, 806260.	1.4	11
2808	A closer look at the mycobiome in Alzheimer's disease: Fungal species, pathogenesis and transmission. European Journal of Neuroscience, 2022, 55, 1291-1321.	1.2	6
2809	Posttranscriptional Regulation of Insulin Resistance: Implications for Metabolic Diseases. Biomolecules, 2022, 12, 208.	1.8	17

#	Article	IF	Citations
2810	Impairment of the autophagyâ€“lysosomal pathway in Alzheimer's diseases: Pathogenic mechanisms and therapeutic potential. Acta Pharmaceutica Sinica B, 2022, 12, 1019-1040.	5.7	56
2811	The amyloid-Î²1â€“42-oligomer interacting peptide D-AIP possesses favorable biostability, pharmacokinetics, and brain region distribution. Journal of Biological Chemistry, 2022, 298, 101483.	1.6	1
2812	Sodiumâ€“calcium exchanger isoform-3 targeted Withania somnifera (L.) Dunal therapeutic intervention ameliorates cognition in the 5xFAD mouse model of Alzheimerâ€™s disease. Scientific Reports, 2022, 12, 1537.	1.6	4
2813	Detection and Management of Amyloid-Related Imaging Abnormalities in Patients with Alzheimerâ€™s Disease Treated with Anti-Amyloid Beta Therapy. journal of prevention of Alzheimer's disease, The, 2022, 9, 211-220.	1.5	25
2814	Turning the tide on Alzheimerâ€™s disease: modulation of Î³-secretase. Cell and Bioscience, 2022, 12, 2.	2.1	22
2815	News about Therapies of Alzheimerâ€™s Disease: Extracellular Vesicles from Stem Cells Exhibit Advantages Compared to Other Treatments. Biomedicines, 2022, 10, 105.	1.4	9
2816	The Ubiquitin E3 Ligase Nedd4 Regulates the Expression and Amyloid-Î² Peptide Export Activity of P-Glycoprotein. International Journal of Molecular Sciences, 2022, 23, 1019.	1.8	4
2817	Donâ€™t forget about tau: the effects of ApoE4 genotype on Alzheimerâ€™s disease cerebrospinal fluid biomarkers in subjects with mild cognitive impairmentâ€”data from the Dementia Competence Network. Journal of Neural Transmission, 2022, 129, 477-486.	1.4	14
2818	Genistein prevents the decrease in ganglioside levels induced by amyloid-beta in the frontal cortex of rats. Neurological Research, 2022, 44, 598-604.	0.6	1
2819	Chronic hypoperfusion due to intracranial large artery stenosis is not associated with cerebral Î²-amyloid deposition and brain atrophy. Chinese Medical Journal, 2022, 135, 591-597.	0.9	1
2820	Modeling Alzheimerâ€™s Disease in Caenorhabditis elegans. Biomedicines, 2022, 10, 288.	1.4	18
2821	MDGA1 negatively regulates amyloid precursor proteinâ€“mediated synapse inhibition in the hippocampus. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	12
2822	Therapeutic effects of anti-amyloid Î² antibody after intravenous injection and efficient nose-to-brain delivery in Alzheimerâ€™s disease mouse model. Drug Delivery and Translational Research, 2022, , 1.	3.0	2
2823	Dynamic changes of CSF sPDGFRÎ² during ageing and AD progression and associations with CSF ATN biomarkers. Molecular Neurodegeneration, 2022, 17, 9.	4.4	24
2824	Quetiapine Combined with Sodium Valproate in Patients with Alzheimerâ€™s Disease with Mental and Behavioral Symptoms Efficacy Observation. Journal of Healthcare Engineering, 2022, 2022, 1-12.	1.1	1
2826	A Disulfide-Stabilized AÎ² that Forms Dimers but Does Not Form Fibrils. Biochemistry, 2022, 61, 252-264.	1.2	4
2827	Is amyloid involved in acute neuroinflammation? A CSF analysis in encephalitis. Alzheimer's and Dementia, 2022, , .	0.4	3
2828	Kinetic profiling of therapeutic strategies for inhibiting the formation of amyloid oligomers. Journal of Chemical Physics, 2022, 156, 164904.	1.2	13

#	Article	IF	Citations
2829	Recent Developments in Positron Emission Tomography Tracers for Proteinopathies Imaging in Dementia. Frontiers in Aging Neuroscience, 2021, 13, 751897.	1.7	12
2830	Segregation of the membrane cargoes, BACE1 and amyloid precursor protein (APP) throughout the Golgi apparatus. Traffic, 2022, , .	1.3	6
2831	Soluble TREM2 inhibits secondary nucleation of AÎ² fibrillization and enhances cellular uptake of fibrillar AÎ². Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	14
2832	TAPPing into the potential of inducible tau/APP transgenic mice. Neuropathology and Applied Neurobiology, 2022, 48, .	1.8	3
2833	Disrupted neural correlates of anesthesia and sleep reveal early circuit dysfunctions in Alzheimer models. Cell Reports, 2022, 38, 110268.	2.9	13
2834	Aminoimidazo[1,2-a]pyridine Bearing Different Pyrazole Moieties as the Structural Scaffold for the Development of BACE1 Inhibitor; Synthesis, Structural Characterization, In vitro and In silico Studies. Current Organic Synthesis, 2022, 19, .	0.7	0
2835	Current structure predictors are not learning the physics of protein folding. Bioinformatics, 2022, 38, 1881-1887.	1.8	50
2836	Potentials of Neuropeptides as Therapeutic Agents for Neurological Diseases. Biomedicines, 2022, 10, 343.	1.4	14
2837	Oral nimodipine treatment has no effect on amyloid pathology or neuritic dystrophy in the 5XFAD mouse model of amyloidosis. PLoS ONE, 2022, 17, e0263332.	1.1	7
2838	Chemicalâ€Driven Outflow of Dissociated Amyloid Burden from Brain to Blood. Advanced Science, 2022, 9, e2104542.	5.6	3
2839	Apolipoprotein E polymorphism Îµ4â€stratified longitudinal association between daytime naps, sleep apnea and mild cognitive impairment: A prospective cohort study. European Journal of Neurology, 2022, 29, 1385-1393.	1.7	4
2840	Molecular packing of lipid membranes and action mechanisms of membrane-active peptides. Colloids and Surfaces B: Biointerfaces, 2022, 213, 112384.	2.5	2
2841	Variant-dependent heterogeneity in amyloid Î² burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study. Lancet Neurology, The, 2022, 21, 140-152.	4.9	34
2842	Anti-Inflammatory Gene Therapy Improves Spatial Memory Performance in a Mouse Model of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2022, 85, 1001-1008.	1.2	4
2843	Can the lack of fibrillar form of alpha-synuclein in Lewy bodies be explained by its catalytic activity?. Mathematical Biosciences, 2022, 344, 108754.	0.9	2
2844	Challenges and hopes for Alzheimerâ€™s disease. Drug Discovery Today, 2022, 27, 1027-1043.	3.2	87
2845	Astrocytes deficient in circadian clock gene Bmal1 show enhanced activation responses to amyloid-beta pathology without changing plaque burden. Scientific Reports, 2022, 12, 1796.	1.6	22
2846	The Dynamic Role of Microglia and the Endocannabinoid System in Neuroinflammation. Frontiers in Pharmacology, 2021, 12, 806417.	1.6	24

#	Article	IF	Citations
2847	Amyloid Î² interaction with model cell membranes â€“ What are the toxicity-defining properties of amyloid Î²?. International Journal of Biological Macromolecules, 2022, 200, 520-531.	3.6	19
2848	Abeta peptides disrupt the barrier integrity and glucose metabolism of human induced pluripotent stem cell-derived brain microvascular endothelial cells. NeuroToxicology, 2022, 89, 110-120.	1.4	6
2849	The amyloid state of proteins: A boon or bane?. International Journal of Biological Macromolecules, 2022, 200, 593-617.	3.6	12
2850	Chronic exposure to environmentally relevant concentrations of guanylurea induces neurotoxicity of Danio rerio adults. Science of the Total Environment, 2022, 819, 153095.	3.9	16
2851	Amyloid-Î² peptide 37, 38 and 40 individually and cooperatively inhibit amyloid-Î² 42 aggregation. Chemical Science, 2022, 13, 2423-2439.	3.7	20
2852	Anatomy and formation mechanisms of early amyloid-Î² oligomers with lateral branching: graph network analysis on large-scale simulations. Chemical Science, 2022, 13, 2649-2660.	3.7	3
2853	Physiology, Diagnosis and Treatment of Cardiac Light Chain Amyloidosis. Journal of Clinical Medicine, 2022, 11, 911.	1.0	7
2854	Peripheral Transport Proteins Were Associated with 4-Year Cognitive Decline in APOE É›4 Non-Carriers: A Longitudinal, Population-Based Study. Journal of Alzheimer's Disease, 2022, 86, 801-812.	1.2	0
2856	What have we learnt from past failures in Alzheimerâ€™s disease drug discovery?. Expert Opinion on Drug Discovery, 2022, 17, 309-323.	2.5	9
2857	Hydrogel-Coated Gate Field-Effect Transistor for Real-Time and Label-Free Monitoring of Î²-Amyloid Aggregation and Its Inhibition. Analytical Chemistry, 2022, , .	3.2	2
2858	Multi-Targets: An Unconventional Drug Development Strategy for Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2022, 14, 837649.	1.7	26
2859	Unconjugated PLGA nanoparticles attenuate temperature-dependent Î²-amyloid aggregation and protect neurons against toxicity: implications for Alzheimerâ€™s disease pathology. Journal of Nanobiotechnology, 2022, 20, 67.	4.2	17
2860	Tolcapone Derivative (Tol-D) Inhibits AÎ²42 Fibrillogenesis and Ameliorates AÎ²42-Induced Cytotoxicity and Cognitive Impairment. ACS Chemical Neuroscience, 2022, 13, 638-647.	1.7	2
2861	Anti-HK antibody reveals critical roles of a 20-residue HK region for AÎ²-induced plasma contact system activation. Blood Advances, 2022, 6, 3090-3101.	2.5	6
2862	The Citrus Flavonoid Hesperetin Encounters Diabetes-Mediated Alzheimer-Type Neuropathologic Changes through Relieving Advanced Glycation End-Products Inducing Endoplasmic Reticulum Stress. Nutrients, 2022, 14, 745.	1.7	16
2863	The Emergence of Model Systems to Investigate the Link Between Traumatic Brain Injury and Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2021, 13, 813544.	1.7	5
2864	Remarked suppression of AÎ²₄₂ protomerâ€“protomer dissociation reaction elucidated by molecular dynamics simulation. Proteins: Structure, Function and Bioinformatics, 2022, 90, 1367-1375.	1.5	4
2865	Protective Role of Capsaicin in Neurological Disorders: An Overview. Neurochemical Research, 2022, 47, 1513-1531.	1.6	9

#	Article	IF	Citations
2866	A unifying framework for amyloid-mediated membrane damage: The lipid-chaperone hypothesis. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2022, 1870, 140767.	1.1	15
2867	Endophenotype-based in silico network medicine discovery combined with insurance record data mining identifies sildenafil as a candidate drug for Alzheimerâ€™s disease. Nature Aging, 2021, 1, 1175-1188.	5.3	87
2868	Physiological clearance of AÎ² by spleen and splenectomy aggravates Alzheimerâ€type pathogenesis. Aging Cell, 2022, 21, e13533.	3.0	14
2870	Tau-PET imaging as a molecular modality for Alzheimer's disease. American Journal of Nuclear Medicine and Molecular Imaging, 2021, 11, 374-386.	1.0	0
2872	A nanoscale polymolybdate builded by two hexavacant Keggin-type fragments via a novel {Ca6P6O38} cluster with Î²-sheet conformation modulation ability. CrystEngComm, 0, , .	1.3	4
2873	Syndapin-2 mediated transcytosis of amyloid-Î² across the bloodâ€“brain barrier. Brain Communications, 2022, 4, fcac039.	1.5	3
2874	Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimerâ€™s Disease. journal of prevention of Alzheimer's disease, The, 2022, 9, 197-210.	1.5	201
2875	Hope or hype? Aducanumab as a magic bullet for Alzheimerâ€™s disease. BIO Integration, 2022, 3, .	0.9	3
2876	Peptide probes for proteases â€“ innovations and applications for monitoring proteolytic activity. Chemical Society Reviews, 2022, 51, 2081-2120.	18.7	29
2877	Anodal transcranial direct current stimulation alleviates cognitive impairment in an APP/PS1 model of Alzheimerâ€™s disease in the preclinical stage. Neural Regeneration Research, 2022, 17, 2278.	1.6	5
2879	Principles of Pharmacology in Dementia. , 2022, , 15-29.		0
2880	Olive polyphenols and bioavailable glutathione: Promising results in patients diagnosed with mild Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2022, 8, e12278.	1.8	2
2882	Computer Simulations Aimed at Exploring Protein Aggregation and Dissociation. Methods in Molecular Biology, 2022, 2340, 175-196.	0.4	1
2883	EPR of copper centers in the prion protein. Methods in Enzymology, 2022, 666, 297-314.	0.4	0
2884	Nanomedical drug delivery for neurodegenerative disease. , 2022, , 67-79.		1
2885	Morinda Officinalis Oligosaccharides Alleviate Cognitive Dysfunction Through Depressing Î²-Amyloid Deposition and ER Stress in Alzheimer'S Disease. SSRN Electronic Journal, 0, , .	0.4	0
2886	Improving mouse models for the study of Alzheimer's disease. Current Topics in Developmental Biology, 2022, 148, 79-113.	1.0	1
2887	Improving Prediction of Amyloid Deposition in Mild Cognitive Impairment With a Timed Motor Task. American Journal of Alzheimer's Disease and Other Dementias, 2022, 37, 15333175211048262.	0.9	4

#	Article	IF	Citations
2888	Robust organometallic gold nanoparticles in nanomedicine engineering of proteins. , 2022, , 73-93.		0
2890	Function and therapeutic value of astrocytes in neurological diseases. Nature Reviews Drug Discovery, 2022, 21, 339-358.	21.5	160
2891	Emerging Electroencephalographic Biomarkers to Improve Preclinical to Clinical Translation in Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2022, 14, 805063.	1.7	2
2892	Aducanumab and Its Effects on Tau Pathology: Is This the Turning Point of Amyloid Hypothesis?. International Journal of Molecular Sciences, 2022, 23, 2011.	1.8	22
2893	Identification of Genetic Networks Reveals Complex Associations and Risk Trajectory Linking Mild Cognitive Impairment to Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2022, 14, 821789.	1.7	2
2894	Optogenetic neuromodulation with gamma oscillation as a new strategy for Alzheimer disease: a narrative review. , 2022, 39, 269-277.		4
2895	Alzheimer's disease amyloid-Î² pathology in the lens of the eye. Experimental Eye Research, 2022, 221, 108974.	1.2	5
2896	Recent Advances in Understanding of Alzheimerâ€™s Disease Progression Through Mass Spectrometry-Based Metabolomics. Phenomics, 2022, 2, 1-17.	0.9	10
2897	Mitochondrial ATP Synthase is a Target of Oxidative Stress in Neurodegenerative Diseases. Frontiers in Molecular Biosciences, 2022, 9, 854321.	1.6	15
2898	Targeted Metabolomic Analysis in Alzheimerâ€™s Disease Plasma and Brain Tissue in Non-Hispanic Whites. Journal of Alzheimer's Disease, 2022, 86, 1875-1895.	1.2	17
2899	Neuroprotective role of herbal alternatives in circumventing Alzheimerâ€™s disease through multi-targeting approach - a review. Egyptian Journal of Basic and Applied Sciences, 2022, 9, 91-124.	0.2	1
2900	Amyloidosis in Alzheimerâ€™s Disease: Pathogeny, Etiology, and Related Therapeutic Directions. Molecules, 2022, 27, 1210.	1.7	45
2901	Calcium Signaling Regulated by Cellular Membrane Systems and Calcium Homeostasis Perturbed in Alzheimerâ€™s Disease. Frontiers in Cell and Developmental Biology, 2022, 10, 834962.	1.8	11
2902	In silico screening of potential Î²-secretase (BACE1) inhibitors from VIETHERB database. Journal of Molecular Modeling, 2022, 28, 60.	0.8	3
2903	Alterations of Neuronal Lysosomes in Alzheimerâ€™s Disease and in APPxPS1-KI Mice. Journal of Alzheimer's Disease, 2022, 87, 273-284.	1.2	2
2904	Identification of Potential Core Genes for the Rupture of Intracranial Aneurysms by a Bioinformatics Analysis. Frontiers in Genetics, 2022, 13, 875007.	1.1	3
2905	Structure Optimization of the Toxic Conformation Model of Amyloid Î²42 by Intramolecular Disulfide Bond Formation. ChemBioChem, 2022, 23, .	1.3	7
2906	Lack of N-glycosylation increases Amyloidogenic processing of the amyloid precursor protein. Glycobiology, 2022, , .	1.3	1

#	Article	IF	Citations
2907	Alzheimerâ€™s Disease: An Update and Insights Into Pathophysiology. Frontiers in Aging Neuroscience, 2022, 14, 742408.	1.7	65
2908	Ras and Rab Interactor 3: From Cellular Mechanisms to Human Diseases. Frontiers in Cell and Developmental Biology, 2022, 10, 824961.	1.8	4
2909	Recent Advances in the Modeling of Alzheimerâ€™s Disease. Frontiers in Neuroscience, 2022, 16, 807473.	1.4	55
2910	Non-alcoholic Fatty Liver Disease: Also a Disease of the Brain? A Systematic Review of the Preclinical Evidence. Neurochemical Research, 2022, , 1.	1.6	5
2911	Firstâ€inâ€human study of blood amyloid Î² removal from early Alzheimer's disease patients with normal kidney function. Therapeutic Apheresis and Dialysis, 2022, , .	0.4	1
2912	Chronic PPARÎ³ Stimulation Shifts Amyloidosis to Higher Fibrillarity but Improves Cognition. Frontiers in Aging Neuroscience, 2022, 14, 854031.	1.7	5
2913	Application of Meta-analysis to Evaluate Relationships Among ARIA-E Rate, Amyloid Reduction Rate, and Clinical Cognitive Response in Amyloid Therapeutic Clinical Trials for Early Alzheimerâ€™s Disease. Therapeutic Innovation and Regulatory Science, 2022, 56, 501-516.	0.8	11
2914	Aducanumab Therapy to Treat Alzheimerâ€™s Disease: A Narrative Review. International Journal of Alzheimer's Disease, 2022, 2022, 1-10.	1.1	25
2915	Mechanistic Kinetic Model Reveals How Amyloidogenic Hydrophobic Patches Facilitate the Amyloid-Î² Fibril Elongation. ACS Chemical Neuroscience, 2022, 13, 987-1001.	1.7	4
2916	Colony-stimulating factor 1 receptor signaling in the central nervous system and the potential of its pharmacological inhibitors to halt the progression of neurological disorders. Inflammopharmacology, 2022, 30, 821-842.	1.9	6
2917	Cav3 T-Type Voltage-Gated Ca2+ Channels and the Amyloidogenic Environment: Pathophysiology and Implications on Pharmacotherapy and Pharmacovigilance. International Journal of Molecular Sciences, 2022, 23, 3457.	1.8	1
2918	Pharmacotherapeutic combinations for the treatment of Alzheimerâ€™s disease. Expert Opinion on Pharmacotherapy, 2022, 23, 727-737.	0.9	6
2920	Bioengineered microglia-targeted exosomes facilitate AÎ² clearance via enhancing activity of microglial lysosome for promoting cognitive recovery in Alzheimer's disease. , 2022, 136, 212770.		9
2921	Evidence for Enhanced Efficacy of Passive Immunotherapy against Beta-Amyloid in CD33-Negative 5xFAD Mice. Biomolecules, 2022, 12, 399.	1.8	1
2922	AÎ² oligomers trigger necroptosis-mediated neurodegeneration via microglia activation in Alzheimerâ€™s disease. Acta Neuropathologica Communications, 2022, 10, 31.	2.4	28
2923	Lipid Homeostasis and Its Links With Protein Misfolding Diseases. Frontiers in Molecular Neuroscience, 2022, 15, 829291.	1.4	11
2925	Causal Relationships Between Relative Intake from the Macronutrients and Alzheimerâ€™s Disease: A Two-Sample Mendelian Randomization Study. Journal of Alzheimer's Disease, 2022, , 1-9.	1.2	0
2926	Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimerâ€™s disease. Molecular Neurodegeneration, 2022, 17, 27.	4.4	30

#	Article	IF	Citations
2927	Intranasal delivery of pro-resolving lipid mediators rescues memory and gamma oscillation impairment in AppNL-G-F/NL-G-F mice. Communications Biology, 2022, 5, 245.	2.0	25
2929	Mass spectrometric studies of the variety of betaâ€amyloid proteoforms in Alzheimer's disease. Mass Spectrometry Reviews, 2022, , e21775.	2.8	7
2930	Effects of subchronic dietary exposure to the engineered nanomaterials SiO2 and CeO2 in C57BL/6J and 5xFAD Alzheimer model mice. Particle and Fibre Toxicology, 2022, 19, 23.	2.8	4
2931	Whole-genome sequencing reveals novel ethnicity-specific rare variants associated with Alzheimerâ€™s disease. Molecular Psychiatry, 2022, 27, 2554-2562.	4.1	14
2932	Calcium signaling in individual APP/PS1 mouse dentate gyrus astrocytes increases ex vivo with AÎ² pathology and age without affecting astrocyte network activity. Journal of Neuroscience Research, 2022, 100, 1281-1295.	1.3	3
2933	Microglia in Alzheimer's Disease: a Key Player in the Transition Between Homeostasis and Pathogenesis. Neurotherapeutics, 2022, 19, 186-208.	2.1	19
2934	Proteins Do Not Replicate, They Precipitate: Phase Transition and Loss of Function Toxicity in Amyloid Pathologies. Biology, 2022, 11, 535.	1.3	14
2935	Intrathecal amyloidâ€beta oligomer administration increases tau phosphorylation in the medial temporal lobe in the African green monkey: A nonhuman primate model of Alzheimer's disease. Neuropathology and Applied Neurobiology, 2022, 48, .	1.8	5
2936	Personalized Management and Treatment of Alzheimerâ€™s Disease. Life, 2022, 12, 460.	1.1	4
2937	Enhanced cleavage of APP by co-expressed Bace1 alters the distribution of APP and its fragments in neuronal and non-neuronal cells. Molecular Neurobiology, 2022, 59, 3073-3090.	1.9	8
2938	Microglial large extracellular vesicles propagate early synaptic dysfunction in Alzheimerâ€™s disease. Brain, 2022, 145, 2849-2868.	3.7	32
2939	MT5-MMP promotes neuroinflammation, neuronal excitability and AÎ² production in primary neuron/astrocyte cultures from the 5xFAD mouse model of Alzheimerâ€™s disease. Journal of Neuroinflammation, 2022, 19, 65.	3.1	9
2940	Modulation of amyloid precursor protein cleavage by Î³-secretase activating protein through phase separation. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2122292119.	3.3	5
2941	Small but Mightyâ€”Exosomes, Novel Intercellular Messengers in Neurodegeneration. Biology, 2022, 11, 413.	1.3	15
2942	Alzheimerâ€™s Disease: Key Insights from Two Decades of Clinical Trial Failures. Journal of Alzheimer's Disease, 2022, 87, 83-100.	1.2	56
2943	PCSK9 acts as a key regulator of AÎ² clearance across the bloodâ€“brain barrier. Cellular and Molecular Life Sciences, 2022, 79, 212.	2.4	16
2944	Microbiota inÂneuroinflammationÂandÂsynaptic dysfunction: a focus on Alzheimerâ€™s disease. Molecular Neurodegeneration, 2022, 17, 19.	4.4	89
2945	Amyloid Î² / PKC-dependent alterations in NMDA receptor composition are detected in early stages of AlzheimerÂ´s disease. Cell Death and Disease, 2022, 13, 253.	2.7	16

#	Article	IF	Citations
2946	Mechanistic Insights into Selective Autophagy Subtypes in Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2022, 23, 3609.	1.8	14
2947	Self-Fluorescent Lone Tryptophan Nanoparticles as Theranostic Agents Against Alzheimerâ€™s Disease. ACS Applied Materials & Interfaces, 2022, 14, 13079-13093.	4.0	4
2948	Mammalian target of rapamycin (mTOR) signaling pathway and traumatic brain injury: A novel insight into targeted therapy. Cell Biochemistry and Function, 2022, 40, 232-247.	1.4	19
2950	Immunotherapy for Alzheimerâ€™s disease: targeting Î²-amyloid and beyond. Translational Neurodegeneration, 2022, 11, 18.	3.6	75
2951	Amiloidosis AL: conceptos actuales. Medicina Y Laboratorio, 2022, 26, 119-139.	0.0	2
2952	Activity-differential search for amyloid-Î² aggregation inhibitors using LC-MS combined with principal component analysis. Bioorganic and Medicinal Chemistry Letters, 2022, 61, 128613.	1.0	4
2953	A Model-Based Approach to Bridging Plasma and Dried Blood Spot Concentration Data for Phase 3 Verubecestat Trials. AAPS Journal, 2022, 24, 53.	2.2	4
2954	Age-related deficits in working memory in 5xFAD mice in the Hebb-Williams maze. Behavioural Brain Research, 2022, 424, 113806.	1.2	7
2955	Ketamine promotes the amyloidogenic pathway by regulating endosomal pH. Toxicology, 2022, 471, 153163.	2.0	3
2956	Associations of plasma soluble CD22 levels with brain amyloid burden and cognitive decline in Alzheimerâ€™s disease. Science Advances, 2022, 8, eabm5667.	4.7	6
2957	Dissecting the clinical heterogeneity of early-onset Alzheimerâ€™s disease. Molecular Psychiatry, 2022, 27, 2674-2688.	4.1	40
2958	Measurement of Protein Turnover Rates in Senescent and Non-Dividing Cultured Cells with Metabolic Labeling and Mass Spectrometry. Journal of Visualized Experiments, 2022, , .	0.2	1
2960	Mechanism of Tripeptide Trimming of Amyloid Î²-Peptide 49 by Î³-Secretase. Journal of the American Chemical Society, 2022, 144, 6215-6226.	6.6	26
2961	Neuroprotective Effects of Cholinesterase Inhibitors: Current Scenario in Therapies for Alzheimerâ€™s Disease and Future Perspectives. Journal of Alzheimer's Disease Reports, 2022, 6, 177-193.	1.2	19
2962	AÎ² Assemblies Promote Amyloidogenic Processing of APP and Intracellular Accumulation of AÎ²42 Through Go/GÎ²Î³ Signaling. Frontiers in Cell and Developmental Biology, 2022, 10, 852738.	1.8	7
2963	An Investigation of Instability in Dried Blood Spot Samples for Pharmacokinetic Sampling in Phase 3 Trials of Verubecestat. AAPS Journal, 2022, 24, 52.	2.2	2
2964	Wnt signaling pathway: A comprehensive review. Cell Biology International, 2022, 46, 863-877.	1.4	83
2965	Mucin-Type O-Glycosylation Proximal to Î²-Secretase Cleavage Site Affects APP Processing and Aggregation Fate. Frontiers in Chemistry, 2022, 10, 859822.	1.8	2

#	Article	IF	Citations
2966	miR-30a-5p induces Aî² production via inhibiting the nonamyloidogenic pathway in Alzheimerâ€™s disease. Pharmacological Research, 2022, 178, 106153.	3.1	19
2967	Cell-Penetrating Peptides with Unexpected Anti-Amyloid Properties. Pharmaceutics, 2022, 14, 823.	2.0	9
2968	Structural basis for the mechanisms of human presequence protease conformational switch and substrate recognition. Nature Communications, 2022, 13, 1833.	5.8	4
2969	Cellular Reprogramming and Its Potential Application in Alzheimerâ€™s Disease. Frontiers in Neuroscience, 2022, 16, 884667.	1.4	3
2970	Aî² profiles generated by Alzheimerâ€™s disease causing PSEN1 variants determine the pathogenicity of the mutation and predict age at disease onset. Molecular Psychiatry, 2022, 27, 2821-2832.	4.1	37
2971	Versatile nanomaterials for Alzheimer's disease: Pathogenesis inspired disease-modifying therapy. Journal of Controlled Release, 2022, 345, 38-61.	4.8	11
2972	Advancements in the development of multi-target directed ligands for the treatment of Alzheimerâ€™s disease. Bioorganic and Medicinal Chemistry, 2022, 61, 116742.	1.4	37
2973	Theranostic F-SLOH mitigates Alzheimer's disease pathology involving TFEB and ameliorates cognitive functions in Alzheimer's disease models. Redox Biology, 2022, 51, 102280.	3.9	41
2974	The Aptamer Ob2, a novel AChE inhibitor, restores cognitive deficits and alleviates amyloidogenesis in 5Ã—FAD transgenic mice. Molecular Therapy - Nucleic Acids, 2022, 28, 114-123.	2.3	8
2975	Electrochemical assessment of dielectric damage to phospholipid bilayers by amyloid Î²-Oligomers. Bioelectrochemistry, 2022, 145, 108091.	2.4	5
2976	Regulation of neuroinflammation with GLP-1 receptor targeting nanostructures to alleviate Alzheimerâ€™s symptoms in the disease models. Nano Today, 2022, 44, 101457.	6.2	11
2977	Octovespin, a peptide bioinspired by wasp venom, prevents cognitive deficits induced by amyloid-Î² in Alzheimer's disease mouse model. Neuropeptides, 2022, 93, 102233.	0.9	4
2978	Recent advances in blood and gut microbiota biomarkers for Alzheimer’s disease. Scientia Sinica Vitae, 2021, , .	0.1	0
2979	Effects of Specific Inhibitors for CaMK1D on a Primary Neuron Model for Alzheimerâ€™s Disease. Molecules, 2021, 26, 7669.	1.7	4
2980	The doubleâ€edged sword effect of HDAC6 in Aî² toxicities. FASEB Journal, 2022, 36, e22072.	0.2	2
2981	Insulin gene expression and functional activity of insulin signaling pathway in Alzheimer's disease. Fundamental and Clinical Medicine, 2021, 6, 8-21.	0.1	0
2982	Telomerase reverse transcriptase preserves neuron survival and cognition in Alzheimerâ€™s disease models. Nature Aging, 2021, 1, 1162-1174.	5.3	24
2983	Connecting the dots: The boons and banes of network modeling. Patterns, 2021, 2, 100374.	3.1	3

#	Article	IF	Citations
2984	Early lysosome defects precede neurodegeneration with amyloid-Î² and tau aggregation in NHE6-null rat brain. Brain, 2022, 145, 3187-3202.	3.7	14
2985	Sleep Quality Improvement Enhances Neuropsychological Recovery and Reduces Blood AÎ²42/40 Ratio in Patients with Mildâ€“Moderate Cognitive Impairment. Medicina (Lithuania), 2021, 57, 1366.	0.8	3
2986	Programmed Cell Death Protein 1 Blockade Reduces Glycogen Synthase Kinase 3Î² Activity and Tau Hyperphosphorylation in Alzheimerâ€™s Disease Mouse Models. Frontiers in Cell and Developmental Biology, 2021, 9, 769229.	1.8	5
2987	Associations of TFEB Gene Polymorphisms With Cognitive Function in Rural Chinese Population. Frontiers in Aging Neuroscience, 2021, 13, 757992.	1.7	2
2988	Practical Considerations in the Administration of Aducanumab for the Neurologist. Neurology: Clinical Practice, 2022, 12, 169-175.	0.8	3
2989	Long-term dynamics of aberrant neuronal activity in awake Alzheimerâ€™s disease transgenic mice. Communications Biology, 2021, 4, 1368.	2.0	14
2991	The Implication of Glial Metabotropic Glutamate Receptors in Alzheimerâ€™s Disease. Current Neuropharmacology, 2023, 21, 164-182.	1.4	3
2992	Predicting Tau accumulation in cerebral cortex with multivariate MRI morphometry measurements, sparse coding, and correntropy. , 2021, 12088, .		1
2993	Alzheimerâ€™s Disease: Current Perspectives and Advances in Physiological Modeling. Bioengineering, 2021, 8, 211.	1.6	6
2994	Modulating adult neurogenesis affects synaptic plasticity and cognitive functions in mouse models of Alzheimer's disease. Stem Cell Reports, 2021, 16, 3005-3019.	2.3	21
2995	Alzheimerâ€™s disease modification mediated by bone marrow-derived macrophages via a TREM2-independent pathway in mouse model of amyloidosis. Nature Aging, 2022, 2, 60-73.	5.3	12
2996	Hybrid Bis-Histidine Phenanthroline-Based Ligands to Lessen AÎ²-Bound Cu ROS Production: An Illustration of Cu(I) Significance. Molecules, 2021, 26, 7630.	1.7	6
2997	Conformational Models of APP Processing by Gamma Secretase Based on Analysis of Pathogenic Mutations. International Journal of Molecular Sciences, 2021, 22, 13600.	1.8	4
2998	MEF2C ameliorates learning, memory, and molecular pathological changes in Alzheimer’s disease <italic>in vivo</italic> and<?A3B2 ACK?><italic>in vitro</italic>. Acta Biochimica Et Biophysica Sinica, 2022, 54, 77-90.	0.9	7
2999	Quantitative analysis of macroscopic solute transport in the murine brain. Fluids and Barriers of the CNS, 2021, 18, 55.	2.4	18
3000	An Association of Pathogens and Biofilms with Alzheimerâ€™s Disease. Microorganisms, 2022, 10, 56.	1.6	5
3001	Rational Design of a Cu Chelator That Mitigates Cuâ€•Induced ROS Production by Amyloid Beta. ChemBioChem, 2022, 23, .	1.3	2
3002	The Dynamics of Î²-Amyloid Proteoforms Accumulation in the Brain of a 5xFAD Mouse Model of Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2022, 23, 27.	1.8	7

#	Article	IF	Citations
3004	EDEM1 Regulates Amyloid Precursor Protein (APP) Metabolism and Amyloid-Î² Production. International Journal of Molecular Sciences, 2022, 23, 117.	1.8	7
3005	Genomics and Functional Genomics of Alzheimer's Disease. Neurotherapeutics, 2022, 19, 152-172.	2.1	26
3006	What have we learned from past failures of investigational drugs for Alzheimerâ€™s disease?. Expert Opinion on Investigational Drugs, 2021, 30, 1175-1182.	1.9	13
3007	APP and DYRK1A regulate axonal and synaptic vesicle protein networks and mediate Alzheimerâ€™s pathology in trisomy 21 neurons. Molecular Psychiatry, 2022, 27, 1970-1989.	4.1	14
3008	Guts Imbalance Imbalances the Brain: A Review of Gut Microbiota Association With Neurological and Psychiatric Disorders. Frontiers in Medicine, 2022, 9, 813204.	1.2	80
3009	The relationship between amyloid-beta and brain capillary endothelial cells in Alzheimerâ€™s disease. Neural Regeneration Research, 2022, 17, 2355.	1.6	26
3012	The niacin receptor HCAR2 modulates microglial response and limits disease progression in a mouse model of Alzheimerâ€™s disease. Science Translational Medicine, 2022, 14, eabl7634.	5.8	35
3013	Optimization of Automatic Synthesis and Separation of [18F] AV-45 and Quality Control. Frontiers in Chemistry, 2022, 10, 826678.	1.8	1
3014	Peripheral Pathways to Neurovascular Unit Dysfunction, Cognitive Impairment, and Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2022, 14, 858429.	1.7	9
3015	Limited proteolysisâ€“mass spectrometry reveals aging-associated changes in cerebrospinal fluid protein abundances and structures. Nature Aging, 2022, 2, 379-388.	5.3	15
3016	Protective Effects against the Development of Alzheimerâ€™s Disease in an Animal Model through Active Immunization with Methionine-Sulfoxide Rich Protein Antigen. Antioxidants, 2022, 11, 775.	2.2	0
3017	Study on the novel usnic acid derivatives: design, synthesis, X-Ray crystal structure of Cu(II) complex and anti-AD activities. Journal of Molecular Structure, 2022, , 133018.	1.8	0
3018	Aberrant miR-339-5p/neuronatin signaling causes prodromal neuronal calcium dyshomeostasis in mutant presenilin mice. Journal of Clinical Investigation, 2022, 132, .	3.9	13
3019	High Correlation among Brain-Derived Major Protein Levels in Cerebrospinal Fluid: Implication for Amyloid-Beta and Tau Protein Changes in Alzheimerâ€™s Disease. Metabolites, 2022, 12, 355.	1.3	3
3020	Clinical and Molecular Findings in a Turkish Family Who Had a (c.869- 1G>A) Splicing Variant in PSEN1 Gene with A Rare Condition: The Variant Alzheimer's Disease with Spastic Paraparesis. Current Alzheimer Research, 2022, 19, 223-235.	0.7	3
3021	Amyloid-Î² Induces Cdh1-Mediated Rock2 Stabilization Causing Neurodegeneration. Frontiers in Pharmacology, 2022, 13, 884470.	1.6	9
3022	Lipid Rafts Act as a Common Platform for Amyloid-Î² Oligomer-Induced Alzheimerâ€™s Disease Pathology. Journal of Alzheimer's Disease, 2022, 87, 1189-1203.	1.2	11
3023	Mitochondrial Calcium: Effects of Its Imbalance in Disease. Antioxidants, 2022, 11, 801.	2.2	42

#	Article	IF	Citations
3024	Optical Nanosensor for Intracellular and Intracranial Detection of Amyloid-Beta. ACS Nano, 2022, 16, 7269-7283.	7.3	14
3025	Transcranial Direct Current Stimulation Alleviates Neurovascular Unit Dysfunction in Mice With Preclinical Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2022, 14, 857415.	1.7	8
3026	Somatic genomic changes in single Alzheimerâ€™s disease neurons. Nature, 2022, 604, 714-722.	13.7	92
3027	Structure and mechanism of the Î³-secretase intramembrane protease complex. Current Opinion in Structural Biology, 2022, 74, 102373.	2.6	13
3100	The Plasma Membrane Ca2+-ATPase, a Molecular Target for Tau-induced Cytosolic Calcium Dysregulation. Neuroscience, 2022, , .	1.1	3
3101	Selective ferroptosis vulnerability due to familial Alzheimerâ€™s disease presenilin mutations. Cell Death and Differentiation, 2022, 29, 2123-2136.	5.0	32
3102	Cell competition from development to neurodegeneration. DMM Disease Models and Mechanisms, 2021, 14, .	1.2	8
3103	Predicting Symptom Onset in Sporadic Alzheimerâ€™s Disease: â€œHow Long Do I Have?â€. Journal of Alzheimer's Disease, 2022, , 1-5.	1.2	1
3104	Glucose Metabolism is a Better Marker for Predicting Clinical Alzheimer's Disease than Amyloid or Tau.. Journal of Cellular Immunology, 2022, 4, 15-18.	0.8	0
3105	Two statins and cromolyn as possible drugs against the cytotoxicity of AÎ²(31â€“35) and AÎ²(25â€“35) peptides: a comparative study by advanced computer simulation methods. RSC Advances, 2022, 12, 13352-13366.	1.7	1
3106	Involvement of cholesterol and Î²-amyloid in the initiation and progression of Alzheimerâ€™s disease. , 2022, , 715-745.		0
3107	Designer Probiotics in Metabolic Disorders. , 2022, , 241-260.		2
3110	Microglia-Mediated Inflammation and Neural Stem Cell Differentiation in Alzheimerâ€™s Disease: Possible Therapeutic Role of KV1.3 Channel Blockade. Frontiers in Cellular Neuroscience, 2022, 16, 868842.	1.8	10
3111	Combination Therapy in Alzheimerâ€™s Disease: Is It Time?. Journal of Alzheimer's Disease, 2022, , 1-17.	1.2	4
3112	Erigeron breviscapus (Vant.) Hand-Mazz.: A Promising Natural Neuroprotective Agent for Alzheimerâ€™s Disease. Frontiers in Pharmacology, 2022, 13, 877872.	1.6	4
3113	Reactive and Senescent Astroglial Phenotypes as Hallmarks of Brain Pathologies. International Journal of Molecular Sciences, 2022, 23, 4995.	1.8	18
3114	Focal liver lesions in cirrhosis: Role of contrast-enhanced ultrasonography. World Journal of Radiology, 2022, 14, 70-81.	0.5	2
3115	Nicotinic Acetylcholine Receptors and Microglia as Therapeutic and Imaging Targets in Alzheimerâ€™s Disease. Molecules, 2022, 27, 2780.	1.7	10

#	Article	IF	Citations
3116	Impact of Cerebral Amyloid Angiopathy in Two Transgenic Mouse Models of Cerebral Î²-Amyloidosis: A Neuropathological Study. International Journal of Molecular Sciences, 2022, 23, 4972.	1.8	8
3117	Reconsideration of Alzheimerâ€™s Disease Therapy from a Viewpoint of Amyloidogenic Evolvability. Journal of Alzheimer's Disease Reports, 2022, 6, 207-210.	1.2	1
3118	Role of Intracellular Amyloid Î² as Pathway Modulator, Biomarker, and Therapy Target. International Journal of Molecular Sciences, 2022, 23, 4656.	1.8	15
3119	Biomarkers for Alzheimerâ€™s Disease in the Current State: A Narrative Review. International Journal of Molecular Sciences, 2022, 23, 4962.	1.8	21
3120	Biomarker modeling of Alzheimerâ€™s disease using PET-based Braak staging. Nature Aging, 2022, 2, 526-535.	5.3	73
3121	The Influence of Selected Antipsychotic Drugs on Biochemical Aspects of Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2022, 23, 4621.	1.8	1
3123	PET Imaging in Preclinical Anti-AÎ² Drug Development. Pharmaceutical Research, 2022, 39, 1481-1496.	1.7	7
3124	Parvalbumin neuroplasticity compensates for somatostatin impairment, maintaining cognitive function in Alzheimerâ€™s disease. Translational Neurodegeneration, 2022, 11, 26.	3.6	13
3125	How can we define the presymptomatic C9orf72 disease in 2022? An overview on the current definitions of preclinical and prodromal phases. Revue Neurologique, 2022, 178, 426-436.	0.6	2
3126	Resveratrol and neuroprotection: an insight into prospective therapeutic approaches against Alzheimerâ€™s disease from bench to bedside. Molecular Neurobiology, 2022, 59, 4384-4404.	1.9	37
3127	Transgenic Mouse Models of Alzheimerâ€™s Disease: An Integrative Analysis. International Journal of Molecular Sciences, 2022, 23, 5404.	1.8	36
3128	Exercise Modifies the Transcriptional Regulatory Features of Monocytes in Alzheimerâ€™s Patients: A Multi-Omics Integration Analysis Based on Single Cell Technology. Frontiers in Aging Neuroscience, 2022, 14, 881488.	1.7	18
3129	Nonlocal models in the analysis of brain neurodegenerative protein dynamics with application to Alzheimerâ€™s disease. Scientific Reports, 2022, 12, 7328.	1.6	9
3130	Resilient Hippocampal Gamma Rhythmogenesis and Parvalbumin-Expressing Interneuron Function Before and After Plaque Burden in 5xFAD Alzheimerâ€™s Disease Model. Frontiers in Synaptic Neuroscience, 2022, 14, .	1.3	5
3132	Adamantinomatous craniopharyngioma cyst fluid can trigger inflammatory activation of microglia to damage the hypothalamic neurons by inducing the production of Î²-amyloid. Journal of Neuroinflammation, 2022, 19, 108.	3.1	7
3133	Cross-seeding between AÎ² and SEVI indicates a pathogenic link and gender difference between alzheimer diseases and AIDS. Communications Biology, 2022, 5, 417.	2.0	8
3134	Multimer Detection System-Oligomerized Amyloid Beta (MDS-OAÎ²): A Plasma-Based Biomarker Differentiates Alzheimerâ€™s Disease from Other Etiologies of Dementia. International Journal of Alzheimer's Disease, 2022, 2022, 1-6.	1.1	3
3135	Highly Specific and Sensitive Target Binding by the Humanized pS396-Tau Antibody hC10.2 Across a Wide Spectrum of Alzheimerâ€™s Disease and Primary Tauopathy Postmortem Brains. Journal of Alzheimer's Disease, 2022, 88, 207-228.	1.2	5

#	Article	IF	Citations
3136	A2A Adenosine Receptor: A Possible Therapeutic Target for Alzheimerâ€™s Disease by Regulating NLRP3 Inflammasome Activity?. International Journal of Molecular Sciences, 2022, 23, 5056.	1.8	9
3137	Circadian clocks, cognition, and Alzheimerâ€™s disease: synaptic mechanisms, signaling effectors, and chronotherapeutics. Molecular Neurodegeneration, 2022, 17, 35.	4.4	23
3138	Exploring the Therapeutic Potential of Phytochemicals in Alzheimerâ€™s Disease: Focus on Polyphenols and Monoterpenes. Frontiers in Pharmacology, 2022, 13, .	1.6	18
3139	Autophagy Regulation Influences Î²-Amyloid Toxicity in Transgenic Caenorhabditis elegans. Frontiers in Aging Neuroscience, 2022, 14, .	1.7	7
3140	Magnetoelectric dissociation of Alzheimerâ€™s Î²-amyloid aggregates. Science Advances, 2022, 8, eabn1675.	4.7	13
3141	Melatonin and zinc supplements with physical and mental activities subside neurodegeneration and hepatorenal injury induced by aluminum chloride in rats: Inclusion of GSK-3Î²-Wnt/Î²-catenin signaling pathway. NeuroToxicology, 2022, 91, 69-83.	1.4	8
3142	Evolution of Î±-synuclein conformation ensemble toward amyloid fibril via liquid-liquid phase separation (LLPS) as investigated by dynamic nuclear polarization-enhanced solid-state MAS NMR. Neurochemistry International, 2022, 157, 105345.	1.9	10
3143	Constructing conformational library for amyloid-Î²42 dimers as the smallest toxic oligomers using two CHARMM force fields. Journal of Molecular Graphics and Modelling, 2022, 115, 108207.	1.3	5
3144	Novel benzofurane carbonyl analogs of donepezil as acetylcholinesterase inhibitors. Journal of Molecular Structure, 2022, 1264, 133193.	1.8	4
3145	Immunity and Autoimmune system-a review. , 0, , 03-07.		0
3146	Brain simulation augments machineâ€learningâ€“based classification of dementia. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2022, 8, .	1.8	10
3147	Amyloid-Î² Oligomers: Multiple Moving Targets. Biophysica, 2022, 2, 91-110.	0.6	17
3148	Modeling neurodegenerative disorders in zebrafish. Neuroscience and Biobehavioral Reviews, 2022, 138, 104679.	2.9	23
3149	Arterial vasodilation drives convective fluid flow in the brain: a poroelastic model. Fluids and Barriers of the CNS, 2022, 19, 34.	2.4	19
3150	QSAR and DFT studies of some Tacrine-hydroxamate derivatives as inhibitors of Cholinesterase (AChEs) in the treatment of Alzheimer's disease. Letters in Drug Design and Discovery, 2022, 19, .	0.4	3
3151	Molecular Insights into Cell Type-specific Roles in Alzheimerâ€™s Disease: Human Induced Pluripotent Stem Cell-based Disease Modelling. Neuroscience, 2023, 518, 10-26.	1.1	5
3152	Active site geometry stabilization of a presenilin homolog by the lipid bilayer promotes intramembrane proteolysis. ELife, 2022, 11, .	2.8	3
3153	Alzheimer disease neuropathology in a patient previously treated with aducanumab. Acta Neuropathologica, 2022, 144, 143-153.	3.9	18

#	Article	IF	Citations
3154	Editorial: Experimental and Innovative Approaches to Multi-Target Treatment of Parkinson's and Alzheimer's Diseases. Frontiers in Neuroscience, 2022, 16, .	1.4	4
3155	Neural Stem Cells Secretome Increased Neurogenesis and Behavioral Performance and the Activation of Wnt/Î²-Catenin Signaling Pathway in Mouse Model of Alzheimerâ€™s Disease. NeuroMolecular Medicine, 2022, , .	1.8	4
3156	Alzheimer's disease amyloidogenesis is linked to altered lower urinary tract physiology. Neurourology and Urodynamics, 2022, 41, 1344-1354.	0.8	1
3157	The amyloid precursor protein: a converging point in Alzheimerâ€™s disease. Molecular Neurobiology, 2022, 59, 4501-4516.	1.9	17
3158	Investigating the Role of Spermidine in a Model System of Alzheimerâ€™s Disease Using Correlative Microscopy and Super-resolution Techniques. Frontiers in Cell and Developmental Biology, 2022, 10, .	1.8	8
3159	Design and Synthesis of 6â€‹Oâ€‹Phosphorylated Heparan Sulfate Oligosaccharides to Inhibit Amyloid Î² Aggregation. ChemBioChem, 2022, 23, .	1.3	3
3160	Decreased 5â€‹HT_{1A} binding in mild Alzheimer's diseaseâ€”A positron emission tomography study. Synapse, 2022, 76, .	0.6	2
3161	The new therapy for Alzheimerâ€™s disease: from a hope for a few to a false hope?. Aging Clinical and Experimental Research, 2022, , .	1.4	1
3162	Soluble brain homogenates from diverse human and mouse sources preferentially seed diffuse AÎ² plaque pathology when injected into newborn mouse hosts.. Free Neuropathology, 2022, 3, .	2.4	2
3163	Role of Aducanumab in the Treatment of Alzheimerâ€™s Disease: Challenges and Opportunities. Clinical Interventions in Aging, 0, Volume 17, 797-810.	1.3	59
3164	Protein interaction networks in neurodegenerative diseases: From physiological function to aggregation. Journal of Biological Chemistry, 2022, 298, 102062.	1.6	30
3165	An internal docking site stabilizes substrate binding to Î³-secretase: Analysis by molecular dynamics simulations. Biophysical Journal, 2022, 121, 2330-2344.	0.2	10
3166	D-ribose-L-cysteine reduces oxidative stress and inflammatory cytokines to mitigate liver damage, and memory decline induced by copper sulfate in mice. Journal of Trace Elements in Medicine and Biology, 2022, 73, 127001.	1.5	3
3167	Molecular Dynamics Simulations of Amyloid-Î² Protein in KCl Salt Solution. , 2022, , .		0
3168	A Prospective Viewpoint on Neurological Diseases and Their Biomarkers. Molecules, 2022, 27, 3516.	1.7	9
3169	The Relationships Among Metal Homeostasis, Mitochondria, and Locus Coeruleus in Psychiatric and Neurodegenerative Disorders: Potential Pathogenetic Mechanism and Therapeutic Implications. Cellular and Molecular Neurobiology, 2023, 43, 963-989.	1.7	4
3170	Tau Aggregation Inhibiting Peptides as Potential Therapeutics for Alzheimer Disease. Cellular and Molecular Neurobiology, 2023, 43, 951-961.	1.7	17
3172	Structural covariance changes in major cortico-basal ganglia and thalamic networks in amyloid-positive patients with white matter hyperintensities. Neurobiology of Aging, 2022, 117, 117-127.	1.5	2

#	Article	IF	Citations
3173	Lipids and EGCG Affect Î±-Synuclein Association and Disruption of Nanodiscs. Biochemistry, 2022, 61, 1014-1021.	1.2	5
3174	Novel Stilbene-Nitroxyl Hybrid Compounds Display Discrete Modulation of Amyloid Beta Toxicity and Structure. Frontiers in Chemistry, 2022, 10, .	1.8	1
3175	Cross-seeding of WT amyloid-Î² with Arctic but not Italian familial mutants accelerates fibril formation in Alzheimer's disease. Journal of Biological Chemistry, 2022, 298, 102071.	1.6	8
3176	The therapeutic potential of the neuroactive peptides of soluble amyloid precursor protein-alpha in Alzheimerâ€™s disease and related neurological disorders. Seminars in Cell and Developmental Biology, 2023, 139, 93-101.	2.3	4
3177	Critical roles of protein disulfide isomerases in balancing proteostasis in the nervous system. Journal of Biological Chemistry, 2022, 298, 102087.	1.6	11
3178	Melatonin Attenuates Methamphetamine-Induced Alteration of Amyloid Î² Precursor Protein Cleaving Enzyme Expressions via Melatonin Receptor in Human Neuroblastoma Cells. Neurotoxicity Research, 2022, 40, 1086-1095.	1.3	4
3179	Combined induction of mTOR-dependent and mTOR-independent pathways of autophagy activation as an experimental therapy for Alzheimer's disease-like pathology in a mouse model. Pharmacology Biochemistry and Behavior, 2022, 217, 173406.	1.3	10
3181	Quantifying cerebrospinal fluid dynamics: A review of human neuroimaging contributions to CSF physiology and neurodegenerative disease. Neurobiology of Disease, 2022, 170, 105776.	2.1	18
3182	Searching for AChE inhibitors from natural compounds by using machine learning and atomistic simulations. Journal of Molecular Graphics and Modelling, 2022, 115, 108230.	1.3	8
3183	In Vivo Detection of Changes Related to Cortical Columnar Organization and Neuroinflammation Across the AD Continuum. journal of prevention of Alzheimer's disease, The, 0, , .	1.5	2
3184	Site specific NMR characterization of abeta-40 oligomers cross seeded by abeta-42 oligomers. Chemical Science, 2022, 13, 8526-8535.	3.7	8
3186	Additions to Alpha-Sheet Based Hypotheses for the Cause of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2022, , 1-10.	1.2	2
3187	Correlating tau pathology to brain atrophy using a physics-based Bayesian model. Engineering With Computers, 2022, 38, 3867-3877.	3.5	6
3188	Autophagy activation by Terminalia chebula Retz. reduce AÎ² generation by shifting APP processing toward non-amyloidogenic pathway in APPswe transgenic SH-SY5Y cells. Phytomedicine, 2022, 103, 154245.	2.3	2
3189	Current Progress on Neuroprotection Induced by Artemisia, Ginseng, Astragalus, and Ginkgo Traditional Chinese Medicines for the Therapy of Alzheimerâ€™s Disease. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-21.	1.9	4
3190	Lipase regulation of cellular fatty acid homeostasis as a Parkinsonâ€™s disease therapeutic strategy. Npj Parkinson's Disease, 2022, 8, .	2.5	5
3191	Curcumin Scaffold as a Multifunctional Tool for Alzheimerâ€™s Disease Research. Molecules, 2022, 27, 3879.	1.7	14
3193	Therapeutic potential for amyloid surface inhibitor: only amyloidâ€Î² oligomers formed by secondary nucleation disrupt lipid membrane integrity. FEBS Journal, 2022, 289, 6767-6781.	2.2	7

#	Article	IF	Citations
3194	Recent Advances on the Role of Brain-Derived Neurotrophic Factor (BDNF) in Neurodegenerative Diseases. International Journal of Molecular Sciences, 2022, 23, 6827.	1.8	42
3195	Longitudinal evaluation of neuroinflammation and oxidative stress in a mouse model of Alzheimer disease using positron emission tomography. Alzheimer's Research and Therapy, 2022, 14, .	3.0	6
3196	Identifying Possible AChE Inhibitors from Drug-like Molecules via Machine Learning and Experimental Studies. ACS Omega, 2022, 7, 20673-20682.	1.6	11
3197	Dysregulated Ca2+ Homeostasis as a Central Theme in Neurodegeneration: Lessons from Alzheimerâ€™s Disease and Wolfram Syndrome. Cells, 2022, 11, 1963.	1.8	13
3198	Mapping the Genetic-Imaging-Clinical Pathway with Applications to Alzheimerâ€™s Disease. Journal of the American Statistical Association, 2022, 117, 1656-1668.	1.8	6
3199	Indirubin-3â€²-monoxime-loaded PLGA-PEG nanoparticles for potential Alzheimer's disease treatment. Medicine in Novel Technology and Devices, 2022, 15, 100150.	0.9	3
3200	Presenilin Deficiency Increases Susceptibility to Oxidative Damage in Fibroblasts. Frontiers in Aging Neuroscience, 0, 14, .	1.7	1
3201	In Alzheimer's disease, amyloid beta accumulation is a protective mechanism that ultimately fails. Alzheimer's and Dementia, 2023, 19, 771-783.	0.4	9
3202	Bio-Evaluation of 99mTc-Labeled Homodimeric Chalcone Derivative as Amyloid-Î²-Targeting Probe. Frontiers in Medicine, 0, 9, .	1.2	1
3203	Effect of the ABCA1 agonist CS-6253 on amyloid-Î² and lipoprotein metabolism in cynomolgus monkeys. Alzheimer's Research and Therapy, 2022, 14, .	3.0	5
3204	Far infrared light irradiation enhances AÎ² clearance via increased exocytotic microglial ATP and ameliorates cognitive deficit in Alzheimerâ€™s disease-like mice. Journal of Neuroinflammation, 2022, 19, .	3.1	10
3205	Inter-organellar Communication in Parkinson's and Alzheimer's Disease: Looking Beyond Endoplasmic Reticulum-Mitochondria Contact Sites. Frontiers in Neuroscience, 0, 16, .	1.4	10
3206	Ganglioside Nanocluster-Targeting Peptidyl Inhibitor Prevents Amyloid Î² Fibril Formation on the Neuronal Membrane. ACS Chemical Neuroscience, 2022, 13, 1868-1876.	1.7	5
3207	Strategies for developing Alzheimerâ€™s disease treatments: application of population pharmacokinetic and pharmacodynamic models. Journal of Pharmaceutical Investigation, 2022, 52, 519-538.	2.7	2
3208	Therapeutic nanotechnologies for Alzheimerâ€™s disease: A critical analysis of recent trends and findings. Advanced Drug Delivery Reviews, 2022, 187, 114397.	6.6	11
3209	Rotor-Tuning Boron Dipyrromethenes for Dual-Functional Imaging of AÎ² Oligomers and Viscosity. ACS Applied Bio Materials, 2022, 5, 3049-3056.	2.3	1
3211	Mouse Models of Alzheimerâ€™s Disease. Frontiers in Molecular Neuroscience, 0, 15, .	1.4	50
3212	Intrinsically disordered proteins and proteins with intrinsically disordered regions in neurodegenerative diseases. Biophysical Reviews, 2022, 14, 679-707.	1.5	20

#	Article	IF	Citations
3214	The Role of Astrocytes in Synapse Loss in Alzheimer's Disease: A Systematic Review. Frontiers in Cellular Neuroscience, 0, 16, .	1.8	16
3215	Differential Diagnosis Between Alzheimerâ€™s Disease-Related Depression and Pseudo-Dementia in Depression: A New Indication for Amyloid-Î² Imaging?. Journal of Alzheimer's Disease, 2022, , 1-7.	1.2	2
3216	The dense-core plaques of Alzheimerâ€™s disease are granulomas. Journal of Experimental Medicine, 2022, 219, .	4.2	15
3217	Microglial polarization differentially affects neuronal vulnerability to the Î²-amyloid protein: Modulation by melatonin. Biochemical Pharmacology, 2022, 202, 115151.	2.0	4
3218	p75NTR Ectodomain Ameliorates Cognitive Deficits and Pathologies in a Rapid Eye Movement Sleep Deprivation Mice Model. Neuroscience, 2022, 496, 27-37.	1.1	3
3219	Anti-Aggregation Potential of Phoenix Dactylifera Phytochemicals on AÎ² Fibrils: An In-Silico Analysis. SSRN Electronic Journal, 0, , .	0.4	0
3221	Functional Studies of Genetic Variants Associated with Human Diseases in Notch Signaling-Related Genes Using Drosophila. Methods in Molecular Biology, 2022, , 235-276.	0.4	1
3222	HCN2 Deficiency Causes Cognitive Impairments via Inducing Hyperexcitability of dCA1 Pyramidal Neurons in a Mouse Model of Alzheimer's Disease. SSRN Electronic Journal, 0, , .	0.4	0
3223	Novel insights into non-alcoholic fatty liver disease and dementia: insulin resistance, hyperammonemia, gut dysbiosis, vascular impairment, and inflammation. Cell and Bioscience, 2022, 12, .	2.1	17
3224	Oral Dysbiosis and Neurodegenerative Diseases: Correlations and Potential Causations. Microorganisms, 2022, 10, 1326.	1.6	6
3225	Mechanistic Models of Protein Aggregation Across Length-Scales and Time-Scales: From the Test Tube to Neurodegenerative Disease. Frontiers in Neuroscience, 0, 16, .	1.4	8
3226	The Interplay between cGMP and Calcium Signaling in Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2022, 23, 7048.	1.8	8
3227	NEU1â€”A Unique Therapeutic Target for Alzheimerâ€™s Disease. Frontiers in Pharmacology, 0, 13, .	1.6	5
3228	Novel Coumarinâ€“Pyridine Hybrids as Potent Multi-Target Directed Ligands Aiming at Symptoms of Alzheimerâ€™s Disease. Frontiers in Chemistry, 0, 10, .	1.8	5
3229	Scan-Find-Scan-Model: Discrete Site-Targeted Suppressor Design Strategy for Amyloid-Î². ACS Chemical Neuroscience, 2022, 13, 2191-2208.	1.7	2
3230	Excessive/Aberrant and Maladaptive Synaptic Plasticity: A Hypothesis for the Pathogenesis of Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 0, 14, .	1.7	4
3232	Differentially Aquaporin 5 Expression in Submandibular Glands and Cerebral Cortex in Alzheimerâ€™s Disease. Biomedicines, 2022, 10, 1645.	1.4	4
3233	RNA-binding protein ELAVL4/HuD ameliorates Alzheimer's disease-related molecular changes in human iPSC-derived neurons. Progress in Neurobiology, 2022, 217, 102316.	2.8	6

#	Article	IF	Citations
3234	Exchange Broadening Underlies the Enhancement of IDE-Dependent Degradation of Insulin by Anionic Membranes. ACS Omega, 2022, 7, 24757-24765.	1.6	1
3235	Evoked Cortical Depolarizations Before and After the Amyloid Plaque Accumulation: Voltage Imaging Study. Journal of Alzheimer's Disease, 2022, 88, 1443-1458.	1.2	1
3236	Regulation of the Human IL-10RB Gene Expression by Sp8 and Sp9. Journal of Alzheimer's Disease, 2022, 88, 1469-1485.	1.2	1
3237	Fatty Acids: A Safe Tool for Improving Neurodevelopmental Alterations in Down Syndrome?. Nutrients, 2022, 14, 2880.	1.7	3
3238	Acute Effects of Focused Ultrasound-Induced Blood-Brain Barrier Opening on Anti-Pyroglu3 Abeta Antibody Delivery and Immune Responses. Biomolecules, 2022, 12, 951.	1.8	9
3239	Tau-binding protein PRMT8 facilitates vacuole degeneration in the brain. Journal of Biochemistry, 2022, 172, 233-243.	0.9	2
3240	Multiscale optical and optoacoustic imaging of amyloid-Î² deposits in mice. Nature Biomedical Engineering, 2022, 6, 1031-1044.	11.6	39
3241	Isolation and characterization of neurotoxic astrocytes derived from adult triple transgenic Alzheimer's disease mice. Neurochemistry International, 2022, 159, 105403.	1.9	3
3242	DNA Damage Response-Associated Cell Cycle Re-Entry and Neuronal Senescence in Brain Aging and Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2023, 94, S429-S451.	1.2	7
3243	Altered Balance of Reelin Proteolytic Fragments in the Cerebrospinal Fluid of Alzheimerâ€™s Disease Patients. International Journal of Molecular Sciences, 2022, 23, 7522.	1.8	3
3244	Interaction Interface of AÎ²42 with Human Na,K-ATPase Studied by MD and ITC and Inhibitor Screening by MD. Biomedicines, 2022, 10, 1663.	1.4	2
3245	HEBP1 - An early trigger for neuronal cell death and circuit dysfunction in Alzheimerâ€™s disease. Seminars in Cell and Developmental Biology, 2023, 139, 102-110.	2.3	6
3246	The effect of citalopram treatment on amyloid-Î² precursor protein processing and oxidative stress in human hNSC-derived neurons. Translational Psychiatry, 2022, 12, .	2.4	2
3247	Titanium dioxide and carbon black nanoparticles disrupt neuronal homeostasis via excessive activation of cellular prion protein signaling. Particle and Fibre Toxicology, 2022, 19, .	2.8	3
3248	Identification of Leukocyte Surface P2X7 as a Biomarker Associated with Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2022, 23, 7867.	1.8	5
3249	Sphingosine 1â€phosphate attenuates neuronal dysfunction induced by amyloidâ€Î²2 oligomers through endocytic internalization of <scp>NMDA</scp> receptors. FEBS Journal, 2023, 290, 112-133.	2.2	4
3252	Exploiting mesoporous silica, silver and gold nanoparticles for neurodegenerative diseases treatment. International Journal of Pharmaceutics, 2022, 624, 121978.	2.6	8
3253	Chlorpyrifos oxon crosslinking of amyloid beta 42 peptides is a new route for generation of self-aggregating amyloidogenic oligomers that promote Alzheimer's disease. Chemico-Biological Interactions, 2022, 363, 110029.	1.7	4

#	Article	IF	Citations
3254	Structural basis of the 24B3 antibody against the toxic conformer of amyloid Î² with a turn at positions 22 and 23. Biochemical and Biophysical Research Communications, 2022, 621, 162-167.	1.0	2
3255	Molecular mechanisms in Alzheimer's disease and related potential treatments such as structural target convergence of antibodies and simple organic molecules. European Journal of Medicinal Chemistry, 2022, 240, 114578.	2.6	19
3256	Mitochondria - Nucleus communication in neurodegenerative disease. Who talks first, who talks louder?. Biochimica Et Biophysica Acta - Bioenergetics, 2022, 1863, 148588.	0.5	8
3257	Exosomes, autophagy and ER stress pathways in human diseases: Cross-regulation and therapeutic approaches. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2022, 1868, 166484.	1.8	15
3258	Significance of native PLGA nanoparticles in the treatment of Alzheimer's disease pathology. Bioactive Materials, 2022, 17, 506-525.	8.6	12
3259	Acid-sensing ion channel 1a: a novel target in Alzheimerâ€™s disease?. Neural Regeneration Research, 2023, 18, 324.	1.6	0
3260	The regulatory role of Pin1 in neuronal death. Neural Regeneration Research, 2023, 18, 74.	1.6	10
3261	Hebbian plasticity: the elusive missing link at the heart of Alzheimerâ€™s disease pathogenesis?. Neural Regeneration Research, 2023, 18, 123.	1.6	0
3262	Effect of Date Palm (Phoenix dactylifera) Phytochemicals on AÎ²1â˜’40 Amyloid Formation: An in-silico Analysis. Frontiers in Neuroscience, 0, 16, .	1.4	2
3263	Promising Role of Oral Cavity Mesenchymal Stem Cell-Derived Extracellular Vesicles in Neurodegenerative Diseases. Molecular Neurobiology, 0, , .	1.9	3
3264	If amyloid drives Alzheimer disease, why have anti-amyloid therapies not yet slowed cognitive decline?. PLoS Biology, 2022, 20, e3001694.	2.6	67
3265	Exercise for the prevention of Alzheimer's disease: Multiple pathways to promote non-amyloidogenic AÎ²PP processing. Aging and Health Research, 2022, 2, 100093.	0.5	3
3266	Amyloid Fibril Formation of Arctic Amyloid-Î² 1â€“42 Peptide is Efficiently Inhibited by the BRICHOS Domain. ACS Chemical Biology, 2022, 17, 2201-2211.	1.6	13
3267	Assessments of Ceanothanes Triterpenes as Cholinesterase Inhibitors: An Investigation of Potential Agents with Novel Inspiration for Drug Treatment of Neurodegenerative Diseases. Metabolites, 2022, 12, 668.	1.3	1
3268	DYRK1a Inhibitor Mediated Rescue of Drosophila Models of Alzheimerâ€™s Disease-Down Syndrome Phenotypes. Frontiers in Pharmacology, 0, 13, .	1.6	4
3269	Hallmarks of neurodegenerative disease: A systems pharmacology perspective. CPT: Pharmacometrics and Systems Pharmacology, 2022, 11, 1399-1429.	1.3	15
3271	Neuroimaging analyses from a randomized, controlled study to evaluate plasma exchange with albumin replacement in mild-to-moderate Alzheimerâ€™s disease: additional results from the AMBAR study. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 4589-4600.	3.3	4
3272	Vitamin K2 and B9 are Dual Inhibitors of Acetylcholinesterase and Î²-Secretase. SSRN Electronic Journal, 0, , .	0.4	0

#	Article	IF	Citations
3273	Capillary Dysfunction Correlates with Cortical Amyloid Load in Early Alzheimer's Disease. SSRN Electronic Journal, 0, , .	0.4	0
3274	The role of amyloid Î² in the pathological mechanism of GNE myopathy. Neurological Sciences, 2022, 43, 6309-6321.	0.9	3
3275	Effects of Aducanumab on treating Alzheimerâ€™s disease: targets and clinical trials. , 0, 6, 292-301.		0
3276	Molecular pathology and biomarker of progression in Alzheimerâ€™s disease. Brain, 2022, 145, 2229-2230.	3.7	0
3277	Evaluation of 18F-flutemetamol amyloid PET image analysis parameters on the effect of verubecestat on brain amlyoid load in Alzheimerâ€™s disease. Molecular Imaging and Biology, 2022, 24, 862-873.	1.3	2
3278	Alzheimerâ€™s disease: Ablating single master site abolishes tau hyperphosphorylation. Science Advances, 2022, 8, .	4.7	40
3279	A large-scale genome-wide cross-trait analysis reveals shared genetic architecture between Alzheimerâ€™s disease and gastrointestinal tract disorders. Communications Biology, 2022, 5, .	2.0	45
3280	Amyloid precursor protein (APP) and amyloid Î² (AÎ²) interact with cell adhesion molecules: Implications in Alzheimerâ€™s disease and normal physiology. Frontiers in Cell and Developmental Biology, 0, 10, .	1.8	17
3282	Nanoscale Infrared Spectroscopy Identifies Structural Heterogeneity in Individual Amyloid Fibrils and Prefibrillar Aggregates. Journal of Physical Chemistry B, 2022, 126, 5832-5841.	1.2	16
3283	Neuronal cell death mechanisms in Alzheimerâ€™s disease: An insight. Frontiers in Molecular Neuroscience, 0, 15, .	1.4	36
3284	Diet, Gut Microbiome, and Cognitive Decline. Current Nutrition Reports, 2022, 11, 643-652.	2.1	15
3285	CD33 isoforms in microglia and Alzheimer's disease: Friend and foe. Molecular Aspects of Medicine, 2023, 90, 101111.	2.7	18
3286	The Potential of Small Molecules to Modulate the Mitochondriaâ€“Endoplasmic Reticulum Interplay in Alzheimerâ€™s Disease. Frontiers in Cell and Developmental Biology, 0, 10, .	1.8	6
3287	Biomarkers for the Diagnosis of Alzheimerâ€™s Disease in Clinical Practice: The Role of CSF Biomarkers during the Evolution of Diagnostic Criteria. International Journal of Molecular Sciences, 2022, 23, 8598.	1.8	9
3288	AÎ²₄₂ oligomers can seed the fibrillization of AÎ²₄₀ peptides. Journal of the Chinese Chemical Society, 2022, 69, 1318-1325.	0.8	2
3289	Functionalization strategies of polymeric nanoparticles for drug delivery in Alzheimerâ€™s disease: Current trends and future perspectives. Frontiers in Neuroscience, 0, 16, .	1.4	16
3290	Therapeutic roles of plants for 15 hypothesised causal bases of Alzheimerâ€™s disease. Natural Products and Bioprospecting, 2022, 12, .	2.0	4
3291	AÎ² and Tau Interact with Metal Ions, Lipid Membranes and Peptide-Based Amyloid Inhibitors: Are These Common Features Relevant in Alzheimerâ€™s Disease?. Molecules, 2022, 27, 5066.	1.7	11

#	Article	IF	Citations
3292	Potential neurotoxic activity of diverse molecules released by astrocytes. Brain Research Bulletin, 2022, 189, 80-101.	1.4	14
3293	MicroRNAs in Learning and Memory and Their Impact on Alzheimerâ€™s Disease. Biomedicines, 2022, 10, 1856.	1.4	8
3294	Mercury Ion Binding to Apolipoprotein E Variants ApoE2, ApoE3, and ApoE4: Similar Binding Affinities but Different Structure Induction Effects. ACS Omega, 2022, 7, 28924-28931.	1.6	3
3295	Current progress of cerebral organoids for modeling Alzheimer's disease origins and mechanisms. Bioengineering and Translational Medicine, 2023, 8, .	3.9	4
3296	Kaempferol as a potential neuroprotector in Alzheimer's disease. Journal of Food Biochemistry, 2022, 46, .	1.2	12
3298	Catechol-containing compounds are a broad class of protein aggregation inhibitors: Redox state is a key determinant of the inhibitory activities. Pharmacological Research, 2022, 184, 106409.	3.1	6
3299	A hybrid structural method for investigating low molecular weight oligomeric structures of amyloid beta. ChemBioChem, 0, , .	1.3	1
3300	Elevated Levels of Naturally-Occurring Autoantibodies Against the Extracellular Domain of p75NTR Aggravate the Pathology of Alzheimerâ€™s Disease. Neuroscience Bulletin, 0, , .	1.5	1
3301	Impact of A2T and D23N mutations on C99 homodimer conformations. Journal of Chemical Physics, 2022, 157, 085102.	1.2	0
3302	Modeling the early stages of Alzheimerâ€™s disease by administering intracerebroventricular injections of human native AÎ² oligomers to rats. Acta Neuropathologica Communications, 2022, 10, .	2.4	11
3303	Enhancing the Amyloid-Î² Anti-Aggregation Properties of Curcumin via Arene-Ruthenium(II) Derivatization. International Journal of Molecular Sciences, 2022, 23, 8710.	1.8	6
3304	Retinal Vascular Physiology Biomarkers in a 5XFAD Mouse Model of Alzheimerâ€™s Disease. Cells, 2022, 11, 2413.	1.8	3
3306	Accelerated long-term forgetting in neurodegenerative disorders: A systematic review of the literature. Neuroscience and Biobehavioral Reviews, 2022, 141, 104815.	2.9	6
3307	Testing the link between isoaspartate and Alzheimer's disease etiology. Alzheimer's and Dementia, 2023, 19, 1491-1502.	0.4	4
3308	COR388 (atuzaginstat): an investigational gingipain inhibitor for the treatment of Alzheimer disease. Expert Opinion on Investigational Drugs, 2022, 31, 987-993.	1.9	7
3309	APOE4 drives inflammation in human astrocytes via TAGLN3 repression and NF-ÎºB activation. Cell Reports, 2022, 40, 111200.	2.9	31
3310	Opportunities and challenges in delivering biologics for Alzheimerâ€™s disease by low-intensity ultrasound. Advanced Drug Delivery Reviews, 2022, 189, 114517.	6.6	13
3311	Focal-type, but not Diffuse-type, Amyloid Beta Plaques are Correlated with Alzheimerâ€™s Neuropathology, Cognitive Dysfunction, and Neuroinflammation in the Human Hippocampus. Neuroscience Bulletin, 2022, 38, 1125-1138.	1.5	8

#	Article	IF	Citations
3312	<scp>N</scp>â€glycosylation induced changes in tau protein dynamics reveal its role in tau misfolding and aggregation: A microsecond long molecular dynamics study. Proteins: Structure, Function and Bioinformatics, 2023, 91, 147-160.	1.5	5
3313	Toluidine blue O attenuates tau phosphorylation in N2a-APPSwe cells. Chemico-Biological Interactions, 2022, 366, 110126.	1.7	2
3314	NLRP3 inflammasome in neurodegenerative disease. Translational Research, 2023, 252, 21-33.	2.2	25
3315	Circadian dysfunction and Alzheimer's disease â€“ An updated review. Aging Medicine (Milton (N S W)), 2023, 6, 71-81.	0.9	12
3316	Update on new trend and progress of the mechanism of polysaccharides in the intervention of Alzheimer's disease, based on the new understanding of relevant theories: A review. International Journal of Biological Macromolecules, 2022, 218, 720-738.	3.6	9
3317	Comparative efficacy of lithium and aducanumab for cognitive decline in patients with mild cognitive impairment or Alzheimerâ€™s disease: A systematic review and network meta-analysis. Ageing Research Reviews, 2022, 81, 101709.	5.0	17
3318	Design, synthesis and structure-activity relationship studies of 3-phenylpyrazino[1,2-a]indol-1(2H)-ones as amyloid aggregation and cholinesterase inhibitors with antioxidant activity. European Journal of Medicinal Chemistry Reports, 2022, 6, 100075.	0.6	1
3319	Theta Band-Power Shapes Amyloid-Driven Longitudinal EEG Changes in Elderly Subjective Memory Complainers At-Risk for Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2022, 90, 69-84.	1.2	6
3320	Shengmai san-derived compound prescriptions: A review on chemical constituents, pharmacokinetic studies, quality control, and pharmacological properties. Phytomedicine, 2022, 107, 154433.	2.3	9
3321	TFEB in Alzheimer's disease: From molecular mechanisms to therapeutic implications. Neurobiology of Disease, 2022, 173, 105855.	2.1	14
3322	How the immune system shapes neurodegenerative diseases. Trends in Neurosciences, 2022, 45, 733-748.	4.2	17
3323	Native PLGA nanoparticles regulate APP metabolism and protect neurons against Î²-amyloid toxicity: Potential significance in Alzheimer's disease pathology. International Journal of Biological Macromolecules, 2022, 219, 1180-1196.	3.6	9
3324	Patchouli alcohol ameliorates the learning and memory impairments in an animal model of Alzheimer's disease via modulating SIRT1. Phytomedicine, 2022, 106, 154441.	2.3	4
3325	Tract-specific differences in white matter microstructure between young adult APOE Îµ4 carriers and non-carriers: A replication and extension study. NeuroImage Reports, 2022, 2, 100126.	0.5	1
3326	Targeting neuronal calcium channels and GSK3Î² for Alzheimerâ€™s disease with naturally-inspired Diels-Alder adducts. Bioorganic Chemistry, 2022, 129, 106152.	2.0	1
3327	EGCG-Derived Carbonized Polymer Dots: A Multifunctional Scavenger Targeting Alzheimer's Î²-Amyloid Plaques. SSRN Electronic Journal, 0, , .	0.4	0
3328	Virus-induced Alzheimerâ€™s disease: Potential roles of viral infections in AD neuropathogenesis from two aspects: Aberrant protein accumulations with neuroinflammatory response and virus-induced ablation of adult neurogenesis. AIP Conference Proceedings, 2022, , .	0.3	0
3329	Locomotor Hyperactivity in the Early-Stage Alzheimerâ€™s Disease-like Pathology of APP/PS1 Mice: Associated with Impaired Polarization of Astrocyte Aquaporin 4. , 2022, 13, 1504.		8

#	Article	IF	Citations
3330	A surrogate marker for very early-stage tau pathology is detectable by molecular magnetic resonance imaging. Theranostics, 2022, 12, 5504-5521.	4.6	3
3331	Endocytosis in Î²-amyloid biology and Alzheimerâ€™s disease. , 2022, , 111-131.		0
3332	Amyloid Conversion is Related to Risk Factors ForÂDementia. SSRN Electronic Journal, 0, , .	0.4	0
3333	Pharmacogenomics of Alzheimerâ€™s Disease: Novel Strategies for Drug Utilization and Development. Methods in Molecular Biology, 2022, , 275-387.	0.4	4
3334	What is new in nuclear medicine imaging for dementia. Noropsikiyatri Arsivi, 2022, , .	0.2	1
3335	Polypharmacology in Clinical Applications: Neurological Polypharmacology. , 2022, , 231-269.		0
3336	Potential of food-derived bioactive peptides in alleviation and prevention of Alzheimer's disease. Food and Function, 2022, 13, 10851-10869.	2.1	5
3337	Misfolded protein oligomers induce an increase of intracellular Ca2+ causing an escalation of reactive oxidative species. Cellular and Molecular Life Sciences, 2022, 79, .	2.4	13
3338	Circular RNAs in Alzheimerâ€™s Disease: A New Perspective of Diagnostic and Therapeutic Targets. CNS and Neurological Disorders - Drug Targets, 2023, 22, 1335-1354.	0.8	7
3339	Scanning Tunneling Microscopy of Biological Structures: An Elusive Goal for Many Years. Nanomaterials, 2022, 12, 3013.	1.9	9
3341	Toward high-throughput oligomer detection and classification for early-stage aggregation of amyloidogenic protein. Frontiers in Chemistry, 0, 10, .	1.8	0
3343	High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 1: Meta-analysis and review of efficacy and safety data, and medico-economical aspects. Revue Neurologique, 2022, 178, 1011-1030.	0.6	40
3344	DYRK1A antagonists rescue degeneration and behavioural deficits of in vivo models based on amyloid-Î², Tau and DYRK1A neurotoxicity. Scientific Reports, 2022, 12, .	1.6	3
3345	Enzymeâ€“substrate interface targeting by imidazoleâ€based Î³â€secretase modulators activates Î³â€secretase and stabilizes its interaction with<scp>APP</scp>. EMBO Journal, 2022, 41, .	3.5	6
3346	Cognitive dysfunctions and spontaneous EEG alterations induced by hippocampal amyloid pathology in rats. Advances in Medical Sciences, 2022, 67, 328-337.	0.9	2
3347	An Alzheimerâ€™s Disease Mechanism Based on Early Pathology, Anatomy, Vascular-Induced Flow, and Migration of Maximum Flow Stress Energy Location with Increasing Vascular Disease. Journal of Alzheimer's Disease, 2022, , 1-27.	1.2	0
3348	The Alzheimer's disease 5xFAD mouse model is best suited to investigate pretargeted imaging approaches beyond the blood-brain barrier. Frontiers in Nuclear Medicine, 0, 2, .	0.7	1
3349	Modulating Nanodroplet Formation En Route to Fibrillization of Amyloid Peptides with Designed Flanking Sequences. Biomacromolecules, 2022, 23, 4179-4191.	2.6	7

#	Article	IF	Citations
3350	Evaluation of Synaptic and Axonal Dysfunction Biomarkers in Alzheimerâ€™s Disease and Mild Cognitive Impairment Based on CSF and Bioinformatic Analysis. International Journal of Molecular Sciences, 2022, 23, 10867.	1.8	3
3351	Prediction of Alzheimerâ€™s Disease Using Patterns of Methylation Levels in Key Immunologic-Related Genes. Journal of Alzheimer's Disease, 2022, 90, 783-794.	1.2	1
3352	Photobiomodulation for Hypertension and Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2022, 90, 1045-1055.	1.2	10
3353	Dramatic impacts on brain pathology, anxiety, and cognitive function in the knock-in APPNL-G-F mouse model of Alzheimer disease following long-term voluntary exercise. Alzheimer's Research and Therapy, 2022, 14, .	3.0	5
3354	The Innate and Adaptive Immune Cells in Alzheimerâ€™s and Parkinsonâ€™s Diseases. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-12.	1.9	9
3355	Optimization of the Linker Length in the Dimer Model of E22P-AÎ²40 Tethered at Position 38. ACS Chemical Neuroscience, 2022, 13, 2913-2923.	1.7	4
3356	Immunotherapies for Alzheimerâ€™s Diseaseâ€”A Review. Vaccines, 2022, 10, 1527.	2.1	12
3357	The Role of Glymphatic System in Alzheimerâ€™s and Parkinsonâ€™s Disease Pathogenesis. Biomedicines, 2022, 10, 2261.	1.4	19
3358	Inflammation-Related microRNAs-146a and -155 Are Upregulated in Mild Cognitive Impairment Subjects Among Older Age Population in Montenegro. Journal of Alzheimer's Disease, 2022, 90, 625-638.	1.2	3
3359	Applications and challenges of rhodopsin-based optogenetics in biomedicine. Frontiers in Neuroscience, 0, 16, .	1.4	3
3360	Cognitive Impairment and Neurodegenerative Diseases Development Associated with Organophosphate Pesticides Exposure: a Review Study. Neurotoxicity Research, 2022, 40, 1624-1643.	1.3	12
3362	Regulation of microglial physiology by the microbiota. Gut Microbes, 2022, 14, .	4.3	14
3364	Beta-amyloid Deposition in Biliary Atresia Reduces Liver Regeneration by Inhibiting Energy Metabolism and Mammalian Target of Rapamycin Signaling. Clinical and Translational Gastroenterology, 2022, 13, e00536.	1.3	2
3365	Multi-Target Mechanisms of Phytochemicals in Alzheimerâ€™s Disease: Effects on Oxidative Stress, Neuroinflammation and Protein Aggregation. Journal of Personalized Medicine, 2022, 12, 1515.	1.1	17
3366	High Soluble Amyloid-Î²42 Predicts Normal Cognition in Amyloid-Positive Individuals with Alzheimerâ€™s Disease-Causing Mutations. Journal of Alzheimer's Disease, 2022, 90, 333-348.	1.2	23
3368	Effect of tricyclic 1,2-thiazine derivatives in neuroinflammation induced by preincubation with lipopolysaccharide or coculturing with microglia-like cells. Pharmacological Reports, 2022, 74, 890-908.	1.5	1
3369	Early stage Î²-amyloid-membrane interactions modulate lipid dynamics and influence structural interfaces and fibrillation. Journal of Biological Chemistry, 2022, 298, 102491.	1.6	12
3370	MIND Dietary Pattern Adherence Is Selectively Associated with Cognitive Processing Speed in Middle-Aged Adults. Journal of Nutrition, 2022, 152, 2941-2949.	1.3	1

#	Article	IF	Citations
3372	AÎ² plaques do not protect against <scp>HSV</scp>â€‘1 infection in a mouse model of familial Alzheimer's disease, and <scp>HSV</scp>â€‘1 does not induce AÎ² pathology in a model of late onset Alzheimer's disease. Brain Pathology, 2023, 33, .	2.1	6
3373	Neuroprotective Properties of Ferulic Acid in Preclinical Models of Alzheimerâ€™s Disease: A Systematic Literature Review. Current Medicinal Chemistry, 2023, 30, 2796-2811.	1.2	1
3375	Curcumin-Loaded Mesoporous Silica Nanoparticles Dispersed in Thermo-Responsive Hydrogel as Potential Alzheimer Disease Therapy. Pharmaceutics, 2022, 14, 1976.	2.0	23
3376	Combination Therapy for the Treatment of Alzheimerâ€™s Disease: Recent Progress and Future Prospects. Current Topics in Medicinal Chemistry, 2022, 22, 1849-1867.	1.0	3
3377	Amyloid fibrils act as a reservoir of soluble oligomers, the main culprits in protein deposition diseases. BioEssays, 2022, 44, .	1.2	14
3378	Activation of PI3k/Akt/mTOR Signaling Induces Deposition of p-tau to Promote Aluminum Neurotoxicity. Neurotoxicity Research, 2022, 40, 1516-1525.	1.3	1
3379	Building in vitro models of the brain to understand the role ofAPOEin Alzheimerâ€™s disease. Life Science Alliance, 2022, 5, e202201542.	1.3	2
3380	Specific Mutations in the Cholesterol-Binding Site of APP Alter Its Processing and Favor the Production of Shorter, Less Toxic AÎ² Peptides. Molecular Neurobiology, 2022, 59, 7056-7073.	1.9	4
3381	Mitochondrial Alterations in Neurons Derived from the Murine AppNL-F Knock-In Model of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2022, 90, 565-583.	1.2	3
3382	Monitoring Alzheimerâ€™s Disease Progression in Mild Cognitive Impairment Stage Using Machine Learning-Based FDG-PET Classification Methods. Journal of Alzheimer's Disease, 2022, , 1-10.	1.2	3
3383	The glymphatic system: Current understanding and modeling. IScience, 2022, 25, 104987.	1.9	85
3384	Willis Lecture: Biomarkers for Inflammatory White Matter Injury in Binswanger Disease Provide Pathways to Precision Medicine. Stroke, 2022, 53, 3514-3523.	1.0	2
3385	Amyloid Î² oligomers disrupt piriform cortical output via a serotonergic pathway. Neurobiology of Aging, 2023, 121, 64-77.	1.5	2
3386	Interactions of Curcuminâ€™s Degradation Products with the AÎ²₄₂ Dimer: A Computational Study. Journal of Physical Chemistry B, 2022, 126, 7627-7637.	1.2	4
3387	Covalent fragment inhibits intramembrane proteolysis. Frontiers in Molecular Biosciences, 0, 9, .	1.6	0
3388	pH Dependence of Amyloidâ€Î² Fibril Assembly Kinetics: Unravelling the Microscopic Molecular Processes. Angewandte Chemie - International Edition, 2022, 61, .	7.2	14
3389	Protective role of IGF-1 and GLP-1 signaling activation in neurological dysfunctions. Neuroscience and Biobehavioral Reviews, 2022, 142, 104896.	2.9	25
3390	pH Dependence of Amyloidâ€Î² Fibril Assembly Kinetics: Unravelling the Microscopic Molecular Processes. Angewandte Chemie, 2022, 134, .	1.6	2

#	Article	IF	Citations
3391	MÃ¼ller cell degeneration and microglial dysfunction in the Alzheimerâ€™s retina. Acta Neuropathologica Communications, 2022, 10, .	2.4	11
3392	Altered glucose metabolism in Alzheimer's disease: Role of mitochondrial dysfunction and oxidative stress. Free Radical Biology and Medicine, 2022, 193, 134-157.	1.3	46
3393	Novel molecular mechanisms in Alzheimerâ€™s disease: The potential role of DEK in disease pathogenesis. Frontiers in Aging Neuroscience, 0, 14, .	1.7	1
3394	Immunosenescence of brain accelerates Alzheimerâ€™s disease progression. Reviews in the Neurosciences, 2023, 34, 85-101.	1.4	3
3395	DoenÃ§a de alzheimer. , 2021, , 374-388.		0
3396	Studying Alzheimerâ€™s Disease Using <i>Drosophila melanogaster</i> as a Powerful Tool. Advances in Alzheimer's Disease, 2022, 11, 23-37.	0.3	1
3398	Lysine-targeting inhibition of amyloid Î² oligomerization by a green perilla-derived metastable chalcone in vitro and in vivo. RSC Chemical Biology, 2022, 3, 1380-1396.	2.0	3
3399	Inhibition of Amyloid-Î² Aggregation by p-Terphenyls from the Mushroom Polyozellus multiplex and Their Neuroprotective Effects. Heterocycles, 2022, 104, 2025.	0.4	1
3400	Big dynorphin is a neuroprotector scaffold against amyloid Î²-peptide aggregation and cell toxicity. Computational and Structural Biotechnology Journal, 2022, 20, 5672-5679.	1.9	7
3401	Amphiphilic stilbene derivatives attenuate the neurotoxicity of soluble AÎ²₄₂ oligomers by controlling their interactions with cell membranes. Chemical Science, 2022, 13, 12818-12830.	3.7	5
3402	Transcriptomic Profiling Identifies CD8+ T Cells in the Brain of Aged and Alzheimerâ€™s Disease Transgenic Mice as Tissue-Resident Memory T Cells. Journal of Immunology, 2022, 209, 1272-1285.	0.4	28
3403	Heart fatty acid-binding protein is associated with phosphorylated tau and longitudinal cognitive changes. Frontiers in Aging Neuroscience, 0, 14, .	1.7	1
3404	The emerging role of autophagy and mitophagy in tauopathies: From pathogenesis to translational implications in Alzheimerâ€™s disease. Frontiers in Aging Neuroscience, 0, 14, .	1.7	9
3405	Pharmacological Investigations of Selected Multitargetâ€Direct Ligands for the Treatment of Alzheimer's Disease. ChemistrySelect, 2022, 7, .	0.7	1
3406	Altering Brain Amyloidosis by Intra-Lingual and Extra-Nasal Exposure of AÎ² Aggregates. Cells, 2022, 11, 3442.	1.8	1
3407	The Flavonol Quercitrin Hinders GSK3 Activity and Potentiates the Wnt/Î²-Catenin Signaling Pathway. International Journal of Molecular Sciences, 2022, 23, 12078.	1.8	2
3408	Hypothesis review: Alzheimer's overture guidelines. Brain Pathology, 2023, 33, .	2.1	18
3410	Neurexin-Î² Mediates the Synaptogenic Activity of Amyloid Precursor Protein. Journal of Neuroscience, 2022, 42, 8936-8947.	1.7	5

#	Article	IF	Citations
3411	Deletion of Small GTPase H-Ras Rescues Memory Deficits and Reduces Amyloid Plaque-Associated Dendritic Spine Loss in Transgenic Alzheimerâ€™s Mice. Molecular Neurobiology, 2023, 60, 495-511.	1.9	3
3412	Moringa Oleifera Alleviates AÎ² Burden and Improves Synaptic Plasticity and Cognitive Impairments in APP/PS1 Mice. Nutrients, 2022, 14, 4284.	1.7	7
3413	Sticker-and-spacer model for amyloid beta condensation and fibrillation. Frontiers in Molecular Neuroscience, 0, 15, .	1.4	2
3414	Targeting Alzheimerâ€™s Disease: The Critical Crosstalk between the Liver and Brain. Nutrients, 2022, 14, 4298.	1.7	13
3415	Synaptogenic effect of APP -Swedish mutation in familial Alzheimerâ€™s disease. Science Translational Medicine, 2022, 14, .	5.8	29
3416	Metalâ€“Organic Framework-Derived Carbon as a Photoacoustic Modulator of Alzheimerâ€™s Î²-Amyloid Aggregate Structure. ACS Nano, 2022, 16, 18515-18525.	7.3	5
3417	Itâ€™s Groundhog Day! What Can the History of Science Say About the Crisis in Alzheimerâ€™s Disease Research?. Journal of Alzheimer's Disease, 2022, 90, 1401-1415.	1.2	2
3418	Molecular basis for isoform-selective inhibition of presenilin-1 by MRK-560. Nature Communications, 2022, 13, .	5.8	9
3420	Epigenetic Changes and Chromatin Reorganization in Brain Function: Lessons from Fear Memory Ensemble and Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2022, 23, 12081.	1.8	7
3421	Amyloid AÎ²25-35 Aggregates Say â€˜NOâ€™ to Long-Term Potentiation in the Hippocampus through Activation of Stress-Induced Phosphatase 1 and Mitochondrial Na+/Ca2+ Exchanger. International Journal of Molecular Sciences, 2022, 23, 11848.	1.8	2
3422	Taylor dispersion analysis discloses the impairment of AÎ² peptide aggregation by the presence of a fluorescent tag. Electrophoresis, 2023, 44, 701-710.	1.3	3
3424	Erythropoietin signaling in peripheral macrophages is required for systemic Î²â€amyloid clearance. EMBO Journal, 0, , .	3.5	3
3425	Immunogenicity of MultiTEP platform technology-based Tau vaccine in non-human primates. Npj Vaccines, 2022, 7, .	2.9	5
3426	Efficacy and Safety of a Brain-Penetrant Biologic TNF-Î± Inhibitor in Aged APP/PS1 Mice. Pharmaceutics, 2022, 14, 2200.	2.0	7
3427	Unveiling the Potential of Polyphenols as Anti-Amyloid Molecules in Alzheimerâ€™s Disease. Current Neuropharmacology, 2023, 21, 787-807.	1.4	1
3428	Mechanistic Insight into the Binding of Huperzine a with Human Transferrin: Computational, Spectroscopic and Calorimetric Approaches. ACS Omega, 2022, 7, 38361-38370.	1.6	2
3429	Calpain-mediated proteolysis as driver and modulator of polyglutamine toxicity. Frontiers in Molecular Neuroscience, 0, 15, .	1.4	4
3430	The Potential Neuroprotective Effect of Cyperus esculentus L. Extract in Scopolamine-Induced Cognitive Impairment in Rats: Extensive Biological and Metabolomics Approaches. Molecules, 2022, 27, 7118.	1.7	5

#	Article	IF	Citations
3431	Patients with Alzheimerâ€™s disease have an increased removal rate of soluble beta-amyloid-42. PLoS ONE, 2022, 17, e0276933.	1.1	7
3432	Unravelling the relationship between amyloid accumulation and brain network function in normal aging and very mild cognitive decline: a longitudinal analysis. Brain Communications, 2022, 4, .	1.5	3
3433	Plasma Phosphorylated Tau at Threonine 181 and Neuropsychiatric Symptoms in Preclinical and Prodromal Alzheimer Disease. Neurology, 2023, 100, .	1.5	24
3434	The central role of tau in Alzheimerâ€™s disease: From neurofibrillary tangle maturation to the induction of cell death. Brain Research Bulletin, 2022, 190, 204-217.	1.4	22
3435	Amyloid-Related Imaging Abnormalities: An Update. American Journal of Roentgenology, 2023, 220, 562-574.	1.0	16
3436	Glycosylated clusterin species facilitate AÎ² toxicity in human neurons. Scientific Reports, 2022, 12, .	1.6	5
3438	Treatment of Alzheimer's disease with small-molecule photosensitizers. Chinese Chemical Letters, 2023, 34, 107966.	4.8	2
3439	Nanotechnology for the diagnosis and treatment of Alzheimer's disease: A bibliometric analysis. Nano Today, 2022, 47, 101654.	6.2	18
3440	The effects and potential of microglial polarization and crosstalk with other cells of the central nervous system in the treatment of Alzheimerâ€™s disease. Neural Regeneration Research, 2023, 18, 947.	1.6	6
3441	Effect of mono- and diketone group in curcumin analogues on amyloid fibrillation of hen egg white lysozyme. Biophysical Chemistry, 2023, 292, 106913.	1.5	3
3442	Fluid biomarkers in Alzheimer's disease. Advances in Clinical Chemistry, 2023, , 249-281.	1.8	7
3443	Role of DNMTs in the Brain. Advances in Experimental Medicine and Biology, 2022, , 363-394.	0.8	5
3444	Testosterone and Alzheimerâ€™s disease. Problemy Endokrinologii, 2022, 68, 97-107.	0.2	1
3445	Linking the Amyloid, Tau, and Mitochondrial Hypotheses of Alzheimerâ€™s Disease and Identifying Promising Drug Targets. Biomolecules, 2022, 12, 1676.	1.8	24
3446	Postnatal neuronal Bace1 deletion impairs neuroblast and oligodendrocyte maturation. Human Molecular Genetics, 0, , .	1.4	0
3447	The Dual Role of Astrocyte-Derived Exosomes and Their Contents in the Process of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2023, 91, 33-42.	1.2	6
3448	Developments in scalable strategies for detecting early markers of cognitive decline. Translational Psychiatry, 2022, 12, .	2.4	7
3449	AAV-mediated neuronal expression of an scFv antibody selective for AÎ² oligomers protects synapses and rescues memory in Alzheimer models. Molecular Therapy, 2023, 31, 409-419.	3.7	3

#	Article	IF	Citations
3452	Females exhibit higher GluA2 levels and outperform males in active place avoidance despite increased amyloid plaques in TgF344-Alzheimerâ€™s rats. Scientific Reports, 2022, 12, .	1.6	4
3453	Astrocytes as a Therapeutic Target in Alzheimerâ€™s Diseaseâ€“Comprehensive Review and Recent Developments. International Journal of Molecular Sciences, 2022, 23, 13630.	1.8	23
3454	Therapeutic Potential of Targeting Mitochondria for Alzheimerâ€™s Disease Treatment. Journal of Clinical Medicine, 2022, 11, 6742.	1.0	5
3455	Sequenceâ€“Activity Relationship of ATCUN Peptides in the Context of Alzheimerâ€™s Disease. Molecules, 2022, 27, 7903.	1.7	3
3457	Reduced Expression of Voltage-Gated Sodium Channel Beta 2 Restores Neuronal Injury and Improves Cognitive Dysfunction Induced by AÎ²1-42. Neural Plasticity, 2022, 2022, 1-21.	1.0	1
3458	Engineering antibody and protein therapeutics to cross the bloodâ€“brain barrier. Antibody Therapeutics, 2022, 5, 311-331.	1.2	4
3459	Alzheimer's disease â€“ Where do we go from here?. Biochemical and Biophysical Research Communications, 2022, 633, 72-76.	1.0	10
3460	Infectious origin of Alzheimerâ€™s disease: Amyloid beta as a component of brain antimicrobial immunity. PLoS Pathogens, 2022, 18, e1010929.	2.1	22
3461	Differential â€œprogressibilityâ€•in human know-how: A conceptual overview. Research Policy, 2023, 52, 104663.	3.3	0
3462	Metal-organic frameworks: A promising option for the diagnosis and treatment of Alzheimer's disease. Journal of Controlled Release, 2023, 353, 1-29.	4.8	13
3463	Terahertz technology in intraoperative neurodiagnostics: A review. Opto-Electronic Advances, 2023, 6, 220071-220071.	6.4	14
3464	An ion mobility-mass spectrometry study of copper-metallothionein-2A: binding sites and stabilities of Cu-MT and mixed metal Cuâ€“Ag and Cuâ€“Cd complexes. Analyst, The, 2023, 148, 546-555.	1.7	3
3465	Ghrelin system in Alzheimer's disease. Current Opinion in Neurobiology, 2023, 78, 102655.	2.0	2
3466	Compromised autophagy and mitophagy in brain ageing and Alzheimerâ€™s diseases. Aging Brain, 2022, 2, 100056.	0.7	8
3467	Current Themes and Controversies in the Alzheimerâ€™s Disease Field: Looking Ahead to the ctad Meeting in San Francisco, November 29-December 2 2022. journal of prevention of Alzheimer's disease, The, 0, , .	1.5	0
3468	Munronin V with 7/7/6 tricarbocyclic framework fromMunronia henryiharms inhibits tau pathology by activating autophagy. Organic and Biomolecular Chemistry, 2023, 21, 514-519.	1.5	2
3469	Probing protein misfolding and dissociation with an infrared free-electron laser. Methods in Enzymology, 2023, , 65-96.	0.4	1
3470	A Univariate Morphometry Index for AD-induced Abnormal Cortical Surface Pattern Similarity Measurement. , 2022, , .		0

#	Article	IF	Citations
3471	HMGCS2-Induced Autophagic Degradation of Tau Involves Ketone Body and ANKRD24. Journal of Alzheimer's Disease, 2022, , 1-20.	1.2	3
3472	DSCR1 deficiency ameliorates the AÎ² pathology of Alzheimerâ€™s disease by enhancing microglial activity. Life Science Alliance, 2023, 6, e202201556.	1.3	1
3473	A Review of the Recent Advances in Alzheimerâ€™s Disease Research and the Utilization of Network Biology Approaches for Prioritizing Diagnostics and Therapeutics. Diagnostics, 2022, 12, 2975.	1.3	5
3474	Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2022, 14, .	3.0	32
3475	PLD3 affects axonal spheroids and network defects in Alzheimerâ€™s disease. Nature, 2022, 612, 328-337.	13.7	43
3476	BACE2: A Promising Neuroprotective Candidate for Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2023, 94, S159-S171.	1.2	2
3477	Studying the trafficking of labeled trodusquemine and its application as nerve marker for lightâ€sheet and expansion microscopy. FASEB Journal, 2022, 36, .	0.2	3
3478	The role of ADAM10 in astrocytes: Implications for Alzheimerâ€™s disease. Frontiers in Aging Neuroscience, 0, 14, .	1.7	4
3479	Transsynaptic Signaling of Ephs in Synaptic Development, Plasticity, and Disease. Neuroscience, 2023, 508, 137-152.	1.1	3
3480	Alzheimerâ€™s Disease: A Systems View Provides a Unifying Explanation of Its Development. Journal of Alzheimer's Disease, 2023, 91, 43-70.	1.2	7
3481	Retrospective Bayesian Evidence of Null Effect in Two Decades of Alzheimerâ€™s Disease Clinical Trials. Journal of Alzheimer's Disease, 2023, 91, 531-535.	1.2	3
3482	Short sleep duration is associated with lower cerebrospinal fluid amyloid beta 42 levels in midlife: a preliminary report. Sleep, 2023, 46, .	0.6	0
3483	The Strategies for Treating â€œAlzheimerâ€™s Diseaseâ€• Insulin Signaling May Be a Feasible Target. Current Issues in Molecular Biology, 2022, 44, 6172-6188.	1.0	5
3484	Role of Polyphenols in Alleviating Alzheimerâ€™s Disease: A Review. Current Medicinal Chemistry, 2023, 30, 4032-4047.	1.2	1
3485	Amyloid-Î² in Alzheimerâ€™s disease â€“ front and centre after all?. Neuronal Signaling, 2023, 7, .	1.7	9
3486	Insights into the Mixture of AÎ²24 and AÎ²42 Peptides from Atomistic Simulations. Journal of Physical Chemistry B, 2022, 126, 10689-10696.	1.2	3
3487	Trilateral association of autophagy, mTOR and Alzheimerâ€™s disease: Potential pathway in the development for Alzheimerâ€™s disease therapy. Frontiers in Pharmacology, 0, 13, .	1.6	17
3488	Reduced excitatory neuron activity and interneuron-type-specific deficits in a mouse model of Alzheimerâ€™s disease. Communications Biology, 2022, 5, .	2.0	12

#	Article	IF	Citations
3489	Type 2 Diabetes Mellitus and Alzheimerâ€™s Disease: Shared Molecular Mechanisms and Potential Common Therapeutic Targets. International Journal of Molecular Sciences, 2022, 23, 15287.	1.8	26
3491	APOE genotype and biological sex regulate astroglial interactions with amyloid plaques in Alzheimerâ€™s disease mice. Journal of Neuroinflammation, 2022, 19, .	3.1	7
3492	Targeting Sterol O-Acyltransferase/Acyl-CoA:Cholesterol Acyltransferase (ACAT): A Perspective on Small-Molecule Inhibitors and Their Therapeutic Potential. Journal of Medicinal Chemistry, 2022, 65, 16062-16098.	2.9	5
3493	The Early Diagnosis of Alzheimerâ€™s Disease: A Patient-Centred Conversation with the Care Team. Neurology and Therapy, 0, , .	1.4	1
3494	SOBA: Development and testing of a soluble oligomer binding assay for detection of amyloidogenic toxic oligomers. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	21
3496	Formation of extramembrane Î² -strands controls dimerization of transmembrane helices in amyloid precursor protein C99. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	2
3497	Natural Carotenoids as Neuroprotective Agents for Alzheimerâ€™s Disease: An Evidence-Based Comprehensive Review. Journal of Agricultural and Food Chemistry, 2022, 70, 15631-15646.	2.4	2
3498	Development of a quantitative semiâ€mechanistic model of Alzheimer's disease based on the amyloid/tau/neurodegeneration framework (the Qâ€ATN model). Alzheimer's and Dementia, 2023, 19, 2287-2297.	0.4	1
3499	Amyloids in synthetic applications. Scientific Reports, 2022, 12, .	1.6	0
3500	Oligomer Formation by Amyloid-Î²42 in a Membrane-Mimicking Environment in Alzheimerâ€™s Disease. Molecules, 2022, 27, 8804.	1.7	5
3501	Inhibition of mGluR5/PI3K-AKT Pathway Alleviates Alzheimerâ€™s Disease-Like Pathology Through the Activation of Autophagy in 5XFAD Mice. Journal of Alzheimer's Disease, 2023, 91, 1197-1214.	1.2	4
3502	Sexual Dimorphism in Neurodegenerative Diseases and in Brain Ischemia. Biomolecules, 2023, 13, 26.	1.8	6
3503	Sulfatide Deficiency, an Early Alzheimerâ€™s Lipidomic Signature, Causes Brain Ventricular Enlargement in the Absence of Classical Neuropathological Hallmarks. International Journal of Molecular Sciences, 2023, 24, 233.	1.8	6
3506	Enhanced potency of aggregation inhibitors mediated by liquid condensates. Physical Review Research, 2022, 4, .	1.3	0
3507	Action of the Purinergic and Cholinergic Anti-inflammatory Pathways on Oxidative Stress in Patients with Alzheimerâ€™s Disease in the Context of the COVID-19 Pandemic. Neuroscience, 2023, 512, 110-132.	1.1	1
3508	MiR-191-5p Attenuates Tau Phosphorylation, AÎ² Generation, and Neuronal Cell Death by Regulating Death-Associated Protein Kinase 1. ACS Chemical Neuroscience, 2022, 13, 3554-3566.	1.7	8
3509	Epidemiological Characteristics and Factors Associated with Alzheimerâ€™s Disease and Mild Cognitive Impairment among the Elderly in Urban and Rural Areas of Hubei Province. Journal of Clinical Medicine, 2023, 12, 28.	1.0	1
3510	Role of Tau in Various Tauopathies, Treatment Approaches, and Emerging Role of Nanotechnology in Neurodegenerative Disorders. Molecular Neurobiology, 2023, 60, 1690-1720.	1.9	11

#	Article	IF	Citations
3511	Epigallocatechin gallate-derived carbonized polymer dots: A multifunctional scavenger targeting Alzheimer's Î²-amyloid plaques. Acta Biomaterialia, 2023, 157, 524-537.	4.1	8
3512	Adherens junctions organize size-selective proteolytic hotspots critical for Notch signalling. Nature Cell Biology, 2022, 24, 1739-1753.	4.6	11
3513	High resolution 16S rRNA gene Next Generation Sequencing study of brain areas associated with Alzheimerâ€™s and Parkinsonâ€™s disease. Frontiers in Aging Neuroscience, 0, 14, .	1.7	4
3514	Self-Assembly of Amyloid-Beta (AÎ²) Peptides from Solution to Near In Vivo Conditions. Journal of Physical Chemistry B, 2022, 126, 10317-10326.	1.2	10
3515	Effects of Melissa officinalis Extract Containing Rosmarinic Acid on Cognition in Older Adults Without Dementia: A Randomized Controlled Trial. Journal of Alzheimer's Disease, 2023, 91, 805-814.	1.2	4
3516	De Novo Transmembrane Aggregation of AÎ²10â€“40 Peptides in an Anionic Lipid Bilayer. Journal of Chemical Information and Modeling, 2022, 62, 6228-6241.	2.5	0
3517	Vascular contributions to Alzheimer's disease. Translational Research, 2023, 254, 41-53.	2.2	26
3518	TREM2 dependent and independent functions of microglia in Alzheimerâ€™s disease. Molecular Neurodegeneration, 2022, 17, .	4.4	25
3519	The Impact of the Cellular Environment and Aging on Modeling Alzheimer's Disease in 3D Cell Culture Models. Advanced Science, 2023, 10, .	5.6	9
3520	Methods to Study Mitochondria: Techniques Used to Study the Effects of Ageâ€Related Diseases Including Alzheimer's. Current Protocols, 2023, 3, .	1.3	0
3521	Analysis of AÎ²-induced neurotoxicity and microglial responses in simple two- and three-dimensional human iPSC-derived cortical culture systems. Tissue and Cell, 2023, 81, 102023.	1.0	2
3522	Apolipoprotein <scp>E4</scp> inhibits Î³â€secretase activity via binding to the Î³â€secretase complex. Journal of Neurochemistry, 2023, 164, 858-874.	2.1	2
3523	Alzheimer's disease and synapse Loss: What can we learn from induced pluripotent stem Cells?. Journal of Advanced Research, 2023, 54, 105-118.	4.4	5
3524	AÎ² efflux impairment and inflammation linked to cerebrovascular accumulation of amyloid-forming amylin secreted from pancreas. Communications Biology, 2023, 6, .	2.0	6
3525	Regulatory role of melatonin in Notch1 signaling pathway in cerebral cortex of AÎ²1â˜’42-induced Alzheimerâ€™s disease rat model. Molecular Biology Reports, 2023, 50, 2463-2469.	1.0	1
3526	Involvement of an Aberrant Vascular System in Neurodevelopmental, Neuropsychiatric, and Neuro-Degenerative Diseases. Life, 2023, 13, 221.	1.1	2
3527	Functions of glutaminyl cyclase and its isoform in diseases. Visualized Cancer Medicine, 2023, 4, 1.	0.5	6
3528	Ensemble feature selection with data-driven thresholding for Alzheimer's disease biomarker discovery. BMC Bioinformatics, 2023, 24, .	1.2	2

#	Article	IF	Citations
3529	Diabetes mellitus and energy dysmetabolism in Alzheimerâ€™s disease: Understanding the relationships and potential therapeutic targets. Current Diabetes Reviews, 2023, 19, .	0.6	3
3530	A genetic variant of the Wnt receptor LRP6 accelerates synapse degeneration during aging and in Alzheimerâ€™s disease. Science Advances, 2023, 9, .	4.7	8
3531	The interactions of amyloid Î² aggregates with phospholipid membranes and the implications for neurodegeneration. Biochemical Society Transactions, 2023, 51, 147-159.	1.6	5
3532	Î±7 nicotinic acetylcholine receptor in memory processing. European Journal of Neuroscience, 0, , .	1.2	3
3533	Alzheimerâ€™s disease: targeting the peripheral circulation. Molecular Neurodegeneration, 2023, 18, .	4.4	3
3534	HumulusÂlupulus L. Extract Protects against Senior Osteoporosis through Inhibiting Amyloid Î² Deposition and Oxidative Stress in APP/PS1 Mutated Transgenic Mice and Osteoblasts. Molecules, 2023, 28, 583.	1.7	4
3535	Fluorescently Guided Optical Photothermal Infrared Microspectroscopy for Protein-Specific Bioimaging at Subcellular Level. Journal of Medicinal Chemistry, 2023, 66, 2542-2549.	2.9	11
3536	Jacobâ€induced transcriptional inactivation of <scp>CREB</scp> promotes AÎ²â€induced synapse loss in Alzheimer's disease. EMBO Journal, 2023, 42, .	3.5	9
3537	Jatrophane Diterpenoids from Euphorbia peplus Linn. as Activators of Autophagy and Inhibitors of Tau Pathology. International Journal of Molecular Sciences, 2023, 24, 1088.	1.8	1
3538	Amyloid-Î² targeting immunisation in aged non-human primate (Microcebus murinus). Brain, Behavior, and Immunity, 2023, 109, 63-77.	2.0	2
3539	The TgF344-AD rat: behavioral and proteomic changes associated with aging and protein expression in a transgenic rat model of Alzheimer's disease. Neurobiology of Aging, 2023, 123, 98-110.	1.5	4
3540	Molecular interactions of resveratrol with AÎ² 42 peptide and fibril during in-vitro AÎ² 42 aggregation. Advances in Redox Research, 2023, 7, 100060.	0.9	1
3541	Taus Influence on Neurodegenerative Diseases (Alzheimerâ€™s) and non Adherence to the Neuroplasticity Principle. , 2022, 1, 50-57.		0
3542	Antibacterial and Antibiofilm Properties of Self-Assembled Dipeptide Nanotubes. International Journal of Molecular Sciences, 2023, 24, 328.	1.8	3
3544	Beneficial Effect of ACI-24 Vaccination on AÎ² Plaque Pathology and Microglial Phenotypes in an Amyloidosis Mouse Model. Cells, 2023, 12, 79.	1.8	2
3545	AÎ²42 oligomer-specific antibody ALZ-201 reduces the neurotoxicity of Alzheimerâ€™s disease brain extracts. Alzheimer's Research and Therapy, 2022, 14, .	3.0	3
3546	Interleukin-3 is associated with sTREM2 and mediates the correlation between amyloid-Î² and tau pathology in Alzheimerâ€™s disease. Journal of Neuroinflammation, 2022, 19, .	3.1	4
3548	PolyQ-Expanded Mutant Huntingtin Forms Inclusion Body Following Transient Cold Shock in a Two-Step Aggregation Mechanism. ACS Chemical Neuroscience, 2023, 14, 277-288.	1.7	2

#	Article	IF	Citations
3549	Advances in Anti-Diabetic Cognitive Dysfunction Effect of Erigeron Breviscapus (Vaniot) Hand-Mazz. Pharmaceuticals, 2023, 16, 50.	1.7	0
3550	Emerging Roles of Extracellular Vesicles in Alzheimerâ€™s Disease: Focus on Synaptic Dysfunction and Vesicleâ€“Neuron Interaction. Cells, 2023, 12, 63.	1.8	6
3551	Methods for the isolation and analysis of AÎ² from postmortem brain. Frontiers in Neuroscience, 0, 17, .	1.4	0
3552	Cultivation Factors That Affect Amyloid-Î² Aggregation Inhibitory Activity in Perilla frutescens var. crispa. Foods, 2023, 12, 486.	1.9	0
3553	An NIR-Driven Upconversion/C₃N₄/CoP Photocatalyst for Efficient Hydrogen Production by Inhibiting Electronâ€“Hole Pair Recombination for Alzheimerâ€™s Disease Therapy. ACS Nano, 2023, 17, 2222-2234.	7.3	13
3554	Role of angiotensin receptor blockers in the context of Alzheimer's disease. Fundamental and Clinical Pharmacology, 2023, 37, 429-445.	1.0	1
3555	Bloodâ€“brain barrier opening of the default mode network in Alzheimerâ€™s disease with magnetic resonance-guided focused ultrasound. Brain, 2023, 146, 865-872.	3.7	11
3556	A Function of Amyloid-Î² in Mediating Activity-Dependent Axon/Synapse Competition May Unify Its Roles in Brain Physiology and Pathology. Journal of Alzheimer's Disease, 2023, , 1-29.	1.2	2
3557	Dendrimers in Neurodegenerative Diseases. Processes, 2023, 11, 319.	1.3	7
3558	Redox Imbalance as a Common Pathogenic Factor Linking Hearing Loss and Cognitive Decline. Antioxidants, 2023, 12, 332.	2.2	6
3559	Modulation of AÎ²42 Aggregation Kinetics and Pathway by Lowâ€Molecularâ€Weight Inhibitors. ChemBioChem, 2023, 24, .	1.3	2
3560	Patchouli alcohol attenuates the cognitive deficits in a transgenic mouse model of Alzheimerâ€™s disease via modulating neuropathology and gut microbiota through suppressing C/EBPÎ²/AEP pathway. Journal of Neuroinflammation, 2023, 20, .	3.1	6
3561	Mitochondrial calcium cycling in neuronal function and neurodegeneration. Frontiers in Cell and Developmental Biology, 0, 11, .	1.8	10
3562	The Vascular-Immune Hypothesis of Alzheimerâ€™s Disease. Biomedicines, 2023, 11, 408.	1.4	5
3563	Alterations of <scp>ATG4A</scp> and <scp>LC3B</scp> in neurons derived from Alzheimer's disease patients. Genes To Cells, 2023, 28, 319-325.	0.5	0
3564	Preparation of near-infrared AIEgen-active fluorescent probes for mapping amyloid-Î² plaques in brain tissues and living mice. Nature Protocols, 2023, 18, 1316-1336.	5.5	24
3565	Adsorption, Aggregation, and Diffusion Behavior of Amyloid Î² on the Lipid Membrane. E-Journal of Surface Science and Nanotechnology, 2023, , .	0.1	0
3566	Atomic Resolution Insights into pH Shift Induced Deprotonation Events in LS-Shaped AÎ²(1â€“42) Amyloid Fibrils. Journal of the American Chemical Society, 2023, 145, 2161-2169.	6.6	4

#	Article	IF	Citations
3567	The Pursuit of the â€œInsideâ€•of the Amyloid Hypothesisâ€”Is C99 a Promising Therapeutic Target for Alzheimerâ€™s Disease?. Cells, 2023, 12, 454.	1.8	3
3568	Lysine Acetylation Changes the Mechanism of AÎ²25â€“35 Peptide Binding and Dimerization in the DMPC Bilayer. ACS Chemical Neuroscience, 2023, 14, 494-505.	1.7	0
3570	Cross interactions between Apolipoprotein E and amyloid proteins in neurodegenerative diseases. Computational and Structural Biotechnology Journal, 2023, 21, 1189-1204.	1.9	4
3571	Analysis of Non-Amyloidogenic Mutations in APP Supports Loss of Function Hypothesis of Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2023, 24, 2092.	1.8	2
3572	Neuroprotective effect of astragalin via activating PI3K/Akt-mTOR-mediated autophagy on APP/PS1 mice. Cell Death Discovery, 2023, 9, .	2.0	8
3573	Apicidin attenuates memory deficits by reducing the AÎ² load in<scp>APP</scp>/<scp>PS1</scp>mice. CNS Neuroscience and Therapeutics, 2023, 29, 1300-1311.	1.9	2
3574	GxxxG Motif Stabilize Ion-Channel like Pores through CÎ±â€•HÂ·Â·Â·O Interaction in AÎ² (1-40). International Journal of Molecular Sciences, 2023, 24, 2192.	1.8	3
3575	MicroRNA-650 Regulates the Pathogenesis of Alzheimerâ€™s Disease Through Targeting Cyclin-Dependent Kinase 5. Molecular Neurobiology, 2023, 60, 2426-2441.	1.9	2
3576	Aerobic exercise does not affect serum neurofilament light in patients with mild Alzheimerâ€™s disease. Frontiers in Neuroscience, 0, 17, .	1.4	4
3577	Current and Future Nano-Carrier-Based Approaches in the Treatment of Alzheimerâ€™s Disease. Brain Sciences, 2023, 13, 213.	1.1	4
3578	Noncanonical regulation of imprinted gene Igf2 by amyloid-beta 1â€“42 in Alzheimerâ€™s disease. Scientific Reports, 2023, 13, .	1.6	3
3579	A Review of the pharmacological treatments of Alzheimerâ€™s disease (AD). Journal of Student Research, 2022, 11, .	0.0	0
3580	Bloodborne Pancreatic Amylin, a Therapeutic Target for Alzheimer's Disease. Current Alzheimer Research, 2022, 19, 905-908.	0.7	0
3581	Alzheimer's Disease: Narrative Review of Clinical Symptoms, Molecular Alterations, and Effective Physical and Biophysical Methods in its Improvement. The Neuroscience Journal of Shefaye Khatam, 2022, 11, 105-118.	0.4	0
3582	The therapeutic potential of carnosine: Focus on cellular and molecular mechanisms. Current Research in Pharmacology and Drug Discovery, 2023, 4, 100153.	1.7	6
3583	How does neurokinin 3 receptor agonism affect pathological and cognitive impairments in an Alzheimerâ€™s disease-like rat model?. Amino Acids, 0, , .	1.2	0
3584	Oxidative Damages on the Alzheimerâ€™s Related-AÎ² Peptide Alters Its Ability to Assemble. Antioxidants, 2023, 12, 472.	2.2	0
3585	NQO1 regulates expression and alternative splicing of apoptotic genes associated with Alzheimer's disease in PC12 cells. Brain and Behavior, 2023, 13, .	1.0	2

#	Article	IF	Citations
3586	Rosmarinus officinalis and Mentha piperita Oils Supplementation Enhances Memory in a Rat Model of Scopolamine-Induced Alzheimerâ€™s Disease-like Condition. Nutrients, 2023, 15, 1547.	1.7	6
3587	An electrochemiluminescence aptasensor for amyloid-Î² protein with signal enhancement from AuNPs/Fe-MOFs nanocomposite. Journal of Electroanalytical Chemistry, 2023, 933, 117293.	1.9	5
3588	Genetically identical twin-pair difference models support the amyloid cascade hypothesis. Brain, 0, , .	3.7	1
3589	Small Molecule Decoys of Aggregation for Elimination of AÎ²-Peptide Toxicity. ACS Chemical Neuroscience, 2023, 14, 1575-1584.	1.7	2
3590	The pathomimetic oAÎ²25â€“35 model of Alzheimer's disease: Potential for screening of new therapeutic agents. , 2023, 245, 108398.		6
3591	Alzheimer HastalÄ±ÄŸÄ±â€™nda In Vivo ve In Vitro Modeller. , 2023, 6, 54-77.		0
3592	The potential roles of ATF family in the treatment of Alzheimer's disease. Biomedicine and Pharmacotherapy, 2023, 161, 114544.	2.5	3
3593	An ongoing journey of chalcone analogues as single and multi-target ligands in the field of Alzheimer's disease: A review with structural aspects. Life Sciences, 2023, 320, 121568.	2.0	7
3594	Prospective analysis of plasma amyloid beta and postoperative delirium in the Interventions for Postoperative Delirium: Biomarker-3 study. British Journal of Anaesthesia, 2023, 130, 546-556.	1.5	2
3595	Phyllodulcin improves hippocampal long-term potentiation in 5XFAD mice. Biomedicine and Pharmacotherapy, 2023, 161, 114511.	2.5	1
3596	Comparative phytochemical studies on the roots of Polygala azizsancarii and P. peshmenii and neuroprotective activities of the two xanthones. Phytochemistry, 2023, 210, 113650.	1.4	2
3597	AÎ²-oligomers: A potential therapeutic target for Alzheimer's disease. International Journal of Biological Macromolecules, 2023, 239, 124231.	3.6	15
3598	An update on the role of Hippo signaling pathway in ischemia-associated central nervous system diseases. Biomedicine and Pharmacotherapy, 2023, 162, 114619.	2.5	5
3599	Comprehensive Bibliometric Analysis of Stem Cell Research in Alzheimerâ€™s Disease from 2004 to 2022. Dementia and Geriatric Cognitive Disorders, 2023, 52, 47-73.	0.7	10
3600	Peripheral apolipoprotein E proteins and their binding to LRP1 antagonize Alzheimerâ€™s disease pathogenesis in the brain during peripheral chronic inflammation. Neurobiology of Aging, 2023, 127, 54-69.	1.5	4
3601	Annualized changes in rate of amyloid deposition and neurodegeneration are greater in participants who become amyloid positive than those who remain amyloid negative. Neurobiology of Aging, 2023, 127, 33-42.	1.5	0
3603	Design, synthesis, and biological evaluation of novel N-Benzyl piperidine derivatives as potent HDAC/AChE inhibitors for Alzheimerâ€™s disease. Bioorganic and Medicinal Chemistry, 2023, 80, 117178.	1.4	5
3604	PSEN2 and ABCA7 variants causing early-onset preclinical pathological changes in Alzheimer's disease: a case report and literature review. Neurological Sciences, 0, , .	0.9	0

#	Article	IF	Citations
3605	Application of Novel Degraders Employing Autophagy for Expediting Medicinal Research. Journal of Medicinal Chemistry, 2023, 66, 1700-1711.	2.9	11
3607	Plantainoside B in <i>Bacopa monniera</i> Binds to AÎ² Aggregates Attenuating Neuronal Damage and Memory Deficits Induced by AÎ². Biological and Pharmaceutical Bulletin, 2023, 46, 320-333.	0.6	0
3608	Immune-mediated platelet depletion augments Alzheimerâ€™s disease neuropathological hallmarks in APP-PS1 mice. Aging, 2023, 15, 630-649.	1.4	1
3609	Physical activity for cognitive health promotion: An overview of the underlying neurobiological mechanisms. Ageing Research Reviews, 2023, 86, 101868.	5.0	22
3610	Combinations of Vitamin A and Vitamin E Metabolites Confer Resilience against Amyloid-Î² Aggregation. ACS Chemical Neuroscience, 2023, 14, 657-666.	1.7	0
3612	Serum sodium, cognition and incident dementia in the general population. Age and Ageing, 2023, 52, .	0.7	1
3613	Employing nanoparticle tracking analysis of salivary neuronal exosomes for early detection of neurodegenerative diseases. Translational Neurodegeneration, 2023, 12, .	3.6	8
3614	Lecanemab (BAN2401): an antiâ€“beta-amyloid monoclonal antibody for the treatment of Alzheimer disease. Expert Opinion on Investigational Drugs, 2023, 32, 89-94.	1.9	19
3615	The Amyloid-Beta Clearance: From Molecular Targets to Glial and Neural Cells. Biomolecules, 2023, 13, 313.	1.8	8
3616	Revisiting the intersection of microglial activation and neuroinflammation in Alzheimer's disease from the perspective of ferroptosis. Chemico-Biological Interactions, 2023, 375, 110387.	1.7	12
3617	Contributions of bloodâ€“brain barrier imaging to neurovascular unit pathophysiology of Alzheimerâ€™s disease and related dementias. Frontiers in Aging Neuroscience, 0, 15, .	1.7	4
3618	Multifactorial glial responses and their contributions to Alzheimer's disease continuum. Clinical and Experimental Neuroimmunology, 2023, 14, 82-91.	0.5	1
3619	Associations Between Plasma Klotho with Renal Function and Cerebrospinal Fluid Amyloid-Î² Levels in Alzheimerâ€™s Disease: The Chongqing Ageing & Dementia Study. Journal of Alzheimer's Disease, 2023, 92, 477-485.	1.2	1
3620	White matter injury, cholesterol dysmetabolism, and APP/Abeta dysmetabolism interact to produce Alzheimerâ€™s disease (AD) neuropathology: A hypothesis and review. Frontiers in Aging Neuroscience, 0, 15, .	1.7	6
3621	Multifunctional Nanoprobes for the Surveillance of Amyloid Aggregation. , 2023, , 1-24.		0
3622	Drug trial for Alzheimerâ€™s disease is a game changer. Nature, 2023, 615, 42-43.	13.7	7
3623	Models of precision medicine for neurodegeneration. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2023, , 21-34.	1.0	3
3624	Effects of presenilin-1 familial Alzheimerâ€™s disease mutations on Î³-secretase activation for cleavage of amyloid precursor protein. Communications Biology, 2023, 6, .	2.0	7

#	Article	IF	Citations
3625	Finding the falsification threshold of the toxic proteinopathy hypothesis in neurodegeneration. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2023, , 143-154.	1.0	6
3627	Specific Mutations near the Amyloid Precursor Protein Cleavage Site Increase Î³-Secretase Sensitivity and Modulate Amyloid-Î² Production. International Journal of Molecular Sciences, 2023, 24, 3970.	1.8	6
3628	The allure and pitfalls of the prion-like aggregation in neurodegeneration. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2023, , 17-22.	1.0	0
3629	Molecular dynamics simulations reveal the importance of amyloid-beta oligomer Î²-sheet edge conformations in membrane permeabilization. Journal of Biological Chemistry, 2023, 299, 103034.	1.6	6
3630	Reconsidering the role of blood-brain barrier in Alzheimerâ€™s disease: From delivery to target. Frontiers in Aging Neuroscience, 0, 15, .	1.7	11
3631	Golgi fragmentation â€“ One of the earliest organelle phenotypes in Alzheimerâ€™s disease neurons. Frontiers in Neuroscience, 0, 17, .	1.4	11
3632	Lessons from antiamyloid-Î² immunotherapies in Alzheimer's disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2023, , 267-291.	1.0	7
3633	An anti-amyloid therapy works for Alzheimerâ€™s disease: why has it taken so long and what is next?. Brain, 2023, 146, 1240-1242.	3.7	15
3634	Administration of Kainic Acid Differentially Alters Astrocyte Markers and Transiently Enhanced Phospho-tau Level in Adult Rat Hippocampus. Neuroscience, 2023, 516, 27-41.	1.1	3
3635	Presenilin 1 deficiency impairs AÎ²42-to-AÎ²40- and angiotensin-converting activities of ACE. Frontiers in Aging Neuroscience, 0, 15, .	1.7	3
3636	Sexâ€specific effects of SNAPâ€25 genotype on verbal memory and Alzheimer's disease biomarkers in clinically normal older adults. Alzheimer's and Dementia, 2023, 19, 3448-3457.	0.4	2
3637	The Role of Heme and Copper in Alzheimerâ€™s Disease and Type 2 Diabetes Mellitus. Jacs Au, 2023, 3, 657-681.	3.6	7
3638	TREM2 splice isoforms generate soluble TREM2 species that disrupt long-term potentiation. Genome Medicine, 2023, 15, .	3.6	6
3639	Electrochemical Analysis in Studying Î²-Amyloid Aggregation. Biochemistry (Moscow), 2023, 88, S88-S104.	0.7	1
3640	Role of Interaction between Zinc and Amyloid Beta in Pathogenesis of Alzheimerâ€™s Disease. Biochemistry (Moscow), 2023, 88, S75-S87.	0.7	1
3641	A Nanoenzyme Constructed from Manganese and Strandberg-Type Phosphomolybdate with Versatility in Antioxidant and Modulating Conformation of AÎ² Protein Misfolding Aggregates In Vitro. International Journal of Molecular Sciences, 2023, 24, 4317.	1.8	2
3642	Natural Alkaloids as Multi-Target Compounds towards Factors Implicated in Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2023, 24, 4399.	1.8	12
3643	Extracellular protein homeostasis in neurodegenerative diseases. Nature Reviews Neurology, 0, , .	4.9	3

#	Article	IF	Citations
3644	Relationship between bloodâ€“brain barrier changes and drug metabolism under high-altitude hypoxia: obstacle or opportunity for drug transport?. Drug Metabolism Reviews, 2023, 55, 107-125.	1.5	1
3645	Pathogenesis of Alzheimer's disease: Involvement of the choroid plexus. Alzheimer's and Dementia, 2023, 19, 3537-3554.	0.4	8
3646	Peripheral metabolism of lipoprotein-amyloid beta as a risk factor for Alzheimerâ€™s disease: potential interactive effects of APOE genotype with dietary fats. Genes and Nutrition, 2023, 18, .	1.2	5
3647	Residue-specific binding of Ni(II) ions influences the structure and aggregation of amyloid beta (AÎ²) peptides. Scientific Reports, 2023, 13, .	1.6	5
3648	Polyphenols: Natural food grade biomolecules for treating neurodegenerative diseases from a multi-target perspective. Frontiers in Nutrition, 0, 10, .	1.6	6
3649	Treatment concept successfully translated into human patients. , 0, , 48-51.		0
3650	Loss of Extrasynaptic Inhibitory Glycine Receptors in the Hippocampus of an AD Mouse Model Is Restored by Treatment with Artesunate. International Journal of Molecular Sciences, 2023, 24, 4623.	1.8	2
3651	The Amyloid Cascade Hypothesis in Alzheimerâ€™s Disease: Should We Change Our Thinking?. Biomolecules, 2023, 13, 453.	1.8	13
3652	Autophagy and Alzheimerâ€™s disease: How far science has to be progressed? â˜† correspondence. Annals of Medicine and Surgery, 2023, 85, 323-325.	0.5	0
3653	Inhibition of microtubule affinity regulating kinase 4 by an acetylcholinesterase inhibitor, Huperzine A: Computational and experimental approaches. International Journal of Biological Macromolecules, 2023, 235, 123831.	3.6	7
3654	Imaging Amyloidâ€Î² Membrane Interactions: Ionâ€Channel Pores and Lipidâ€Bilayer Permeability in Alzheimer's Disease. Angewandte Chemie, 2023, 135, .	1.6	0
3655	Imaging Amyloidâ€Î² Membrane Interactions: Ionâ€Channel Pores and Lipidâ€Bilayer Permeability in Alzheimer's Disease. Angewandte Chemie - International Edition, 2023, 62, .	7.2	9
3657	Evaluation of therapeutic effects of tetramethylpyrazine nitrone in Alzheimerâ€™s disease mouse model and proteomics analysis. Frontiers in Pharmacology, 0, 14, .	1.6	4
3658	A Preliminary Study on the Mechanism of Alcohol Abuse in Alzheimerâ€™s Disease. Open Journal of Natural Science, 2023, 11, 147-155.	0.1	0
3659	Î²-Carotene, a Potent Amyloid Aggregation Inhibitor, Promotes Disordered AÎ² Fibrillar Structure. International Journal of Molecular Sciences, 2023, 24, 5175.	1.8	1
3660	Metalâ€“Organic Frameworks as Sensors for Human Amyloid Diseases. ACS Sensors, 2023, 8, 1033-1053.	4.0	14
3661	Beyond the amyloid cascade: An update of Alzheimer's disease pathophysiology. Revue Neurologique, 2023, 179, 812-830.	0.6	6
3662	Intracellular Amyloid-Î² Detection from Human Brain Sections Using a Microfluidic Immunoassay in Tandem with MALDI-MS. Analytical Chemistry, 2023, 95, 5522-5531.	3.2	0

#	Article	IF	Citations
3663	Disturb mitochondrial associated proteostasis: Neurodegeneration and imperfect ageing. Frontiers in Cell and Developmental Biology, 0, 11, .	1.8	4
3665	Transferability of Alzheimer's disease progression subtypes to an independent population cohort. NeuroImage, 2023, 271, 120005.	2.1	3
3666	Mass Spectrometry Imaging in Alzheimer's Disease. Brain Connectivity, 2023, 13, 319-333.	0.8	4
3667	Alleviating the unwanted effects of oxidative stress on AÎ² clearance: a review of related concepts and strategies for the development of computational modelling. Translational Neurodegeneration, 2023, 12, .	3.6	2
3668	TGF-Î²1 signalling in Alzheimerâ€™s pathology and cytoskeletal reorganization: a specialized Tau perspective. Journal of Neuroinflammation, 2023, 20, .	3.1	16
3669	New Pathways Identify Novel Drug Targets for the Prevention and Treatment of Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2023, 24, 5383.	1.8	7
3670	A Comprehensive Investigation of the Potential Role of Lipoproteins and Metabolite Profile as Biomarkers of Alzheimerâ€™s Disease Compared to the Known CSF Biomarkers. International Journal of Alzheimer's Disease, 2023, 2023, 1-9.	1.1	1
3671	Strategies for generating mouse model resources of human disease. Protein and Cell, 0, , .	4.8	2
3672	Alzheimerâ€™s Disease: a Search for the Best Experimental Models to Decode Cellular and Molecular Mechanisms of Its Development. Journal of Evolutionary Biochemistry and Physiology, 2023, 59, 119-132.	0.2	0
3673	Impairment of Neural Rhythms in the Hippocampus in Different Behavioral Phases Induced by Amyloid-Î² Accumulation. , 2022, , .		0
3675	The Î-secretase-derived APP fragment Î·CTF is localized in Golgi, endosomes and extracellular vesicles and contributes to AÎ² production. Cellular and Molecular Life Sciences, 2023, 80, .	2.4	4
3676	Fluorine-18-Labeled Diaryl-azines as Improved Î²-Amyloid Imaging Tracers: From Bench to First-in-Human Studies. Journal of Medicinal Chemistry, 2023, 66, 4603-4616.	2.9	6
3677	Exercise suppresses neuroinflammation for alleviating Alzheimerâ€™s disease. Journal of Neuroinflammation, 2023, 20, .	3.1	19
3678	Light, Water, and Melatonin: The Synergistic Regulation of Phase Separation in Dementia. International Journal of Molecular Sciences, 2023, 24, 5835.	1.8	4
3679	Exploring Whether Iron Sequestration within the CNS of Patients with Alzheimerâ€™s Disease Causes a Functional Iron Deficiency That Advances Neurodegeneration. Brain Sciences, 2023, 13, 511.	1.1	6
3680	MCP-1 levels in astrocyte-derived exosomes are changed in preclinical stage of Alzheimer's disease. Frontiers in Neurology, 0, 14, .	1.1	4
3682	Different transmembrane domains determine the specificity and efficiency of the cleavage activity of the Î³-secretase subunit presenilin. Journal of Biological Chemistry, 2023, 299, 104626.	1.6	0
3683	S100B chaperone multimers suppress the formation of oligomers during AÎ²42 aggregation. Frontiers in Neuroscience, 0, 17, .	1.4	7

#	Article	IF	Citations
3684	Dityrosine cross-linking and its potential roles in Alzheimerâ€™s disease. Frontiers in Neuroscience, 0, 17, .	1.4	2
3685	Endothelial Senescence in Neurological Diseases. , 2023, 14, 2153.		2
3686	Mechanistic insights into the inhibition of amyloid-Î² aggregation by chitosan. Physical Chemistry Chemical Physics, 2023, 25, 10113-10120.	1.3	1
3687	Targeting amyloid Î² in Alzheimer's disease: Metaâ€analysis of lowâ€dose solanezumab in Alzheimer's disease with mild dementia studies. Alzheimer's and Dementia, 2023, 19, 4619-4628.	0.4	8
3688	Oligomeric Î²-Amyloid Suppresses Hippocampal Î³-Oscillations through Activation of the mTOR/S6K1 Pathway. , 2023, .		0
3690	ADAM10 Gene Variants in AD Patients and Their Relationship to CSF Protein Levels. International Journal of Molecular Sciences, 2023, 24, 6113.	1.8	0
3692	Physiological Î²-amyloid clearance by the liver and its therapeutic potential for Alzheimerâ€™s disease. Acta Neuropathologica, 2023, 145, 717-731.	3.9	19
3693	Human neurons lacking amyloid precursor protein exhibit cholesterolâ€associated developmental and presynaptic deficits. Journal of Cellular Physiology, 0, , .	2.0	2
3694	Insulinâ€like growth factorâ€2 is a promising candidate for the treatment and prevention of Alzheimer's disease. CNS Neuroscience and Therapeutics, 2023, 29, 1449-1469.	1.9	2
3695	Sigma-2 Receptorsâ€”From Basic Biology to Therapeutic Target: A Focus on Age-Related Degenerative Diseases. International Journal of Molecular Sciences, 2023, 24, 6251.	1.8	7
3696	Clinical Management in Alzheimerâ€™s Disease in the Era of Disease-Modifying Therapies. Current Treatment Options in Neurology, 2023, 25, 121-133.	0.7	1
3697	Differential Binding and Conformational Dynamics of Tau Microtubule-Binding Repeats with a Preformed Amyloid-Î² Fibril Seed. ACS Chemical Neuroscience, 2023, 14, 1321-1330.	1.7	3
3698	Epigenetic regulons in Alzheimer's disease. Progress in Molecular Biology and Translational Science, 2023, , .	0.9	0
3699	Structural polymorphism of the low-complexity C-terminal domain of TDP-43 amyloid aggregates revealed by solid-state NMR. Frontiers in Molecular Biosciences, 0, 10, .	1.6	2
3700	Oligomeric, phosphorylated, and truncated tau and spliceosome pathology within the entorhinalâ€“hippocampal connectome across stages of Alzheimer's disease. Journal of Comparative Neurology, 2023, 531, 2080-2108.	0.9	0
3701	Characterization of the role of Kunitzâ€type protease inhibitor domain in dimerization of amyloid precursor protein. Journal of Computational Chemistry, 2023, 44, 1437-1445.	1.5	1
3702	Zn2+-responsive palladium nanoclusters synergistically manage Alzheimerâ€™s disease through neuroprotection and inhibition of oxidative stress. Chemical Engineering Journal, 2023, 464, 142679.	6.6	0
3703	Iron(III) Complexes with Non-Steroidal Anti-Inflammatory Drugs: Structure, Antioxidant and Anticholinergic Activity, and Interaction with Biomolecules. International Journal of Molecular Sciences, 2023, 24, 6391.	1.8	2

#	Article	IF	Citations
3704	Predicting cognitive stage transition using pâ€tau181, Centiloid, and other measures. Alzheimer's and Dementia, 2023, 19, 4641-4650.	0.4	4
3705	Myelin, aging, and physical exercise. Neurobiology of Aging, 2023, 127, 70-81.	1.5	4
3707	Oxytocin attenuates microglial activation and restores social and non-social memory in APP/PS1 Alzheimer model mice. IScience, 2023, 26, 106545.	1.9	6
3708	Brain Amyloid in Sporadic Young Onset Alzheimerâ€™s Disease. Journal of Alzheimer's Disease Reports, 2023, 7, 263-270.	1.2	1
3709	Moving beyond amyloid and tau to capture the biological heterogeneity of Alzheimerâ€™s disease. Trends in Neurosciences, 2023, 46, 426-444.	4.2	11
3710	T cell aging and Alzheimerâ€™s disease. Frontiers in Immunology, 0, 14, .	2.2	7
3711	Effect of Î²-amyloid on blood-brain barrier properties and function. Biophysical Reviews, 0, , .	1.5	2
3712	A Dual-Function â€œTRE-Loxâ€•System for Genetic Deletion or Reversible, Titratable, and Near-Complete Downregulation of Cathepsin D. International Journal of Molecular Sciences, 2023, 24, 6745.	1.8	0
3713	Stem cells in the treatment of Alzheimer's disease â€“ Promises and pitfalls. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2023, 1869, 166712.	1.8	1
3714	Metastable alphaâ€rich and betaâ€rich conformations of small AÎ²42 peptide oligomers. Proteins: Structure, Function and Bioinformatics, 0, , .	1.5	1
3715	Retromer proteins reduced in Down syndrome and the Dp16 model: impact of APP dose and preclinical studies of a Î³â€secretase modulator. Annals of Neurology, 0, , .	2.8	2
3716	Interaction between KLOTHO-VS Heterozygosity and APOE Îµ4 Allele Predicts Rate of Cognitive Decline in Late-Onset Alzheimerâ€™s Disease. Genes, 2023, 14, 917.	1.0	1
3718	Phytochemical Interactions with Calmodulin and Critical Calmodulin Binding Proteins Involved in Amyloidogenesis in Alzheimerâ€™s Disease. Biomolecules, 2023, 13, 678.	1.8	1
3719	The role of HDAC3 and its inhibitors in regulation of oxidative stress and chronic diseases. Cell Death Discovery, 2023, 9, .	2.0	4
3720	Pre-symptomatic synaptic dysfunction and longitudinal decay of hippocampal synaptic function in APPPS1 mouse model of Alzheimerâ€™s disease is sex-independent. Brain Research Bulletin, 2023, 198, 36-49.	1.4	2
3721	Double Mutations in a Patient with Early-Onset Alzheimerâ€™s Disease in Korea: An APP Val551Met and a PSEN2 His169Asn. International Journal of Molecular Sciences, 2023, 24, 7446.	1.8	0
3722	Discoveries and future significance of research into amyloid-beta/Î±7-containing nicotinic acetylcholine receptor (nAChR) interactions. Pharmacological Research, 2023, 191, 106743.	3.1	3
3723	Vector enabled CRISPR gene editing â€“ A revolutionary strategy for targeting the diversity of brain pathologies. Coordination Chemistry Reviews, 2023, 487, 215172.	9.5	0

#	Article	IF	Citations
3726	Ferulic Acid Improves Synaptic Plasticity and Cognitive Impairments by Alleviating the PP2B/DARPP-32/PP1 Axis-Mediated STEP Increase and AÎ² Burden in Alzheimer's Disease. Neurotherapeutics, 2023, 20, 1081-1108.	2.1	5
3727	Molecular Mechanisms of Cellular Senescence in Neurodegenerative Diseases. Journal of Molecular Biology, 2023, 435, 168114.	2.0	9
3728	Age-related and amyloid-beta-independent tau deposition and its downstream effects. Brain, 2023, 146, 3192-3205.	3.7	6
3730	Proteostasis failure exacerbates neuronal circuit dysfunction and sleep impairments in Alzheimerâ€™s disease. Molecular Neurodegeneration, 2023, 18, .	4.4	4
3741	Multifunctional Nanoprobes for the Surveillance of Amyloid Aggregation. , 2023, , 489-512.		0
3744	Step by step: towards a better understanding of the genetic architecture of Alzheimerâ€™s disease. Molecular Psychiatry, 2023, 28, 2716-2727.	4.1	14
3745	Structural Dynamics of Amyloid-Î² Protofibrils and Actions of Anti-Amyloid-Î² Antibodies as Observed by High-Speed Atomic Force Microscopy. Nano Letters, 2023, 23, 6259-6268.	4.5	4
3777	Malnutrition and early-stage Alzheimer's disease. , 2023, , 87-101.		0
3782	Pharmacological Treatment of Cognitive and Behavioral Disorders in Dementia. Practical Issues in Geriatrics, 2023, , 269-287.	0.3	0
3790	Amyloid-Î² Can Form Fractal Antenna-Like Networks Responsive to Electromagnetic Beating and Wireless Signaling. Lecture Notes in Networks and Systems, 2023, , 323-344.	0.5	0
3797	Matrine exerts its neuroprotective effects by modulating multiple neuronal pathways. Metabolic Brain Disease, 2023, 38, 1471-1499.	1.4	3
3833	Understanding the Mechanisms of Amyloid Beta (AÎ²) Aggregation by Computational Modeling. Neuromethods, 2023, , 51-71.	0.2	0
3844	In the Slip Stream of Amyloid: The Tau and Tangle Hypothesis. , 2023, , 227-260.		0
3845	Concerns about the Amyloid Cascade Hypothesis and Reappraisals. , 2023, , 167-183.		1
3846	The Amyloid Cascade Hypothesis Has to Deliver, Finally. , 2023, , 309-350.		0
3851	Heavy Metal Mediated Progressive Degeneration and Its Noxious Effects on Brain Microenvironment. Biological Trace Element Research, 2024, 202, 1411-1427.	1.9	4
3855	A Comprehensive Review onÂtheÂIdentification ofÂBlood-Based Biomarkers forÂAlzheimerâ€™s Disease Detection Through Computational Approaches. Lecture Notes in Networks and Systems, 2023, , 435-449.	0.5	0
3856	Machine Learning for Alzheimerâ€™s Disease and Related Dementias. Neuromethods, 2023, , 807-846.	0.2	1

#	Article	IF	Citations
3857	Anti-Amyloid Immunotherapies for Alzheimer's Disease: A 2023 Clinical Update. Neurotherapeutics, 2023, 20, 914-931.	2.1	22
3867	Understanding the multifaceted role of miRNAs in Alzheimerâ€™s disease pathology. Metabolic Brain Disease, 2024, 39, 217-237.	1.4	1
3868	Pathological Roles of INPP5D in Alzheimerâ€™s Disease. Advances in Experimental Medicine and Biology, 2023, , 289-301.	0.8	0
3871	Recent advances in nanotechnology for combating Alzheimer's disease. Materials Chemistry Frontiers, 0, , .	3.2	0
3903	Multi-Target-Directed Ligand Approach in Anti-Alzheimerâ€™s Drug Discovery. , 2023, , 285-319.		0
3928	Adenosine A2A Receptor Antagonists: Chemistry, SARs, and Therapeutic Potential. Topics in Medicinal Chemistry, 2023, , 101-141.	0.4	0
3963	Angiotensin-converting enzyme. , 2024, , 239-253.		0
3996	The supersaturation perspective on the amyloid hypothesis. Chemical Science, 2023, 15, 46-54.	3.7	2
4035	The probable role of tissue plasminogen activator/neuroserpin axis in Alzheimerâ€™s disease: a new perspective. Acta Neurologica Belgica, 0, , .	0.5	2
4059	Identifying Candidate Biomarkers forÂAlzheimerâ€™s Disease Diagnoses Using Saliva ^{1}H NMR-Based Metabolomics. Lecture Notes in Networks and Systems, 2023, , 585-593.	0.5	0
4062	Fat and Alzheimerâ€™s Disease. , 2023, , 67-89.		0
4091	Metal Chelators as a Potential Therapeutic Agent for Alzheimerâ€™s Disease. , 2023, , 347-374.		0
4095	Astrocytes Reprogramming for Neurodegenerative Disease Management. Advances in Bioinformatics and Biomedical Engineering Book Series, 2023, , 313-330.	0.2	0
4123	Advancing piezoelectric 2D nanomaterials for applications in drug delivery systems and therapeutic approaches. Nanoscale Horizons, 2024, 9, 365-383.	4.1	0
4124	Microbubbles-based drug delivery for antiAlzheimer's drugs. , 2024, , 403-419.		0
4128	Nutraceuticalâ€™s potentials in neurodegenerative disease. , 2024, , 199-213.		0
4134	Study progress in regulating microglia in Alzheimer's disease. , 2024, , .		0
4145	Medical potentials of natural neuroprotectants derived from herbal extracts and their phytochemicals. , 2024, , 105-120.		0

#	Article	IF	Citations
4152	Etiology, pathogenesis of Alzheimer's disease and amyloid beta hypothesis. , 2024, , 1-11.		0
4189	Anti-amyloid Antibody Therapies for Alzheimerâ€™s Disease. Nuclear Medicine and Molecular Imaging, 0, , .	0.6	0
4199	Machine Learning of Brain Functional Network Characteristics for AD Classification. Lecture Notes in Electrical Engineering, 2024, , 590-599.	0.3	0